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 II 
Summary  
Context: Autoimmune polyendocrine syndrome type 1 (APS1) is characterised by multiple 
autoimmune endocrinopathies and results from mutations in the AIRE (autoimmune 
regulator) gene. Approximately 80% of patients present with hypoparathyroidism which is 
suggested to result from autoimmune responses against the parathyroid glands. The 
calcium-sensing receptor (CaSR), which plays a pivotal role in maintaining calcium 
homeostasis by sensing blood calcium levels and regulating release of parathyroid 
hormone, has been identified as a parathyroid autoantibody target in APS1. 
Aims: The main aims of this study were to characterise APS1 patient anti-CaSR 
autoantibodies in relation to their prevalence, disease associations, epitopes, specificity, 
IgG subclass and effects upon CaSR function, and to develop an ELISA to detect CaSR 
autoantibodies in patient sera. 
Methodology: Immunoprecipitation; radioligand binding assays; phage-display; ELISA; 
bioassays; protein expression. 
Results: Autoantibodies against the CaSR were detected in 16 out of 44 (36%) APS1 
patients and in none of 38 healthy control subjects (P = < 0.0001). No statistically 
significant associations were found between the presence of CaSR autoantibodies and the 
disease manifestations of APS1 including hypoparathyroidism. The detection of CaSR 
autoantibodies had a specificity of 83%, and a sensitivity of 39% for the diagnosis of 
hypoparathyroidism. There were no significant associations between the presence of CaSR 
antibodies and either sex, age or disease presentation age. However, a significant 
association between a shorter APS1 duration (< 10 years) and positivity for CaSR 
autoantibodies was noted (P = 0.019). 
CaSR autoantibody epitopes were identified between amino acids 41–69, 114–126, 171–
195 and 260-340 in the extracellular domain of the receptor. Autoantibodies against CaSR 
epitopes 41–69, 171-195 and 260-340 were exclusively of the IgG1 subclass. Autoantibody 
responses against CaSR epitope 114-126 were predominantly of the IgG1 with a minority 
of the IgG3 subclass. CaSR autoantibodies were analysed for their ability to increase Ca2+-
dependent inositol phosphate accumulation in HEK293 cells expressing the CaSR. The 
results indicated that 4/16 (25%) APS1 patients had anti-CaSR-activating autoantibodies, 
suggesting that although the majority of APS1 patients do not have CaSR-stimulating 
autoantibodies, there may be a small minority of patients in whom the hypoparathyroid 
state is the result of functional suppression of the parathyroid glands. 
As part of this study, an ELISA was developed using the extracellular domain of the CaSR 
expressed in Escherichia coli as the antibody-capture antigen. Although this assay was able 
to detect the presence of autoantibodies in APS1 patient sera, the experimental method 
still requires further optimisations in order to attain a validated and robust ELISA, as this 
was not achievable during the present study.    
Conclusion: The study provides a detailed analysis of the characteristics of CaSR 
autoantibodies in APS1 patients, although further investigations are required to determine 
the exact role played by the autoimmune response against the CaSR in the pathogenesis of 
APS1.  
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Review of the Literature 
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1 Review of the Literature 
 Autoimmune polyendocrine syndromes 1.1
Autoimmune polyendocrine syndromes are a group of diseases caused by autoimmune 
activity against body organs (Kahaly, 2009). Usually, these disorders are characterised 
by at least two endocrine disease components, but affected individuals may also have 
non-endocrine manifestations (Kahaly, 2009, Cutolo, 2014). Patients have a 
lymphocytic infiltrate in their affected glands and organ-specific autoantibodies in their 
serum (Kisand and Peterson, 2011, Kahaly, 2012). Autoimmune polyendocrine 
syndromes have been classified into four main types (Kahaly, 2012, Cutolo, 2014). 
Autoimmune polyendocrine syndrome type 1 (APS1) is a rare disease due to mutations 
in the autoimmune regulator (AIRE) gene which impair the development of immune 
tolerance leading to autoimmunity (Nagamine et al., 1997). The disease is also called 
autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED). Onset 
of APS1 usually occurs during childhood (Perheentupa, 2006), and, clinically, the 
disease is characterised by at least two of the following manifestation; chronic 
mucocutaneous candidiasis, hypoparathyroidism, and Addison’s disease (Perheentupa, 
2006). Other diseases can be present including hypothyroidism, vitiligo, alopecia 
areata and type 1 diabetes mellitus (Perheentupa, 2006). As patients with this 
syndrome are analysed in this thesis, the disease will be discussed in more detail in 
Section 1.2. 
Autoimmune polyendocrine syndrome type 2 (APS2) or Schmidt’s syndrome is the 
commonest autoimmune polyendocrine syndrome with a prevalence of 1:20,000 
(Kahaly, 2012). There is a higher prevalence in women, and the disease usually 
presents in adulthood, although children can be affected (Kahaly, 2012, Betterle et al., 
2002). It is characterised by the presence of Addison’s disease, which is the main 
component, thyroid autoimmunity (Graves’ disease or hypothyroidism), and/or type 1 
diabetes mellitus (Neufeld et al., 1981, Kahaly, 2012, Cutolo, 2014). In addition, APS2 
can involve non-endocrine conditions such as myasthenia gravis, celiac disease, vitiligo, 
stiff-man syndrome, alopecia areata, and pernicious anaemia (Kahaly, 2012, Cutolo, 
2014). In common with many autoimmune diseases, the primary genetic association of 
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APS2 is with alleles of class II human leukocyte antigens (HLA), notably with haplotypes 
DR3/DQ2 and DR4/DQ8 (Kahaly, 2012, Cutolo, 2014). 
Autoimmune polyendocrine syndrome type 3 is defined by the presence of 
autoimmune thyroid disease and autoimmune disorders other than Addison’s disease 
and hypoparathyroidism (Kahaly, 2012). Type 4 APS is defined by a combination of 
autoimmune endocrine disorders that does not fulfil the markers of the other three 
types (Cutolo, 2014). Other diseases outside of this autoimmune polyendocrine 
syndrome classification, but which nevertheless include polyendocrinopathy, are 
immune dysfunction polyendocrinopathy X-linked (IPEX), POEMS (polyneuropathy, 
organomegaly, endocrinopathy, M-protein, skin changes) disease, and Kearns–Sayre 
syndrome (Cutolo, 2014).  
 Autoimmune polyendocrine syndrome type 1: aetiology and pathogenesis 1.2
 The AIRE gene and AIRE protein 1.2.1
Autoimmune polyendocrine syndrome type 1 arises from mutations in the 
autoimmune regulator (AIRE) gene which are deleterious to the functioning of the 
autoimmune regulator (AIRE) protein (Nagamine et al., 1997). The AIRE gene is located 
on chromosome 21 at position q22.3. The gene is 13-kilobase, is composed of 14 exons 
(Nagamine et al., 1997), and encodes the 58-kDa AIRE transcription factor which is 
composed of 545 amino acids (Peterson et al., 2008). The AIRE protein is composed of 
several domains (Figure 1.1) including a central putative DNA-binding domain called 
the SAND (Sp100, AIRE1, Nuc P41/75, DEAF1) domain, a proline-rich region (PRR) 
which is suggested to be involved in transcription, a caspase-recruitment domain 
(CARD) which is a six-helix structure located at the N-terminal and is required for AIRE 
oligomerisation, and two plant homeodomains PHD1 and PHD2 which take part in 
protein-protein and protein-DNA interactions (Peterson et al., 2008). At the N-
terminal, there is a nuclear localisation signal, and the C-terminal is also required for 
activation of the transcription process. 
In the cell, the AIRE protein is located in nuclear bodies, which are the sites of 
chromatin-associated, transcriptionally active proteins (Bjorses et al., 2000, Gaetani et 
al., 2012). Moreover, recent studies have shown that AIRE promotes transcription 
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‘non-classically’ through interacting with chromatin in complexes with the 
transcriptional regulator CREB-binding protein, the positive transcription-elongation 
factor b, RNA polymerase II, DNA-dependent protein kinase, and topoisomerase 2 
(Figure 1.2) (Pitkanen et al., 2005, Abramson et al., 2010, Gaetani et al., 2012).  
 AIRE function in promoting central and peripheral tolerance  1.2.2
Mainly, the AIRE gene is expressed in medullary thymic epithelial cells (mTEC) where 
the AIRE transcription factor promotes the expression of tissue-specific antigens 
(Heino et al., 1999, Peterson et al., 2008). Via major histocompatibility complex (MHC) 
class II antigens, mTECs then present tissue-restricted antigens to developing 
thymocytes (precursor immune cells) causing their apoptosis so that potentially 
autoreactive T cells are eliminated by negative selection enabling self-tolerance to be 
established (Anderson et al., 2002, Liston et al., 2003) (Figure 1.2 and 1.3). In addition 
to its role in affecting negative selection, there is now evidence that AIRE-driven 
expression of tissue-specific antigens also supports the generation of naturally 
occurring regulatory T cells (Tregs) (Malchow et al., 2013, Yang et al., 2015). The action 
of the AIRE transcription factor has also been shown to be required for the maturation 
of mTECs (Matsumoto, 2011, Wang et al., 2012), and for the regulation of intra-thymic 
chemokines that are needed for the correct localisation of thymocytes and dendritic 
cells (DCs) so that proper antigen presentation in the thymus is ensured (Kurobe et al., 
2006, Lei et al., 2011). Although several of these proposed functions require more 
detailed study, ultimately, they may all contribute to the development of central 
tolerance. 
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Figure ‎1.1: Schematic representation of the human AIRE protein. 
The AIRE protein is composed of several domains including a central putative DNA-binding 
domain called the SAND (Sp100, AIRE1, Nuc P41/75, DEAF1) domain, a proline-rich region 
(PRR) which is suggested to be involved in transcription, a caspase-recruitment domain (CARD) 
which is a six-helix structure located at the N-terminal and is required for AIRE oligomerisation, 
and two plant homeodomains PHD1 and PHD2 which take part in protein-protein and protein-
DNA interactions. The image, from a paper (Meloni et al., 2002), was used with kind 
permission from Endocrine Society.  
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Figure ‎1.2: AIRE interaction with transcriptional partners 
In medullary thymic epithelial cells (mTEC), AIRE transcription factor drives expression of 
tissue-specific antigens through interaction with chromatin in complexes with DNA-dependent 
protein kinase (DNA-PK), topoisomerase 2 (TOP2), positive transcription elongation factor (P-
TEFb), CREB-binding protein (CBP) and Sirtuin 1 (SIRT1). The expressed antigens are processed 
within the cell and presented by major histocompatibility complex (MHC) antigens to 
developing thymocytes. Those thymocytes which express T cell receptors (TCR) with high 
affinity towards self-peptides are deleted or are selected for development as regulatory T cells. 
The image, from a paper by (Kisand and Peterson, 2015), was used with kind permission from 
Springer. 
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The role of AIRE in establishing central tolerance has been well-studied. Nevertheless, 
central tolerance alone does not remove entirely mature T cells which have the 
potential to react against self-antigens. Peripheral mechanisms are therefore required 
to ensure immune responses against tissues are negated. However, AIRE’s possible 
function in peripheral tolerance, which includes mechanisms such as the induction of 
functional energy in autoreactive T lymphocytes, the deletion of self-reactive T cells 
through apoptosis, and the suppressive action of Tregs, is not as well-defined (Metzger 
and Anderson, 2011). There is evidence that extra-thymic AIRE-expressing cells present 
in secondary lymphoid tissue (Poliani et al., 2010) have the capacity to present 
peripheral tissue antigens to autoreactive T cells ultimately causing their deletion 
(Figure 1.3) (Gardner et al., 2008). Interestingly, the self-antigens were different from 
those presented in the thymus (Eldershaw et al., 2011). In mice, Aire protein has been 
detected in the spleen and lymph nodes (Adamson et al., 2004).  
 AIRE gene mutations in APS1 1.2.3
In 1997, mutations in the AIRE gene were first identified as the cause of APS1 
(Nagamine et al., 1997). Since then, over 100 AIRE mutations have been found (Table 
1.1) (Heino et al., 2001, Michels and Eisenbarth, 2009, Kisand and Peterson, 2011). 
Examples include the common 967-979del13bp and R257X mutations (Table 1.1) 
which are present in more than 95% of APS1 patients (Nagamine et al., 1997). 
Particularly, R257X is present in 83% of patients of Finnish origin (Nagamine et al., 
1997). Among Sardinians (Rosatelli et al., 1998) and Iranian Jews (Zlotogora and 
Shapiro, 1992), the R139X and Y85C mutations (Table 1.1), respectively, are more 
common.  
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Figure ‎1.3: AIRE function in promoting central and peripheral tolerance 
(a) Tissue-specific antigens are expressed by medullary thymic epithelial cells (mTECs) and 
myeloid cells under the control of AIRE. T cells which recognise these tissue-specific antigens 
with high affinity are eliminated by apoptosis. AIRE-driven expression of tissue-specific 
antigens also supports the generation of naturally occurring regulatory T cells in the thymus. 
(b) Any self-reactive T cells that do not interact with their cognate antigen and escape to the 
periphery are eliminated following exposure to tissue-specific antigens displayed in the 
peripheral lymphoid tissue by extra-thymic AIRE-expressing cells (eTAC). In the periphery, the 
suppressive action of regulatory T cells can also help in the establishment of self-tolerance. 
AIRE expressed in the periphery may control the expression of different tissue-specific 
antigens to those under AIRE control in the thymus. The image, from a paper by (Eldershaw et 
al., 2011), was used with kind permission from John Wiley and Sons. 
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The mutations are distributed throughout the coding region of AIRE, and they are 
either nonsense or frame-shift mutations that result in deletion of part of the protein, 
or are missense mutations that result in a single amino acid change (Peterson and 
Peltonen, 2005). For example, Y85C is a missense mutation located in the CARD 
domain (Figure 1.1) which disrupts AIRE multimerisation or localisation to nuclear 
bodies (Ferguson et al., 2008). The G228W mutation (Table 1.1) is found within the 
SAND domain (Figure 1.1) and impedes AIRE localisation to nuclear bodies and 
severely affects the transcriptional activity of the AIRE protein (Ilmarinen et al., 2005). 
Several mutations such as the 967-979del13bp deletion (Table 1.1) occur in the PHD 
domains (Figure 1.1), and so reduce AIRE’s transcriptional functionality (Chignola et al., 
2009). 
The majority of AIRE mutations such as the R257X and 967-979del13bp are 
homozygous recessive, although they can occur as compound heterozygotes resulting 
in APS1 (Cervato et al., 2009). The G228W variant has been reported as a dominant 
mutation (Ilmarinen et al., 2005). In a recent study, the C311Y mutation (Table 1.1) 
was identified in AIRE’s PHD1 domain (Figure 1.1) and was shown to be heterozygous 
dominant (Oftedal et al., 2015). The APS1 phenotypes of these patients were typically 
characterised by a later onset of autoimmune disorders and milder disease 
manifestations (Oftedal et al., 2015). Chronic Candida infection appears to be most 
prevalent in patients with the nonsense genotypes R257X or R139X, with 100% of 
individuals affected (Kisand et al., 2011, Kisand et al., 2010). This disease component 
occurs with less prevalence in APS1 patients with the 967-979del13bp mutation, and in 
those with AIRE missense genotypes such as Y85C (Kisand et al., 2011, Kisand et al., 
2010, Zlotogora and Shapiro, 1992). Otherwise, there are no significant correlations 
with particular AIRE mutations and many of the clinical phenotypes (Section1.3.3) of 
APS1 patients (Halonen et al., 2002). 
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Table ‎1.1: Examples of AIRE mutations identified in APS1 patients 
 
Mutation Exon 
Effect on coding 
sequence 
Population References 
30-52dup23bp E1 R15fsX19 Hungarian, Austrian 
(Cihakova et al., 
2001) 
47C>T E1 T16M Russian 
(Cihakova et al., 
2001) 
191-226del36bp E2 del64-75 and D76Y 
American, 
Caucasian 
(Nagamine et al., 
1997) 
254A>G E2 Y85C Iranian Jewish 
(Zlotogora and 
Shapiro, 1992) 
415C>T E3 R139X Sardinian (Rosatelli et al., 1998) 
508^509ins13bp E4 A170fsX219 German 
(Nagamine et al., 
1997) 
607C>T E5 R203X Italian (Scott et al., 1998) 
769C>T E6 R257X Italian, Finnish 
(Nagamine et al., 
1997) 
809G>T E6 G228W Italian (Cetani et al., 2001) 
969^970insCCTG E8 L323fsX372 Italian 
(Rosatelli et al., 1998, 
Bjorses et al., 2000) 
967-979del13bp E8 C322fsX372 
Finnish, British, 
Dutch, German, 
Canadian, Swedish 
(Nagamine et al., 
1997, Rosatelli et al., 
1998) 
923G>A E8 C311Y Finnish 
(Bjorses et al., 2000, 
Oftedal et al., 2015) 
1072C>T E9 Q358X Italian (Meloni et al., 2002) 
Ains1283–1284 E10 P422fsX Finnish (Bjorses et al., 2000) 
C1309del E10 P436fsX478 French (Bjorses et al., 2000) 
1296delGinsAC E11 R433fsX502 
American 
Caucasian 
(Heino et al., 1999) 
1344delCinsTT E11 C449fsX502 Japanese (Heino et al., 2001) 
1638A>T E14 X564C+59aa Finnish (Bjorses et al., 2000) 
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 Models of pathogenesis in APS1 1.2.4
Given AIRE’s role in promoting central tolerance (Section 1.2.2), there has been much 
research into the exact mechanism by which AIRE mutations result in APS1. The 
simplest model of APS1 pathogenesis, which has been suggested from the study of 
AIRE knock-out mice (Anderson et al., 2002, Ramsey et al., 2002, Jiang et al., 2005, Niki 
et al., 2006), is one of deficient negative selection in the thymus due to the inability of 
mutant AIRE transcription factor to promote tissue-specific antigen expression (Figure 
1.4a) (Kisand and Peterson, 2011). Consequently, naive autoreactive T cells are 
allowed to escape to the periphery where T helper cells become activated on antigen 
recognition producing pro-inflammatory cytokines and promoting the activation of 
autoreactive B lymphocytes (Devoss et al., 2008). These actions result in organ 
destruction, autoantibody production and, ultimately, the autoimmune diseases which 
are seen in APS1 (Sections 1.3.3). 
Although it is highly likely that the first model has a part to play in APS1 development, 
in humans, this model does not explain the existence of autoantibodies against type I 
interferons and T helper 17 cell-related cytokines (Section 1.2.6) (Meager et al., 2006) 
which can predate the onset of any clinical symptoms and the appearance of tissue-
specific autoantibodies. AIRE does not regulate the expression of these cytokines in 
the thymus, so it is difficult to see how the loss of antigen expression alone can 
account for this particular immune response. There are also findings that naïve CD8+ T 
lymphocytes are pre-activated in the thymus of APS1 patients (Laakso et al., 2011). 
These observations have led to the suggestion that in the AIRE-deficient thymus of 
APS1 patients, in addition to defective negative selection, the development of tertiary 
lymphoid tissue occurs, where pre-activated autoreactive T cells, and B cells that 
produce cytokine-targeting autoantibodies, are generated and exported (Figure 1.4b) 
(Kisand and Peterson, 2011). However, the mechanisms that are involved in such a 
process have yet to be defined. 
Whatever the exact mechanism of dysregulation in the thymus in APS1, the 
autoimmune diseases found in the syndrome are thought to result from T cell-
mediated damage of the specific organs. This has been supported by the examination 
of available tissue samples from various endocrine glands which show lymphocytic 
infiltration (Betterle and Zanchetta, 2003). In a study of an ASP1 patient with alopecia, 
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in addition to other diseases, a biopsy of the affected scalp showed a significant 
infiltration of T cells in the hair follicles (Figure 1.5) (Faiyaz-Ul-Haque et al., 2009). 
A number of studies have examined different T cell subsets within APS1 patients. 
There are alterations in the CD4+ T lymphocyte population of APS1 patients with an 
increased frequency of activated cells being reported in one study (Perniola et al., 
2005). However, this observation does conflict with other reports which indicate 
normal CD4+ T cell numbers (Wolff et al., 2010). Notably, the analysis of T helper 17 
cell subsets has shown a diminution of them, and thus a concomitant reduction in the 
expression of the protective cytokines interleukin (IL)-22 and IL-17 (Wolff et al., 2010, 
Laakso et al., 2014). Likewise, there is an increased frequency of highly differentiated 
CD8+ T lymphocytes in APS1 patients which express the cytolytic mediator perforin 
(Laakso et al., 2011). To date, however, the targets of cytotoxic T cells in APS1 patients 
have not been studied extensively, but there are some examples such as aromatic L-
amino acid decarboxylase (Kluger et al., 2015). This autoantigen was recognised by 
cytotoxic T cells in 43% of APS1 patients with gastrointestinal dysfunction (Kluger et al., 
2015). 
Concomitant to thymic defects in the control of autoreactive effector T cells, the 
defective development of Tregs in the AIRE-deficient thymus may also lead to 
inadequate suppression of autoreactive T lymphocytes in the periphery (Laakso et al., 
2010, Malchow et al., 2013). Indeed, defects in Tregs have been reported in several 
studies. A reduction in the number of CD4+ CD25+ T cells was found in APS1 patients 
when compared with healthy controls (Ryan et al., 2005, Wolff et al., 2010). In 
addition, the frequency of FOXP3+ Tregs was reported to be decreased in patients with 
APS1, and the cells themselves expressed lower levels of FOXP3, the key Tregs key 
regulator, when compared with Tregs from individuals without disease (Kekalainen et 
al., 2007, Miyara et al., 2009, Laakso et al., 2010). The suppressive function of Tregs 
from APS1 patients against effector T lymphocytes is also impaired (Kekalainen et al., 
2007). However, as yet, it has not been clarified as to whether Tregs defects in APS1 
patients are due to defective selection events in the thymus or to altered homeostasis 
of Tregs in the periphery (Metzger and Anderson, 2011). 
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Figure ‎1.4: Current and alternative model of AIRE deficiency 
(a) The current model of deficient negative selection. (1) In medullary thymic epithelial cells, 
AIRE deficiency leads to down-regulation of the expression of tissue-specific autoantigens 
(dark oval) that are not presented to thymocytes. (2) Self-reactive thymocytes (grey circles) are 
not negatively selected. (3) They are exported to the periphery together with non-self-reactive 
thymocytes (white circles). (4) Naive autoreactive T cells become activated on antigen 
recognition causing tissue destruction, the production of pro-inflammatory cytokines, and the 
activation of autoreactive B lymphocytes. (b) The alternative model of an aberrant 
microenvironment in the thymus. (1) Tertiary lymphoid tissue is formed where cytokines 
(rectangles) are presented in an immunogenic manner to T and B cells. (2) Neutralising anti-
cytokine autoantibodies are released directly from the thymus. (3) CD8+ thymocytes are 
exported to the periphery and are activated after tissue-specific antigen (dark oval) is released 
and presented by dendritic cells. (4) Immune attack toward tissues. The image, taken from a 
paper by (Kisand and Peterson, 2011), is used with kind permission from John Wiley and Sons.  
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Figure ‎1.5: Immunohistochemistry staining of the hair follicles from an APS1 patient. 
The image shows T cell infiltration of the hair follicle. The image, taken from a paper by 
(Faiyaz-Ul-Haque et al., 2009), is used with kind permission from John Wiley and Sons. 
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 Organ-specific autoantibodies in APS1 1.2.5
Organ-specific autoantibodies (Table 1.2) are a hallmark of APS1 (Peterson and 
Peltonen, 2005). Many tissue-specific autoantibody targets are intracellular enzymes 
involved in the synthesis of hormones or neurotransmitter biosynthesis (Gylling et al., 
2000). It has been suggested, therefore, that the humoral immune response against 
such autoantigens results from the release of the proteins upon organ destruction 
mostly likely as a result of autoreactive T cell activity (Kisand and Peterson, 2015). 
Another theory proposed to explain the presence of autoantibodies in APS1 also 
comes from the Aire-deficient mouse model (Lindh et al., 2008). Here, the production 
of autoantibodies by B cells in the spleen was reported to be independent of activation 
by T cells and linked to the overproduction of B cell-activating factor (BAFF) by DCs 
(Figure 1.6) (Lindh et al., 2008). Although this mechanism has not been analysed in 
relation to APS1, patients have do have elevated levels of BAFF (Lindh et al., 2008).  
Many of the autoantibodies found in APS1 patients are considered unlikely to have a 
pathogenic role in vivo (Kisand and Peterson, 2015). However, autoantibodies against 
some autoantigens such as the calcium-sensing receptor (CaSR) have been shown to 
have stimulatory activity (Kemp et al., 2009), which might prevent parathyroid 
hormone (PTH) secretion leading to clinical hypoparathyroidism (Section 1.3.3.2). In 
addition, anti-parietal cell autoantibodies have cytolytic activity and contribute to the 
destruction of gastric parietal cells in APS1 (Perniola et al., 2000). Autoantibodies 
against secreted intrinsic factor can render it unable to bind vitamin B12 resulting in 
autoimmune gastritis (Section 1.3.3.8) (Proust-Lemoine et al., 2010, Betterle et al., 
1998). 
Associations exist between the presence of certain autoantibodies and the occurrence 
of a particular APS1 clinical manifestation. For example, humoral immune responses 
against steroid 21-hydroxylase, tyrosine phosphatase-like protein IA-2, and 
cytochrome P450 1A2 are diagnostic for Addison’s disease, type 1 diabetes mellitus, 
and hepatitis, respectively (Table 1.2) (Soderbergh et al., 2004). However, many organ-
specific autoantibodies can occur in patients regardless of their disease manifestations, 
so are not useful in making an exact diagnosis (Table 1.2) (Soderbergh et al., 2004).  
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Table ‎1.2: Examples of autoantibody targets in APS1 
Autoantibody target 
Prevelance of 
autoantibodies in 
APS1 (%) 
Reported association 
with APS1 disease 
component 
Reference 
NACHT leucine-rich- 
repeat protein 5 
32-49 Hypoparathyroidism 
(Alimohammadi et al., 
2008, Meloni et al., 2012) 
Calcium-sensing 
receptor 
12-86 
Association with 
hypoparathyroidism 
contraversial 
(Gylling et al., 2003, 
Gavalas et al., 2007) 
Steroid 21-hydroxylase
1
 55-69 Addison’s disease 
(Wolff et al., 2007, 
Meloni et al., 2012) 
Steroid 17α-hydroxylase 24-58 
Addison’s disease; 
premature ovarian failure 
(Soderbergh et al., 2004, 
Meloni et al., 2012) 
Side-chain cleavage 
enzyme 
36-68 Premature ovarian failure 
(Soderbergh et al., 2004, 
Wolff et al., 2007) 
Thyroglobulin 15-21 Hypothyroidism 
(Proust-Lemoine et al., 
2010, Meloni et al., 2012) 
Thyroid peroxidase 15-21 Hypothyroidism 
(Proust-Lemoine et al., 
2010, Meloni et al., 2012) 
Tyrosine phosphatase-
like protein IA-2
1
 
7 Type 1 diabetes mellitus 
(Soderbergh et al., 2004, 
Proust-Lemoine et al., 
2010) 
Tudor domain-
containing protein 6 
49 
Not associated with 
hypopituitarism 
(Bensing et al., 2007) 
49-kDa pituitary enolase 68 
Not associated with 
hypopituitarism 
(O'Dwyer et al., 2007) 
Intrinsic factor
1
 15-30 Chronic atrophic gastritis 
(Betterle et al., 1998, 
Proust-Lemoine et al., 
2010) 
Gastric parietal cell 
proton pump 
24 Chronic atrophic gastritis (Perniola et al., 2000) 
Glutamic acid 
decarboxylase 65 
27-42 
Gastro-intestinal 
dysfunction 
(Wolff et al., 2007, 
Proust-Lemoine et al., 
2010, Meloni et al., 2012) 
Tryptophan hydroxylase 28-61 Intestinal dysfunction 
(Ekwall et al., 1998, Dal 
Pra et al., 2004) 
Histidine decarboxylase 37 Intestinal dysfunction (Skoldberg et al., 2003) 
Alpha 5 defensin of 
Paneth cells 
27 Intestinal dysfunction (Dobes et al., 2015) 
Cytochrome P450 1A2
1
 6-8 Hepatitis 
(Clemente et al., 1997, 
Gebre-Medhin et al., 
1997, Obermayer-Straub 
et al., 2001) 
Cytochrome P450 2A6 6-8 Hepatitis 
(Clemente et al., 1998, 
Obermayer-Straub et al., 
2001) 
Tyrosine hydroxylase 44-50 
Alopecia areata; dental 
enamel dysplasia 
(Hedstrand et al., 2000, 
Soderbergh et al., 2004, 
Bratland et al., 2013) 
SOX9 transcription 
factor 
15 Vitiligo (Hedstrand et al., 2001) 
SOX10 transcription 
factor 
22 Vitiligo (Hedstrand et al., 2001) 
Aromatic L-amino acid 
decarboxylase 
39-68 Vitiligo; hepatitis 
(Husebye et al., 1997, 
Soderbergh et al., 2004) 
1
Autoantibodies with good predictive value for a specific disease manifestation in APS1. 
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Figure ‎1.6: Schematic picture of the possible role for AIRE in interferon-γ receptor 
signaling. 
In the absence of AIRE, the transcriptional co-activator protein inhibitor of activated STAT1 
(PIAS1) cannot mediate inhibition of STAT1 signaling upon interferon (IFN)-γ receptor 
stimulation, resulting in excessive B cell-activating factor (BAFF) production by dendritic cells 
(DC). Subsequently, the increased levels of BAFF result in overly activated B cells (MZB) that 
produce autoantibodies (IgG) against a specific antigen (Ag). Thus, BAFF contributes to the 
phenotype seen in Aire-deficient mice and possibly in APS1 patients. From a paper by (Lindh et 
al., 2008), this figure did not require permission for use in this thesis.  
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 Anti-cytokine autoantibodies in APS1  1.2.6
Anti-cytokine autoantibodies are highly prevalent in APS1 patients (Table 1.3). 
Interferon (IFN)-ω autoantibodies have been reported in 100% of APS1 cases. 
Autoantibodies against IFN-α and IFN-β have been detected at a lower prevalence of 
95% and 22%, respectively (Meager et al., 2006). Autoantibodies against IFN-ω and 
IFN-α present as early as the first year of age and, in some APS1 cases, can be detected 
prior to the onset of clinical manifestation or the appearance of organ-specific 
autoantibodies (Toth et al., 2010, Wolff et al., 2013). Due to their prevalence and high 
titres, IFN-ω and IFN-α autoantibodies are considered appropriate serum markers for 
APS1 (Husebye et al., 2009). In terms of activity, autoantibodies against type I 
interferons (IFN-ω and IFN-α) are able to neutralise the effects of their target cytokine 
(Meager et al., 2006), and have also been shown to reduce the expression of genes 
that are normally stimulated by interferons (Kisand et al., 2008). 
In more recent studies, autoantibodies that specifically neutralise the activity of either 
interleukin (IL)-22, IL-17F or IL-17A have been identified in APS1 patients (Table 1.3) 
(Kisand et al., 2010, Puel et al., 2010). High titre autoantibodies against IL-22 can be 
detected very early, within months after birth (Wolff et al., 2013), and are the most 
prevalent humoral immune response against T helper 17 cell-related cytokines (Kisand 
et al., 2010, Puel et al., 2010). Usually, autoantibodies against IL-17 cytokines appear 
later and are less prevalent (Kisand et al., 2010, Puel et al., 2010). The correlations of 
IL-22, IL-17F and IL-17A autoantibodies with the development of candidiasis in APS1 
are detailed in Section 1.3.3.1. 
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Table ‎1.3: Prevalence of autoantibodies against cytokines in APS1 patients 
 
Cytokine target1 
Prevalence of 
autoantibodies in APS1 (%) 
Reference 
IFN-ω 100 (Meager et al., 2006) 
IFN-α 95 (Meager et al., 2006) 
IFN-β 22 (Meager et al., 2006) 
IFN-λ 14 (Meager et al., 2006) 
IL-22 91 
(Kisand et al., 2010, Puel et al., 
2010) 
IL-17F 75 
(Kisand et al., 2010, Puel et al., 
2010) 
IL-17A 41 
(Kisand et al., 2010, Puel et al., 
2010) 
 
1
IFN, interferon; IL, interleukin. 
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 Autoimmune polyendocrine syndrome type 1: diagnosis, epidemiology and 1.3
clinical features 
 Diagnosis 1.3.1
Although, the clinical diagnosis of APS1 is normally based upon at least two of the 
characteristic triad of major disease components of chronic mucocutaneous 
candidiasis (Candida infection), hypoparathyroidism (low serum PTH and calcium 
levels), and Addison’s disease (adrenal insufficiency) (Perheentupa, 2006), when a 
sibling is affected, the presence of only one of these manifestations is enough to justify 
diagnosis (Husebye et al., 2009). In cases with an atypical presentation, the 
confirmation of AIRE gene mutations will aid in clinical diagnosis (Husebye et al., 2009). 
Finally, autoantibodies against IFN-ω and IFN-α are detectable in the majority of 
patients (Meager et al., 2006), so they are now included in the diagnostic criteria of 
APS1 (Husebye et al., 2009). 
 Epidemiology 1.3.2
Autoimmune polyendocrine syndrome type 1 is found worldwide with small numbers 
of patients (1:10,000,000) reported in Japan (Sato et al., 2002), India (Zaidi et al., 
2009), and the USA (Wang et al., 1998). However, by far, the greatest concentration of 
APS1 cases is found in Europe where the disease affects approximately 1:100,000 
individuals in the Irish, Norwegian and Polish populations (Dominguez et al., 2006, 
Stolarski et al., 2006), and 1:500,000 French (Proust-Lemoine et al., 2012). In some 
European ethnicities APS1 is even more prevalent. For example, 1:25,000 in Finnish 
(Perheentupa, 2006), 1:14,000 in Sardinians (Rosatelli et al., 1998), and 1:35,000 in 
Apulians (Meloni et al., 2002). A high number of Iranian Jews in Israel also suffer from 
APS1 with a prevalence of 1:9,000 (Zlotogora and Shapiro, 1992). Depending on the 
population, some reports suggest a different in the prevalence of APS1 between men 
and women, with a female:male ratio ranging from 0.81:1 to 2.4:1 (Kahaly, 2009).  
 Clinical manifestations  1.3.3
Mostly, APS1 becomes apparent during childhood or in adolescence (Husebye et al., 
2009), although, rarely, the disease has been reported to initially manifest in young 
adults between the ages of 18 and 25 years (Magitta et al., 2008). The classic disease 
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triad is usually in evidence by the third decade of life, but there are cases where not all 
three diseases develop (Husebye et al., 2009). Albeit with less frequency, several other 
disease manifestations can be present including hypothyroidism, type 1 diabetes 
mellitus, hepatitis, alopecia and vitiligo (Perheentupa, 2006). Notably, the number of 
diseases afflicting patients can vary considerably ranging from one to 10 (Perheentupa, 
2006). The various clinical manifestations of APS1 are detailed in the next sections and 
are summarised for different populations in Table 1.4. 
 Chronic mucocutaneous candidiasis  1.3.3.1
Chronic mucocutaneous candidiasis (Figure 1.7a) is most usually the first clinical sign to 
appear in those affected by APS1, although in some cases, it can appear after the main 
endocrinopathies of hypoparathyroidism and Addison’s disease (Ahonen et al., 1990). 
The prevalence of chronic mucocutaneous candidiasis in APS1 varies between 70-100% 
depending on patient ethnicity (Table 1.4) (Myhre et al., 2001), although exceptionally, 
this falls to 18% in Iranian APS1 patients (Zlotogora and Shapiro, 1992). Typically, 
chronic mucocutaneous candidiasis manifests in APS1 patients within the first decade 
of life (Husebye et al., 2009), and the development of chronic mucocutaneous 
candidiasis is rarer once APS1 patients have reached adulthood (Ahonen et al., 1990, 
Meloni et al., 2012). For example, chronic mucocutaneous candidiasis is present in 26% 
of Finnish APS1 patients within the first year after birth, and in over 50% by the age of 
five years (Ahonen et al., 1990). A report on Sardinians indicated appearance of 
chronic mucocutaneous candidiasis at a median age of three years in 86% of patients 
(Meloni et al., 2012).  
The severity of Candida infection can vary between patients. Generally, infection starts 
with oral thrush with symptoms such as ulceration, redness and soreness at the 
corners of the mouth (Husebye et al., 2009). However, it can be life-threatening, as the 
initial mouth infection can become chronic and may progress to oral mucous 
squamous cell carcinoma (Husebye et al., 2009, Kluger et al., 2012). Candida 
oesophagitis has also been reported in APS1 patients resulting in pain while 
swallowing, retrosternal pain, and dysphagia (Collins et al., 2006, Perheentupa, 2006). 
This can progress to local stricture and, exceptionally, to oesophageal cancer (Rosa et 
al., 2008, Koch et al., 2009). Moreover, chronic mucocutaneous candidiasis affecting 
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the intestinal tract can lead to chronic diarrhoea (Kluger et al., 2013), and infection of 
the fingernails to chronic paronychia (Collins et al., 2006). It is noteworthy that chronic 
mucocutaneous candidiasis can be present in the oesophagus and the intestine 
without any signs of oral candidiasis (Husebye et al., 2009, Kluger et al., 2012). 
The basis for the extensive Candida infection in APS1 is thought to be impaired 
responses by T helper 17 cells. These cells normally produce the protective cytokines 
IL-17A, IL-17F, and IL-22 (Kisand et al., 2011, Lindh et al., 2013), which induce the 
synthesis of anti-microbial peptides (Liang et al., 2006). However, the T helper 17 
lymphocytes of APS1 patients are unable to produce IL-17F and IL-22 (Laakso et al., 
2014). In addition, high levels of autoantibodies against the IL-17 family of cytokines 
are detected in patients with APS1 (Section 1.2.6; Table 1.3), and these are thought to 
predispose individuals to candidiasis by virtue of their neutralising activities (Kisand et 
al., 2010). Correlating with this, APS1 patients with no or mild candidiasis have low or 
undetectable levels of autoantibodies against IL-17A, IL-17F, and IL-22 (Kisand et al., 
2010, Sarkadi et al., 2014).  
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Table ‎1.4: Clinical manifestations in APS1 patients 
 
Clinical manifestation Prevalence (%) Studies included1 
Chronic mucocutaneous candidiasis 70-100 1-20 
Hypoparathyroidism 50-100 1-20 
Addison's disease 22-100 1-20 
Hypothyroidism 0-50 1-20 
Type 1 diabetes mellitus 0-18 1, 3, 4, 6-9, 11-13, 15-22 
Gonadal insufficiency - male 0-40 2-4, 16, 20 
Gonadal insufficiency - female 7-71 2-4, 7, 16-20 
Hypopituitarism 0-7 3, 7, 12, 13,16, 18, 19 
Chronic atrophic gastritis 0-33 1-4, 6-12, 15-17, 19, 20 
Intestinal dysfunction malabsorption 5-27 1-3, 5,6, 8-11, 13, 16-20 
Hepatitis 18 1-3, 5-11, 15-20 
Alopecia areata 13-50 1-5, 6-20 
Vitiligo 0-33 1-3, 5, 7-13, 15-20 
Ocular abnormalities - keratitis 0-37 2-4, 7-9, 11-13, 15-19 
Nail dystrophy 0-50 2, 3, 12 
Dental enamel dysplasia 25-77 2, 7, 9-12, 14, 16, 18 
Lung disease 6-7 23, 24 
Kidney impairment 2-9 3, 17, 18, 20 
Asplenia 2-9 3, 7, 17 
 
1
[1] North American (Neufeld et al., 1981); [2] Finnish (Ahonen et al., 1990); [3] Finnish, (Perheentupa, 
2006); [4] Iranian (Zlotogora and Shapiro, 1992); [5] North American (Wang et al., 1998); [6] Italian, 
(Perniola et al., 2000); [7] Sardinian (Meloni et al., 2012); [8] Italian (Betterle et al., 2002); [9] Norwegian 
(Myhre et al., 2001); [10] Slovenian (Podkrajsek et al., 2005); [11] Slovenian (Podkrajsek et al., 2008); 
[12] Irish, (Collins et al., 2006); [13] Polish, (Stolarski et al., 2006); [14] Slovakian(Magitta et al., 2008); 
[15] Italian (Mazza et al., 2011); [16] French, (Proust-Lemoine et al., 2010); [17] Russian (Orlova et al., 
2010); [18] Norwegian (Wolff et al., 2007); [19] Italian, (Betterle et al., 1998); [20] Italian (Cervato et al., 
2009); [21] Finnish (Tuomi et al., 1996); [22] Finnish (Gylling et al., 2000); [23] European (Alimohammadi 
et al., 2009); [24] Swedish (Shum et al., 2013). 
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(e)
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Figure ‎1.7: Clinical manifestations of APS1. 
The following clinical manifestations of APS1 are shown (a) chronic mucocutaneous candidiasis 
(b) alopecia areata, (c) vitiligo, (d) keratitis, (e) nail dystrophy, and (f) dental enamel dysplasia. 
Images (a), taken from a paper by (Collins et al., 2006), (b), taken from a paper by (Faiyaz-Ul-
Haque et al., 2009), and (d), taken from a paper by (Merenmies and Tarkkanen, 2000), are 
used with kind permission from John Wiley and Sons. Images (c), (e) and (f), taken from a 
paper by (Walter, 2000), are used with kind permission from the American Medical 
Association. 
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 Hypoparathyroidism 1.3.3.2
Hypoparathyroidism is the most common endocrine abnormality associated with APS1 
affecting 50-100% of patients, depending on the population (Table 1.4) (Perheentupa, 
2006). In most cases, it is the first endocrine disease to appear and manifests between 
the ages of four and five years (Perheentupa, 2006). By the age of 30 years, up to 85% 
of APS1 patients are affected by parathyroid dysfunction (Husebye et al., 2009), 
although it can be diagnosed in later adulthood (Gylling et al., 2003, Zlotogora and 
Shapiro, 1992). Of interest, the presence of hypoparathyroidism shows a distinct 
gender difference affecting 98% of females compared with 71% of males 
(Perheentupa, 2006). 
Patients with this particular endocrinopathy present with normal or low levels of PTH, 
hypocalcaemia and high serum phosphate concentrations (Husebye et al., 2009). 
Symptoms are related to hypoparathyroidism include clumsiness, seizures, diarrhoea, 
muscle cramps, and paraesthesia (Husebye et al., 2009). The manifestation is thought 
to be caused by aberrant autoimmune responses against the parathyroid glands 
(Brandi et al., 1986). Autoantibodies against proteins highly expressed in the 
parathyroid (Table 1.2), including the NACHT leucine-rich-repeat protein 5 (NALP5) and 
the CaSR have been reported in APS1 patients (Table 1.2) (Gavalas et al., 2007). As it is 
relevant to this thesis, parathyroid autoimmunity including autoantibodies against the 
glands will be discussed in more detail in Section 1.4. 
 Addison’s disease 1.3.3.3
Addison’s disease is the second most common endocrine manifestation of APS1 with a 
prevalence of between 22% and 100% (Table 1.4) (Neufeld et al., 1981, Perniola et al., 
2000, Meloni et al., 2012). It usually appears subsequent to chronic mucocutaneous 
candidiasis and hypoparathyroidism (Perheentupa, 2006). The age of onset of 
Addison’s disease in APS1 patients varies widely. In the Finnish population, the disease 
begins after three years of age (Perheentupa, 2006). By the end of first decade, 40% of 
patients present with adrenal insufficiency (Perheentupa, 2006). This rises to just 
under three-quarters of patients by the second decade, and to almost all cases by the 
fourth decade (Perheentupa, 2006). A median age of 10 years was reported in the 
same study (Perheentupa, 2006). 
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Due to low levels of cortisol and aldosterone, patients suffer from low blood pressure, 
weight loss, general fatigue, and significant pigmentation of the skin (Husebye et al., 
2009). In terms of pathogenicity, Addison’s disease in APS1 is suggested to result from 
destructive autoimmune reactivity against the adrenal glands (Bratland et al., 2009, 
Rottembourg et al., 2010, Dawoodji et al., 2014). There is a close association in APS1 
patients between Addison’s disease and autoantibodies against several targets related 
to the adrenal glands, including steroid 17α-hydroxylase, steroid 21-hydroxylase, and 
side-chain cleavage enzyme (Table 1.2) (Soderbergh et al., 2004, Wolff et al., 2010). 
Autoantibodies can be detected years before the symptoms of Addision’s disease 
presents, so they are an early marker of adrenal insufficiency in APS1 (Soderbergh et 
al., 2004, Wolff et al., 2010). This enables Addison’s disease to be diagnosed and 
monitored to avoid a life-threatening adrenal crisis.  
 Hypothyroidism 1.3.3.4
Unlike the common endocrine diseases which appear in APS1 patients, thyroid 
autoimmunity affects a minority ranging from 0-50% (Table 1.4) (Wolff et al., 2007). 
Graves’ disease or hyperthyroidism is not usually a feature of APS1, and very few cases 
have been reported (Pelletier-Morel et al., 2008). Hypothyroidism usually manifests 
following puberty and, in one-third of patients, an underactive thyroid is detectable by 
middle-age (Perheentupa, 2006). The age range of presenting with hypothyroidism is 
4.7–45 years, with a median age of 26.5 years (Perheentupa, 2006). The symptoms of 
hypothyroidism in APS1 are similar to those of isolated autoimmune hypothyroidism 
including enlargement of the thyroid glands, thyroid failure, high levels of thyroid-
stimulating hormone and low levels of free thyroxine (Perniola et al., 2008, Weetman, 
2004). The thyroid gland is targeted and damaged by infiltrating T lymphocytes 
(Weetman, 2004), resulting in high titres of thyroid peroxidase and thyroglobulin 
autoantibodies which serve as markers for this disease component (Table 1.2) 
(Perniola et al., 2000, Perniola et al., 2008).  
 Type 1 diabetes mellitus  1.3.3.5
The prevalence type 1 diabetes mellitus in APS1 varies between populations ranging 
from 0-18% (Table 1.4) (Tuomi et al., 1996). Typically, the age of onset lies between 30 
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and 50 years (Husebye et al., 2009, Perheentupa, 2006). The disease is caused by 
autoimmune destruction of pancreatic islet cells which results in a lack of insulin 
production and high blood glucose levels, both hallmarks of type 1 diabetes mellitus 
not associated with APS1 (Nokoff et al., 2012). In APS1, type 1 diabetes mellitus is 
associated with autoantibodies that target tyrosine phosphatase-like protein IA-2 
(Table 1.2) (Soderbergh et al., 2004, Van den Driessche et al., 2009, Boitard, 2012).  
 Gonadal insufficiency  1.3.3.6
Hypogonadism caused causes premature ovarian insufficiency in women and testicular 
insufficiency in men. Premature ovarian failure is one of the more common 
endocrinopathies (Table 1.4) (Ahonen et al., 1990, Zlotogora and Shapiro, 1992, 
Meloni et al., 2012), with approximately two-thirds of female APS1 patients eventually 
developing this feature by the third decade of life (Perheentupa, 2006). High levels of 
follicle-stimulating hormone and luteinising hormone, in addition to a reduction in 
oestrogen levels, are characteristic, and the result is arrested or interrupted pubertal 
development or premature menopause (Husebye et al., 2009). Patients may also suffer 
from amenorrhea, infertility, and psychological stress (Dragojević-Dikić et al., 2010). 
Testicular insufficiency is rare in male APS1 patients, occurring in 0-40% of cases (Table 
1.4) (Ahonen et al., 1990, Zlotogora and Shapiro, 1992, Cervato et al., 2009). Generally, 
the condition develops in adulthood (Perheentupa, 2006). Again, high follicle-
stimulating hormone and luteinising hormone levels are definitive, along with low 
testosterone (Husebye et al., 2009). 
Most of the patients with gonadal insufficiency also have Addison’s disease and, 
therefore, they present with autoantibodies against several steroid-producing organs 
including the adrenal cortex, testes, placenta and ovary (Dragojević-Dikić et al., 2010, 
Husebye et al., 2009). The presence of anti-side-chain cleavage enzyme autoantibodies 
correlates significantly with premature ovarian failure (Table 1.2) (Soderbergh et al., 
2004).  
 Hypopituitarism 1.3.3.7
Hypopituitarism has been reported only in a minority of APS1 patients ranging from 0-
7% of cases (Table 1.4) (Betterle et al., 1998, Stolarski et al., 2006, Meloni et al., 2012). 
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This clinical feature usually has an early onset (Perheentupa, 2006). Affected 
individuals display growth hormone, gonadotropin or adrenocorticotropic hormone 
deficiency (Husebye et al., 2009, Perheentupa, 2006). Autoimmune responses against 
the pituitary are thought to be responsible for this particular disease manifestation. 
However, although autoantibodies against the pituitary (Table 1.2), such as against 
tudor domain-containing protein 6 (Bensing et al., 2007) and pituitary enolase 
(O'Dwyer et al., 2007), have been shown in APS1 patients with pituitary failure, there is 
as yet no clear marker to predict hypopituitarism. 
 Chronic atrophic gastritis  1.3.3.8
By middle-age, up to 33% of APS1 patients are affected by chronic atrophic gastritis 
(Table 1.2) (Perheentupa, 2006), which is also referred to as pernicious anaemia. The 
condition normally presents in early adulthood (Betterle et al., 1998), although some 
cases have been reported in children with APS1 (Oliva-Hemker et al., 2006). Symptoms 
may include atrophic glossitis, diarrhoea, anaemia, leukopenia, thrombopenia, and 
pancytopenia peripheral neuropathy which are due to a chronic deficiency in vitamin 
B12 resulting from gastric atrophy (Husebye et al., 2009). Histopathology of gastric 
tissue has revealed an infiltration of T lymphocytes which eventually leads to gastric 
gland destruction (Skoldberg et al., 2003). Autoantibodies against the gastric parietal 
cell protein pump have also been implicated in the destruction of gastric parietal cells 
(Perniola et al., 2000). As a consequence, the level of intrinsic factor is diminished and 
because this is required for the uptake of vitamin B12, there is a concomitant 
development of pernicious anaemia. In addition, patients have autoantibodies against 
vitamin B12 binding protein (Table 1.2) which prevent the normal uptake of vitamin 
B12 (Toh et al., 1997).  
 Intestinal dysfunction 1.3.3.9
Intestinal dysfunction can manifest with different several symptoms (Kluger et al., 
2013). Chronic diarrhoea occurs in 5% of APS1 cases (Perheentupa, 2006). Less 
frequently, constipation is found in 2% of patients (Perheentupa, 2006). Malabsorption 
is more prevalent, affecting 5-27% of APS1 patients depending on the series (Table 
1.4) (Betterle et al., 1998). In some cases of APS1, the symptoms may result from 
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Candida infection of the gut (Gianani and Eisenbarth, 2003, Kluger et al., 2013), and 
chronic diarrhoea has also been linked to the hypocalcaemia associated 
hypoparathyroidism (Kluger et al., 2013). With respect to autoimmunity, there doesn’t 
appear to be appreciable lymphocyte infiltration in intestinal biopsies (Kluger et al., 
2013), although gastrointestinal endocrine cells can be targeted by autoimmune 
responses (Gianani and Eisenbarth, 2003). The presence of autoantibodies against 
tryptophan hydroxylase (Ekwall et al., 1998), and Paneth cell-specific alpha 5 defensin 
(Dobes et al., 2015) has been associated with intestinal dysfunction in APS1 (Table 
1.2).  
 Hepatitis 1.3.3.10
Hepatitis develops in 5-36% of APS1 patients (Table 1.4) (Betterle et al., 1998, 
Perheentupa, 2006), and is usually present before the age of 20 years (Betterle et al., 
1998, Perheentupa, 2006). Clinical symptoms can range from asymptomatic to mild, 
but in severe cases the disease can be fatal as a result of liver necrosis (Obermayer-
Straub et al., 2001). APS1-associated hepatitis is considered to be caused by 
autoimmune reactivity and there has been much research to identify and characterise 
autoantibody targets which could act as markers for the disease (Table 1.2). These 
include cytochromes P450 1A2 and P450 2A6 (Obermayer-Straub et al., 2001), and 
aromatic L-amino acid decarboxylase (Soderbergh et al., 2004) Of these, anti-
cytochrome P450 1A2 autoantibody levels have been found to correlate with the 
presence and severity of hepatitis (Obermayer-Straub et al., 2001).  
 Alopecia areata 1.3.3.11
In APS1, the hair loss disease alopecia areata (Figure 1.7b) is present in 13-50% of 
patients (Table 1.4) (Neufeld et al., 1981, Zlotogora and Shapiro, 1992, Betterle et al., 
2002), and is the most common ectodermal feature (Perheentupa, 2006). Normally, 
the onset occurs during adulthood and alopecia areata is not usually an initial clinical 
sign of APS1 (Perheentupa, 2006). There is evidence that autoimmune attack of the 
hair follicles is responsible for patchy or total hair loss. For example, histopathological 
examination of alopecia areata scalp lesions shows an intra-follicular and peri-follicular 
infiltration of T cells, Langerhans cells and macrophages (Perret et al., 1984, Todes-
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Taylor et al., 1984). In addition, autoantibodies against hair follicle components have 
been detected in APS1 patients with alopecia areata (Hedstrand et al., 2000). More 
specifically, anti-tyrosine hydroxylase autoantibodies have been found to correlate 
significantly with alopecia areata in APS1 (Table 1.2) (Hedstrand et al., 2000). However, 
further investigations are required to determine any significance of tyrosine 
hydroxylase autoantibodies in relation to the pathogenesis of alopecia areata. 
 Vitiligo 1.3.3.12
Vitiligo (Figure 1.7c), characterised by the loss of cutaneous melanocytes, can become 
extensive and affects from 0-33% of APS1 patients depending on the patient series 
(Table 1.4) (Perheentupa, 2006). The disorder can present not only in the first month 
after birth up to the second decade of life, but it can appear at later ages (Betterle et 
al., 1998, Perheentupa, 2006). As in isolated vitiligo, destruction of pigment-producing 
cells is mediated via cytotoxic T cells which target melanocyte-specific proteins such as 
tyrosinase (van den Boorn et al., 2009). In addition, several proteins have been 
identified as autoantibody targets in APS1 patient with vitiligo (Table 1.2), including 
the melanocyte-specific transcription factors SOX9 and SOX10 (Hedstrand et al., 2001). 
 Ocular abnormalities 1.3.3.13
Ocular abnormalities can affect the eyelashes, cornea, retina and optic nerve (Wolff et 
al., 2013). Symptoms normally appear as early as two years of age (Mezgueldi et al., 
2015), but the onset can also occur in adults (Perheentupa, 2006). The predominant 
eye manifestation is keratitis (Figure 1.7d) which occurs in APS1 with a large variation 
in prevalence ranging from 0-37% of patients (Table 1.4) (Proust-Lemoine et al., 2010). 
Keratitis in APS1 begins with indicators such as intense photophobia, a feeling of sand 
in the eyes, blepharospasm, and a reduction in lacrimation (Husebye et al., 2009). 
More serious effects can ensue including corneal scarring and perforation which can 
lead to sight loss (Yeh and Matoba, 2007). Although the aetiology of keratitis remains 
obscure, it has been suggested to arise from an autoimmune response against the 
corneal/conjunctival epithelium. Indeed, in APS1 patients, the progression of epithelial 
edema and superficial opacity can be reversed under topical steroid therapy 
(Tarkkanen and Merenmies, 2001). 
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 Nail dystrophy 1.3.3.14
Nail dystrophy (Figure 1.7e) is frequently evident in patients with up to 50% of 
individuals being affected (Table 1.4) (Ahonen et al., 1990, Perheentupa, 2006). The 
aetiology of nail dystrophy, however, remains controversial. In one study of Irish APS1 
patients, all nail changes were related to infection by Candida and did not display the 
characteristic nail pitting associated with nail dystrophy (Collins et al., 2006). In 
contrast, approximately 50% of the cases of distinctive nail dystrophy in a Finnish APS1 
patient series were not related to Candida or other fungal infections (Ahonen et al., 
1990, Perheentupa, 2006).  
 Dental enamel dysplasia 1.3.3.15
Approximately 25-77% of APS1 patients are affected by dental enamel dysplasia 
(Figure 1.7f) (Table 1.4) (Perheentupa, 2006). The presentation varies between 
patients, some cases present with mild symptoms like transverse grooves in the 
enamel, while others present with rows of pits of inconstant size alternating with 
zones of well-formed enamel (Perheentupa, 2006). In severe forms of disease, all 
permanent teeth have hypoplastic enamel (Perheentupa, 2006). The cause of enamel 
dysplasia in APS1 has yet to be established. A study of Norwegian APS1 patients found 
a significant correlation between dental disease and autoantibodies against tyrosine 
hydroxylase, these being present in 70% (7/10) of patients with enamel dysplasia and 
22% (4/18) of those without (Bratland et al., 2013). However, it was not explained how 
tyrosine hydroxylase autoantibodies could instigate disease pathogenesis (Bratland et 
al., 2013), although it has been suggested that immune responses which adversely 
affecting ameloblasts may play a part (Pavlic and Waltimo-Siren, 2009). 
 Lung disease 1.3.3.16
Involvement of the respiratory system in APS1 is quite rare with a prevalence of 6-7% 
(Table 1.4) (Alimohammadi et al., 2009). Symptoms can vary from airway hyper-
responsiveness, lower respiratory infections, and chronic cough. Progressive 
worsening of the symptoms over time can result in chronic respiratory failure which 
can be fatal (Alimohammadi et al., 2009). Autoantibodies against a potassium channel 
regulating protein, a protein expressed in the epithelial cells of terminal bronchioles, 
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have been identified in 88% (7/8) of cases with respiratory problems, but less than 1% 
(1/102) of those without lung involvement (Alimohammadi et al., 2009). In addition, 
the lung-specific protein bactericidal/permeability-increasing fold-containing B1 
(BPIFB1) was identified as an autoantibody target in 100% (6/6) of APS1 patients with 
respiratory problems, the majority of whom also had bronchiolar inflammation (Shum 
et al., 2013). However, anti-BPIFB1 autoantibodies were found in only 4% (4/98) of 
APS1 cases where no lung disease was evident (Shum et al., 2013). The immune 
responses against lung tissue indicate a possible role for autoimmunity in the 
development of respiratory disease in some APS1 patients.  
 Kidney impairment 1.3.3.17
Kidney disease has not been noted as a common problem in APS1, being reported in 2-
9% of patients albeit in a limited number of studies (Table 1.4) (Wolff et al., 2007, 
Cervato et al., 2009, Orlova et al., 2010). Kidney manifestations include renal tubular 
acidosis, nephrocalcinosis, and in later stages chronic renal failure. Indeed, half of 
those patients affected develop renal failure by their third decade of life (Perheentupa, 
2006), and this can prove fatal (Betterle et al., 1998). Renal biopsies from patients have 
shown lymphocytic infiltration and deposition of complement components (Al-Owain 
et al., 2010), and anti-proximal renal tubular autoantibodies have been detected in 
some cases (Ulinski et al., 2006) Both observations suggest the involvement of 
autoimmune pathogenic mechanisms in the development of renal complications, at 
least in some APS1 patients.  
 Asplenia 1.3.3.18
Asplenia in APS1 (Parker et al., 1990, Pollak et al., 2009) is rare with a prevalence of 2-
9% (Table 1.4) (Perheentupa, 2006, Orlova et al., 2010, Meloni et al., 2012), although 
this has been reported at 19% in adult patients (Perheentupa, 2006). The decrease in 
spleen size makes patients vulnerable to bacterial infections, so vaccination of APS1 
patients with asplenia against Streptococcus pneumoniae and Haemophilus influenzae 
may be required (Husebye et al., 2009). Although autoimmune destruction of the 
spleen has been proposed (Friedman et al., 1991), the pathogenic mechanisms 
involved in the development of asplenia are still unclear. 
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 Hypoparathyroidism in APS1 1.4
Since APS1 is due to a defect in the AIRE gene, the diseases that form part of the 
clinical picture are assumed to be autoimmune in origin. For example, as is the case for 
the isolated form of the disease not in the context of APS1, Addison’s disease and type 
1 diabetes mellitus are caused by autoimmunity against the affected gland. 
Consequently, there has been some study to characterise autoimmunity against the 
parathyroid. 
 Animal models of autoimmunity against the parathyroid 1.4.1
Establishing animal models that replicate the disease in humans is an important piece 
of evidence that suggests autoimmunity. Although this has not been thoroughly 
investigated, hypoparathyroidism has indeed been induced in rats and dogs after 
immunisation with parathyroid tissue (Lupulescu et al., 1968a). In these animals, a 
infiltration of lymphocytes into the parathyroid was noted, along with the presence of 
serum autoantibodies against the gland (Lupulescu et al., 1968b) In addition, the 
immunisation of rabbits with homogenised parathyroid tissue originating from rats or 
cows resulted in the production of parathyroid tissue-specific autoantibodies (Altenahr 
and Jenke, 1974). Furthermore, passive immunisation of rats with the serum from the 
immunised rabbits caused a very severe infiltration of lymphocytes into the 
parathyroid, although hypoparathyroidism was not evident in the animals (Altenahr 
and Jenke, 1974). 
 T cells in hypoparathyroidism 1.4.2
The presence of a lymphocytic infiltration in the target tissue and the demonstration of 
T cell reactivity to putative tissue antigens are indicative of autoimmunity (Rose and 
Bona, 1993). There have been case reports of histological changes in the parathyroid in 
idiopathic hypoparathyroidism including T and B lymphocyte infiltration (Figure 1.8) 
(Kossling and Emmrich, 1971, Vandecas and Gepts, 1973). In a study of idiopathic 
hypoparathyroid patients, an increase in circulating activated T cells compared to 
controls has been reported (Wortsman et al., 1992). However, so far, T cell reactivity 
against antigens of the parathyroid has not been shown convincingly. 
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Figure ‎1.8: Infiltration of the parathyroid with lymphocytes. 
Lymphocyte infiltration can be seen in the parathyroid glands of a patient with autoimmune 
hypoparathyroidism. The image, from a paper by (Vandecas and Gepts, 1973), was used with 
kind permission from Springer. 
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 Anti-parathyroid autoantibodies 1.4.3
Many early studies revealed autoantibodies against the parathyroid glands in patients 
with hypoparathyroidism (Blizzard et al., 1966, Irvine and Scarth, 1969, Betterle et al., 
1985, Brandi et al., 1986, Fattorossi et al., 1988). However, none of these reported the 
exact antigen specificity of the antibodies, and the cellular components the antibodies 
reacted against differed between each of the studies. Better evidence in support of 
humoral immune responses against the parathyroid came from the analysis of isolated 
parathyroid cells by measuring inhibition of PTH-secretion as an index of autoantibody 
binding (Posillico et al., 1986). In this study of 23 sera from patients with idiopathic 
hypoparathyroidism, three inhibited the secretion of PTH. In one patient, a reduction 
in antibody levels along with spontaneous improvement of the disease was found over 
time. Such findings suggested an aetiological role for autoantibodies against the 
parathyroid in some patients suffering from hypoparathyroidism. However, additional 
characterisation of parathyroid autoantigens was not undertaken for a considerable 
period of time. 
 Autoantibodies against NACHT leucine-rich-repeat protein 5  1.4.4
Antibody reactivity against the NACHT leucine-rich-repeat protein 5 (NALP5) was 
initially discovered during the immunoscreening of a human parathyroid cDNA library 
with an APS1 patient’s serum (Alimohammadi et al., 2008). A subsequent evaluation 
using a radioligand binding assay showed that NALP5 autoantibodies were detectable 
in 41% of 87 patients with APS1 (Alimohammadi et al., 2008). Furthermore, 
immunostaining of human parathyroid gland tissue using sera from the APS1 patients 
who had NALP5 autoantibodies identified antibody reaction towards parathyroid chief 
cells (Alimohammadi et al., 2008). Absorption of the serum with recombinant NALP5 
protein blocked the parathyroid staining, which suggested the antibody reactivity was 
against NALP5 (Alimohammadi et al., 2008). In addition, no staining of parathyroid 
tissue was found when using APS1 patient sera without NALP5 autoantibodies 
(Alimohammadi et al., 2008). Interestingly, NALP5 autoantibodies were not detected in 
20 patients with idiopathic hypoparathyroidism, indicating that autoimmunity against 
NALP5 might be specific for APS1 (Alimohammadi et al., 2008). 
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Subsequently, the association of NALP5 autoantibodies with APS1 was established in a 
report of 147 patients who had idiopathic hypoparathyroidism. A single case showed 
reactivity against NALP5 autoantibodies (Tomar et al., 2012). Further genetic and 
serological analysis confirmed that this patient had occult APS1. Autoantibodies 
against NALP5 have also been detected in a patient with thymoma who had acquired 
APS1 and hypoparathyroidism (Cheng et al., 2010), and in an APS1 patient who was 
suffering from chronic hypoparathyroidism (Cervato et al., 2010). 
In the study of Alimohammadi and colleagues, even though all 14 APS1 patients 
presenting without hypoparathyroidism were negative for NALP5 autoantibodies, the 
usefulness of NALP5 autoantibodies as a marker for APS1-associated 
hypoparathyroidism is open to question, as 51% of patients with parathyroid 
underactivity were not positive for NALP5 autoantibodies (Alimohammadi et al., 2008). 
In addition, two further cases of APS1 with hypoparathyroidism were also negative for 
antibody reactivity against NALP5 (Tomar et al., 2012).  
 Autoantibodies against the calcium-sensing receptor 1.4.5
The calcium-sensing receptor (Section 1.4.6) has a prominent role in controlling PTH- 
secretion in response to the concentration of extracellular calcium (Brown et al., 1993, 
Brown et al., 1995). It was first identified as a potential parathyroid autoantigen by Li 
and co-workers (Li et al., 1996). Antibody reactivity against the CaSR was found in 
14/25 (56%) of sera from patients with hypoparathyroidism using a radioligand binding 
assay (Table 1.5). With regard to the 14 patients who were CaSR antibody-positive, six 
had APS1 and eight had adult-onset hypoparathyroidism. Interestingly, there was a 
reduced chance of finding positivity for CaSR if the patient had had 
hypoparathyroidism for more than five years. In an independent study, an attempt to 
confirm these results using a radioligand binding assay was not successful (Gylling et 
al., 2003). Furthermore, of 60 APS1 patients (17% of whom were studied within a year 
of diagnosis), only 12% showed reactivity against the CaSR using a radioligand binding 
assay, while 4% of the control sera were also positive (Gylling et al., 2003). This study 
did not report an obvious difference between the APS1 patients with and without 
hypoparathyroidism in term of the presence of CaSR autoantibodies (Table 1.5). 
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In contrast, other studies were able to demonstrate CaSR autoantibodies in patients 
with hypoparathyroidism. For instance, a study of 147 idiopathic hypoparathyroid 
patients, showed one-quarter of the patients had CaSR autoantibodies (Table 1.5) 
(Tomar et al., 2013). In another study, the extracellular domain of the CaSR was 
expressed in E. coli and then used in immunoblotting experiments to detect CaSR 
autoantibodies (Mayer et al., 2004). Just below one-third of the patients with 
idiopathic hypoparathyroidism were positive for CaSR autoantibodies. Also, 
autoantibodies against the receptor were detected in one out of eight APS1 patients 
with hypoparathyroidism and one out of six APS2 patients with hypoparathyroidism 
using the same detection method (Table 1.5) (Mayer et al., 2004).  
Autoantibodies that affected the function of the receptor were first recognised in a 
study of four patients with hypocalciuric hypercalcemia (Kifor et al., 2003). Anti-
parathyroid antibodies were identified in these patients by immunofluorescence, while 
CaSR autoantibodies were identified using an immunoprecipitation method (Table 
1.5). The functional effects of the autoantibodies on the receptor were revealed by 
demonstrating that patient IgG could increase the secretion of PTH from human 
parathyroid cells in culture. The activating effect could be blocked by pre-absorption of 
the patient sera with extracts of HEK293 cells containing expressed CaSR. In two cases, 
affinity-purified patient antibodies inhibited CaSR-mediated accumulation of inositol-
phosphate and activation of mitogen-activated protein (MAP)-kinase activity in 
response to high extracellular Ca2+. Later, two patients with idiopathic 
hypoparathyroidism were described by Kifor and colleagues (Kifor et al., 2004). In both 
patients, CaSR-stimulating antibodies could be detected using the same methods as in 
their previous study (Kifor et al., 2003). One patient had Graves’ disease, but had 
undamaged parathyroid glands. The second patient had Addison’s disease and 
spontaneously remitting hypoparathyroidism. In both patients, the fact that the 
parathyroid glands showed no structural abnormalities suggested that their 
hypoparathyroidism was due to autoantibodies against the CaSR which induced 
abnormal receptor function (Kifor et al., 2003).  
More recently, using an immunoprecipitation assay with CaSR expressed in HEK293 
cells, 86% (12/14) of the APS1 patients that participated in the study were found to be 
positive for CaSR autoantibodies, whereas all control sera showed a negative result 
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(Table 1.5) (Gavalas et al., 2007). Surprisingly, the same sera were negative when a 
radioligand binding assay was used as the CaSR antibody detection method. This 
highlighted the importance of the choice of assay employed to detect the 
autoantibodies (Gavalas et al., 2007). The prevalence of CaSR autoantibodies was 
significantly increased in APS1 patients compared with controls (Table 1.5). Although 
12 of 13 patients with APS1-related hypoparathyroidism were positive for CaSR 
autoantibodies, the availability of only one patient without hypoparathyroidism meant 
it was not possible to conclude firmly that autoantibodies against the receptor were a 
serological marker for low parathyroid function (Gavalas et al., 2007). 
In a later study, phage-display technology was applied to the analysis of the binding 
sites of CaSR autoantibodies in the 12 CaSR antibody-positive APS1 patients (Kemp et 
al., 2010). This study identified amino acids between residues 41-69 in the extracellular 
domain of the CaSR as the major epitope recognised by the CaSR autoantibodies in 
APS1 patients. Other epitopes identified were amino acids between residues 114-126 
and 171-195 (Kemp et al., 2010). Further studies on the same 12 APS1 patients 
revealed that IgG samples from two of the patients (both with hypoparathyroidism) 
with CaSR autoantibodies elevated both Ca2+-dependent inositol-phosphate 
accumulation and MAP-kinase phosphorylation in HEK293 cells expressing the CaSR, 
indicating a stimulatory effect on the receptor (Kemp et al., 2009). While the majority 
of APS1 patients in this study did not have detectable CaSR-stimulating autoantibodies, 
the study highlighted a small minority of patients whose hypoparathyroidism was the 
result of functional suppression of the parathyroid glands rather than their irreversible 
destruction. 
Overall, a number of aspects of CaSR autoantibodies in idiopathic hypoparathyroidism 
and APS1 need to be investigated. Firstly, the variability of their prevalence (Table 1.5) 
could be due to differences in the type of measurement method employed, as no gold 
standard test for CaSR autoantibodies is currently available. Importantly, the CaSR 
antigen (used to detect reactivity) can have a major impact on the frequency of 
autoantibody detection (Gylling et al., 2003, Gavalas et al., 2007). In addition, the 
ethnicity and size of the patient and control groups, as well as the criteria to identify 
positivity may affect the reported prevalence of CaSR autoantibodies. Secondly, while 
they might just be markers for parathyroid gland destruction resulting from the action 
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of cytotoxic T cells (Wortsman et al., 1992), the effects of CaSR autoantibodies on 
receptor function, which could lead to the development hypoparathyroidism, needs 
further investigation. Although only a small number of cases have been reported of 
CaSR-activating autoantibodies (Kifor et al., 2004, Kemp et al., 2009), it could be that 
CaSR autoantibodies have effects such as complement-fixation or antibody-dependent 
cellular cytotoxicity, processes that could lead to parathyroid destruction (Brandi et al., 
1986). Finally, the question as to the correlation of CaSR autoantibodies and 
hypoparathyroidism in APS1 requires clarification.  
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Table‎1.5: Prevalence of CaSR autoantibodies in idiopathic and APS1-associated 
hypoparathyroidism 
 
 
1
HP, hypoparathyroidism. 
2
Patients compared with controls. 
3
APS1 or APS2 patients with hypoparathyroidism compared to those without hypoparathyroidism.  
 
  
Method of CaSR 
autoantibody detection 
Number of participants with 
CaSR autoantibodies (%) 
P 
value2 
P 
value3 
Reference 
Radioligand binding assay with in 
vitro translated CaSR 
APS1 with HP
1
  
HP 
Controls 
6/17 (35) 
8/8 (100) 
0/22 (0) 
0.004 
< 0.0001 
- (Li et al., 
1996) 
Radioligand binding assay with in 
vitro translated CaSR 
APS1 with HP 
APS1 no HP 
Controls 
6/50 (12) 
1/10 (10) 
8/192 (4) 
0.044 
0.370 
1.000 (Gylling et 
al., 2003) 
Radioligand binding assay with in 
vitro translated CaSR 
APS1 with HP 
APS1 no HP  
Controls 
0/73 (0) 
0/17 (0) 
0/100 (0) 
- 
- 
- (Soderbergh 
et al., 2004) 
Immunoblotting of the CaSR 
expressed in Escherichia coli 
APS1 with HP 
HP 
APS2 with HP 
APS2 no HP 
Controls 
1/8 (13) 
5/17 (29) 
1/6 (17) 
0/27 (0) 
0/32 (0) 
0.200 
0.003 
0.162 
- 
- 
- 
0.182 
(Mayer et 
al., 2004) 
Immunoprecipitation of the CaSR 
expressed in HEK293 cells 
HP 
Controls  
2/2 (100) 
0/5 (0) 
0.048 - (Kifor et al., 
2003) 
Immunoprecipitation of the CaSR 
expressed in HEK293 cells 
APS1 with HP 
APS1 no HP 
Controls 
12/13 (92) 
0/1 (0) 
0/28 (0) 
< 0.0001 
- 
 
0.143 (Gavalas et 
al., 2007) 
Immunoblotting of the CaSR 
expressed in HEK293 cells 
HP 
Controls 
36/147 (25) 
27/199 (14) 
0.011 - (Tomar et 
al., 2013) 
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 The calcium-sensing receptor 1.4.6
Since the CaSR has been identified as a target of autoantibodies in APS1 and these are 
analysed in this thesis, the structure and the functioning of the receptor in the 
parathyroid are summarised in the next sections. 
 Structure of the calcium-sensing receptor 1.4.6.1
The gene encoding the G-protein-coupled CaSR is located on the long arm of 
chromosome 3, and is composed of seven exons, six of which encode the extracellular 
domain and one of which encodes both the transmembrane and intracellular domains 
(Brown and MacLeod, 2001). The CaSR is 120 kDa in size, is composed of 1,078 amino 
acids, and consists of three different parts (Figure 1.9). The extracellular N-terminal 
domain, which is composed of 612 amino acids, contains all the Ca2+-binding sites 
(Brauner-Osborne et al., 1999). All CaSR agonists and antagonists also act on this 
domain (Brauner-Osborne et al., 1999). The second part of the CaSR is a 250-amino 
acid seven transmembrane domain. Finally, the C-terminal intracellular domain is 
composed of 216 amino acids (Brown et al., 1998, Garrett et al., 1995). From the high 
resolution crystal structure of the related metabotropic glutamate receptor type 1 
(Kunishima et al., 2000), a conformational structure for the CaSR has been suggested 
(Figure 1.10). The CaSR is proposed to exist as a dimer (Gama et al., 2001) with the 
paired extracellular domains assuming a bi-lobed, venus-flytrap structure (Hermans 
and Challiss, 2001). 
The extracellular domain contains a cysteine-rich region which connects the venus-
flytrap structure of the CaSR with the transmembrane domain (Figure 1.10), and which 
appears to be necessary for signalling between these two parts of the protein (Hu et 
al., 2000). It has been reported that mutations in the cysteine-rich region which change 
the cysteine residues lead to abnormalities in expression and function of the receptor 
(Fan et al., 1998). Furthermore, deletion of this region adversely affects CaSR function, 
even though it does not bind Ca2+ directly (Hu et al., 2000). Biochemical studies of 
several other cysteine residues within the extracellular domain, for example C129 and 
C131 (Figure 1.9), have found that they are important in ensuring the correct receptor 
conformation (Bai, 2004). 
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Further analysis of the extracellular domain shows it contains 11 N-linked glycosylation 
sites which have a role in the folding and export of the CaSR, but not in its function 
(Figure 1.9) (Ray et al., 1998). This extracellular domain contains four loop structures 
(Figure 1.9), three of which have been shown by mutational analysis to have a critical 
role in CaSR function (Reyes-Cruz et al., 2001). For example, mutations in loop 1 (G39-
G67) and loop 4 (C437-C449) lead to a reduction in the receptor’s response to Ca2+, 
and deletion of loop 2 (Q117-S137) can obliterate receptor function. Mutations in loop 
3 (F356-I416) have not been found mutations to affect receptor function (Reyes-Cruz 
et al., 2001). 
The Ca2+-binding sites in the extracellular domain of the CaSR have not been defined 
exactly due to the lack of a crystal structure for the receptor and the limitation of 
methods used to measure direct binding of Ca2+. The current identified sites are 
predicted based on the crystal structures of metabotropic glutamate receptor type 1 
(Kunishima et al., 2000, Zhang et al., 2015). Ca2+-binding site 1 is a pocket involving 
amino acids S147, S170, D190, Y218 and E297, and is located between loops 1 and 2 
(Silve et al., 2005, Huang et al., 2007) (Figure 1.11). Mutating any of these amino acid 
residues causes abnormalities in receptor function (Silve et al., 2005, Huang et al., 
2007). Site 1 is the most convincing as a Ca2+-binding site compared to the four other 
sites that have been proposed (Zhang et al., 2015).  
In the CaSR, 250 amino acids form the transmembrane domain consisting of seven 
membrane-spanning regions which connect the extracellular and intracellular parts of 
the receptor (Figure 1.9 and Figure 1.10) (Brown and MacLeod, 2001). The 
transmembrane domain is involved in phospholipase C activation and thus receptor 
activity (Chang et al., 2000). The inner C-terminal domain of the receptor is crucial for 
signalling and contains two protein kinase A and five protein kinase C phosphorylation 
sites which are involved in CaSR activity (Figure 1.9 and Figure 1.10) (Bai et al., 1997, 
Jiang et al., 2002).  
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Figure ‎1.9: Schematic representation of the calcium-sensing receptor 
The amino acid sequence of the calcium-sensing receptor is shown with the single letter code. 
The following are features are shown: cysteine residues in black, amino (N)-linked 
glycosylation sites indicated by the Y symbol, the beginning and end of the venus-flytrap (VFT) 
region in the extracellular domain, loops 1-4 of the extracellular domain, and the cysteine-rich 
region that connects the VFT region to the transmembrane domain. The image, from a paper 
by (Hu and Spiegel, 2007), is used with kind permission from John Wiley and Sons. 
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Figure ‎1.10: A model of the dimeric form of the extracellular CaSR. 
The CaSR is composed of a dimer pair, which is shown in red and blue. The extracellular 
domains assume a bi-lobed, venus-flytrap modelled on the known crystal structure of the 
metabotropic glutamate receptor type 1 (Kunishima et al., 2000). Each amino (N)-terminal 
extracellular domain is composed of 612 amino acids. Each CaSR monomer has a 250-amino 
acid seven transmembrane domain. The cysteine residues that comprise the cysteine-rich 
domain between the extracellular domain and the transmembrane domain are indicated as 
grey circles. The carboxy (C)-terminal intracellular domain is composed of 216 amino acids. The 
locations of the internal putative protein kinase C phosphorylation sites are indicated as yellow 
triangles. The image, from a paper by (Hofer and Brown, 2003), is used with kind permission 
from Nature Publishing Group.  
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Figure ‎1.11: Ca2+ binding sites on the CaSR. 
The predicted Ca2+ binding sites were taken from Huang et al., 2010. (a) The location of Ca2+ 
binding sites with respect to the CaSR are site 1 in cyan, site 2 in yellow and site 3 in blue; (b) 
Site 1 showing the amino acid residues involved; (c) Site 2 showing the amino acid residues 
involved; and (d) Site 3 showing the amino acid residues involved. These figures were 
generated by PyMol software. 
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 Functioning of the CaSR in the parathyroid in response to Ca2+ 1.4.6.2
The CaSR is predominantly expressed in the parathyroid gland (Brown and MacLeod, 
2001) where it controls the release of PTH in order to maintain blood calcium levels 
within strict limits 2.25-2.5 mmol/L (Brown et al., 1993). The receptor is activated by 
direct contact of Ca2+ at the Ca2+-binding sites in the extracellular domain (Figure 1.12). 
The presence of high Ca2+ concentrations stimulates the CaSR triggering a Gq-protein-
mediated activation of phospholipase C (Figure 1.12). Activated phospholipase C 
hydrolyses phosphatidylinositol-4,5-bisphosphate to inositol 1,4,5-trisphosphate, 
which in turn evokes the release of Ca2+ from cytosolic stores (Squires, 2000). In 
addition, Ca2+ can enter the cellular space by tissue-specific voltage dependent Ca2+ 
channels (Scherubl et al., 1991) and/or non-selective cation channels (Silva et al., 
1994). The elevation of intracellular Ca2+ inhibits the exocytosis of PTH and, therefore, 
a return to normal blood calcium concentrations is achieved (Chattopadhyay et al., 
1996). 
Conversely, when low serum Ca2+ concentrations are detected by the CaSR, the 
secretion of PTH from the parathyroid is initiated (Brown et al., 1995). As a 
consequence, uptake of Ca2+ by the intestine is increased as PTH induces the 
production of 1,25-dihydroxyvitamin D (Figure 1.13) (Brown, 1999). Higher PTH levels 
also cause the release of Ca2+ from bone tissue and re-absorption of Ca2+ by the 
kidneys (Figure 1.13) (Kurokawa, 1994, Manolagas and Jilka, 1995). As a consequence, 
serum Ca2+ levels are returned to a normal baseline value. 
Abnormally elevated activity of the CaSR in the presence of low serum Ca2+ can be 
caused by activating mutations or stimulating autoantibodies results in lowering of 
PTH-secretion. Mutations that activate the CaSR are associated with autosomal 
dominant hypocalcemia (Pollak et al., 1994, Pearce et al., 1996, Lienhardt et al., 2001). 
In patients with this disease, the receptor gains high sensitivity to serum Ca2+ (Brown, 
2007) leading to the clinical symptoms of low PTH levels, hypocalcemia, hypercalciuria, 
and hyperphosphatemia (Winter et al., 1983). Autoantibodies that stimulate the 
receptor have an analogous effect upon PTH secretion and thus autoimmune 
hypoparathyroidism can result (Section 1.4.5) (Kifor et al., 2004, Kemp et al., 2009). 
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Figure ‎1.12: Functioning of the calcium-sensing receptor in the parathyroid in 
response to Ca2+. 
High serum Ca2+ concentrations stimulate, via the calcium-sensing receptor on parathyroid 
chief cells, a Gq-protein-mediated activation of phospholipase C (PLC). The resulting formation 
of inositol 1,4,5-trisphosphate (IP3) evokes an increase in Ca2+ from cytosolic stores in the 
endoplasmic reticulum (ER). Activation of CaSR leads to production of arachidonic acid (AA) 
metabolites, which inhibit the release of parathyroid hormone (PTH) and increase the 
expression of vitamin D receptor (VDR), which in addition to the elevation of intracellular Ca2+ 
inhibits the exocytosis of PTH. A return to normal blood calcium concentrations is therefore 
achieved. Conversely, a low serum Ca2+ concentration leads to PTH release which causes 
uptake of Ca2+ by the intestine, release of Ca2+ from bone tissue and re-absorption of Ca2+ by 
the kidneys. Consequently, serum Ca2+ levels are returned to a normal baseline level. The 
image, from a paper by (Kopic and Geibel, 2013), did not require permission for use in this 
thesis. 
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Figure ‎1.13: Schematic view of Ca2+ homeostasis controlled by parathyroid 
hormone. 
Reduced serum Ca2+ concentrations activate the calcium-sensing receptor causing secretion of 
parathyroid hormone (PTH) from the parathyroid. In consequence, higher PTH levels cause the 
release of Ca2+ from bone tissue and re-absorption of Ca2+ by the kidneys, also uptake of Ca2+ 
by the intestine is increased as PTH induces the production of 1,25-dihydroxyvitamin D. As a 
consequence, serum Ca2+ levels are returned to a normal baseline value. 
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 Project Aims 1.5
Previous work in our laboratory detected CaSR autoantibodies in 12/14 of patients 
with APS1 using CaSR expressed in mammalian cells in an immunoprecipitation assay 
(Gavalas et al., 2007). In addition, CaSR autoantibodies that stimulate the CaSR have 
been found in a small minority (2/14) of APS1 patients (Kemp et al., 2009). Further 
studies have identified the binding sites (epitopes) of the CaSR autoantibodies in APS1 
patients. The epitopes were mapped to amino acid residues 41-69 (12/14 patients), 
114-126 (5/14 patients) and 171-195 (4/14 patients) at the amino-terminal of the 
extracellular domain of the receptor (Kemp et al., 2010). The current project will aim 
to investigate further the properties of and the role of CaSR autoantibodies in APS1 
patients. The specific aims will be: 
 To investigate the prevalence of CaSR autoantibodies in a larger cohort of APS1 
patients. 
 To investigate the association of CaSR autoantibodies with the clinical 
manifestations, particularly hypoparathyroidism.  
 To examine any adverse functional affects upon the CaSR of any detected CaSR 
autoantibodies. 
 To determine the binding sites of any newly detected CaSR autoantibodies. 
 To determine the IgG subclasses of CaSR autoantibodies.  
 To develop a convenient ELISA format using recombinant CaSR for detecting CaSR 
autoantibodies in patient sera. 
 
  
 
 
 
 
Chapter 2 
General Materials and Methods 
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2 General Materials and Methods  
 Reagents 2.1
The majority of reagents, including chemicals, buffers, solvents, acids and media 
components were purchased from Sigma-Aldrich (Poole, UK), Melford Laboratories 
(Ipswich, UK) or Fisher Scientific UK Ltd. (Loughborough, UK), and were of analytical or 
molecular biology grade. The source of some reagents is indicated in the text.  
 Plasticware 2.2
Plasticware including: 90-mm petri-dishes, 96-well microtitre plates, 6-well plates, 0.5-
ml and 1.5-ml tubes, universal tubes, pipette tips, pipettes, and Oak Ridge centrifuge 
tubes, cell culture flasks and dishes were from either Sarstedt Ltd. (Numbrecht, 
Germany), Starlab (UK) Ltd. (Milton Keynes, UK), Corning Incorporated (Corning, NY, 
USA), Nalgene Nunc International (Rochester, NY, USA) or Bibby Sterilin Ltd. (Bargoed, 
UK). 
 Bacterial growth medium 2.3
Luria Bertani (LB) medium was prepared in deionised water and contained: 1% (w/v) 
tryptone, 0.5% (w/v) yeast extract, and 1% (w/v) sodium chloride. Medium 2YT was 
also made in deionised water and was composed of: 1.6% (w/v) tryptone, 1% (w/v) 
yeast extract, and 0.5% (w/v) sodium chloride. Media were sterilised by autoclaving at 
121°C for 20 min. Solid media were prepared by adding 1.5% (w/v) agar to the 
appropriate liquid medium before sterilisation. After autoclaving, the agar was left to 
cool to about 40-45°C before adding any required antibiotic(s). The cooled agar was 
poured into 90-mm petri-dishes and allowed to set. Plates were then dried and stored 
at 4°C until required. 
Antibiotics were prepared as 1000x concentrated stocks. Ampicillin (sodium salt) and 
kanamycin sulphate were prepared in deionised water, chloramphenicol in 100% 
ethanol, and tetracycline hydrochloride in 50% (w/v) ethanol. Solutions were sterilised 
by filtration through 0.22 micron Millex® Filter Units (Millipore Corp., Bedford, MA, 
USA). Antibiotic solutions were stored at –20°C and used in culture medium and agar 
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plates when required at the following concentrations: ampicillin (sodium salt), 100 
µg/ml; kanamycin sulphate, 50 µg/ml; chloramphenicol, 30 µg/ml; tetracycline 
hydrochloride, 10 µg/ml. 
 Bacterial strains 2.4
The bacterial strains used in this study were derivatives of Escherichia coli and are 
given in Table 2.1. Derivatives of bacterial strains carrying plasmid vectors or 
recombinant plasmids were constructed by transformation (Section 2.13). All E. coli 
strains were routinely grown from frozen stocks by initially streaking onto LB agar 
plates (Section 2.3), containing selective antibiotic(s) where required (Section 2.3). 
Plates were then incubated at 37°C overnight. A single colony of the desired bacterial 
strain was then inoculated into LB medium with the appropriate antibiotic 
supplementation, and incubated at 37°C overnight in a rotary incubator shaking at 250 
revolutions per minute (rpm). For long-term storage at -80°C, 0.7-ml aliquots of an 
overnight-grown bacterial culture were mixed with 0.3-ml aliquots of sterile 50% (v/v) 
glycerol. 
 Plasmids 2.5
The plasmids used in this study are listed in Table 2.2. They were stored at -20°C in 
sterile TE buffer (10 mM Tris-hydrochloride; 1 mM ethylenediaminetetraacetic acid 
(EDTA); pH 8.0) (Promega, Southampton, UK). Diagrams of plasmids pDEST14-CaSR 
(Source BioScience imaGenes, Berlin, Germany), pCR®2.1-TOPO® (Life Technologies Ltd., 
Paisley, UK), pET14b (Novagen/Merck KgaA, Darmstadt, Germany) are shown in 
Figures 6.4, 6.6 and 6.1, respectively. 
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Table ‎2.1: Bacterial strains 
 
Strain Details Source 
JM109 
Used for the propagation of plasmid 
vectors and recombinant plasmids. 
Promega 
(Southampton, UK) 
BL21 (DE3) 
Used for the expression of cloned 
DNA. 
Agilent Technologies Inc. 
(Santa Clara, CA, USA) 
BL21 (DE3)pLysS 
Used for the expression of cloned 
DNA. Chloramphenicol resistant. 
Agilent Technologies Inc. 
BL21 GOLD (DE3) 
Used for the expression of cloned 
DNA. Tetracyline resistant. 
Agilent Technologies Inc. 
BL21 GOLD (DE3)pLysS 
Used for the expression of cloned 
DNA. Chloramphenicol and 
tetracycline resistant. 
Agilent Technologies Inc. 
BL21 CODONPLUS (DE3)-RIPL 
Used for the expression of cloned 
DNA. Chloramphenicol, tetracycline 
and streptomycin resistant. 
Agilent Technologies Inc. 
TOP10F’ 
Used for recovery of cloned PCR 
amplification products from TOPO
®
 
cloning reactions. 
Life Technologies Ltd. 
(Paisley, UK) 
JM109/pCMV6-XL5-NALP5 
Carries recombinant plasmid 
pCMV6-XL5-NALP5 (Table 2.2) 
Dr. Helen Kemp (Department 
of Oncology and 
Metabolism, University of 
Sheffield, Sheffield, UK) 
JM109/pcCaSR-FLAG 
Carries recombinant plasmid 
pcCaSR-FLAG (Table 2.2) 
Dr. Helen Kemp 
JM109/pDEST14-CaSR 
Carries recombinant plasmid 
pDEST14-CaSR (Table 2.2). 
This study (Chapter 6) 
JM109/pET14b 
Carries plasmid vector pET14b 
(Table 2.2). 
This study (Chapter 6) 
JM109/pET14b-CaSRECD 
Carries recombinant plasmid 
pET14b-CaSRECD (Table 2.2). 
This study (Chapter 6) 
TOP10F’/pCR2.1-TOPO-
CaSRECD 
Carries recombinant plasmid 
pCR2.1-TOPO-CaSRECD (Table 2.2). 
This study (Chapter 6) 
BL21 (DE3)/pET14b-CaSRECD 
Carries recombinant plasmid 
pET14b-CaSRECD (Table 2.2). 
This study (Chapter 6) 
BL21 (DE3)pLysS /pET14b-
CaSRECD 
Carries recombinant plasmid 
pET14b-CaSRECD (Table 2.2). 
This study (Chapter 6) 
BL21 GOLD (DE3)/pET14b-
CaSRECD 
Carries recombinant plasmid 
pET14b-CaSRECD (Table 2.2). 
This study (Chapter 6) 
BL21 GOLD (DE3)pLysS 
/pET14b-CaSRECD 
Carries recombinant plasmid 
pET14b-CaSRECD (Table 2.2). 
This study (Chapter 6) 
BL21 CODONPLUS (DE3)-RIPL/ 
pET14b-CaSRECD 
Carries recombinant plasmid 
pET14b-CaSRECD (Table 2.2). 
This study (Chapter 6) 
BL21 (DE3)/pET14b 
Carries plasmid vector pET14b 
(Table 2.2). 
This study (Chapter 6) 
BL21 (DE3)pLysS /pET14b 
Carries plasmid vector pET14b 
(Table 2.2). 
This study (Chapter 6) 
BL21 GOLD (DE3)/pET14b 
Carries plasmid vector pET14b 
(Table 2.2). 
This study (Chapter 6) 
BL21 GOLD (DE3)pLysS 
/pET14b 
Carries plasmid vector pET14b 
(Table 2.2). 
This study (Chapter 6) 
BL21 CODONPLUS (DE3)-RIPL/ 
pET14b 
Carries plasmid vector pET14b 
(Table 2.2). 
This study (Chapter 6) 
BL21 CODONPLUS (DE3)-RIPL/ 
pPROEX-HTb-CaSREx 
Carries plasmid vector pPROEX-HTb 
(Table 2.2). 
This study (Chapter 6) 
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Table ‎2.2: Plasmid vectors and recombinant plasmids 
 
Plasmid Details Source 
pDEST14-CaSR 
Plasmid vector pDEST14 containing full-length  
Calcium-sensing receptor (CaSR) cDNA (3.2-
kilobase). Selectable marker is ampicillin 
resistance (Figure 6.4). 
Source BioScience 
imaGenes (Berlin, 
Germany) 
pCR®2.1-TOPO® 
A 3.9-kilobase vector for cloning PCR products. 
Contains binding sites for T7 Promoter and M13 
Reverse primers flanking the cloning site. 
Selectable markers are ampicillin and kanamycin 
resistance (Figure 6.6). 
Life Technologies Ltd. 
(Paisley, UK) 
pCR2.1-TOPO- 
CaSRECD 
Plasmid vector pCR®2.1-TOPO® containing CaSR-
extracellular domain cDNA (base pairs 1-1800). 
Selectable markers are ampicillin and kanamycin 
resistance. 
This study (Chapter 6 ) 
pET14b 
A 4.7-kilobase expression vector with a selectable 
resistance marker to ampicillin. Contains binding 
sites for T7 Promoter and T7 Terminator primers 
flanking a multiple cloning site (Figure 6.1). 
Novagen/Merck KgaA 
(Darmstadt, Germany) 
pET14b-
CaSRECD 
Plasmid vector pET14b containing CaSR 
extracellular domain cDNA (base pairs 1-1800) 
cloned into the XhoI restriction site. Selectable 
marker is ampicillin resistance. 
This study (Chapter 6) 
pCMV6-XL5-
NALP5 
Plasmid vector pCMV-XL5 containing NACHT 
leucine-rich-repeat protein 5 (NALP5) cDNA (3.6-
kilobase). Selectable marker is ampicillin 
resistance (Figure 3.4). 
Professor Olle Kampe 
(Department of Medical 
Sciences, Uppsala 
University Hospital, 
Uppsala, Sweden) 
pcCaSR-FLAG 
Plasmid vector pcDNA3 containing full-length 
CaSR cDNA (3.2-kilobase) with a FLAG tag. 
Selectable marker is ampicillin resistance (Figure 
3.1).  
Dr. Helen Kemp 
(Department of 
Oncology and 
Metabolism, University 
of Sheffield, Sheffield, 
UK) 
pcDNA3-CaSR 
Plasmid vector pcDNA3 containing full-length 
CaSR cDNA (3.2-kilobase). Selectable marker is 
ampicillin resistance (Figure 3.2). 
Dr. Helen Kemp  
pPROEX-HTb-
CaSREx 
Plasmid vector pPROEX-HTb containing CaSR 
extracellular domain cDNA (base pairs 58-1800) 
cloned into the XhoI restriction site. Selectable 
marker is ampicillin resistance (Figure 6.3). 
Professor Ravinder 
Goswami (Department of 
Endocrinology and 
Metabolism, All India 
Institute of Medical 
Sciences, New Delhi, 
India). 
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 Small-scale plasmid preparations 2.6
This method was carried out according to the protocol of Dr Helen Kemp (Department 
of Oncology and Metabolism, University of Sheffield, Sheffield, UK). The Wizard® Plus 
SV Minipreps DNA Purification System (Promega) was used to purify plasmid DNA from 
a 5-ml or 10-ml overnight culture of the required bacterial strain, according to the 
manufacturer’s protocol. Briefly, a single colony of the desired bacterial strain was 
isolated by streaking out 20 µl of frozen bacterial stock onto LB agar containing the 
appropriate antibiotic(s). A single colony from the selective plate was then used to 
inoculate 10 ml of LB medium containing the relevant antibiotic(s) which was 
subsequently shaken in a rotary incubator at 250 rpm at 37°C overnight. The bacterial 
cell pellet was obtained by centrifugation at 10,000 g for 10 min and resuspended in 
250 µl of Cell Resuspension Solution (50 mM Tris-hydrochloride, pH 7.5; 10 mM EDTA; 
100 µg/ml RNase A). The cells were lysed by the addition of 250 µl of Cell Lysis Solution 
(200 mM sodium hydroxide; 1% (w/v) sodium dodecyl sulphate (SDS)). The cell extract 
was then neutralised by the addition of 350 µl of Neutralisation Solution (759 mM 
potassium acetate; 4.09 M guanidine hydrochloride; 2.12 M glacial acetic acid; pH 4.2), 
mixed gently and centrifuged at 10,000 g for 10 min at room temperature. The cleared 
lysate was then loaded on to a Wizard® SV Minicolumn which was centrifuged at 
10,000 g for 1 min at room temperature and the flow- through discarded. The 
Minicolumn was washed with 750 µl of Column Wash Solution (60% (v/v) ethanol; 60 
mM potassium acetate; 8.3 mM Tris-hydrochloride; 0.04 mM EDTA) and then with 250 
µl of Column Wash Solution with centrifugation at for 2 min at room temperature each 
time. To recover the DNA bound to the column, 100 µl of nuclease-free water was 
added to the column and this was centrifuged at 10,000 g for 1 min at room 
temperature. The concentration of the DNA was measured by spectrophotometry at 
260 nm using a NanoDrop ND-1000 Spectrometer (Labtech, Wilmington, DE, USA) and 
NanoDrop Software (Labtech). Plasmids were checked qualitatively by agarose gel 
electrophoresis (Section 2.8). 
 Large-scale plasmid preparations 2.7
This method was carried out according to the protocol of Dr Helen Kemp (Department 
of Oncology and Metabolism, University of Sheffield, Sheffield, UK). A large-scale 
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culture of the bacterial strain carrying the desired plasmid was prepared by inoculation 
of 0.5-1 litres of LB medium containing the appropriate antibiotic(s), with a 10-ml 
starter culture. This was followed by incubation overnight with shaking at 37°C. The 
culture was then centrifuged at 4,000 g for 30 min and plasmid extracted from the cell 
pellet using a Qiagen Plasmid DNA Maxiprep Kit (Qiagen Ltd., Crawley, UK) as directed 
in the manufacturer’s protocol. The bacterial cell pellet was resuspended in 10 ml of 
P1 Buffer (50 mM Tris-hydrochloride, pH 8.0; 10 mM EDTA; 100 μg/ml RNase A) in a 
50-ml Oak Ridge centrifuge tube. An equal volume of P2 Buffer (200 mM sodium 
hydroxide; 1% (w/v) SDS) was then added to the resuspended cells and mixed by 
gentle inversion, followed by incubation at room temperature for 5 min. After the 
addition of 10 ml of P3 Buffer (1.32 M potassium acetate, pH 5.5), the lysed cells were 
mixed gently but thoroughly and incubated on ice for 20 min. The cell extract was 
subsequently centrifuged at 20,000 g for 30 min at 4°C resulting in a clear supernatant. 
A Qiagen column was equilibrated by adding QBT Buffer (750 mM sodium chloride; 50 
mM 3-[N-morpholino]propanesulphonic acid (MOPS), pH 7.0; 15% (v/v) isopropanol; 
0.15% (v/v) Triton X-100) and was allowed to empty by gravity flow. The clear 
supernatant was then loaded onto the column and left to flow through before washing 
the column twice with 30 ml of QC Buffer (1 M sodium chloride; 50 mM MOPS, pH 7.0; 
15% (v/v) isopropanol). Subsequently, plasmid DNA was eluted with 15 ml of QF Buffer 
(1.25 M sodium chloride; 50 mM Tris-hydrochloride, pH 8.5; 15% (v/v) isopropanol) 
and precipitated by the addition of 10.5 ml of 100% isopropanol and centrifugation at 
15,000 g for 30 min at 4°C. The resulting DNA pellet was washed with 70% (v/v) 
ethanol, centrifuged at 15,000 g for 10 min at 4°C and finally resuspended in 300 μl of 
TE buffer. The concentration of the DNA was measured by spectrophotometry (Section 
2.6). Plasmids were also checked qualitatively by agarose gel electrophoresis (Section 
2.8). 
 Agarose gel electrophoresis 2.8
This method was carried out according to the protocol of Dr Helen Kemp (Department 
of Oncology and Metabolism, University of Sheffield, Sheffield, UK). For analysis of 
DNA, agarose gels, 0.8-1% (w/v), were prepared by boiling molecular biology grade 
agarose in TAE electrophoresis buffer (40 mM Tris-acetate; 1 mM EDTA; pH 8.3) 
(Promega) for 1-2 min in a microwave oven. For every 50 ml of the gel solution, 1 μl of 
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ethidium bromide solution (10 mg/ml) (Promega) The molten agarose was cooled and 
poured into the casting deck of a Sub-Cell® Horizontal Electrophoresis System (Bio-Rad 
Laboratories Ltd., Hemel Hempstead, UK). After the gel had set, the combs were 
removed and the gel placed in the electrophoresis tank with TAE as the running buffer. 
Blue/Orange Loading Dye 6x (0.4% (w/v) orange G; 0.03% (w/v) bromphenol blue; 
0.03% (w/v) xylene cyanol FF; 15% (w/v) Ficoll® 400; 10 mM Tris-hydrochloride, pH 7.5; 
50 mM EDTA, pH 8.0) (Promega) was added to the DNA sample at 1/6th of the volume, 
and the sample was then loaded into a gel slot. To size DNA products after they had 
migrated through the gel, a ‘marker’ lane was included which contained a 0.5-1.0-μg 
sample of either HindIII-restricted bacteriophage λ DNA (125-23,130-bp DNA 
fragments) (Promega) or 1-kb DNA Ladder (500-10,000-bp DNA fragments) (New 
England Biolabs®, Hitchin, UK). Gels were run in a Sub-Cell® Horizontal Electrophoresis 
System (Bio-Rad Laboratories Ltd.) at 50-70 volts using a PowerPac Basic Power Supply 
(Bio-Rad Laboratories Ltd.), and subsequently viewed and recorded using a GBOX Gel 
Documentation System (Syngene, Cambridge, UK) and GeneSnap Image Acquisition 
Software (Syngene). 
 Restriction enzyme digests 2.9
This method was carried out according to the protocol of Dr Helen Kemp (Department 
of Oncology and Metabolism, University of Sheffield, Sheffield, UK). Restriction 
enzymes (Table 2.3) and restriction enzyme buffers (Table 2.3) were supplied by 
Promega. Restriction enzyme digests of plasmids and polymerase chain reaction (PCR) 
amplification products were carried out in 0.5-ml tubes in a volume not normally 
exceeding 25 μl and contained up to 1 μg of DNA, 10 units of enzyme(s) and 0.1 
volumes of the appropriate 10x restriction enzyme buffer. Each reaction proceeded for 
90 min at 37°C, unless otherwise stated. Restriction digests were analysed by agarose 
gel electrophoresis (Section 2.8). 
  
 58 
Table ‎2.3: Restriction enzymes and buffers 
 
Enzyme1 Buffer (10x concentration)1 Restriction site 
XhoI Buffer D: 60 mM Tris-HCl, pH 7.9; 1.5 M 
NaCl; 60 mM MgCl2; 10 mM dithiothreitol. 
5’-CTCGAG-3’ 
 
1Enzymes and buffers were supplied by Promega (Southampton, UK). 
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 Polymerase chain reaction amplification 2.10
This method was carried out according to the protocol of Dr Helen Kemp (Department 
of Oncology and Metabolism, University of Sheffield, Sheffield, UK). For polymerase 
chain reaction (PCR) amplification, forward and reverse oligonucleotide primers were 
appropriately designed to amplify the required regions of a DNA fragment. Primers 
were synthesised to order by Eurofins Genetic Services Ltd. (London, UK) and were 
stored at -40°C in sterile, nuclease-free water at a concentration of 100 pmol/µl. The 
PCR primers used in this study are listed in Table 2.4. The exact primers used for PCR 
amplification of a particular DNA are given at the relevant points in the Results 
Chapters. Reactions were carried out in 0.5-ml tubes in 50-μl volumes comprising, 
unless otherwise indicated: 50 ng of template DNA, 0.01-1 µM of each required 
(forward and reverse) primer, 1.25 units of GoTaq® Flexi DNA polymerase (Promega), 
0.2 mM deoxynucleotides (dATP, dGTP, dCTP and dTTP) (Promega), 1.5 mM 
magnesium chloride (Promega) and 0.2 volumes of 5x GoTaq® Flexi Buffer (50 mM Tris-
hydrochloride, pH 8.5; 0.05% (w/v) gelatine; 250 mM potassium chloride; 0.5% (v/v) 
Tween 20; 0.5% (v/v) Nonidet P-40) (Promega). Reactions without template DNA were 
included as controls. Each reaction was overlaid with mineral oil (Sigma-Aldrich) to 
prevent evaporation during heating, and was then subjected to PCR amplification in a 
DNA Thermal Cycler (Perkin-Elmer/Cetus, Norwalk, CT, USA). Unless stated otherwise, 
the cycling conditions were denaturation at 95°C for 1 min, annealing at 55°C for 1 min 
and extension at 72°C for 2 min for 30 cycles. The reactions were completed by a final 
extension at 72°C for 10 min, followed by a soak at 4°C. Amplification products were 
analysed by agarose gel electrophoresis (Section 2.8) 
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Table ‎2.4: Oligonucleotide PCR amplification primers 
 
Primer Sequence1 Source 
CASR-ECD-F 5’-ttctcgagatggcattttatagc-3’ Eurofins Genetic 
Services Ltd. (London, 
UK) 
CASR-ECD-R 5’-aactcgagcgcctatcaggcaatgcaggaggt-3’ Eurofins Genetic 
Services Ltd.  
 
1
The XhoI restriction sites are underlined in the forward (F) and reverse (R) primers.  
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 Extraction and purification of DNA fragments from agarose gels 2.11
When electrophoresis was performed to purify a required DNA fragment, generated 
either from a PCR amplification reaction or a restriction enzyme digest, the DNA 
fragment was recovered from an agarose gel using a Wizard® PCR Preps DNA 
Purification Kit (Promega). Briefly, the area of the gel containing the relevant band of 
DNA was visualised using an ultra-violet transilluminator, excised using a clean scalpel 
and placed in a 1.5-ml tube. The gel slice was dissolved in 1 ml of Wizard® PCR Preps 
DNA Purification Resin and applied to a Wizard® Minicolumn. The column was washed 
with 2 ml of 80% (v/v) isopropanol and then was centrifuged at 10,000 g for 2 min. The 
DNA was eluted in 30 μl of sterile TE buffer and stored at -20°C until required. Purified 
DNA fragments were analysed by agarose gel electrophoresis (Section 2.8) and the 
concentration of the DNA was measured by spectrophotometry (Section 2.6). 
 DNA ligations 2.12
This method was carried out according to the protocol of Dr Helen Kemp (Department 
of Oncology and Metabolism, University of Sheffield, Sheffield, UK). Ligation of plasmid 
vector and DNA fragments was performed using T4 DNA ligase (Promega) in in a 0.5-ml 
tube in a reaction volume of 10-20 μl. Reactions usually contained 20-100 ng of 
plasmid vector. The amount of insert DNA was calculated as: ng vector x size of insert 
(kilobase)/size of vector (kilobase) x molar ratio of insert to vector. Vector and insert 
DNA were usually at a molar ratio of between 1 and 3. The following were then added: 
1-2 units of T4 DNA ligase (Promega), 0.1 volumes of 10x DNA ligase buffer (300 mM 
Tris-hydrochloride, pH 7.8; 100 mM magnesium chloride; 100 mM dithiothreitol; 10 
mM adenosine triphosphate) (Promega) and the required volume of nuclease-free 
water. The reaction was subsequently incubated at 15°C overnight before using in the 
transformation of bacterial cells (Section 2.14). 
 Bacterial transformation 2.13
When required, a 50-100-μl aliquot of chemically competent E. coli JM109 cells 
(Promega) was thawed from storage at -80°C. The appropriate DNA sample (plasmid 
DNA or DNA in a ligation reaction) was gently mixed with the cells which were 
incubated on ice for 5-10 min. The cells were then heat shocked at exactly 42°C for 45 
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sec and returned to ice. After 2 min, the cells were transferred to a culture tube 
containing 900-950 μl of chilled SOC medium (2% (w/v) tryptone; 0.5% (w/v) yeast 
extract; 10 mM sodium chloride; 2.5 mM potassium chloride; 10 mM magnesium 
chloride; 10 mM magnesium sulphate; 20 mM glucose) (Life Technologies Ltd.). The 
culture tube was placed in the rotary incubator shaking at 150 rpm and grown for 1 h, 
to allow expression of the antibiotic resistance genes carried by the transforming 
plasmid DNA. A 100-μl aliquot of undiluted transformed cells, and of 1:10 and 1:100 
dilutions, were then spread on agar plates containing the appropriate antibiotic(s), and 
the plates incubated at 37°C overnight. As a control in each transformation 
experiment, an aliquot of untransformed cells was also plated on to selective medium. 
Individual colonies were subsequently purified by streaking onto fresh LB agar plates 
with selective antibiotic(s) for growth overnight at 37°C. 
For E. coli BL21 strains (Table 2.1), a 100-μl aliquot of chemically competent cells 
(Agilent Technologies Inc., Santa Clara, CA, USA) was thawed from storage at -80°C. β-
mercaptoethanol was added to a final concentration of 24 mM and 28 mM to BL21 
(DE3) and BL21 CODONPLUS (DE3)-RIPL cells, respectively. The appropriate DNA 
sample was gently mixed with the cells which were then incubated on ice for 30 min. 
BL21(DE3) and BL21(DE3)pLysS cells were subsequently heat shocked at exactly 42°C 
for 45 sec and returned to ice. BL21 Gold (DE3), BL21 Gold (DE3)pLysS and BL21 
CODONPLUS (DE3)-RIPL cells were heat shocked at exactly 42°C for 20 sec and 
returned to ice. After 2 min, the cells were transferred to a culture tube containing 900 
μl of chilled SOC medium and the protocol continued as above.  
 TOPO® cloning reactions 2.14
TOPO® cloning reactions were used to directly clone PCR amplification products into 
plasmid vector pCR®2.1-TOPO® (Figure 6.6) (Life Technologies Ltd.) according to a 
TOPO® TA Cloning Kit (Life Technologies Ltd.). Each 6-μl reaction was set up in a 0.5-ml 
tube with: 2 μl of fresh PCR amplification product, 1 μl of reaction buffer (1.2 M 
sodium chloride; 60 mM magnesium chloride), 1 μl of pCR®2.1-TOPO® linearised 
vector, and 2 μl of nuclease-free water. The reaction was mixed gently and incubated 
at the room temperature for 15 min and then placed on ice. To recover cloned PCR 
amplification products, 2 µl of the TOPO® cloning reaction were added into a vial of 
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One Shot® Chemically Competent E. coli TOP10F’ cells (Life Technologies Ltd.) and 
mixed gently. The cells were incubated on ice for 5 min and then heat-shocked for 30 
sec at 42°C without shaking. The cells were immediately transferred to ice and 250 µl 
of room temperature SOC medium were added. The cells were then incubated at 37°C 
in a rotary incubator shaking at 200 rpm. After 1 h, 10-50 μl of the culture were plated 
onto LB agar containing kanamycin at 50 μg/ml, and the plates incubated at 37°C 
overnight. Individual colonies were then purified by streaking onto fresh LB agar plates 
with kanamycin at 50 μg/ml and growing overnight at 37°C. 
 DNA sequencing 2.15
Automated DNA sequencing was carried out by the Genetics Core Facility of the 
Medical School at the University of Sheffield, Sheffield, UK. DNA templates (plasmids 
or PCR amplification products) and oligonucleotide sequencing primers were provided 
to the service at 50-100 ng/μl and 1 pmol/μl, respectively. Sequencing primers M13 
Reverse and T7 promoter (Table 2.5) were purchased from Promega. Primer T7 
Terminator was from Novagen/Merck KgaA. Other primers (Table 2.5) were 
synthesised to order by Eurofins Genetic Services Ltd. Sequencing reactions were 
performed using a BigDye® Terminator Cycle Sequencing Kit Version 3.1 (Applied 
Biosystems, Foster City, CA, USA) and an ABI 3730 Capillary Sequencer (Applied 
Biosystems). 
 DNA and protein analyses 2.16
Analyses of DNA and protein sequences were carried out using Lasergene Core Suite 
sequence analysis software (DNASTAR, Inc. Madison, WI, USA) and the network 
facilities of the European Bioinformatics Institute-European Molecular Biology 
Laboratory (EBI-EMBL) (http://www.ebi.ac.uk/) (Cambridge, UK), and the ExPASy 
Bioformatics Resources Portal (http://web.expasy.org) (SIB Swiss Institute of 
Bioinformatics, Switzerland). Protein and DNA homology searches against the GenBank 
database were performed using the BLAST service of the National Center for 
Biotechnology Information (NCIB) (http://www.ncbi.nlm.nih.gov/) (Bethesda, MD, 
USA).  
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Table ‎2.5: Oligonucleotide sequencing primers 
 
Primer Sequence Source 
T7 Promoter 5’-taatacgactcactataggg-3’ Promega (Southampton, 
UK) 
T7 Terminator 5'-gctagttattgctcagcgg-3' Novagen/Merck KgaA 
(Darmstadt, Germany) 
M13 Reverse 5’-caggaaacagctatgac-3’ Promega 
CASR-646F 5’-gccatggcagacatc-3’ Eurofins Genetic Services 
Ltd. (London, UK) 
pc3prim1  5’-gtggcggccgcaaattc-3’ Eurofins Genetic Services 
Ltd. 
CaSR-451 5’-acggcagtggcaaatctg-3’ Eurofins Genetic Services 
Ltd. 
CaSR-951  5’-cattggattcgctct-3’ Eurofins Genetic Services 
Ltd. 
CaSR-1151 5’-ttagcaacagctcga-3’ Eurofins Genetic Services 
Ltd. 
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 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 2.17
This method was carried out according to the protocol of Dr Helen Kemp (Department 
of Oncology and Metabolism, University of Sheffield, Sheffield, UK). Sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) of proteins was performed in 
7.5, 8, 10% (w/v) polyacrylamide gels. Resolving gels consisted of: 7.5, 8, or 10% (v/v) 
ProtoGel (37.5:1 acrylamide:bisacrylamide) (GeneFlow, Lichfield, UK), 375 mM Tris-
hydrochloride (pH8.8), 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulphate and 0.1% 
(v/v) N, N, N, N’-tetramethylethylenediamine (TEMED). Stacking gels contained: 4% 
(v/v) ProtoGel, 125 mM Tris-hydrochloride (pH6.8), 0.1% (w/v) SDS, 0.05% (w/v) 
ammonium persulphate and 0.1% (v/v) TEMED. 
The gels were created using a Bio-Rad Mini-Protean Tetra Cell apparatus (Bio-Rad 
Laboratories Ltd.). Briefly, glass plates and spacers were assembled using the 
dedicated equipment according to the manufacturer’s instructions. The resolving gel 
solution was poured into the space between the plates and overlaid with 100 µl of 
butan-1-ol. After the gel had polymerized, the butan-1-ol was poured off and a gel 
comb was inserted before the solution for the stacking gel was poured in on top. Then, 
the gel comb was removed and the full apparatus assembled into the gel running tank. 
Laemmli buffer (25 mM Tris-base; 0.1% (w/v) SDS; 192 mM glycine; pH 8.3) (GeneFlow) 
was poured into the tank until the bottom of the plates was covered and the top 
buffer reservoir was full. 
Prior to loading, protein samples were mixed with SDS-sample buffer (2% (w/v) SDS; 
25% (v/v) glycerol; 0.01% (w/v) bromophenol blue; 2% (v/v) 2-mercaptoethanol; 62.5 
mM Tris-hydrochloride, pH 6.8) (Bio-Rad Laboratories Ltd.) and heated at 95°C for 5 
min. Samples were then loaded into the gel wells. Protein size markers were 
Prestained SDS-PAGE Standards, Low Range (20-104 kDa) (Bio-Rad Laboratories Ltd.) or 
Precision Plus Protein All Blue Standards (10-250 kDa) (Bio-Rad Laboratories Ltd.). Gels 
were run at 35 milli-amperes for 3-5 h or until the visible dye front had reached the 
bottom of the plates. The apparatus was subsequently dismantled and, when staining 
was required, the gel transferred to a plastic tray and stained with Coomassie® Blue 
stain (0.05% (w/v) Coomassie® Brilliant Blue (Bio-Rad Laboratories Ltd.); 10% (v/v) 
glacial acetic acid; 25% (v/v) isopropanol) on a rocking platform. After a minimum of 30 
min of staining, the gel was destained by repeated fresh additions of destain solution 
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(10% (v/v) glacial acetic acid; 25% (v/v) isopropanol), until the protein markers were 
clearly visible. 
 Antibodies 2.18
The antibodies used in this study are listed in Table 2.6. These were stored in 
accordance with the manufacturers’ instructions at 4°C or -20°C. 
 Western blotting 2.19
Proteins separated in SDS-polyacrylamide gels by SDS-PAGE (Section 2.18) were 
transferred to Whatman™ Westran® Clear Signal polyvinylidene difluoride 
(PVDF) blotting membrane (GE Healthcare Life Sciences, Little Chalfont, UK) using a 
Bio-Rad Mini Trans-Blot Cell (Bio-Rad Laboratories Ltd.). Before transfer, membranes 
were soaked in 100% methanol for 30 sec, and then in transfer buffer (25 mM Tris-
base; 192 mM glycine; pH 8.3) for 5 min. SDS-polyacrylamide gels, 3 MM Whatman 
paper (Whatman International Ltd., Maidstone, UK) and sponges needed for the 
blotting sandwich were also soaked in transfer buffer for 5 min. After assembly, the 
blotting sandwich was placed into a Bio-Rad Mini Trans-Blot Cell and subjected to 100 
volts for 1 h (Figure 2.1). 
Following transfer, the membrane was incubated in phosphate-buffered saline (137 
mM sodium chloride; 2.7 mM potassium chloride; 8.1 mM disodium hydrogen 
phosphate; 1.5 mM Potassium dihydrogen phosphate; pH 7.4) (PBS) (Sigma-Aldrich)/1 
% (v/v) Blocking Reagent (Roche Diagnostics, Mannheim, Germany) at room 
temperature with shaking for 60 min, or overnight at 4°C. The membrane was then 
washed for 15 min with PBS/0.1% (v/v) Tween-20 (washing buffer). Primary antibody 
was applied to the membrane at the required dilution in PBS/0.5 % (v/v) Blocking 
Reagent and incubated with shaking at room temperature for 1.5 h. Subsequently, the 
membrane was washed with washing buffer for 3 x 10 min. The appropriate secondary 
antibody conjugated to horseradish peroxidase (Table 2.6) was applied to the 
membrane at the required dilution in PBS/0.5 % (v/v) Blocking Reagent and incubated 
for 1 h at room temperature with shaking. Afterwards, the membrane was washed 
with washing buffer for 3 x 15 min. Excess buffer was drained from the membrane and 
the binding of the secondary antibody conjugated to horseradish peroxidase was 
 67 
detected by enhanced chemiluminescence using a BM Chemiluminescence Blotting 
Substrate (POD) Kit (Roche Diagnostics) and as explained in the manufacturer’s 
manual. The detection reagent system consisted of luminol, hydrogen peroxide and 4-
iodophenol and was applied to the membrane for 1 min before draining and wrapping 
the membrane in Saran Wrap (Baco professional, Telford, UK). The membrane was 
placed into a Hypercassette™ (GE Healthcare Life Sciences, Little Chalfont, UK) with 
Fuji Medical X-Ray Film (FujiFilm Europe GmbH, Dusseldorf, Germany). After exposure 
of the film for the required time, it was developed using Photosol CD18 x-ray 
developer (Photosol Ltd., Basildon, UK), rinsed in water and then fixed in Photosol 
CF40 fixer (Photosol Ltd.). 
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Table ‎2.6 : Antibodies 
 
Antibody Details Source 
Anti-His-tag Mouse monoclonal antibody 
against six histidine residues 
(6xHis epitope tag). 
Life Technologies Ltd. 
(Paisley, UK) 
Anti-FLAG-HRP Mouse monoclonal antibody 
against the FLAG epitope 
(DYKDDDDK) conjugated to 
horseradish peroxidase (HRP).  
Sigma-Aldrich (Poole, 
UK) 
Anti-CaSR (ab79829) Rabbit polyclonal antibody 
against the amino acid residues 
47-69 of the calcium-sensing 
receptor (CaSR). 
Abcam, Inc. (Cambridge, 
MA, USA) 
Anti-CaSR (ab19347) Mouse monoclonal antibody 
against the amino acid residues 
214-235 of the CaSR 
Abcam 
Anti-CaSR11-S Rabbit polyclonal antiserum 
against a C-terminal peptide of 
the CaSR. 
Alpha Diagnostics 
(International, San 
Antonio, TX, USA) 
Anti-NALP5  Goat polyclonal antibody against 
an internal peptide of NACHT 
leucine-rich-repeat protein 5 
(NALP5). 
Santa Cruz 
Biotechnology, Inc. 
(Santa Cruz, CA, USA) 
Anti-mouse IgG-HRP Goat polyclonal antibody against 
mouse IgG conjugated to HRP. 
Life Technologies Ltd.  
Anti-rabbit IgG-HRP Goat polyclonal antibody against 
rabbit IgG conjugated to HRP. 
Sigma-Aldrich  
Anti-human IgG-AP Goat polyclonal antibody against 
human IgG (γ-chain-specific) 
conjugated to alkaline 
phosphatase (AP). 
Sigma-Aldrich  
Anti-rabbit IgG-AP  Goat polyclonal antibody against 
rabbit IgG conjugated to alkaline 
phosphatase (AP). 
Sigma-Aldrich  
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Figure ‎2.1: Assembly of blotting sandwich in submerged transfer apparatus. 
 
  
 
 
 
 
 
 
 
Chapter 3 
Prevalence and Clinical Associations of Calcium-Sensing Receptor and 
NALP5 Autoantibodies in Finnish Patients with Autoimmune Polyendocrine 
Syndrome Type 1 
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3 Prevalence and Clinical Associations of Calcium-Sensing Receptor and 
NALP5 Autoantibodies in Finnish Patients with Autoimmune 
Polyendocrine Syndrome Type 1 
  Introduction 3.1
The autoimmune regulator transcription factor encoded by AIRE is mainly expressed in 
medullary thymic epithelial cells (mTEC) where it regulates expression of peripheral tissue-
specific antigens in order to establish self-tolerance in developing T lymphocytes (Zuklys et 
al., 2000). Mutations in the AIRE gene (Finnish-German, 1997, Nagamine et al., 1997) 
cause the development of autoimmune polyendocrine syndrome type 1 (APS1) also 
referred to as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy 
(APECED) (Perheentupa, 2006). The majority of APS1 patients have high IgG antibody 
titers against type I interferons (IFN) and T helper type 17 (Th17) cell-related cytokines 
(Kisand et al., 2008, Puel et al., 2010), and these represent useful diagnostic markers for 
APS1 due to their early appearance and long persistence (Kisand et al., 2008, Puel et al., 
2010). 
Clinically, APS1 is characterised in the majority of cases by the presence of chronic 
mucocutaneous candidiasis, hypoparathyroidism and Addison’s disease (adrenal 
insufficiency) (Perheentupa, 2006). Occurring less frequently are hypothyroidism, type 1 
diabetes mellitus, vitiligo, alopecia areata, hepatitis and pernicious anaemia 
(Perheentupa, 2006). Patients suffer from chronic inflammation of their internal organs 
due to infiltrating autoreactive T lymphocytes, and usually have variety of autoantibodies 
against the affected tissue (Soderbergh et al., 2004). In many cases, a correlation between 
a disease component and an autoantibody target is observed (Soderbergh et al., 2004). 
Examples include tyrosine hydroxylase and alopecia, tryptophan hydroxylase and 
intestinal dysfunction, and side-chain cleavage enzyme and ovarian insufficiency, in each 
case, the autoantigen being expressed in the affected tissue (Soderbergh et al., 2004). 
Likewise, antibodies against parathyroid-expressed NALP5 have been associated with the 
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clinical and biochemical manifestations of hypoparathyroidism, which include 
hypocalcemia, hyperphosphatemia and low serum levels of PTH (Alimohammadi et al., 
2008). In addition, the CaSR, which plays a critical role in keeping calcium homeostasis by 
sensing serum calcium levels and regulating PTH production and secretion, also represents 
a parathyroid-expressed antibody target in APS1 (Li et al., 1996, Gylling et al., 2003, Mayer 
et al., 2004, Gavalas et al., 2007), although this has not been a consistent finding 
(Soderbergh et al., 2004). However, it is unclear as to whether or not CaSR antibodies are 
a specific or sensitive marker for hypoparathyroidism in patients with this autoimmune 
syndrome (Gylling et al., 2003, Gavalas et al., 2007). 
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 Aims  3.2
The aims of this part of the project were: 
 To determine the AIRE genotypes and cytokine antibody profiles of the APS1 
patient group in order to confirm the clinical diagnosis of APS1. 
 To investigate the prevalence of CaSR and NALP5 antibodies in the APS1 patients. 
 To assess associations between the presence of CaSR and NALP5 antibodies and 
APS1 disease components and patient demographic characteristics. 
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 Materials and Methods 3.3
 Patients and controls 3.3.1
The study was approved by the Medical Ethics Committee of Helsinki University Central 
Hospital, and was performed in accordance with the Declaration of Helsinki. Informed 
written consent was obtained from all participants or their parents prior to inclusion in the 
study. The APS1 patients were under the care of Professor Annamari Ranki and Dr Nicolas 
Kluger at the Department of Dermatology, Allergology and Venereology, Institute of 
Clinical Medicine, University of Helsinki and Helsinki University Central Hospital, Helsinki, 
Finland. Forty-four unrelated Finnish APS1 patients were included and were 18 males and 
26 females with a mean age of 33 years (range: 8-67 years). Individual patient sex and age 
details are given in Table 3.1. The diagnostic criteria for the various endocrine, ectodermal 
and other disease components have been detailed previously (Ahonen et al., 1990), and 
the diagnosis of APS1 was based upon the presence of at least two of the three classical 
clinical criteria of chronic mucocutaneous candidiasis, hypoparathyroidism and Addison’s 
disease (Ahonen et al., 1990). Thirty eight healthy blood donors to the Finnish Red Cross 
Blood Service, who had no clinical signs or a family history of APS1 or of other 
autoimmune disease, served as controls and included 16 males and 22 females with a 
mean age of 36 years (range: 19-64 years). Serum samples obtained from participants 
were stored at -80oC until required for analysis. 
 AIRE gene genotyping 3.3.2
The AIRE genotypes of the APS1 patients were determined by Professor Annamari Ranki 
and Dr Nicolas Kluger by PCR amplification and DNA sequencing of the 14 AIRE exons, as 
detailed previously (Wolff et al., 2007). 
 Cytokine enzyme-linked immunosorbent assays  3.3.3
Antibodies against cytokines were detected in enzyme-linked immunosorbent assays 
(ELISAs). Interleukin (IL)-22, IL-17A, IL-17F (all from R and D Systems, Minneapolis, MN, 
USA), interferon (IFN)-omega, IFN-alpha2A and IFN-lambda1 (IL-29) (all from Sigma-
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Aldrich) were received dried and were solubilised and stored according to the 
manufacturer’s instructions. For ELISAs, the required cytokine was diluted in PBS to 100 
ng/ml and 100-μl samples used to coat the wells of a 96-well microtitre plate. An 
equivalent number of wells were coated with 100 μl of 0.1% (w/v) bovine serum albumin 
for the measurement of non-specific binding of the sera. The plates were then incubated 
overnight at 4°C.  
Excess cytokine was removed by decanting and all the wells were blocked with blocking 
buffer (PBS/ 0.1% (w/v) Tween-20/3% (w/v) bovine serum albumin) for 30 min at 37°C. 
Plates were washed four times with washing buffer (PBS/0.1% (v/v) Tween-20). Aliquots 
(100 µl) of APS1 patient or control sera at a 1:100 dilution in blocking buffer were added 
to the wells. PBS was applied as a control to measure any non-specific binding of the 
secondary antibody. The plates were incubated at room temperature for 1 h and then 
washed four times with washing buffer. A 100-µl aliquot of goat anti-human IgG 
polyclonal antibody conjugated to alkaline phosphatase (Sigma-Aldrich) diluted to 1:2000 
in blocking buffer was added to each well for 1 h at room temperature. After washing five 
times with washing buffer, 100 µl of alkaline phosphatase substrate Sigma Fast p-
nitrophenyl phosphate (Sigma-Aldrich) were applied to each well and plates incubated at 
room temperature to allow colour development. A LabSystems Integrated EIA 
Management System spectrophotometer (Life Sciences International, Basingstoke, UK) 
was used to read absorption of the wells at 405 nm. All sera were tested in duplicate and 
the mean OD405 value taken. Each mean OD405 value was corrected for background 
binding of the sera to the well without antigen. 
The binding reactivity of each patient and control sera to the cytokine was expressed as an 
antibody index calculated as: mean OD405 of tested serum/mean OD405 of a population of 
healthy control sera. Each serum was tested in at least two experiments and the mean 
cytokine antibody index calculated. The upper limit of normal for each cytokine ELISA was 
calculated using the mean antibody index + 3SD of a population of healthy control sera. 
Sera with a cytokine antibody index greater than the upper limit of normal were regarded 
as positive for cytokine antibodies. 
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 Detection of CaSR antibodies 3.3.4
As detailed below, antibodies against the CaSR were detected using CaSR 
immunoprecipitation assays with CaSR-FLAG protein expressed in human embryonic 
kidney 293 (HEK293) cells. 
 Culture and maintenance of HEK293 cells 3.3.4.1
Human embryonic kidney 293 cells (ECACC, Public Health England, Salisbury, UK) were 
cultured in DMEM medium (25 mM D-glucose; 1 mM sodium pyruvate; 2 mM L-glutamine; 
10% (v/v) fetal calf serum; 100 units/ml penicillin G; 100 g/ml streptomycin) (all from Life 
Technologies Ltd., Paisley, UK) in T75 tissue culture flasks at 37°C in a 95% humidified 
atmosphere of 5% CO2. Cells were passaged by trypsin digestion when 70-100% confluent. 
At each passage, the culture medium was removed from the cells which were then 
washed in phosphate-buffered saline (137 mM sodium chloride; 2.7 mM potassium 
chloride; 8.1 mM disodium hydrogen phosphate; 1.5 mM potassium dihydrogen 
phosphate; pH 7.4) (PBS) (Sigma-Aldrich, Poole, UK). Subsequently, the cells were 
incubated in trypsin solution (0.05% (w/v) trypsin; 0.53 mM ethylenediaminetetraacetic 
acid) (Life Technologies Ltd.) for 2-3 min at 37°C. The cells were then resuspended in 
culture medium prior to centrifuging for 5 min. The cell pellet was resuspended in culture 
medium and cells were counted in a haemocytometer before plating out at the required 
cell density. 
 Transfection of HEK293 cells 3.3.4.2
For transfections, HEK293 cells were plated at 1 x 106 cells in 100-mm dishes in 10 ml of 
culture medium and grown to 50-60% confluence. The cells were then incubated with 10 
ml of fresh culture medium for 6 h at 37°C before transfection with either plasmid pcCaSR-
FLAG (Kemp et al., 2007) or pcDNA3-CaSR (Kemp et al., 2014) using a Calcium Phosphate 
Transfection System (Life Technologies Ltd.) according to the manufacturer’s protocol. 
Plasmids were a gift from Dr. Helen Kemp (Department of oncology and Metabolism, 
University of Sheffield, Sheffield, UK). Plasmid pcCaSR-FLAG was vector pcDNA3 (Life 
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Technologies Ltd.) containing full-length CaSR cDNA (3,234-basepairs) with an inserted 
nucleotide sequence (21-basepairs) encoding part of a FLAG epitope (YKDDDDK) for 
expression immediately after the CaSR amino acid residue aspartate-371 (Figure 3.1). 
Plasmid pcDNA3-CaSR was pcDNA3 containing full-length CaSR cDNA without an 
incorporated FLAG epitope (Figure 3.2). Briefly, 20 μg of plasmid DNA were mixed with 
300 μl of sterile water and 36 μl of 2 M calcium chloride. This solution was added drop-
wise into 300 μl of HEPES-buffered saline whilst passing air through the latter. The 
resulting precipitate was left at room temperature for 20 min. The precipitate was added 
to the HEK293 cells which were then incubated for 16 h at 37°C. Transfected cells were 
washed twice in PBS and incubated in serum-free culture medium for a further 48 h at 
37°C to allow expression of the encoded CaSR protein. Untransfected HEK293 cells were 
also included for use as a control. 
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Figure ‎3.1: Details of plasmid pcCaSR-FLAG. 
Plasmid pcCaSR-FLAG is vector pcDNA3 containing full-length CaSR cDNA (3,234-basepairs) with an 
inserted nucleotide sequence (21-basepairs) encoding part of a FLAG epitope (YKDDDDK) for 
expression immediately after CaSR amino acid residue aspartate-371. The CaSR cDNA was cloned 
between the KpnI and XbaI restriction sites and was in the correct orientation for expression in 
mammalian cells from the cytomegalovirus (CMV) promoter present in pcDNA3. The selectable 
marker for propagation in bacteria was ampicillin resistance.  
Amino acid sequence of cDNA-encoded CaSR-FLAG protein 
 
MAFYSCCWVLLALTWHTSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSR
PESVECIRYNFRGFRWLQAMIFAIEEINSSPALLPNLTLGYRIFDTCNTVSKAL
EATLSFVAQNKIDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYI
PQVSYASSSRLLSNKNQFKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADD
DYGRPGIEKFREEAEERDICIDFSELISQYSDEEEIQHVVEVIQNSTAKVIVVF
SSGPDLEPLIKEIVRRNITGKIWLASEAWASSSLIAMPQYFHVVGGTIGFALKA
GQIPGFREFLKKVHPRKSVHNGFAKEFWEETFNCHLQEGAKGPLPVDYKDDDDK
TFLRGHEESGDRFSNSSTAFRPLCTGDENISSVETPYIDYTHLRISYNVYLAVY
SIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTF
DECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEEKILWSGF
SREVPFSNCSRDCLAGTRKGIIEGEPTCCFECVECPDGEYSDETDASACNKCPD
DFWSNENHTSCIAKEIEFLSWTEPFGIALTLFAVLGIFLTAFVLGVFIKFRNTP
IVKATNRELSYLLLFSLLCCFSSSLFFIGEPQDWTCRLRQPAFGISFVLCISCI
LVKTNRVLLVFEAKIPTSFHRKWWGLNLQFLLVFLCTFMQIVICVIWLYTAPPS
SYRNQELEDEIIFITCHEGSLMALGFLIGYTCLLAAICFFFAFKSRKLPENFNE
AKFITFSMLIFFIVWISFIPAYASTYGKFVSAVEVIAILAASFGLLACIFFNKI
YIILFKPSRNTIEEVRCSTAAHAFKVAARATLRRSNVSRKRSSSLGGSTGSTPS
SSISSKSNSEDPFPQPERQKQQQPLALTQQEQQQQPLTLPQQQRSQQQPRCKQK
VIFGSGTVTFSLSFDEPQKNAMAHRNSTHQNSLEAQKSSDTLTRHQPLLPLQCG
ETDLDLTVQETGLQGPVGGDQRPEVEDPEELSPALVVSSSQSFVISGGGSTVTE
NVVNS 
Nucleotide sequence of CaSR-FLAG cDNA 
 
atggcattttatagctgctgctgggtcctcttggcactcacctggcacacctctgcctacgggccagaccagcgagcccaaaagaagggggacattatccttggggggctctttcctattcattttg
gagtagcagctaaagatcaagatctcaaatcaaggccggagtctgtggaatgtatcaggtataatttccgtgggtttcgctggttacaggctatgatatttgccatagaggagataaacagcagccc
agcccttcttcccaacttgacgctgggatacaggatatttgacacttgcaacaccgtttctaaggccttggaagccaccctgagttttgttgctcaaaacaaaattgattctttgaaccttgatgag
ttctgcaactgctcagagcacattccctctacgattgctgtggtgggagcaactggctcaggcgtctccacggcagtggcaaatctgctggggctcttctacattccccaggtcagttatgcctcct
ccagcagactcctcagcaacaagaatcaattcaagtctttcctccgaaccatccccaatgatgagcaccaggccactgccatggcagacatcatcgagtatttccgctggaactgggtgggcacaat
tgcagctgatgacgactatgggcggccggggattgagaaattccgagaggaagctgaggaaagggatatctgcatcgacttcagtgaactcatctcccagtactctgatgaggaagagatccagcat
gtggtagaggtgattcaaaattccacggccaaagtcatcgtggttttctccagtggcccagatcttgagcccctcatcaaggagattgtccggcgcaatatcacgggcaagatctggctggccagcg
aggcctgggccagctcctccctgatcgccatgcctcagtacttccacgtggttggcggcaccattggattcgctctgaaggctgggcagatcccaggcttccgggaattcctgaagaaggtccatcc
caggaagtctgtccacaatggttttgccaaggagttttgggaagaaacatttaactgccacctccaagaaggtgcaaaaggacctttacctgtggactacaaggatgacgatgacaagacctttctg
agaggtcacgaagaaagtggcgacaggtttagcaacagctcgacagccttccgacccctctgtacaggggatgagaacatcagcagtgtcgagaccccttacatagattacacgcatttacggatat
cctacaatgtgtacttagcagtctactccattgcccacgccttgcaagatatatatacctgcttacctgggagagggctcttcaccaatggctcctgtgcagacatcaagaaagttgaggcgtggca
ggtcctgaagcacctacggcatctaaactttacaaacaatatgggggagcaggtgacctttgatgagtgtggtgacctggtggggaactattccatcatcaactggcacctctccccagaggatggc
tccatcgtgtttaaggaagtcgggtattacaacgtctatgccaagaagggagaaagactcttcatcaacgaggagaaaatcctgtggagtgggttctccagggaggtgcccttctccaactgcagcc
gagactgcctggcagggaccaggaaagggatcattgagggggagcccacctgctgctttgagtgtgtggagtgtcctgatggggagtatagtgatgagacagatgccagtgcctgtaacaagtgccc
agatgacttctggtccaatgagaaccacacctcctgcattgccaaggagatcgagtttctgtcgtggacggagccctttgggatcgcactcaccctctttgccgtgctgggcattttcctgacagcc
tttgtgctgggtgtgtttatcaagttccgcaacacacccattgtcaaggccaccaaccgagagctctcctacctcctcctcttctccctgctctgctgcttctccagctccctgttcttcatcgggg
agccccaggactggacgtgccgcctgcgccagccggcctttggcatcagcttcgtgctctgcatctcatgcatcctggtgaaaaccaaccgtgtcctcctggtgtttgaggccaagatccccaccag
cttccaccgcaagtggtgggggctcaacctgcagttcctgctggttttcctctgcaccttcatgcagattgtcatctgtgtgatctggctctacaccgcgcccccctcaagctaccgcaaccaggag
ctggaggatgagatcatcttcatcacgtgccacgagggctccctcatggccctgggcttcctgatcggctacacctgcctgctggctgccatctgcttcttctttgccttcaagtcccggaagctgc
cggagaacttcaatgaagccaagttcatcaccttcagcatgctcatcttcttcatcgtctggatctccttcattccagcctatgccagcacctatggcaagtttgtctctgccgtagaggtgattgc
catcctggcagccagctttggcttgctggcgtgcatcttcttcaacaagatctacatcattctcttcaagccatcccgcaacaccatcgaggaggtgcgttgcagcaccgcagctcacgctttcaag
gtggctgcccgggccacgctgcgccgcagcaacgtctcccgcaagcggtccagcagccttggaggctccacgggatccaccccctcctcctccatcagcagcaagagcaacagcgaagacccattcc
cacagcccgagaggcagaagcagcagcagccgctggccctaacccagcaagagcagcagcagcagcccctgaccctcccacagcagcaacgatctcagcagcagcccagatgcaagcagaaggtcat
ctttggcagcggcacggtcaccttctcactgagctttgatgagcctcagaagaacgccatggcccacaggaattctacgcaccagaactccctggaggcccagaaaagcagcgatacgctgacccga
caccagccattactcccgctgcagtgcggggaaacggacttagatctgaccgtccaggaaacaggtctgcaaggacctgtgggtggagaccagcggccagaggtggaggaccctgaagagttgtccc
cagcacttgtagtgtccagttcacagagctttgtcatcagtggtggaggcagcactgttacagaaaacgtagtgaattca 
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Figure ‎3.2: Details of plasmid pcDNA3-CaSR. 
Plasmid pcDNA3-CaSR is vector pcDNA3 containing full-length CaSR cDNA (3,234-basepairs). The 
CaSR cDNA was cloned between the KpnI and XbaI restriction sites and was in the correct 
orientation for expression in mammalian cells from the cytomegalovirus (CMV) promoter present 
in pcDNA3. The selectable marker for propagation in bacteria was ampicillin resistance.  
  
Amino acid sequence of cDNA-encoded CaSR protein 
 
MAFYSCCWVLLALTWHTSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPE
SVECIRYNFRGFRWLQAMIFAIEEINSSPALLPNLTLGYRIFDTCNTVSKALEATL
SFVAQNKIDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYA
SSSRLLSNKNQFKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIE
KFREEAEERDICIDFSELISQYSDEEEIQHVVEVIQNSTAKVIVVFSSGPDLEPLI
KEIVRRNITGKIWLASEAWASSSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKK
VHPRKSVHNGFAKEFWEETFNCHLQEGAKGPLPVDTFLRGHEESGDRFSNSSTAFR
PLCTGDENISSVETPYIDYTHLRISYNVYLAVYSIAHALQDIYTCLPGRGLFTNGS
CADIKKVEAWQVLKHLRHLNFTNNMGEQVTFDECGDLVGNYSIINWHLSPEDGSIV
FKEVGYYNVYAKKGERLFINEEKILWSGFSREVPFSNCSRDCLAGTRKGIIEGEPT
CCFECVECPDGEYSDETDASACNKCPDDFWSNENHTSCIAKEIEFLSWTEPFGIAL
TLFAVLGIFLTAFVLGVFIKFRNTPIVKATNRELSYLLLFSLLCCFSSSLFFIGEP
QDWTCRLRQPAFGISFVLCISCILVKTNRVLLVFEAKIPTSFHRKWWGLNLQFLLV
FLCTFMQIVICVIWLYTAPPSSYRNQELEDEIIFITCHEGSLMALGFLIGYTCLLA
AICFFFAFKSRKLPENFNEAKFITFSMLIFFIVWISFIPAYASTYGKFVSAVEVIA
ILAASFGLLACIFFNKIYIILFKPSRNTIEEVRCSTAAHAFKVAARATLRRSNVSR
KRSSSLGGSTGSTPSSSISSKSNSEDPFPQPERQKQQQPLALTQQEQQQQPLTLPQ
QQRSQQQPRCKQKVIFGSGTVTFSLSFDEPQKNAMAHRNSTHQNSLEAQKSSDTLT
RHQPLLPLQCGETDLDLTVQETGLQGPVGGDQRPEVEDPEELSPALVVSSSQSFVI
SGGGSTVTENVVNS 
Nucleotide sequence of CaSR cDNA 
 
atggcattttatagctgctgctgggtcctcttggcactcacctggcacacctctgcctacgggccagaccagcgagcccaaaagaagggggacattatccttggggggctctttcctattcatttt
ggagtagcagctaaagatcaagatctcaaatcaaggccggagtctgtggaatgtatcaggtataatttccgtgggtttcgctggttacaggctatgatatttgccatagaggagataaacagcagc
ccagcccttcttcccaacttgacgctgggatacaggatatttgacacttgcaacaccgtttctaaggccttggaagccaccctgagttttgttgctcaaaacaaaattgattctttgaaccttgat
gagttctgcaactgctcagagcacattccctctacgattgctgtggtgggagcaactggctcaggcgtctccacggcagtggcaaatctgctggggctcttctacattccccaggtcagttatgcc
tcctccagcagactcctcagcaacaagaatcaattcaagtctttcctccgaaccatccccaatgatgagcaccaggccactgccatggcagacatcatcgagtatttccgctggaactgggtgggc
acaattgcagctgatgacgactatgggcggccggggattgagaaattccgagaggaagctgaggaaagggatatctgcatcgacttcagtgaactcatctcccagtactctgatgaggaagagatc
cagcatgtggtagaggtgattcaaaattccacggccaaagtcatcgtggttttctccagtggcccagatcttgagcccctcatcaaggagattgtccggcgcaatatcacgggcaagatctggctg
gccagcgaggcctgggccagctcctccctgatcgccatgcctcagtacttccacgtggttggcggcaccattggattcgctctgaaggctgggcagatcccaggcttccgggaattcctgaagaag
gtccatcccaggaagtctgtccacaatggttttgccaaggagttttgggaagaaacatttaactgccacctccaagaaggtgcaaaaggacctttacctgtggacacctttctgagaggtcacgaa
gaaagtggcgacaggtttagcaacagctcgacagccttccgacccctctgtacaggggatgagaacatcagcagtgtcgagaccccttacatagattacacgcatttacggatatcctacaatgtg
tacttagcagtctactccattgcccacgccttgcaagatatatatacctgcttacctgggagagggctcttcaccaatggctcctgtgcagacatcaagaaagttgaggcgtggcaggtcctgaag
cacctacggcatctaaactttacaaacaatatgggggagcaggtgacctttgatgagtgtggtgacctggtggggaactattccatcatcaactggcacctctccccagaggatggctccatcgtg
tttaaggaagtcgggtattacaacgtctatgccaagaagggagaaagactcttcatcaacgaggagaaaatcctgtggagtgggttctccagggaggtgcccttctccaactgcagccgagactgc
ctggcagggaccaggaaagggatcattgagggggagcccacctgctgctttgagtgtgtggagtgtcctgatggggagtatagtgatgagacagatgccagtgcctgtaacaagtgcccagatgac
ttctggtccaatgagaaccacacctcctgcattgccaaggagatcgagtttctgtcgtggacggagccctttgggatcgcactcaccctctttgccgtgctgggcattttcctgacagcctttgtg
ctgggtgtgtttatcaagttccgcaacacacccattgtcaaggccaccaaccgagagctctcctacctcctcctcttctccctgctctgctgcttctccagctccctgttcttcatcggggagccc
caggactggacgtgccgcctgcgccagccggcctttggcatcagcttcgtgctctgcatctcatgcatcctggtgaaaaccaaccgtgtcctcctggtgtttgaggccaagatccccaccagcttc
caccgcaagtggtgggggctcaacctgcagttcctgctggttttcctctgcaccttcatgcagattgtcatctgtgtgatctggctctacaccgcgcccccctcaagctaccgcaaccaggagctg
gaggatgagatcatcttcatcacgtgccacgagggctccctcatggccctgggcttcctgatcggctacacctgcctgctggctgccatctgcttcttctttgccttcaagtcccggaagctgccg
gagaacttcaatgaagccaagttcatcaccttcagcatgctcatcttcttcatcgtctggatctccttcattccagcctatgccagcacctatggcaagtttgtctctgccgtagaggtgattgcc
atcctggcagccagctttggcttgctggcgtgcatcttcttcaacaagatctacatcattctcttcaagccatcccgcaacaccatcgaggaggtgcgttgcagcaccgcagctcacgctttcaag
gtggctgcccgggccacgctgcgccgcagcaacgtctcccgcaagcggtccagcagccttggaggctccacgggatccaccccctcctcctccatcagcagcaagagcaacagcgaagacccattc
ccacagcccgagaggcagaagcagcagcagccgctggccctaacccagcaagagcagcagcagcagcccctgaccctcccacagcagcaacgatctcagcagcagcccagatgcaagcagaaggtc
atctttggcagcggcacggtcaccttctcactgagctttgatgagcctcagaagaacgccatggcccacaggaattctacgcaccagaactccctggaggcccagaaaagcagcgatacgctgacc
cgacaccagccattactcccgctgcagtgcggggaaacggacttagatctgaccgtccaggaaacaggtctgcaaggacctgtgggtggagaccagcggccagaggtggaggaccctgaagagttg
tccccagcacttgtagtgtccagttcacagagctttgtcatcagtggtggaggcagcactgttacagaaaacgtagtgaattca 
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 Preparation of cell extracts and protein determination 3.3.4.3
This method was carried out according to the protocol of Dr Helen Kemp (Department of 
Oncology and Metabolism, University of Sheffield, Sheffield, UK). For cell extract 
preparation, untransfected and transfected HEK293 cells were transferred into PBS 
containing Protease Inhibitor Cocktail (Sigma-Aldrich) and washed three times. The cell 
pellet was resuspended in immunoprecipitaion buffer (150 mM sodium chloride; 25 mM 
sodium phosphate (pH 6.9); 1% (v/v) Triton X-100; 0.5% (v/v) Nonidet P40; Protease 
Inhibitor Cocktail), sonicated four times for 20 sec on ice and then centrifuged. The total 
protein content of cell extracts was determined using a Bio-Rad Protein Assay Kit (Bio-Rad 
Laboratories Ltd., Hemel Hempstead, UK) according to the manufacturer’s instructions. A 
protein standard curve was prepared using bovine serum albumin (Sigma-Aldrich) 
standards (0.1 mg/ml, 0.08 mg/ml, 0.06 mg/ml, 0.04 mg/ml, and 0.02 mg/ml), 100 μl of 
which were added to 200 μl of Bradford Reagent plus 700 μl of distilled water in a plastic 
0.1-cm cuvette. Readings were taken for all samples at OD595 in a LabSystems Integrated 
EIA Management System spectrophotometer. The reading values were then plotted 
against the protein concentration to create a protein standard curve. Every cell extract 
sample to be measured was mixed with 200 μl Bradford reagent plus the necessary 
amount of distilled water to make up a volume of 1 ml in a plastic 0.1-cm cuvette. The 
protein concentration in each sample was determined by direct comparison of the OD595 
reading against the standard curve values. Cell extracts were stored at -80°C at a protein 
concentration of 10 mg/ml. 
 Detection of CaSR expression 3.3.4.4
Human embryonic kidney 293 cell extracts were analysed for the presence of expressed 
CaSR-FLAG or CaSR by western blotting (Section 2.19). Aliquots of cell extract containing 
10 µg of protein were added to 20 µl of sodium dodecyl sulphate (SDS)-sample buffer (2% 
(w/v) SDS; 25% (v/v) glycerol; 0.01% (w/v) bromophenol blue; 2% (v/v) 2-
mercaptoethanol; 62.5 mM Tris-hydrochloride, pH 6.8) (Bio-Rad Laboratories Ltd.) and 
heated at 95°C for 5 min. Proteins were subjected to SDS-PAGE in 7.5% (w/v) 
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polyacrylamide gels along with Precision Plus Protein All Blue Standards (10-250 kDa) (Bio-
Rad Laboratories. Ltd.), as described in Section 2.17. 
The separated proteins were transferred onto Whatman™ Westran® Clear Signal 
polyvinylidene difluoride (PVDF) blotting membrane (GE Healthcare Life Sciences), as 
detailed in Section 2.19. The membranes were subjected to western blotting with either 
rabbit anti-CaSR (C-terminal peptide) polyclonal antiserum used at 1:100 dilution (anti-
CASR11-S antiserum; Alpha Diagnostics, International, San Antonio, TX, USA) and goat 
anti-rabbit IgG polyclonal antibody conjugated to horseradish peroxidase used at a 
dilution of 1:1000 (anti-rabbit IgG antibody-HRP; Sigma-Aldrich) or mouse anti-FLAG 
epitope (DYKDDDDK) monoclonal antibody conjugated to horseradish peroxidase used at 
a dilution of 1:1000 (anti-FLAG antibody-HRP; Sigma-Aldrich). Blots were developed using 
enhanced chemiluminescence (Section 2.19) and then exposed to Fuji Medical X-Ray Film 
(FujiFilm Europe GmbH, Dusseldorf, Germany) for 5-min periods in a Hypercassette™ (GE 
Healthcare Life Sciences) at room temperature. Exposed films were subsequently 
developed using Photosol CD18 x-ray developer (Photosol Ltd., Basildon, UK), rinsed in 
water and then fixed in Photosol CF40 fixer (Photosol Ltd.). 
 CaSR immunopreciptation assays 3.3.4.5
For each CaSR immunoprecipitation assay (Figure 3.3), a 50-µl aliquot of pre-washed 
GammaBind G Sepharose beads (GE Healthcare Life Sciences, Little Chalfont, UK) was 
incubated with a 1:50 dilution of APS1 patient or control serum in 1 ml of 
immunoprecipitation buffer for 1 h at 4°C. As a positive control, anti-CaSR11-S antiserum 
was used in the assay at a 1:100 dilution. Assays without serum were used as controls for 
non-specific binding of the CaSR-FLAG protein to the beads. Bead-IgG complexes were 
then collected by centrifugation and subsequently incubated in 1 ml of 
immunoprecipitation buffer with an aliquot of HEK293-CaSR-FLAG cell extract containing 
500 µg of total protein at 4°C for 16 h. Subsequently, the bead-IgG-protein complexes 
were collected by centrifugation and washed three times for 15 min at 4°C with 
immunoprecipitation buffer. Finally, 20 µl of SDS-sample buffer were added to the bead-
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IgG-protein complexes and the sample heated at 95°C for 5 min. Immunoprecipitated 
proteins were subjected to SDS-PAGE and western blotting exactly as described above 
(Section 3.3.4.4). Densitometry of the bands on exposed film was carried out in a Bio-Rad 
GS 690 Scanning Densitometer with Multi-Analyst Version 1.1 Software (Bio-Rad 
Laboratories Ltd.), which produced a densitometry value for each individual band. Sera 
were always tested in duplicate and the mean densitometry value was calculated from the 
two samples.  
A CaSR antibody index for each serum was calculated as: densitometry value of tested 
serum/mean densitometry value of a population of healthy control sera. Each serum was 
tested in at least two experiments and the mean CaSR antibody index calculated. The 
upper limit of normal for the CaSR immunoprecipitation assay was calculated using the 
mean CaSR antibody index + 3SD of a population of healthy individuals. Any serum with a 
CaSR antibody index above the upper limit of normal was designated as positive for CaSR 
antibodies. 
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Figure ‎3.3: Schematic representation of the CaSR immunoprecipitation assay. 
The stages of the assay are (a) Gammabind® G Sepharose beads bind to APS1 patient’s IgG, (b) 
CaSR-FLAG protein in the HEK293 cell extract binds to specific anti-CaSR antibodies if there are any 
present in the APS1 patient’s serum, and (c) the complexes of the beads-IgG-CaSR-FLAG protein 
are collected and analysed by SDS-PAGE and western blotting to determine if the CaSR has been 
immunoprecipitated. 
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 Detection of NALP5 antibodies 3.3.5
As detailed below, NALP5 antibodies were detected using radioligand binding assays 
(RLBAs) with in vitro translated radiolabelled NALP5 as the ligand. 
 In vitro translation of NALP5 cDNA 3.3.5.1
A TnT® T7-Coupled Reticulocyte Lysate System (Promega, Southampton, UK) was used to 
produce NALP5 labelled with [35S]-methionine, as detailed previously (Alimohammadi et 
al., 2008) The plasmid pCMV6-XL5-NALP5 (Figure 3.4) was vector pCMV6-XL5 (OriGene 
Technologies Inc., Rockville, MD, USA) containing NALP5 cDNA (3,600-basepairs) and was 
a gift from Professor Olle Kampe (Department of Medical Sciences, Uppsala University 
Hospital, Uppsala, Sweden). In vitro translation reactions were set up in 0.5 ml tubes in 50-
μl volumes containing: 0.5 μg of plasmid pCMV6-XL5-NALP5, 0.5 volumes of TnT® Rabbit 
Reticulocyte Lysate, 10 units of TnT® T7 RNA Polymerase, 0.02 mM amino acid mixture 
minus methionine, 0.04 volumes of 25x TnT® Reaction Buffer, 40 units of RNasin® 
Ribonuclease Inhibitor (Promega) and 0.04 volumes of 10 mCi/ml translation-grade [35S]-
methionine (1,000 Ci/mmol) (Perkin-Elmer LAS UK Ltd., Beaconsfield, UK). Reactions were 
incubated at 30°C for 120 min and then stored at -40°C until needed. 
The percentage incorporation of [35S]-methionine into the translated NALP5 protein was 
determined by trichloroacetic acid-precipitation, as detailed by the manufacturer 
(Promega). In brief, 2 µl of the in vitro translation reaction were added to 98 µl of 1 M 
sodium hydroxide/2% (v/v) hydrogen peroxide and incubated at 37°C for 10 min. 
Subsequently, 900 µl of ice-cold 25% (w/v) trichloroacetic acid/2% (w/v) casamino acids 
(Difco, Detroit, MI, USA) were added and the reaction incubated on ice for 30 min. To 
collect the precipitated translation products, 250 µl of the trichloroacetic acid reaction 
mixture were vacuum filtered onto a Whatman GF/A glass fibre filter (Whatman 
International Ltd., Maidstone, UK) pre-wetted with cold 5% (w/v) trichloroacetic acid. The 
filter was rinsed three times with 1 ml of ice-cold 5% (w/v) trichloroacetic acid, once with 
1 ml of acetone and then allowed to dry at room temperature before immersing in 3 ml of 
Ultima-Gold® XR scintillation fluid (Packard Bioscience, Groningen, The Netherlands) and 
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counting in a Beckman LS 6500 Multi-Purpose Scintillation Counter (Beckman Coulter, Inc., 
Fullerton, CA, USA). To determine total counts per min (cpm) present in the reaction, a 5-
µl aliquot of the trichloroacetic acid reaction mixture was spotted directly on to a filter. 
This was dried for 10 min before counting as above. The percent incorporation of [35S]-
methionine was determined as: 100 x (cpm of washed filter/cpm of unwashed filter x 50), 
and this ranged from 7-15%. 
For qualitative analysis of radiolabelled NALP5 protein, a 5-µl aliquot of the in vitro 
translation reaction containing [35S]-NALP5 was added to 20 µl of SDS-sample buffer and 
heated at 95°C for 5 min prior to SDS-PAGE in an 8% (w/v) polyacrylamide gel, as detailed 
in Section 2.17. Precision Plus Protein All Blue Standards (10-250 kDa) were also loaded 
onto the gel as protein size markers. After running, the gel was treated with Coomassie 
Blue® stain (0.05% (w/v) Coomassie® Brilliant Blue (Bio-Rad Laboratories Ltd.); 10% (v/v) 
glacial acetic acid; 25% (v/v) isopropanol) and then destain solution (10% (v/v) glacial 
acetic acid; 25% (v/v) isopropanol) before soaking for 30 min in Amersham Amplify™ 
Fluorographic Reagent (GE Healthcare Life Sciences), before drying for 2 h at 60°C on to 
3MM Whatman paper (Whatman International Ltd.) in a Bio-Rad Gel Dryer 583 (Bio-Rad 
Laboratories Ltd.). The dried gel was subjected to autoradiography by exposure to Fuji 
Medical X-Ray Film in a Hypercassette™ at room temperature for 24 h. Exposed film was 
subsequently developed using Photosol CD18 x-ray developer, rinsed in water and then 
fixed in Photosol CF40 fixer. 
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Figure ‎3.4: Details of plasmid pCMV6-XL5-NALP5. 
Plasmid pCMV6-XL5-NALP5 is vector pCMV6-XL5 containing full-length NALP5 cDNA (3,600-
basepairs) cloned in the EcoRI and SalI restriction sites of the multi-cloning site (MCS) and was in 
the correct orientation for expression from the T7 promoter present in the pCMV6-XL5. The 
selectable marker for propagation in bacteria was ampicillin resistance. 
  
Amino acid sequence of NALP5 protein 
 
MKVAGGLELGAAALLSASPRALVTLSTGPTCSILPKNPLFPQNLSSQPCIKMEG
DKSLTFSSYGLQWCLYELDKEEFQTFKELLKKKSSESTTCSIPQFEIENANVEC
LALLLHEYYGASLAWATSISIFENMNLRTLSEKARDDMKRHSPEDPEATMTDQG
PSKEKVPGISQAVQQDSATAAETKEQEISQAMEQEGATAAETEEQEISQAMEQE
GATAAETEEQGHGGDTWDYKSHVMTKFAEEEDVRRSFENTAADWPEMQTLAGAF
DSDRWGFRPRTVVLHGKSGIGKSALARRIVLCWAQGGLYQGMFSYVFFLPVREM
QRKKESSVTEFISREWPDSQAPVTEIMSRPERLLFIIDGFDDLGSVLNNDTKLC
KDWAEKQPPFTLIRSLLRKVLLPESFLIVTVRDVGTEKLKSEVVSPRYLLVRGI
SGEQRIHLLLERGIGEHQKTQGLRAIMNNRELLDQCQVPAVGSLICVALQLQDV
VGESVAPFNQTLTGLHAAFVFHQLTPRGVVRRCLNLEERVVLKRFCRMAVEGVW
NRKSVFDGDDLMVQGLGESELRALFHMNILLPDSHCEEYYTFFHLSLQDFCAAL
YYVLEGLEIEPALCPLYVEKTKRSMELKQAGFHIHSLWMKRFLFGLVSEDVRRP
LEVLLGCPVPLGVKQKLLHWVSLLGQQPNATTPGDTLDAFHCLFETQDKEFVRL
ALNSFQEVWLPINQNLDLIASSFCLQHCPYLRKIRVDVKGIFPRDESAEACPVV
PLWMRDKTLIEEQWEDFCSMLGTHPHLRQLDLGSSILTERAMKTLCAKLRHPTC
KIQTLMFRNAQITPGVQHLWRIVMANRNLRSLNLGGTHLKEEDVRMACEALKHP
KCLLESLRLDCCGLTHACYLKISQILTTSPSLKSLSLAGNKVTDQGVMPLSDAL
RVSQCALQKLILEDCGITATGCQSLASALVSNRSLTHLCLSNNSLGNEGVNLLC
RSMRLPHCSLQRLMLNQCHLDTAGCGFLALALMGNSWLTHLSLSMNPVEDNGVK
LLCEVMREPSCHLQDLELVKCHLTAACCESLSCVISRSRHLKSLDLTDNALGDG
GVAALCEGLKQKNSVLARLGLKACGLTSDCCEALSLALSCNRHLTSLNLVQNNF
SPKGMMKLCSAFACPTSNLQIIGLWKWQYPVQIRKLLEEVQLLKPRVVIDGSWH
SFDEDDRYWWKN 
 
Nucleotide sequence of NALP5 cDNA 
 
atgaaggttgcaggaggacttgaacttggagctgctgctctgctctcagcatcaccacgtgctcttgtcactctttccacaggtcctacttgctctatattaccaaagaatccacttttccccc
aaaacctgagctctcagccttgtatcaagatggaaggagacaaatcgctcaccttttccagctacgggctgcaatggtgtctctatgagctagacaaggaagaatttcagacattcaaggaatt
actaaagaagaaatcttcagaatcgaccacatgctctattccacagtttgaaatcgagaatgccaacgtggaatgtctggcactcctcttgcatgagtattatggagcatcgctggcctgggct
acgtccattagcatctttgaaaacatgaacctgcgaaccctctcggagaaggcacgggatgacatgaaaagacattcaccagaagatcctgaagcaacgatgactgaccaaggaccaagcaagg
aaaaagtgccaggaatttcacaagctgtgcaacaagatagtgccacagctgcagagacaaaagaacaagaaatttcacaagctatggaacaagaaggtgccacagcagcagagacagaagaaca
agaaatttcacaagctatggaacaagaaggtgccacagcagcagagacagaagaacaaggacatggaggtgacacatgggactacaagagtcacgtgatgaccaaattcgctgaggaggaggat
gtacgtcgtagttttgaaaacactgctgctgactggccggaaatgcaaacgttggctggtgcttttgattcagaccggtggggcttccggcctcgcacggtggttctgcacggaaagtcaggaa
ttgggaaatcggctctagccagaaggatcgtgctgtgctgggcgcaaggtggactctaccagggaatgttctcctacgtcttcttcctccccgttagagagatgcagcggaagaaggagagcag
tgtcacagagttcatctccagggagtggccagactcccaggctccggtgacggagatcatgtcccgaccagaaaggctgttgttcatcattgacggtttcgatgacctgggctctgtcctcaac
aatgacacaaagctctgcaaagactgggctgagaagcagcctccgttcaccctcatacgcagtctgctgaggaaggtcctgctccctgagtccttcctgatcgtcaccgtcagagacgtgggca
cagagaagctcaagtcagaggtcgtgtctccccgttacctgttagttagaggaatctccggggaacaaagaatccacttgctccttgagcgcgggattggtgagcatcagaagacacaagggtt
gcgtgcgatcatgaacaaccgtgagctgctcgaccagtgccaggtgcccgccgtgggctctctcatctgcgtggccctgcagctgcaggacgtggtgggggagagcgtcgcccccttcaaccaa
acgctcacaggcctgcacgccgcttttgtgtttcatcagctcacccctcgaggcgtggtccggcgctgtctcaatctggaggaaagagttgtcctgaagcgcttctgccgtatggctgtggagg
gagtgtggaataggaagtcagtgtttgacggtgacgacctcatggttcaaggactcggggagtctgagctccgtgctctgtttcacatgaacatccttctcccagacagccactgtgaggagta
ctacaccttcttccacctcagtctccaggacttctgtgccgccttgtactacgtgttagagggcctggaaatcgagccagctctctgccctctgtacgttgagaagacaaagaggtccatggag
cttaaacaggcaggcttccatatccactcgctttggatgaagcgtttcttgtttggcctcgtgagcgaagacgtaaggaggccactggaggtcctgctgggctgtcccgttcccctgggggtga
agcagaagcttctgcactgggtctctctgttgggtcagcagcctaatgccaccaccccaggagacaccctggacgccttccactgtcttttcgagactcaagacaaagagtttgttcgcttggc
attaaacagcttccaagaagtgtggcttccgattaaccagaacctggacttgatagcatcttccttctgcctccagcactgtccgtatttgcggaaaattcgggtggatgtcaaagggatcttc
ccaagagatgagtccgctgaggcatgtcctgtggtccctctatggatgcgggataagaccctcattgaggagcagtgggaagatttctgctccatgcttggcacccacccacacctgcggcagc
tggacctgggcagcagcatcctgacagagcgggccatgaagaccctgtgtgccaagctgaggcatcccacctgcaagatacagaccctgatgtttagaaatgcacagattacccctggtgtgca
gcacctctggagaatcgtcatggccaaccgtaacctaagatccctcaacttgggaggcacccacctgaaggaagaggatgtaaggatggcgtgtgaagccttaaaacacccaaaatgtttgttg
gagtctttgaggctggattgctgtggattgacccatgcctgttacctgaagatctcccaaatccttacgacctcccccagcctgaaatctctgagcctggcaggaaacaaggtgacagaccagg
gagtaatgcctctcagtgatgccttgagagtctcccagtgcgccctgcagaagctgatactggaggactgtggcatcacagccacgggttgccagagtctggcctcagccctcgtcagcaaccg
gagcttgacacacctgtgcctatccaacaacagcctggggaacgaaggtgtaaatctactgtgtcgatccatgaggcttccccactgtagtctgcagaggctgatgctgaatcagtgccacctg
gacacggctggctgtggttttcttgcacttgcgcttatgggtaactcatggctgacgcacctgagccttagcatgaaccctgtggaagacaatggcgtgaagcttctgtgcgaggtcatgagag
aaccatcttgtcatctccaggacctggagttggtaaagtgtcatctcaccgccgcgtgctgtgagagtctgtcctgtgtgatctcgaggagcagacacctgaagagcctggatctcacggacaa
tgccctgggtgacggtggggttgctgcgctgtgcgagggactgaagcaaaagaacagtgttctggcgagactcgggttgaaggcatgtggactgacttctgattgctgtgaggcactctccttg
gccctttcctgcaaccggcatctgaccagtctaaacctggtgcagaataacttcagtcccaaaggaatgatgaagctgtgttcggcctttgcctgtcccacgtctaacttacagataattgggc
tgtggaaatggcagtaccctgtgcaaataaggaagctgctggaggaagtgcagctactcaagccccgagtcgtaattgacggtagttggcattcttttgatgaagatgaccggtactggtggaa
aaac 
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 NALP5 radioligand binding assays 3.3.5.2
This method was carried out according to the protocol of Dr Helen Kemp (Department of 
Oncology and Metabolism, University of Sheffield, Sheffield, UK). For each NALP5 RLBA 
(Figure 3.5), a 1 to 2-μl aliquot of the required in vitro translation reaction (equivalent to 
50,000-100,000 cpm of trichloroacetic acid-precipitable material) was suspended in 50 μl 
of immunoprecipitation buffer (20 mM Tris-hydrochloride, pH 8.0; 150 mM sodium 
chloride; 1% (v/v) Triton X-100; 10 mg/ml aprotinin (Bayer, Newbury, UK)) in a 1.5-ml 
tube. An APS1 patient or control serum was added to a tube at a 1:100 dilution. As a 
positive control, goat anti-NALP5 (internal peptide) polyclonal antibody (anti-NALP5 
antibody) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was added to a tube at a 
1:200 dilution. Assay tubes without serum were also included as controls for non-specific 
binding of radiolabelled NALP5 protein to protein G Sepharose™ 4 Fast Flow (GE 
Healthcare Life Sciences). The assay tubes were incubated overnight with shaking at 4°C. 
Subsequently, 50 μl of protein G Sepharose™ 4 Fast Flow, prepared according to the 
manufacturer, were added to each of the tubes, which were then incubated for a further 
90 min at 4°C. Subsequently, the protein G Sepharose-antibody-antigen complexes were 
collected by centrifugation at 5,000 g and washed six times for 15 min in 
immunoprecipitation buffer at 4°C. The complexes were then transferred to 1 ml of 
Ultima-Gold® XR scintillation fluid contained in a 10-ml scintillation vial (Molecular 
Devices, Sunnyvale, CA, USA). Immunoprecipitated radioactivity in cpm was evaluated in a 
Beckman LS 6500 Multi-Purpose Scintillation Counter. Sera were always tested in 
duplicate and the mean cpm was calculated from the two samples. 
Antibody levels were expressed as a NALP5 antibody index. This was calculated for each 
serum tested as: cpm immunoprecipitated by tested serum/mean cpm 
immunoprecipitated by the population of healthy control sera. Each serum was tested in 
at least two experiments and the mean NALP5 antibody index calculated. The upper limit 
of normal for the NALP5 RLBA was calculated using the mean NALP5 antibody index + 3SD 
of a population of healthy controls. Any serum sample with a NALP5 antibody index above 
the upper limit of normal was designated as NALP5 antibody-positive. 
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For qualitative analysis of immunoprecipitated NALP5 protein, the protein G Sepharose™-
antibody-antigen complexes were resuspended in 100 μl of SDS-sample buffer, heated at 
95°C for 5 min, centrifuged, and the supernatants recovered for SDS-PAGE and 
autoradiography as described in Section 3.3.5.1. 
 Statistical analyses 3.3.6
As appropriate, Fisher’s exact test for 2 x 2 contingency tables for comparing categorical 
data, non-parametric Mann-Whitney tests for comparing two unpaired groups of 
continuous data, non-parametric Spearman’s rank (r) correlation test to measure the 
statistical dependence between two variables, and multiple regression analysis for 
estimating the relationship between a dependent variable and one or more independent 
variables, were carried out using GraphPad Instat 3 software (GraphPad Software, La Jolla, 
CA, USA). In all tests, P values (two-tailed) < 0.05 were regarded as significant. 
Antibody assay precision was evaluated by calculating the intra-assay coefficient of 
variation (expressed as a percentage) for a series of different serum samples that were 
measured in duplicate within the same assay run. Antibody assay reproducibility was 
evaluated by calculating the inter-assay coefficient of variation (expressed as a 
percentage) for a series of different serum samples that were measured in several 
consecutive assay runs. 
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Figure ‎3.5: Schematic diagram of the NALP5 radioligand binding assay. 
The stages of the assay are (a) in vitro translated NALP5 binds to specific anti-NALP5 antibodies if 
there are any present in the APS1 patient’s serum, (b) protein G Sepharose binds to IgG molecules, 
and (c) the protein G Sepharose-IgG-radiolabelled NALP5 complexes are collected and analysed in 
a scintillation counter to determine if the NALP5 protein has been immunoprecipitated.  
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 Results 3.4
 Clinical characteristics of APS1 patients 3.4.1
The clinical profile of each of the APS1 patients is given in Table 3.1. The mean age at 
APS1 presentation was five years (range: 0-18 years) and the mean APS1 duration was 28 
years (range: 5.5-53 years). Of the 44 patients, 43 (98%) had either two or three of the 
major APS1 clinical manifestations of chronic mucocutaneous candidiasis, 
hypoparathyroidism and Addison’s disease. The remaining patient had chronic 
mucocutaneous candidiasis, no hypoparathyroidism nor Addison’s disease, but had five 
other APS1 component diseases. Thirty eight of the 44 patients (86%) had at least one 
other disease component outside of the classic APS1 triad, four patients had seven (16%), 
with the median being five. The number and percentage of the 44 APS1 patients with the 
various endocrine, ectodermal and other disease manifestations are summarised in Figure 
3.6.  
Excluding premature ovarian failure and male hypogonadism, there were no significant 
differences between the sexes with regard to the presence of the APS1 component 
diseases, except in the case of hypoparathyroidism. This disease manifestation was 
present in 25 out of 26 (96%) females and 13 out of 18 (72%) males (P = 0.034, Fisher’s 
exact test for 2 x 2 contingency tables). The mean age at hypoparathyroidism presentation 
was seven years (range: 1.5-19 years) and the mean duration of hypoparathyroidism was 
25 years (range: 0-54 years). 
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Table ‎3.1: APS1 patient demographic and clinical characteristics and AIRE genotypes 
 
 
Patient Sex
1
 
Age 
(years) 
Age at 
APS1 
onset 
(years) 
Age at 
HP 
onset 
(years)
2
 
APS1 
duration 
(years) 
HP 
duration 
(years)
2
 
Disease components
3
 AIRE genotype 
APS1-1 F 46 2 1.9 44 44.1 
CMC; HP; AD; HT; POF; AA; 
AS; TIN 
c.769C>T /c.769C>T 
APS1-2 M 46 7 6.7 39 39.3 
CMC; HP; AD; HT; HG; AA; 
V; T1D; AS; K 
c.769C>T /c.967-
979del13bp 
APS1-3 F 51 3 3.1 48 47.9 
CMC; AD; HP; POF; T1D; 
AS; OBS 
c.769C>T /c.769C>T 
APS1-4 M 37 2 2 35 35 CMC; AD; HP; T1D; c.769C>T /c.769C>T 
APS1-5 F 10 5 5.3 5 4.7 CMC; HP; AD c.769C>T /c.769C>T 
APS1-6 F 12 3 4.5 9 7.5 CMC; HP; AD; POF; GHD c.769C>T /c.769C>T 
APS1-7 M 9 4 4 5 5 CMC; HP; AD; K c.769C>T /c.769C>T 
APS1-8 M 13 5 15.5 8 0 CMC; HP; AD; K; V; CD; AS c.769C>T /c.769C>T 
APS1-9 M 30 7 7.3 21 22.7 CMC; HP; AD; T1D c.769C>T /c.769C>T 
APS1-10 M 47 15 NA 32 NA CMC; AD; PA; AA c.769C>T /c.769C>T 
APS1-11 F 16 4 6.5 12 9.5 CMC; HP; AD; H; POF; OBS c.769C>T /c.769C>T 
APS1-12 F 27 2 6.8 25 20.2 
CMC; HP; AD; K; AA; POF; 
OBS 
c.769C>T /c.769C>T 
APS1-13 M 25 4 15 21 10 
CMC; HP; AD; K; AA; V; 
OBS; AS; HG 
c.769C>T /c.769C>T 
APS1-14 F 43 5 5 38 38 
CMC; HP; AD; POF; AA; V; 
CD 
c.769C>T /c.769C>T 
APS1-15 M 9 5 7.5 4 1.5 CMC; HP; AD c.769C>T /c.769C>T 
APS1-16 F 11 5 8.5 6 2.5 CMC; HP; AD c.769C>T /c.769C>T 
APS1-17 M 12 7 7.7 5 4.3 CMC; HP; AD c.769C>T /c.769C>T 
APS1-18 F 26 1 1.6 25 24.4 
CMC; HP; AD; POF; PA; AA; 
EPA; T1D; AS; V 
c.769C>T /c.769C>T 
APS1-19 M 23 1 1.5 22 21.5 
CMC; HP; AD; AA; V; T1D; 
HT; AS; AT 
c.769C>T /c.769C>T 
APS1-20 F 46 2 6.8 44 39.2 
CMC; HP; AD; POF; AA; 
K;OBS 
c.769C>T /c.769C>T 
APS1-21 F 43 5 4.2 38 38.8 
CMC; HP; AD; POF; PA; AA; 
V; T1D; AS; OBS 
c.769C>T /c.769C>T 
APS1-22 M 67 18 NA 49 NA CMC; AD; T1D c.769C>T /c.769C>T 
APS1-23 M 32 3 18.9 29 13.1 CMC; AD; HP; AA c.769C>T /c.769C>T 
APS1-24 F 32 6 6.5 26 25.5 CMC; AD; HP; POF; OBS c.769C>T /c.769C>T 
APS1-25 F 56 4 2.5 51 53.5 
CMC; AD; HP; HT; POF ; K; 
OBS 
c.769C>T /c.769C>T 
APS1-26 F 32 7 8 25 24 CMC; HP; HT; OBS 
c.769C>T/1163^1164i
nsA 
APS1-27 F 25 10 10.9 15 14.1 CMC; HP; POF; TIN; OBS c.769C>T /c.769C>T 
APS1-28 F 46 5 4.9 41 41.1 
CMC; HP; AD; POF; AS; 
OBS 
c.769C>T /c.923G>A 
APS1-29 F 50 8 NA 42 NA CMC; AD; HT; AA; AS c.769C>T /c.923G>A 
APS1-30 M 43 0 15 28 28 
CMC; HP; AD; HT; AA; V; 
AS ; K; OBS 
c.769C>T /c.1638A>T 
APS1-31 F 17 4 4.2 13 12.8 CMC; HP; AD; POF; GHD 
c.769C>T /c.967-
979del13bp 
APS1-32 M 17 2 4.4 15 12.6 
CMC; HP; AD; V; AA; HT; 
GHD; H; K; OBS 
c.769C>T /c.769C>T 
APS1-33 F 52 3 14.2 49 37.8 CMC; HP c.769C>T /c.769C>T 
APS1-34 M 18 2 NA 16 NA CMC; V; AA; HG; TIN; OBS 
c.769C>T /c.967-
979del13bp 
APS1-35 F 54 6 2.0 48 54 CMC; HP; HT; K c.769C>T /c.769C>T 
APS1-36 F 58 5 4.5 53 53.5 CMC; AD; HP; AA;V; POF; c.769C>T /c.769C>T 
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APS1-37 F 8 2.5 2.5 5.5 5.5 CMC; AD; HP; OBS c.769C>T /c.1638A>T 
APS1-38 F 35 2 2.9 33 32.1 CMC; HP; HT; OBS c.769C>T /c.769C>T 
APS1-39 M 30 1 6.1 29 23.9 
CMC; AD; HP; AA; V; GHD; 
H; OBS 
c.769C>T /c.769C>T 
APS1-40 M 41 5 NA 36 NA CMC; AD; AA c.769C>T /c.769C>T 
APS1-41 F 44 2 3.6 42 40.4 
CMC; AD; HP; HT; POF; AS; 
AA; PA; K 
c.769C>T /c.769C>T 
APS1-42 M 44 6 NA 38 NA CMC; AD; AA c.769C>T /c.769C>T 
APS1-43 F 20 3 3.5 17 16.5 
CMC; AD; HP; HT; AA; POF; 
AS 
c.769C>T /c.769C>T 
APS1-44 F 56 10 10 46 46 CMC; AD; HP c.769C>T /c.769C>T 
 
1
F, female; M, male. 
2
NA, not applicable. 
3
AA, alopecia areata; AD, Addison’s disease; AT, arterial hypertension; AS, asplenia; CD, chronic diarrhoea; CMC, chronic 
mucocutaneous candidiasis; EPA, exocrine pancreatic atrophy; GHD, growth hormone deficiency; H, hepatitis; HG, 
hypogonadism (male); HP, hypoparathyroidism; HT, hypothyroidism; K, keratoconjunctivitis; OBS, chronic obstipation; 
PA, pernicious anaemia; POF, premature ovarian failure; T1D, type 1 diabetes mellitus; TIN, tubulonephritis; V, vitiligo.  
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Figure ‎3.6: Summary of disease components in APS1 patients. 
The number and percentage of the 44 APS1 patients with various endocrine, ectodermal and other 
disease manifestations are shown. 
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 AIRE genotypes of the APS1 patients 3.4.2
To confirm the clinical diagnosis of APS1, the AIRE gene of each patient was analysed for 
the presence of mutations by DNA sequencing. The AIRE genotypes of the individual APS1 
patients are given in Table 3.1. The exon 6 AIRE mutation c.769C>T (R257X) was found in 
all 44 (100%) patients, with 36 (82%) homozygous for this mutation. The remaining eight 
patients were compound heterozygotes with the c.769C>T mutation at one allele. The 
number and percentage of the 44 APS1 patients with different AIRE genotypes are 
summarised in Figure 3.7.  
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Figure ‎3.7: AIRE genotypes of APS1 patients. 
The number and percentage of the 44 APS1 patients with each AIRE genotype are shown. The 
effect of each AIRE gene mutation on the amino acid sequence of the protein is given in 
parentheses. c.769C>T (R257X) is in exon 6; c.967-979del13bp (C322fsX372) is in exon 8; c.923G>A 
(C311Y) is in exon 8; c.1638A>T (X546C) is in exon 14; and c.1163^1164insA (M388fsX422) is in 
exon 10. 
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 Detection of cytokine antibodies in APS1 patients and controls 3.4.3
To detect the presence of antibodies against IL-22, IL-17A, IL-17F, IFN-omega, IFN-
alpha2A, and IFN-lambda1, serum samples from 44 APS1 patients and 18 healthy controls 
were analysed in an ELISA format carried out as detailed in Section 3.3.3. The results are 
shown in Figures 3.8 and 3.9. For each cytokine ELISA, the mean antibody index of the 
APS1 patient and control groups, and the antibody index range of the APS1 patient and 
control groups are summarised in Table 3.2. In all cases, except in the IFN-lambda1 ELISA, 
there was a significant difference between the antibody indices of the APS1 patient and 
control groups (P values were < 0.0001, Mann-Whitney test). In the IFN-lambda1 ELISA, 
there was no significant different between the antibody indices of the APS1 patients and 
controls (P = 0.052, Mann-Whitney test). The intra- and inter-assay coefficients of 
variation for each of the ELISAs are given in Table 3.2. 
The upper limits of normal (mean antibody index + 3SD of 18 healthy individuals) for the 
cytokine ELISAs were antibody indices of 1.29 for the IL-22 ELISA; 1.29 for the IL-17F ELISA; 
1.29 for the IL-17A ELISA; 1.84 for the IFN-omega ELISA; 2.83 for the IFN-alpha2A ELISA; 
and 1.59 for the IFN-lambda1 ELISA. All control sera were negative for antibodies against 
all the cytokines tested, as their antibody indices (Table 3.2) were below the upper limit of 
normal. In the APS1 patient group, antibody indices above the upper limit of normal 
(Table 3.3), indicated that the prevalence of antibody-positivity against each cytokine was 
44/44 (100%) for IL-22; 41/44 (93%) for IL-17F; 25/44 (57%) for IL-17A; 29/44 (66%) for 
IFN-omega; 40/44 (91%) for IFN-alpha2A; and 5/44 (11%) for IFN-lambda1. With the 
exception of IFN-lambda1, antibody positivity was significantly more frequent in the APS1 
patient group than in the healthy controls: All P values were < 0.0001 (Fisher’s exact test 
for 2 x 2 contingency tables). In contrast, the antibody response against IFN-lambda1 was 
not elevated to statistical significance in the APS1 patient group when compared with 
healthy controls (P = 0.309, Fisher’s exact test for 2 x 2 contingency tables).  
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Figure ‎3.8: Interleukin (IL)-22, IL-17F and IL-17A antibody indices of APS1 patient and 
control sera. 
Sera from 44 APS1 patients and 18 healthy controls were evaluated for (a) IL-22, (b) IL-17F, and (c) 
IL-17A antibodies using ELISAs. The antibody index is shown for each APS1 patient and control 
serum and is the mean antibody index of at least two experiments. The mean antibody index ± SD 
for the APS1 patient group and the control group was, respectively, 27.0 ± 10.9 (range: 1.94-44.5) 
and 0.99 ± 0.10 (range: 0.88-1.11) in the IL-22 ELISA; 23.8 ± 13.7 (range: 1.12-42.2) and 0.99 ± 0.10 
(range: 0.87-1.19) in the IL-17F ELISA; and 5.56 ± 10.7 (range: 0.77-36.9) and 0.96 ± 0.11 (range: 
0.83-1.24) in the IL-17A ELISA. In all three ELISAs, there was a significant difference between the 
antibody indices of the APS1 patient and control groups (P values were < 0.0001, Mann-Whitney 
test). 
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Figure ‎3.9: Interferon (IFN)-omega, IFN-alpha2A and IFN-lambda1 antibody indices of 
APS1 patient and control sera. 
Sera from 44 APS1 patients and 18 healthy controls were evaluated for (a) IFN-omega, (b) IFN-
alpha2A, and (c) IFN-lambda1 antibodies using ELISAs. The antibody index is shown for each APS1 
patient and control serum and is the mean antibody index of at least two experiments. The mean 
antibody index ± SD for the APS1 patient group and the control group was, respectively, 6.85 ± 
6.56 (range: 0.47-20.2) and 0.79 ± 0.35 (range: 0.51-1.80) in the IFN-omega ELISA; 8.37 ± 3.90 
(range: 1.15-16.2) and 1.26 ± 0.52 (range: 0.76-2.75) in the IFN-alpha2A ELISA; and 1.41 ± 1.60 
(range: 0.48-9.38) and 0.84 ± 0.25 (range: 0.64-1.60) in the IFN-lambda1 ELISA. In the IFN-omega 
and IFN-alpha2A ELISAs, there was a significant difference between the antibody indices of the 
APS1 patient and control groups (P values were < 0.0001, Mann-Whitney test). In the IFN-lambda1 
ELISA, there was no significant different between the antibody indices of the APS1 patients and 
controls (P = 0.052, Mann-Whitney test). 
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Table ‎3.2: Summarised results of cytokine ELISAs 
 
ELISA detail Result 
IL-22 ELISA   
 Mean antibody index ± SD of APS1 patients  27.0 ± 10.9 
 Antibody index range of APS1 patients 1.94-44.5 
 Mean antibody index ± SD of healthy controls 0.99 ± 0.10 
 Antibody index range of healthy controls 0.88-1.11 
 Intra-assay coefficient of variation 4.3% 
 Inter-assay coefficient of variation 10.7% 
IL-17F ELISA  
 Mean antibody index ± SD of APS1 patients  23.8 ± 13.7 
 Antibody index range of APS1 patients 1.12-42.2 
 Mean antibody index ± SD of healthy controls 0.99 ± 0.10 
 Antibody index range of healthy controls 0.87-1.19 
 Intra-assay coefficient of variation 4.0% 
 Inter-assay coefficient of variation 4.8% 
IL-17A ELISA  
 Mean antibody index ± SD of APS1 patients  5.56 ± 10.7 
 Antibody index range of APS1 patients 0.77-36.9 
 Mean antibody index ± SD of healthy controls 0.96 ± 0.11 
 Antibody index range of healthy controls 0.83-1.24 
 Intra-assay coefficient of variation 4.1% 
 Inter-assay coefficient of variation 6.1% 
IFN-omega ELISA  
 Mean antibody index ± SD of APS1 patients  6.85 ± 6.56 
 Antibody index range of APS1 patients 0.47-20.2 
 Mean antibody index ± SD of healthy controls 0.79 ± 0.35 
 Antibody index range of healthy controls 0.51-1.80 
 Intra-assay coefficient of variation 3.0% 
 Inter-assay coefficient of variation 12.8% 
IFN-alpha2A ELISA  
 Mean antibody index ± SD of APS1 patients  8.37 ± 3.90 
 Antibody index range of APS1 patients 1.15-16.2 
 Mean antibody index ± SD of healthy controls 1.26 ± 0.52 
 Antibody index range of healthy controls 0.76-2.75 
 Intra-assay coefficient of variation 3.2% 
 Inter-assay coefficient of variation 10.8% 
IFN-lambda1 ELISA  
 Mean antibody index ± SD of APS1 patients  1.41 ± 1.60 
 Antibody index range of APS1 patients 0.48-9.38 
 Mean antibody index ± SD of healthy controls 0.84 ± 0.25 
 Antibody index range of healthy controls 0.64-1.60 
 Intra-assay coefficient of variation 2.7% 
 Inter-assay coefficient of variation 5.2% 
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Table ‎3.3: Summary of APS1 patient antibody reactivities 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
Bold type-face indicates antibody-positive APS1 patient serum. 
Patient 
Antibody index in each antibody assay
1 
CaSR NALP5 IL-22 IL-17F IL-17A 
IFN-
omega 
IFN-
alpha2A 
IFN-
lambda1 
APS1-1 2.63 0.57 31.2 6.98 1.29 6.09 8.97 0.70 
APS1-2 2.83 0.61 23.4 38.3 36.9 0.82 4.99 0.72 
APS1-3 4.59 1.35 22.8 22.1 4.86 4.23 7.40 3.76 
APS1-4 8.64 1.25 19.4 3.32 8.37 8.82 7.59 5.15 
APS1-5 33.2 1.09 15.2 1.30 0.98 0.80 5.84 0.87 
APS1-6 16.5 121.7 38.5 15.5 34.3 3.09 14.1 1.31 
APS1-7 21.7 32.5 10.0 1.12 1.84 14.6 13.0 1.25 
APS1-8 4.25 1.41 38.0 22.0 2.01 7.06 13.7 1.09 
APS1-9 52.4 1.11 40.2 37.9 1.73 1.83 16.2 1.11 
APS1-10 42.3 0.62 1.94 4.13 2.37 10.4 12.8 1.44 
APS1-11 8.50 1.14 43.4 38.6 3.64 5.47 13.4 1.15 
APS1-12 21.2 19.3 15.9 30.9 1.52 0.99 3.74 0.95 
APS1-13 4.22 0.65 38.5 38.7 1.88 11.6 15.2 1.04 
APS1-14 49.1 0.87 36.6 38.0 1.65 19.6 13.6 1.08 
APS1-15 77.9 3.45 28.5 33.6 1.54 0.97 1.85 0.69 
APS1-16 120.2 0.84 14.8 1.19 0.77 0.47 3.33 0.48 
APS1-17 1.03 0.86 35.8 5.60 1.76 1.83 10.8 1.30 
APS1-18 1.98 28.5 37.6 38.7 1.68 8.49 15.2 1.36 
APS1-19 1.00 0.89 44.5 38.5 3.49 20.2 15.5 1.07 
APS1-20 0.74 1.40 16.5 23.9 0.95 1.18 2.60 0.64 
APS1-21 1.10 0.63 40.7 31.2 1.24 0.93 2.87 0.73 
APS1-22 1.65 3.59 29.2 16.2 1.61 2.57 6.67 0.93 
APS1-23 0.96 1.20 23.3 23.5 0.98 17.6 6.23 0.63 
APS1-24 0.59 8.98 32.3 39.7 1.71 2.05 7.29 0.79 
APS1-25 0.64 1.41 34.4 42.2 1.11 3.62 7.66 0.60 
APS1-26 1.19 1.16 30.3 13.5 4.18 7.51 6.73 0.77 
APS1-27 0.76 1.04 37.3 23.2 1.09 1.69 8.77 1.18 
APS1-28 0.73 39.5 31.3 17.1 0.94 1.36 1.15 0.64 
APS1-29 0.68 12.4 11.0 7.22 1.04 1.56 2.31 0.59 
APS1-30 0.71 0.90 36.8 36.4 1.16 6.36 8.87 0.72 
APS1-31 1.11 0.82 6.36 24.5 1.18 7.72 8.25 5.37 
APS1-32 0.77 36.0 34.5 36.4 1.09 18.1 8.74 1.19 
APS1-33 1.42 0.92 23.6 4.48 1.61 1.86 8.73 1.44 
APS1-34 1.95 1.13 28.2 34.9 34.6 19.1 8.10 9.38 
APS1-35 0.81 0.91 33.0 8.95 1.02 4.18 8.84 0.76 
APS1-36 0.53 0.70 28.1 25.9 34.8 0.82 6.53 0.58 
APS1-37 1.35 6.72 29.2 36.7 33.1 17.6 9.27 0.79 
APS1-38 0.93 1.25 14.4 35.2 1.90 12.8 7.82 0.99 
APS1-39 1.04 37.8 35.7 38.3 1.29 17.4 8.30 1.67 
APS1-40 0.64 25.4 21.4 21.3 0.92 1.56 7.59 1.01 
APS1-41 0.75 0.92 7.93 0.91 0.99 4.30 6.41 0.83 
APS1-42 1.27 1.37 21.0 32.1 1.66 2.62 8.03 1.14 
APS1-43 0.95 1.19 30.9 34.9 0.94 1.11 6.85 0.85 
APS1-44 0.78 0.64 16.0 20.5 0.98 18.5 6.42 1.25 
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 Detection of CaSR antibodies in APS1 patients and controls 3.4.4
 Expression of CaSR-FLAG in HEK293 cells 3.4.4.1
The CaSR-FLAG protein expressed in HEK293 cells was detected as a 140-kDa band on 
western blots using anti-FLAG antibody-HRP or anti-CASR11-S antiserum plus anti-rabbit 
IgG antibody-HRP (Figure 3.10). No binding of the anti-FLAG antibody-HRP was observed 
on western blots containing extracts of HEK293 cells expressing CaSR without a FLAG 
epitope or extracts of untransfected HEK293 cells (Figure 3.10), indicating that the anti-
FLAG antibody-HRP did not bind non-specifically to other peptide sequences. 
 Results of CaSR immunoprecipitation assays 3.4.4.2
To detect the presence of antibodies against the CaSR, serum samples from 44 APS1 
patients and 23 healthy controls were analysed in CaSR immunoprecipitation assays, as 
detailed in Section 3.3.4. The results are shown in Figure 3.11. The mean CaSR antibody 
index of the APS1 patient group, the healthy control group and the anti-CASR11-S 
antiserum was, respectively, 11.3 ± 23.8 (range: 0.59-120.2), 1.00 ± 0.39 (range: 0.62-
1.93), and 31.6 ± 1.66 (range: 29.9-33.2). There was a significant difference between the 
CaSR antibody indices of the APS1 patient and control groups (P = 0.034, Mann-Whitney 
test). The intra- and inter-assay coefficients of variation for the CaSR immunoprecipitation 
assay were, respectively, 3.5% and 14.9%. 
The upper limit of normal for the CaSR immunoprecipitation assay was a CaSR antibody 
index of 2.17 (mean CaSR antibody index + 3SD of 23 healthy individuals). As expected, the 
CaSR was immunoprecipitated by the anti-CASR11-S antiserum which had a CaSR antibody 
index of 31.6, this being above the upper limit of normal. All healthy controls were CaSR 
antibody-negative as their CaSR antibody indices (range: 0.62-1.93) were below the upper 
limit of normal. Of the 44 APS1 patient sera, 16 (36%) were considered CaSR antibody-
positive, as their CaSR antibody index was above the upper limit of normal value of 2.17 
(Table 3.3). Compared with controls, the prevalence of CaSR antibodies was significantly 
 102 
elevated in the APS1 patient group (P = 0.0001, Fisher’s exact test for 2 x 2 contingency 
tables). 
Figure 3.12 illustrates western blotting for the detection of CaSR-FLAG protein with anti-
FLAG antibody-HRP following immunoprecipitation with patient sera, control sera or anti-
CASR11-S antiserum. In the absence of serum or anti-CASR-S11 antiserum in the CaSR 
immunoprecipitation assay reaction, the CaSR-FLAG protein could not be detected on the 
subsequent western blots with anti-FLAG antibody-HRP, indicating that there were no 
detectable levels of CaSR-FLAG binding to GammaBind G Sepharose beads. 
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Figure ‎3.10: Western blot of detection of CaSR and CaSR-FLAG proteins in HEK293 cell 
extracts 
Cell extracts from untransfected HEK293 cells and HEK293 cells transfected with either pcCaSR-
FLAG or pCDNA3-CaSR were subjected to SDS-PAGE in 7.5% (w/v) polyacrylamide gels and 
transferred to Whatman™ Westran® Clear Signal PVDF blotting membrane. Proteins were 
detected on the blots by enhanced chemiluminescence following probing with anti-CASR11-S 
antiserum plus anti-rabbit IgG antibody-HRP, or with anti-FLAG antibody-HRP. The CaSR protein 
appears as a 140-kDa band. The results are shown for: untransfected HEK293 cell extract probed 
with anti-CASR11-S antiserum plus anti-rabbit IgG antibody-HRP (lane 1); untransfected HEK293 
cell extract probed with anti-FLAG antibody-HRP (lane 2); pcDNA3-CaSR-transfected HEK293 cell 
extract probed with anti-CASR11-S antiserum plus anti-rabbit IgG antibody-HRP (lane 3); pcDNA3-
CaSR-transfected HEK293 cell extract probed with anti-FLAG antibody-HRP (lane 4); pcCaSR-FLAG-
transfected HEK293 cell extract probed with anti-CASR11-S antiserum plus anti-rabbit IgG 
antibody-HRP (lane 5); pcCaSR-FLAG-transfected HEK293 cell extract probed with anti-FLAG 
antibody-HRP (lane 6). 
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Figure ‎3.11: CaSR antibody indices of APS1 patient and control sera. 
Sera from 44 APS1 patients and 23 healthy controls were evaluated for CaSR antibodies using CaSR 
immunoprecipitation assays. The CaSR antibody index is shown for each APS1 patient and control 
serum and is the mean antibody index of at least two experiments. The mean CaSR antibody index 
± SD for the APS1 patient group and for the control group was, respectively, 11.3 ± 23.8 (range: 
0.59-120.2) and 1.00 ± 0.39 (range: 0.62-1.93). There was a significant difference between the 
CaSR antibody indices of the APS1 patient and control groups (P = 0.034, Mann-Whitney test).  
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Figure ‎3.12: Western blot for detection of CaSR-FLAG protein following 
immunoprecipitation with APS1 patient and control sera. 
APS1 patient and control sera, and anti-CASR11-S antiserum, were analysed for CaSR-FLAG binding 
in CaSR immunoprecipitation assays. Proteins immunoprecipitated from the HEK293 cell extract 
containing expressed CaSR-FLAG protein were separated by SDS-PAGE in 7.5% (w/v) 
polyacrylamide gels and transferred to Whatman™ Westran® Clear Signal PVDF blotting 
membrane. The CaSR-FLAG protein was detected on the blots using anti-FLAG antibody-HRP and 
enhanced chemiluminescence. The results are shown for immunoprecipitation of CaSR-FLAG by: 
anti-CASR11-S antiserum (lane 1); CaSR antibody-positive APS1 patient sera (lanes 2, 3 and 6); 
control sera (lanes 4, 5 and 7); GammaBind G Sepharose beads alone (no serum or anti-CASR11-
S antiserum) (lane 8). The image is from an article by Kemp et al, 2014, and is taken with kind 
permission from The Endocrine Society (2055 L Street NW, Suite 600, Washington, DC 20036, 
USA).  
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 Detection of NALP5 antibodies in APS1 patients and controls 3.4.5
 In vitro translation of NALP5 3.4.5.1
In vitro translation of NALP5 cDNA in plasmid pCMV6-XL5-NALP5 (Figure 3.5) produced a 
protein product with an estimated molecular weight of approximately 134 kDa (Figure 
3.13), which agreed well with the molecular weight of 132 kDa predicted from the amino 
acid sequence of the protein with 1201 residues (Brown et al., 1993). 
 Results of NALP5 radioligand binding assays 3.4.5.2
Forty-four APS1 patient and 38 control sera were tested for the presence of NALP5 
antibodies using NALP5 RLBAs, as detailed in Section 3.3.5. The results are shown in 
Figure 3.14. The mean NALP5 antibody index of the APS1 patient group, the healthy 
control group, and the anti-NALP5 antibody was, respectively, 9.24 ± 20.7 (range: 0.57-
121.7), 1.01 ± 0.24 (range: 0.57-1.38), and 28.9 ± 0.35 (range: 28.6-29.3). There was a 
significant difference between the NALP5 antibody indices of the APS1 patient and control 
groups (P = 0.038, Mann-Whitney test). The intra- and inter-assay coefficients of variation 
for the NALP5 RLBA were, respectively, 5.4% and 5.5%. 
The upper limit of normal for the NALP5 RLBA was an NALP5 antibody index of 1.73 (mean 
NALP5 antibody index + 3SD of 38 healthy individuals). As expected, NALP5 was 
immunoprecipitated by the anti-NALP5 antibody which had a NALP5 antibody index of 
28.9, this being above the upper limit of normal. Healthy controls were all NALP5 
antibody-negative, each with a NALP5 antibody index (range: 0.57-1.38) below the upper 
limit of normal. Of the 44 APS1 patient sera, 13 (30%) were considered NALP5 antibody-
positive, as their NALP5 antibody index was above the upper limit of normal value of 1.73 
(Table 3.3). Compared with controls, the prevalence of NALP5 antibodies was significantly 
elevated in the APS1 patient group (P = 0.0001, Fisher’s exact test for 2 x 2 contingency 
tables). 
Qualitative analysis of the proteins immunoprecipitated in the NALP5 RLBA by APS1 
patient and control sera indicated that all of the 13 NALP5 antibody-positive APS1 patient 
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sera tested immunoprecipitated a protein band of 134 kDa, which is of the expected size 
for NALP5 in SDS-polyacrylamide gels. This is illustrated in Figure 3.15, for three APS1 
patients, one healthy control, and the anti-NALP5 antibody. There was no detectable 
binding of [35S]-NALP5 to protein G SepharoseTM 4 Fast Flow in the absence of serum or 
anti-NALP5 antibody (Figure 3.15). 
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Figure ‎3.13: SDS-PAGE and autoradiography of [35S]-NALP5. 
Radiolabelled NALP5 was produced in vitro in a TnT® T7-Coupled Reticulocyte Lysate System using 
plasmid pCMV6-XL5-NALP5. [35S]-labelled NALP5 protein was analysed by SDS-PAGE in an 8% (w/v) 
SDS-polyacrylamide gel followed by autoradiography. Precision Plus Protein All Blue Standards (10-
250 kDa) are indicated.  
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Figure ‎3.14: NALP5 antibody indices of APS1 patient and control sera. 
Sera from 44 APS1 patients and 38 healthy controls were evaluated for NALP5 antibodies using 
NALP5 RLBAs. The NALP5 antibody index is shown for each APS1 patient and control serum and is 
the mean NALP5 antibody index of at least two experiments. The mean NALP5 antibody index ± SD 
for the APS1 patient group and the control group was, respectively, 9.24 ± 20.7 (range: 0.57-121.7) 
and 1.01 ± 0.24 (range: 0.57-1.38). There was a significant difference between the NALP5 antibody 
indices of the APS1 patient and control groups (P = 0.038, Mann-Whitney test). 
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Figure ‎3.15: SDS-PAGE and autoradiography of immunoprecipitated [35S]-NALP5 
following NALP5 radioligand binding assays with APS1 patient and control sera. 
Radiolabelled NALP5 was produced in vitro in a TnT® T7-Coupled Reticulocyte Lysate System and 
then used in NALP5 RLBAs with APS1 patient and control sera, and anti-NALP5 antibody. 
Immunoprecipitation of [35S]-labelled NALP5 protein was analysed by SDS-PAGE in 8% (w/v) 
polyacrylamide gels followed by autoradiography. The results are shown for: [35S]-NALP5 with 
protein G SepharoseTM 4 Fast Flow alone (no serum or anti-NALP5 antibody) (lane 1); [35S]-NALP5 
immunoprecipitated with a NALP5 antibody-negative control serum (lane 2); in vitro translated 
[35S]-NALP5 (without immunoprecipitation) (lane 3); [35S]-NALP5 immunoprecipitated with anti-
NALP5 antibody (lane 4); [35S]-NALP5 immunoprecipitated with NALP5 antibody-positive APS1 
patient sera (lanes 5-7). The image is from an article by Kemp et al, 2014, and is taken with kind 
permission from The Endocrine Society (2055 L Street NW, Suite 600, Washington, DC 20036, 
USA).  
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 Associations of CaSR and NALP5 antibodies with the clinical and demographic 3.4.6
characteristics and AIRE genotypes of APS1 patients 
No statistically significant associations were found between the presence of CaSR or 
NALP5 antibodies and the disease components of APS1, including hypoparathyroidism 
(Table 3.4) With respect to hypoparathyroidism diagnosis, the detection of CaSR and 
NALP5 antibodies had specificities (percentage of patients correctly identified with no 
hypoparathyroidism and calculated as: 100 x true negatives/true negatives + false 
positives) of 83% and 50%, and sensitivities (percentage of patients correctly diagnosed 
with hypoparathyroidism and calculated as: 100 x true positives/true positives + false 
negatives) of 39% and 26%, respectively (Table 3.4) In addition, there was no significant 
difference between the combined prevalence of CaSR and NALP5 antibodies (whether 
occurring alone or together) in patients with (21/38 = 55%) or without (4/6 = 66%) 
hypoparathyroidism (P = 0.68, Fisher’s exact test). Furthermore, the frequencies of CaSR 
and NALP5 antibodies were not significantly greater in females with APS1-associated 
hypoparathyroidism when compared with males with APS1-associated 
hypoparathyroidism (Table 3.5).  
There were no significant associations between the presence of CaSR or NALP5 antibodies 
and either the sex or age of the patients (Table 3.5). A significant association between a 
shorter APS1 duration (< 10 years) and positivity for CaSR antibodies was revealed, 
although this was not the case for NALP5 antibodies (Table 3.5). Furthermore, higher CaSR 
antibody indices correlated with a shorter duration of APS1 (Spearman’s r = -0.44 with 
95% confidence intervals: -0.66 to -0.16; P = 0.0027) (Figure 3.16). Multiple regression 
analysis indicated that the correlation of higher CaSR antibody indices with shorter APS1 
duration was not independent of age (P = 0.099), but was independent of sex (P = 0.010). 
In contrast, there was no significant correlation between higher NALP5 antibody indices 
and the duration of APS1 (Spearman’s r = -0.16 with 95% confidence intervals: -0.44 to 
0.15; P = 0.30).  
No significant associations were found with the AIRE genotypes of the APS1 patients and 
the presence of antibodies against the CaSR or NALP5. Fifteen patients were homozygous 
 112 
for the c.769C>T mutation. The remaining patient had a c.769C>T/c.967-979del13bp 
genotype. Amongst the 13 patients with NALP5 antibodies, there were 10 c.769C>T 
homozygotes, two c.769C>T/c.923G>A heterozygotes, and one c.769C>T/ c.1638A>T 
heterozygote. 
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Table ‎3.4: Prevalence of CaSR and NALP5 antibodies in APS1 patients with and without disease components 
 
1
P values were calculated using 2 x 2 contingency tables and Fisher’s exact test for comparing the prevalence of CaSR or NALP5 antibodies in APS1 
patients with or without disease components. P values < 0.05 were considered significant. 
 
2
ND, not determined. 
The table is from an article by Kemp et al, 2014, and is taken with kind permission from The Endocrine Society (2055 L Street NW, Suite 600, Washington, 
DC 20036, USA).  
  
 
Disease component 
 
Number of 
APS1 patients 
with disease 
component (%) 
Number of 
patients with 
disease 
component and 
CaSR antibodies 
(%) 
Number of 
patients 
without disease 
component and 
CaSR antibodies 
(%) 
 
P value
1
 
Number of 
patients with 
disease 
component and 
NALP5 antibodies 
(%) 
Number of 
patients without 
disease 
component and 
NALP5 antibodies 
(%) 
 
P 
value
1
 
Hypoparathyroidism 38/44 (86) 15/38 (39) 1/6 (17) 0.39 10/38 (26) 3/6 (50) 0.34 
Chronic mucocutaneous 
candidiasis 
44/44 (100) 16/44 (36) 0/0 (0) ND
2
 13/44 (30) 0/0 (0) ND
2
 
Addison’s disease 38/44 (86) 16/38 (42) 0/6 (0) 0.072 13/38 (34) 0/6 (0) 0.16 
Type 1 diabetes mellitus 8/44 (18) 4/8 (50) 12/36 (33) 0.43 2/8 (25) 11/36 (31) 1.00 
Alopecia areata 21/44 (45) 6/21 (29) 10/23 (43) 0.36 6/21 (29) 7/23 (30) 1.00 
Pernicious anaemia 4/44 (9.1) 1/4 (25) 15/40 (38) 1.00 1/4 (25) 12/40 (30) 1.00 
Premature ovarian failure 17/26 (65) 6/17 (35) 2/9 (22) 0.67 5/17 (29) 2/9 (22) 1.00 
Hypothyroidism 12/44 (27) 2/12 (17) 14/32 (44) 0.16 2/12 (17) 11/32 (34) 0.46 
Vitiligo 12/44 (27) 4/12 (33) 12/32 (38) 1.00 3/12 (25) 10/32 (31) 1.00 
Keratoconjunctivitis 11/44 (25) 5/11 (45) 11/33 (30) 0.49 3/11 (27) 10/33 (30) 1.00 
Asplenia 13/44 (23) 5/13 (38) 11/31 (35) 1.00 3/13 (23) 10/31 (32) 0.72 
Growth hormone deficiency 4/44 (9.1) 1/4 (25) 15/40 (38) 1.00 3/5 (60) 10/39 (26) 0.14 
Exocrine pancreatic atrophy 1/44 (2.3) 0/1 (0) 16/43 (37) 1.00 1/1 (100) 12/43 (30) 0.30 
Chronic diarrhoea 2/44 (4.5) 2/2 (100) 14/42 (33) 0.13 0/2 (0) 13/42 (31) 1.00 
Hepatitis 3/44 (6.8) 1/3 (33) 15/41 (37) 1.00 2/3 (67) 11/41 (27) 0.20 
Chronic obstipation 17/44 (39) 4/17 (24) 12/27 (44) 0.21 6/17 (35) 7/27 (26) 0.52 
Arterial hypertension 1/44 (2.3) 0/1 (0) 16/43 (37) 1.00 0/1 (0) 13/43 (30) 1.00 
Hypogonadism (male) 4/18 (22) 2/4 (50) 6/14 (43) 1.00 1/4 (25) 5/14 (36) 1.00 
Tubulonephritis 3/44 (6.8) 1/3 (33) 15/41 (37) 1.00 0/3 (0) 13/41 (32) 0.54 
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Table ‎3.5: Comparison of demographic and clinical characteristics of APS1 patients with and without CaSR or NALP5 
antibodies 
 
       
1
Mean age or disease duration and SD of the APS1 patient group. 
2
P value calculated using Fisher’s exact test for 2 x 2 contingency tables for comparing the prevalence of demographic and clinical characteristics in CaSR or 
NALP5 antibody-positive and antibody-negative patient groups. P values < 0.05 were considered significant. 
3
P value calculated using the Mann-Whitney test for comparing demographic and clinical characteristics in CaSR or NALP5 antibody-positive and antibody-
negative patient groups. P values < 0.05 were considered significant. 
The table is from an article by Kemp et al, 2014, and is taken with kind permission from The Endocrine Society (2055 L Street NW, Suite 600, Washington, 
DC 20036, USA).  
  
Demographic/clinical characteristic Number of CaSR 
antibody-positive 
APS1 patients with 
characteristic (%) 
(except detail of 
the whole group
1
) 
Number of CaSR 
antibody-negative 
APS1 patients with 
characteristic (%) 
(except detail of 
the whole group
1
) 
P value Number of NALP5 
antibody-positive 
APS1 patients with 
characteristic (%) 
(except detail of 
the whole group
1
) 
Number of NALP5 
antibody-negative 
APS1 patients with 
characteristic (%) 
(except detail of 
the whole group
1
) 
P value
 
Sex 
All APS1 patients (n = 44) 
 Male  
 Female  
APS1 patients with hypoprathyroidism (n =38) 
 Male  
 Female  
 
 
8/16 (50) 
8/16 (50) 
 
7/15 (47) 
8/15 (53) 
 
 
10/28 (36) 
18/28 (64) 
 
6/23 (26) 
17/23 (74) 
 
 
0.53
2 
 
 
0.30
2 
 
 
6/13 (46) 
7/13 (54) 
 
4/10 (40) 
6/10 (60) 
 
 
12/31 (39) 
19/31 (61) 
 
9/28 (32) 
19/28 (68) 
 
 
0.74
2 
 
 
0.71
2
 
Age  
Mean (years) ± SD of the group (n = 44) 
< 10 years 
> 10 years 
  
27.0 ± 15.9
1
 
3/16 (19) 
13/16 (81) 
  
36.7 ± 15.6
1
 
1/28 (4) 
27/28 (96) 
 
0.067
3
 
0.13
2
 
 
28.8 ± 18.3
1
 
3/13 (23) 
10/13 (77) 
 
35.0 ± 15.3
1
 
1/31 (3) 
30/31 (97) 
 
0.18
3
 
0.071
2
 
APS1 duration 
Mean (years) ± SD of the group (n = 44) 
< 10 years 
> 10 years  
 
22.0 ± 15.5
1
 
6/16 (38) 
10/16 (62) 
 
31.4 ± 14.2
1
 
2/28 (7) 
26/28 (93) 
 
0.044
3
 
0.019
2
 
 
23.9 ± 15.3
1
  
4/13 (31) 
9/13 (69) 
 
29.7 ± 15.1
1
 
4/31 (13) 
27/31 (87) 
 
0.26
3
 
0.21
2
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Figure ‎3.16: Correlation of CaSR antibody index with APS1 disease duration. 
Higher CaSR antibody indices correlated with a shorter duration of APS1 (Spearman’s r = -0.44 
with 95% confidence intervals: -0.66 to -0.16; P = 0.0027). 
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 Discussion 3.5
Patient clinical details Clinically, 43 patients in the current cohort of 44 displayed at 
least two of the major APS1 disease manifestations of chronic mucocutaneous 
candidiasis, hypoparathyroidism and Addison’s disease (Perheentupa, 2006). 
Hypoparathyroidism was present in 86% of patients and had a significantly greater 
prevalence in females (96%) than in males (72%). Both observations concur with 
previous reports that hypoparathyroidism affects more than 80% of APS1 patients 
(Perheentupa, 2006), and is the only disease component that has a difference in 
prevalence between males and females (Gylling et al., 2003). The other APS1 disease 
manifestations were also found at a similar prevalence to previous studies (Soderbergh 
et al., 2004, Perheentupa, 2006). 
AIRE genotype and cytokine antibodies To further confirm the clinical diagnosis of 
APS1, each patient’s AIRE gene was analysed for the presence of mutations. The 
predominant Finnish AIRE mutation c.769C>T was evident in 100% of the individuals 
(Perheentupa, 2006), and the majority (82%) were homozygous for this AIRE genotype. 
Eight patients were compound heterozygotes with one c.769C>T mutated allele and a 
second well-known mutation occurring elsewhere in their AIRE gene coding region. 
Serologically, antibodies against cytokines are extremely useful as diagnostic markers 
for APS1 and, indeed, antibodies against type I IFNs (IFN-alpha2, IFN-omega and IFN-
lambda1), and IL-22 and Th17 cell-related cytokines (IL-17A and IL-17F) were found in 
our patients at a similar prevalence to earlier reports (Meager et al., 2006, Cervato et 
al., 2010). 
Prevalence of CaSR and NALP5 antibodies Previous studies on APS1 patients have 
identified the CaSR (Li et al., 1996, Gylling et al., 2003, Mayer et al., 2004, Gavalas et 
al., 2007) and NALP5 (Alimohammadi et al., 2008, Cervato et al., 2010, Tomar et al., 
2012) as autoantibody targets, both of which are expressed to a high level in the 
parathyroid gland (Brown et al., 1993, Alimohammadi et al., 2008). Here, NALP5 
antibodies were detected at a slightly lower prevalence to that already reported: 30% 
of APS1 patients were NALP5 antibody-positive in this study versus 40% of patients in 
the analysis by Alimohammadi and colleagues (Alimohammadi et al., 2008). Depending 
on the study, antibodies against the CaSR have been documented to occur in 0-86% of 
APS1 patients (Li et al., 1996, Gylling et al., 2003, Mayer et al., 2004, Soderbergh et al., 
 117 
2004, Gavalas et al., 2007). In the present analysis, the receptor was confirmed as an 
autoantigen, although CaSR antibodies were detected at a lower prevalence (36%) 
than found earlier by our group (86%) (Gavalas et al., 2007). The variability of CaSR and 
NALP5 antibody prevalence in APS1 cohorts could be due to differences in the size and 
origin of the patient and control groups, the criteria used to define positivity or the 
type of antibody assay employed (Li et al., 1996, Gylling et al., 2003, Mayer et al., 2004, 
Soderbergh et al., 2004, Gavalas et al., 2007, Alimohammadi et al., 2008, Tomar et al., 
2013). For example, the previous report of NALP5 antibodies included APS1 patients of 
several origins (Alimohammadi et al., 2008), whereas only Finnish patients were 
recruited for the present study. Indeed, in the case of the frequency of antibodies 
against tryptophan hydroxylase, there is variation between APS1 patients from 
different countries in that 100%, 37% and 22% of Swedish, Finnish and Norwegian 
patients, respectively, were positive (Ekwall et al., 1998). Although the type of assay 
employed can have an effect upon the detection rate of CaSR antibodies (Gavalas et 
al., 2007, Tomar et al., 2013), it is most likely that the lower frequency found in the 
present study, compared with a previous report (Gavalas et al., 2007), is due to the 
difference in cohort size (44 patients versus 14 patients), as the same CaSR 
immunoprecipitation assay was used with APS1 patients of the same origin (Finnish) 
(Gavalas et al., 2007). 
Association of CaSR and NALP5 antibodies with hypoparathyroidism Since the clinical 
manifestations in APS1 have been associated with specific autoantibodies (Soderbergh 
et al., 2004), it is not unreasonable to assume there is a parathyroid autoantigen(s) 
which could act as an independent marker for hypoparathyroidsim. Therefore, the 
main aim of the present study was to investigate any potential association between 
clinical hypoparathyroidism and the presence of CaSR and NALP5 antibodies. However, 
although CaSR antibodies were detected in a higher percentage (15/38 = 39%) of 
patients with hypoparathyroidism compared to those without (1/6 = 17%), the 
difference in their frequency did not reach statistical significance (P = 0.392). In 
contrast to a previous study (Alimohammadi et al., 2008), NALP5 antibodies did not 
have 100% specificity for the diagnosis of hypoparathyroidism in this APS1 patient 
cohort since immunoreactivity against NALP5 was detected too in three out of six 
(50%) patients without hypoparathyroidism. Again, this contrast could be due to the 
somewhat different origins of the populations included in this and the previous study 
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(Alimohammadi et al., 2008). Indeed, tryptophan hydroxylase antibodies have been 
reported to significantly associate with intestinal dysfunction in APS1 in a mixed 
population of Scandinavian background (Ekwall et al., 1998), but this was not the case 
for Italian APS1 patients (Dal Pra et al., 2004). Furthermore, there is also the issue of 
the very small numbers of APS1 patients without hypoparathyroidism that are 
available for testing. Between studies, this rarity can have a significant impact on the 
reported specificity of CaSR and NALP5 antibodies for diagnosing hypoparathyroidism 
in APS1. Interestingly, the combined prevalence of CaSR and NALP5 antibodies 
(whether occurring alone or together) also did not significantly differ between patients 
with (21/38 = 55%) and without (4/6 = 66%) hypoparathyroidism (P = 0.684). 
Furthermore, despite earlier reports that CaSR antibodies were more prevalent in 
females than in males with APS1-associated hypoparathyroidism (72% versus 14%, 
respectively) (Li et al., 1996), the frequency of CaSR and NALP5 antibodies was not 
significantly greater in our female patient group with hypoparathyroidism, even 
though the disease was more common in our female APS1 patients than in the males. 
The absence of both CaSR and NALP5 antibodies in a high percentage of APS1 patients 
with hypoparathyroidism (17/38 = 45% in this study) could be explained by the 
existence in some patients of autoantibodies against different parathyroid antigens or 
that some patients simply never develop autoantibodies against the parathyroid gland. 
Alternatively, the absence of NALP5 and CaSR antibodies could be due to loss of the 
antigen required to drive their production before they could be studied. Indeed, with 
type 1 diabetes mellitus, antibodies against islet cells are not longer detectable after 
the clinical onset of disease when the pancreatic ß cells have been destroyed and the 
islet cell autoantigen has disappeared (Hermitte et al., 1998). In keeping with this, Li 
and colleagues (Li et al., 1996) reported there was significantly less chance of detecting 
CaSR antibodies in APS1 patients if hypoparathyroidism had been present for more 
than five years. Likewise, we found a significant association between a shorter APS1 
duration (< 10 years) and CaSR sero-positivity, although this was not the case for 
NALP5 antibodies. 
Aetiology and pathogenesis of hypoparathyroidism in APS1 Since other APS1 
endocrinopathies are typical autoimmune diseases with T cell infiltration of the 
affected organ and circulating tissue-specific autoantibodies, there is an assumption 
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that hypoparathyroidism has a similar pathogenesis. Cases of idiopathic 
hypoparathyroidism with lymphocytic infiltration of the parathyroid gland have been 
reported (Vandecas and Gepts, 1973) and, in one case, this was accompanied by a 
positive leukocyte migration inhibition test (Vandecas and Gepts, 1973). However, T 
cell reactivity against specific parathyroid antigens has not been convincingly 
demonstrated, although in one study of patients with idiopathic hypoparathyroidism, 
there was an increase in activated T lymphocytes in the circulation compared to 
controls (Wortsman et al., 1992). In APS1, autoreactive T lymphocytes which have 
escaped clonal deletion due to the lack of AIRE expression in thymic medullary 
epithelial cells (Zuklys et al., 2000) may target and damage the parathyroid leading to 
hypoparathyroidism and the secondary development of autoantibodies such as those 
against the CaSR and NALP5.  
In organ-specific autoimmune disorders like type 1 diabetes mellitus and Hashimoto’s 
thyroiditis, autoimmune destruction of tissue is provoked by T cells, and 
autoantibodies have a limited pathogenic role (Liblau et al., 1995). Therefore, CaSR and 
NALP5 antibodies and other humoral immune responses against the parathyroid 
(Betterle et al., 1985, Brandi et al., 1986, Posillico et al., 1986, Fattorossi et al., 1988) 
may just represent an epiphenomenon with T lymphocytes being primarily responsible 
for parathyroid damage. Conversely, due to their cell surface target, CaSR antibodies 
could destroy parathyroid cells through the fixing of complement or through antibody-
dependent cellular cytotoxicity. Indeed, Brandi and colleagues (Brandi et al., 1986) 
have demonstrated antibody-mediated cellular cytotoxicity against cultured bovine 
parathyroid cells when exposed to serum from patients with idiopathic 
hypoparathyroidism. Alternatively, CaSR antibodies might lead to a decline in PTH-
release essentially by acting as an agonist for binding to the CaSR expressed on the 
surface of parathyroid chief cells. Well-known examples of the organ-specific 
autoantigens that are extracellular receptors include the thyrotropin receptor in 
Graves’ hyperthyroidism and the acetylcholine receptor in myasthenia gravis 
(Morgenthaler et al., 2007, Jacob et al., 2012). Initial evidence in support of a 
functional humoral immune response against the parathyroid gland came from the 
inhibition of PTH secretion from dispersed human parathyroid cells by three patients 
with idiopathic hypoparathyroidism (Posillico et al., 1986). So far, however, few 
patients have been identified with CaSR-activating antibodies that could potentially 
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reduce PTH secretion (Kifor et al., 2004, Kemp et al., 2009). IgG from two patients with 
APS1 (both with hypoparathyroidism) activated the receptor expressed in HEK293 cells 
(Kemp et al., 2009), and sera from two patients with idiopathic hypoparathyroidism 
inhibited PTH-secretion from human parathyroid cells (Kifor et al., 2004). Of the two 
idiopathic hypoparathyroid patients, one had transient hypoparathyroidism and the 
second had a morphologically intact parathyroid gland, despite many years of 
hypoparathyroidism, suggesting that CaSR-activating antibodies need not irreversibly 
destroy the parathyroid (Kifor et al., 2004).  
Conclusions To conclude, neither CaSR nor NALP5 antibodies were found to be specific 
or sensitive markers for hypoparathyroidism in APS1. Finding a parathyroid-specific 
antigen which can be associated with hypoparathyroidism to allow serologic diagnosis 
of the disease is therefore still necessary. The discovery of novel parathyroid antibody 
targets, even if they are just markers of disease, are likely also to reveal important T 
cell autoantigens in an analogous way to thyroid peroxidase antibodies in autoimmune 
thyroid disease. Further investigations are also required to determine the exact role of 
the autoimmune response against both the CaSR and NALP5 in the pathogenesis of 
APS1. Particularly, the identification of T cells against both autoantigens and the 
detailed characterisation of potential CaSR antibody effects will allow insights into 
possible pathogenic processes that might lead to impaired parathyroid function in 
APS1. 
 
  
 
 
 
 
 
 
 
 
 
Chapter 4 
Mapping of autoantibody binding sites on the calcium-sensing receptor  
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4 Mapping of autoantibody binding sites on the calcium-sensing 
receptor  
 Introduction 4.1
 Antibody-antigen interactions  4.1.1
The term epitope is used to describe the exact region on an antigen that is recognised 
by an antibody. The part of the antibody that interacts with the epitope is referred to 
as the paratope. Although antigenic epitopes vary enormously in terms of size, primary 
amino acid sequence, secondary structure, and post-translational modifications 
(Westwood and Hay, 2001), they are usually defined as either linear or conformational. 
Linear epitopes are distinguished by their amino acid sequence and can range from 5-6 
amino acid residues (Roitt and Delves, 1997) to 15-22 amino acid residues (von Mikecz 
et al., 1995). In contrast, conformational epitopes are distinguished by the secondary 
or tertiary structure of the antigen (Roitt and Delves, 1997). Usually, antibodies 
recognise epitopes that depend on the structure of a native antigen, so B cell epitopes 
are often hydrophilic and exposed on the antigen surface (Westwood and Hay, 2001). 
This knowledge does allow the prediction of antibody binding sites, but their 
identification ultimately requires confirmation by experimental methods (Westwood 
and Hay, 2001).  
 B cell epitope mapping techniques 4.1.2
Several different approaches are available for mapping antibody epitopes and these 
are summarised in Table 4.1. X-ray crystallography and nuclear magnetic resonance 
are powerful techniques for studying antigen-antibody interactions, particularly in 
relation identifying to conformational epitopes (Amit et al., 1986, Morris, 2001, Hore, 
2015). A second methodology uses the manipulation of cDNA to create substitutions 
and/or deletions in the primary sequence of the antigen molecule (Pettersson, 1992, 
Westwood and Hay, 2001). The immunoreactivity of the altered protein can then be 
tested in ELISAs, immunoblots or by immunoprecipitation. Thirdly, antibody reactivity 
can be analysed directly against synthetic peptides or enzymatically digested protein 
fragments (Pettersson, 1992). The latter two techniques can only identify linear 
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epitopes which may or may not be part of a conformational epitope, although, more 
recently, the creation of chimeric antigens has been applied with these methods to 
characterise antibody binding sites which are structure dependent (Hu et al., 2007). 
Finally, phage-display technology has proved useful for identifying linear and 
conformational epitopes (Williams et al., 2001). 
 Phage-display technology  4.1.3
Filamentous bacteriophage particles comprise of a single-stranded DNA genome 
enclosed in a tube of major phage coat protein pVIII. At either end of the tube there 
are 4-5 copies of each of four species of minor phage coat proteins (Figure 4.1) (Wilson 
and Finlay, 1998, Russel et al., 2004, Bazan et al., 2012). The development of phage-
display technology stemmed from the finding that inserting DNA fragments into gene 
gIII of the phage genome resulted in the expression of the encoded peptide as a fusion 
protein with the minor phage coat protein pIII, and the ‘display’ of the fusion on the 
surface of the phage particle (Smith, 1985). Subsequently, phage libraries displaying an 
array of fusion proteins can be screened rapidly in panning experiments to identify 
peptides with the required binding activities. That the selected peptides are linked to 
the DNA that encodes them is a major advantage of the technology. 
Phage-display has a variety of applications including the analysis of the interactions of 
transcription factors and receptors with their ligand (Bass et al., 1990, Butteroni et al., 
2000), enzymes with their substrate (Redl et al., 1999), and antibodies with their 
recognised antigen (Barbas, 1993, Kemp et al., 2002). Phage-display technology has 
also been utilised to identify autoantigenic epitopes by screening phage libraries 
displaying random peptide sequences generated from a selected antigen with 
autoimmune disease patient sera (Table 4.2).  
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Table ‎4.1: Methods used for identifying B cell epitopes 
 
Method Type of epitope Reference 
X-ray crystallography 
Allows direct analysis of the 3-dimensional 
structure of an antigen-antibody complex.
 
Linear; conformational  (Amit et al., 
1986) 
Nuclear magnetic resonance Linear; conformational (Hore, 2015) 
Mass spectrometry Conformational; post-
translationally modified 
(Hager-Braun 
and Tomer, 
2005) 
Phage-display technology 
Epitopes are determined by affinity selection 
screening with monoclonal antibody or 
polyclonal. 
Linear; conformational  (Williams et al., 
2001) 
Synthetic peptides or peptide fragments 
Can be used in a number of different assay 
systems including enzyme-linked immunosorbent 
assay (ELISA) and immunoprecipitation using 
monoclonal antibody or polyclonal sera. 
Linear (Pettersson, 
1992, Westwood 
and Hay, 2001) 
Recombinant proteins 
Sub-cloning and expression of cDNA encoding 
antigen peptide fragments generated by 
naturally occurring restriction sites, exonuclease 
digestion, polymerase chain reaction or site-
directed mutagenesis.
 
Can be used in a number 
of different assay systems including 
immunoblotting, ELISA, immunoprecipitation and 
radiobinding assays using monoclonal antibody 
or polyclonal sera.  
Linear (Pettersson, 
1992, Westwood 
and Hay, 2001) 
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Figure ‎4.1: Schematic representation of a filamentous phage particle. 
A single-stranded circular DNA genome is encased in 2,700 copies of the major coat protein 
pVIII, and four or five copies of each of four types of minor coat proteins, including pIII. The 
figure was used with kind permission from NRC Research Press from a paper by Wilson and 
Finlay, 1998. 
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Table ‎4.2: Identification of B cell epitopes using phage-display technology 
 
Autoantigen Autoimmune disease 
Epitope type 
identified 
Reference 
Glutamic acid 
decarboxylase 
Autoimmune 
polyendocrine syndrome 
type 2; Stiffman syndrome 
Linear 
(Al-bukhari et al., 
2002) 
Glutamic acid 
decarboxylase 
Type 1 diabetes mellitus Linear (Myers et al., 2000) 
Tyrosinase 
phosphatase-like 
protein IA-2/ICA512bdc 
Type 1 diabetes mellitus Linear 
(Farilla et al., 2002, 
Dromey et al., 2004) 
Smith autoantigen 
Systemic lupus 
erythematosus 
Linear 
(del Rincon et al., 
2000) 
Gliadin Celiac disease Linear (Osman et al., 2000) 
Pyruvate 
dehydrogenase 
complex E2 
Primary biliary cirrhosis Conformational (Rowley et al., 2000) 
Platelet autoantigen 
Autoimmune 
thrombocytopenic purpura 
Conformational 
(Gevorkian et al., 
1998) 
Melanin-concentrating 
hormone receptor 1 
Vitiligo Linear (Gavalas et al., 2009) 
Calcium-sensing 
receptor 
Autoimmune 
polyendocrine syndrome 
type 1 
Linear (Kemp et al., 2010) 
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 Identification of antibody binding sites on the CaSR  4.1.4
Several techniques have been used to map epitopes on the CaSR. Previously, a CaSR 
cDNA fragment library was constructed in the phage-display vector pComb3 (Kemp et 
al., 2010). In this library, peptides encoded by cloned CaSR cDNA fragments were 
expressed from the lacZ gene promoter as fusions at the amino terminus with the PelB 
leader sequence and at the carboxy terminus with phage coat protein pIII (Figure 4.2). 
Subsequently, the expressed CaSR peptides were exposed on the surface of phage 
particles (Figure 4.2). The CaSR peptide phage-display library was used in panning 
experiments as detailed in Figure 4.3 to map the epitopes of CaSR antibodies found in 
12 APS1 patients (Kemp et al., 2010). The identified antibody binding sites are listed in 
Table 4.3, In addition, peptide ELISAs (Table 4.4) have been used both to identify and 
to confirm epitopes recognised by CaSR antibodies found in patients with APS1 (Kemp 
et al., 2010), autoimmune hypoparathyroidism (Kifor et al., 2004) and autoimmune 
hypocalciuric hypercalcaemia (Kifor et al., 2003, Pallais et al., 2004, Kemp et al., 2010) 
(Table 4.3). The positions of the epitopes identified on the CaSR are shown in Figure 
4.4. 
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(b) 
GGTGGCGGCCGCAAATTCTATTTCAAGGAGACAGTCATAATGAAATACCTATTGCCTACGGCAGCCGCTGGATTG 
 G  G  G  R  K  F  Y  F  K  E  T  V  I  M  K  Y  L  L  P  T  A  A  A  G  L  
TTATTACTCGCTGCCCAACCAGCCATGGCCCAGGTGAAACTGCTCGAGGTCGACGGTATCGATAAGCTTGATCAT 
 L  L  L  A  A  Q  P  A  M  A  Q  V  K  L  L  E  V  D  G  I  D  K  L  D  H  
TTTGGAGTAGCAGCTAAAGATCAAGATCTCAAATCAAGGCCGGAGTCTGTGGAATGTATCAGGTATAATTTCCGT 
 F  G  V  A  A  K  D  Q  D  L  K  S  R  P  E  S  V  E  C  I  R  Y  N  F  R  
GGGTTTCGCTGGTTACAGGCTATGATCGAATTCCTGCAGCCCGGGGGATCCACTAGTGGTGGCGGTGGCTCTCCA 
 G  F  R  W  L  Q  A  M  I  E  F  L  Q  P  G  G  S  T  S  G  G  G  G  S  P  
TTCGTTTGTGAATATCAAGGCCAATCGTCTGACCTGCCTCAA 
 F  V  C  E  Y  Q  G  Q  S  S  D  L  P  Q  
 
 
 
Figure ‎4.2: The pComb3 phage-display system. 
(a) The expression of CaSR peptides, from cDNA fragments cloned into the EcoRV site of 
pComb3 (highlighted in yellow), as fusion proteins to coat protein pIII (highlighted in red and 
encoded by gIII) is controlled by the lacZ gene promoter. The PelB leader sequence 
(highlighted in grey and encoded by pelB) allows the secretion of the CaSR peptide fusion 
proteins into the periplasm of the bacterial cell. Subsequently, the CaSR peptide fusion 
proteins are assembled into phage particles and displayed on the surface of the phage by 
virtue of coat protein pIII. Sequencing primer pc3prim1 (highlighted in green) anneals prior to 
the pelB gene sequence. The figure was used with kind permission from John Wiley and Sons 
from a paper by (Crameri et al., 1994). (b) An example of a CaSR peptide cloned in the +1 
frame with respect the PelB leader sequence and in-frame with coat protein pIII is shown in 
turquoise. 
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Figure ‎4.3: Enrichment of phage displaying IgG binding CaSR peptides on their 
surface. 
 
1. Phage expressing immunoreactive CaSR peptides from cloned CaSR cDNA fragments. 2. IgGs 
in patient serum. 3. IgGs capture phage expressing immunoreactive CaSR peptides. 4. Non-
specifically bound phage are removed by washing. 5. Phage displaying peptides that bind 
specifically to IgG molecules are eluted with acidified glycine. 6. The eluted phage are infected 
into E. coli to enrich specifically-bound phage. 7. The number of phage eluted is determined 
and, in round five of panning, phagemid DNA is isolated from infected cells and analysed by 
sequencing to identify CaSR cDNA inserts. 8. The eluted phage are grown and a new phage 
display library then prepared for further rounds of panning. The figure was used with kind 
permission from the Nature Publishing Group from a paper by (Waterman et al., 2010). 
  
 131 
Table ‎4.3: Previously reported CaSR antibody binding sites on the CaSR 
 
CaSR 
epitope1 
Patient detail 
Number of 
patients 
Technique Reference 
41-69 
APS1 12 Phage-display 
and CaSR 
peptide ELISAs 
(Kemp et al., 
2010) 
Autoimmune hypocalciuric 
hypercalcemia 
1 
(Kemp et al., 
2010) 
114-126 APS1 5 Phage-display 
and CaSR 
peptide ELISAs 
(Kemp et al., 
2010) 
171-195 APS1 4 
(Kemp et al., 
2010) 
214-236 
Autoimmune hypocalciuric 
hypercalcaemia 
1 
CaSR peptide 
ELISAs 
(Pallais et al., 
2004) 
Autoimmune hypocalciuric 
hypercalcaemia 
4 
(Kifor et al., 
2003) 
Autoimmune 
hypoparathyroidism 
2 
(Kifor et al., 
2004) 
344-358 
Autoimmune hypocalciuric 
hypercalcaemia 
1 
CaSR peptide 
ELISAs 
(Pallais et al., 
2004) 
Autoimmune hypocalciuric 
hypercalcaemia 
4 
(Kifor et al., 
2003) 
Autoimmune 
hypoparathyroidism 
2 
(Kifor et al., 
2004) 
374-391 
Autoimmune hypocalciuric 
hypercalcaemia 
1 
CaSR peptide 
ELISAs 
(Pallais et al., 
2004) 
Autoimmune hypocalciuric 
hypercalcaemia 
4 
(Kifor et al., 
2003) 
Autoimmune 
hypoparathyroidism 
2 
(Kifor et al., 
2004) 
 
1
Amino acid residues are numbered according to CaSR peptide sequence with the ATG initiation codon 
as residue number 1. 
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Table ‎4.4: CaSR peptides used in ELISAs 
 
CaSR 
peptide1 
Number of 
amino acids 
Amino acid sequence of peptide 
41-69 38 HFGVAAKDQDLKSRPESVECIRYNFRGFR 
75-115 41 IFAIEEINSSPALLPNLTLGYRIFDTCNTVSKALEATLSFV 
114-126 13 FVAQNKIDSLNLD 
138-170 33 TIAVVGATGSGVSTAVANLLGLFYIPQVSYASS 
171-195 25 SRLLSNKNQFKSFLRTIPNDEHQAT 
214-238 25 ADDDYGRPGIEKFREEAEERDICID 
260-340 81 
QNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWASSSLI
AMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPR 
344-358 15 HNGFAKEFWEETFNC 
374-391 18 LRGHEESGDRFSNSSTAF 
 
1
Amino acid residues are numbered according to CaSR peptide sequence with the ATG initiation codon 
as residue number 1. 
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MAFYSCCWVLLALTWHTSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVE
CIRYNFRGFRWLQAMIFAIEEINSSPALLPNLTLGYRIFDTCNTVSKALEATLSFVAQN
KIDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNK
NQFKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDIC
IDFSELISQYSDEEEIQHVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLA
SEAWASSSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPRKSVHNGFAKEFWEE
TFNCHLQEGAKGPLPVDTFLRGHEESGDRFSNSSTAFRPLCTGDENISSVETPYIDYTH
LRISYNVYLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNN
MGEQVTFDECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEEKILWS
GFSREVPFSNCSRDCLAGTRKGIIEGEPTCCFECVECPDGEYSDETDASACNKCPDDFW
SNENHTSCIAKEIEFLSWTEPFGIALTLFAVLGIFLTAFVLGVFIKFRNTPIVKATNRE
LSYLLLFSLLCCFSSSLFFIGEPQDWTCRLRQPAFGISFVLCISCILVKTNRVLLVFEA
KIPTSFHRKWWGLNLQFLLVFLCTFMQIVICVIWLYTAPPSSYRNQELEDEIIFITCHE
GSLMALGFLIGYTCLLAAICFFFAFKSRKLPENFNEAKFITFSMLIFFIVWISFIPAYA
STYGKFVSAVEVIAILAASFGLLACIFFNKIYIILFKPSRNTIEEVRCSTAAHAFKVAA
RATLRRSNVSRKRSSSLGGSTGSTPSSSISSKSNSEDPFPQPERQKQQQPLALTQQEQQ
QQPLTLPQQQRSQQQPRCKQKVIFGSGTVTFSLSFDEPQKNAMAHRNSTHQNSLEAQKS
SDTLTRHQPLLPLQCGETDLDLTVQETGLQGPVGGDQRPEVEDPEELSPALVVSSSQSF
VISGGGSTVTENVVNS 
 
 
 
Figure ‎4.4: Position of previously identified CaSR epitopes. 
Epitopes are shown at amino acid residues 41-69 (red), 114-126 (yellow), 171-195 (pink), 214-
236 (grey), 344-358 (green), and 374-391 (purple). 
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 Aim  4.2
The aim of this part of the project was to identify the binding sites on the CaSR 
recognised by APS1 patient CaSR antibodies. This information could help in (a) 
understanding how CaSR antibodies can adversely affect the function of the receptor 
(Kemp et al, 2009; Kifor et al, 2004) if they bind at functionally relevant sites, (b) 
developing new and more specific CaSR antibody assays. For example, if the epitope of 
a pathogenic antibody can be defined exactly, recombinant proteins containing only 
the epitope site could be used in the titration of pathogenic antibodies within a 
patient’s heterogeneous antibody population, (c) providing insights into the initiation 
of the autoimmune process. For example by molecular mimicry, if epitopes on the 
CaSR are recognised by antibodies arising from the immune response against infecting 
microbes (Wucherpfennig, 2001a), (d) characterising the light chain usage of CaSR 
antibodies, as in the case of thyroid peroxidase antibodies in autoimmune thyroid 
disease (McIntosh et al., 1997), and (e) engineering specific functional monoclonal 
antibodies, for instance for treatment of hypercalcaemia.  
The specific objectives of this part of the project were: 
 To use panning experiments with a CaSR peptide phage display library and 
APS1 patient sera to identify consensus peptides representing potential CaSR 
epitopes. 
 To verify potential CaSR epitopes by analysing the reactivity of APS1 patient 
and control sera in CaSR peptide ELISAs. 
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 Materials and Methods 4.3
 Patient and control sera 4.3.1
The clinical and demographic details of the 44 APS1 patients (16 CaSR antibody-
positive and 28 CaSR antibody-negative) and 16 healthy controls used in this part of 
the study are given in Chapter 3 (Section 3.3.1 and Table 3.1).  
 CaSR peptide phage-display library 4.3.2
The CaSR peptide phage-display library made in pComb3 (Figure 4.2) (Kemp et al., 
2010) was provided by Dr Helen Kemp (Department of Oncology and Metabolism, 
University of Sheffield, Sheffield, UK) and was stored at -80°C. To determine the phage 
titre of the library, Escherichia coli XL1-Blue MRF’ (Agilent Technologies, Wokingham, 
UK) was grown to exponential phase at 37°C with shaking in 0.5 ml of LB medium 
(Section 2.3) with tetracycline at 10 μg/ml. The culture was then infected with a 2-μl 
aliquot of a 10-4 dilution of the phage-display library and incubated at room 
temperature for 15 min. Samples (1, 10 and 100-μl) of the culture were plated onto LB 
agar containing 100 μg/ml ampicillin (Section 2.3). An uninfected 100-μl sample of the 
culture was plated as a negative control. Plates were incubated at 37°C overnight, the 
colonies counted, and the phage titre as colony-forming units (cfu) per ml was 
determined. 
To check that the library contained random CaSR cDNA fragments, 20 randomly 
selected bacterial colonies isolated in the titration experiment were firstly purified by 
streaking onto fresh LB agar with ampicillin at 100 µg/ml, and then later inoculated 
into 10 ml of LB medium with ampicillin at 100 µg/ml and grown overnight at 37°C. 
Subsequently, phagemid DNA was extracted from the cells using a Wizard® Plus SV 
Minipreps DNA Purification System (Section 2.6) and sequenced (Section 2.16) with 
pComb3-specific primer pc3prim1 (5’-GGTGGCGGCCGCAAATTC-3’) (Eurofins Genetic 
Services Ltd., London, UK) (Figure 4.2). Each cloned DNA fragment was translated and 
then analysed for matches to the CaSR amino acid sequence (Section 4.3.6). The 
reading frame of each cloned DNA fragment with respect to the PelB leader sequence 
and phage coat protein pIII was also determined.  
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 Enrichment of the CaSR peptide phage-display library (panning experiments) 4.3.3
Panning experiments were carried out according to the protocol of Dr Helen Kemp 
(Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK) 
(Kemp et al., 2010). For panning experiments (Figure 4.3), 10-μl aliquots of APS1 
patient sera or rabbit anti-CaSR (amino acid residues 47-69) polyclonal antibody 
ab79829 (anti-CaSR antibody ab79829) (Abcam, Cambridge, UK) were applied to the 
wells of 96-well microtitre plates in 50 μl of coating buffer (1.5 mM sodium carbonate; 
3.5 mM sodium hydrogen carbonate; pH 9.2). Plates were incubated at room 
temperature for 2 h to allow antibody-binding before washing with PBS/0.05% (w/v) 
Tween 20 (PBS/Tween). To block any non-specific phage binding later in the 
procedure, 400 μl of 2% (w/v) bovine serum albumin in PBS were added to the wells 
and incubation at room temperature continued for 2 h. The wells were again rinsed 
with PBS/Tween before the addition of a 100-μl sample of phage display library 
containing an estimated 109 to 1010 phage (depending on the exact phage display 
library used). Plates were incubated overnight at 4oC to allow the interaction of CaSR 
antibodies with peptides displayed on the surface of the phage particles. The wells 
were washed extensively with PBS/Tween to remove unbound phage. Bound phage 
were then eluted with 150 μl of 100 mM hydrochloric acid (adjusted to pH 2.2 with 
glycine) and then neutralised with 9 μl of 2 M Tris-base. The phage suspension was 
subsequently used to infect 2 ml of exponentially growing E. coli XL1-Blue MRF’ for 15 
min at room temperature. Aliquots (10 and 100-μl) of the infected cells were then 
plated onto LB agar containing 10 μg/ml tetracycline and 100 μg/ml ampicillin and the 
plates incubated overnight at 37°C. This allowed the assessment of the total number of 
eluted phage in each round of panning.  
A phage-display library for the next round of panning was then generated. The E. coli 
XL1-Blue MRF’ culture infected with eluted phage was made up to 10 ml with LB 
medium and incubated for 1 h with shaking at 37°C before superinfection with of 1 x 
1011 plaque-forming units of VCS-M13 helper phage (Agilent Technologies). Following 
incubation at room temperature for 30 min, the cells were transferred to 100 ml of LB 
medium containing 10 μg/ml tetracycline, 100 μg/ml ampicillin and 10 μg/ml 
kanamycin (Section 2.3) and grown overnight with shaking at 37°C. The 100-ml culture 
was centrifuged at 2,000 g for 15 min to remove all bacterial cells. Phage particles 
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were precipitated from the supernatant with 15 ml of 40% (w/v) polyethylene glycol 
4000 and 15 ml of 5 M sodium chloride per 100 ml. Following overnight incubation at 
4°C, the phage were harvested by centrifugation at 2,000 g for 30 min and the pellet 
resuspended in 1-2 ml of PBS before storage at -20°C. This first round phage-display 
library, enriched in phage particles displaying IgG-binding peptides, was titrated as 
detailed above (Section 4.3.2), and was then used in a second round of panning in the 
same way as the original library. In all, five rounds of panning were undertaken for 
each sample. 
In each round, the ratio of the number of phage eluted to the number of phage 
applied initially to the ELISA plate well was determined. Compared to the ratio found in 
the round one of panning, the fold increase in this ratio in each subsequent panning 
round was calculated.  
 Analysis of the panned phage-display library 4.3.4
After the fifth round of panning, 10-16 randomly selected bacterial colonies, isolated 
by plating out the culture infected with eluted phage, were purified by streaking onto 
fresh LB agar containing ampicillin at 100 µg/ml. The bacterial clones were then grown 
overnight with shaking at 37°C in 10 ml of LB medium containing 100 μg/ml ampicillin. 
Subsequently, phagemid DNA was prepared from each culture using a Wizard® Plus SV 
Minipreps DNA Purification System. In order to identify any immunoreactive CaSR 
peptides that had been enriched during the panning procedure, each phagemid DNA 
sample was subjected to sequencing using primer pc3prim1. This allowed the 
sequence of the cloned DNA fragments to be determined. As detailed in Section 4.3.6, 
each cloned DNA fragment was translated and then analysed for matches to the CaSR 
amino acid sequence. The reading frame of each cloned DNA fragment with respect to 
the PelB leader sequence and phage coat protein pIII was also determined. 
 CaSR peptide ELISAs 4.3.5
Antibodies against CaSR peptides were detected in ELISAs as previously described 
(Kemp et al., 2010). All CaSR peptides (Table 4.4) were received dried and were 
solubilised and stored according to the manufacturer’s instructions (Cambridge 
Peptides Ltd., Birmingham, UK). For ELISAs, the required peptide was diluted in PBS to 
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200 ng/ml and 100-μl samples used to coat the wells of a 96-well microtitre plate. An 
equivalent number of wells were coated with 100 μl of 0.1% (w/v) bovine serum 
albumin for the measurement of non-specific binding of the sera. The plates were then 
incubated overnight at 4°C. 
Excess peptide was removed by decanting and the wells were blocked with blocking 
buffer (PBS; 0.1% (w/v) Tween-20; 3% (w/v) bovine serum albumin) for 30 min at 37°C. 
Plates were washed four times with washing buffer (PBS/0.1% (v/v) Tween-20). 
Aliquots (100 µl) of serum at a 1:100 dilution in blocking buffer were added to the 
wells. PBS was applied as a control to measure any non-specific binding of the 
secondary antibody. Positive control antibodies were: anti-CaSR antibody ab79829 and 
mouse anti-CaSR (amino acid residues 214-235) monoclonal antibody ab19347 (anti-
CaSR antibody ab19347) (Abcam, Cambridge, UK), and were used at a 1:500 dilution. 
The plates were incubated at room temperature for 1 h and then washed four times 
with washing buffer. A 100-µl of goat anti-human IgG polyclonal antibody conjugated 
to alkaline phosphatase (Sigma-Aldrich) diluted to 1:2000 in blocking buffer was added 
to each well for 1 h at room temperature. To detect the positive control antibodies, 
goat anti-rabbit IgG or goat anti-mouse IgG polyclonal antibodies conjugated to 
alkaline phosphatase (Sigma-Aldrich) were used at a 1:2000 dilution. After washing five 
times with washing buffer, 100 µl of alkaline phosphatase substrate Sigma Fast p-
nitrophenyl phosphate (Sigma-Aldrich) were applied to each well and plates incubated 
at room temperature to allow colour development. A LabSystems Integrated EIA 
Management System spectrophotometer was used to read absorption of the wells at 
405 nm. All sera were tested in duplicate and the average OD405 value taken. Each 
mean OD405 value was corrected for background binding of the sera to the well 
without antigen. 
The binding reactivity of each patient and control sera to the peptide was expressed as 
an antibody index calculated as: mean OD405 of tested serum/mean OD405 of a 
population of healthy control sera. Each serum was tested in at least two experiments 
and the mean antibody index calculated. The upper limit of normal for each ELISA was 
calculated using the mean antibody index + 3SD of a population of healthy control 
sera. Sera with an antibody index greater than the upper limit of normal were 
regarded as antibody-positive.  
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 Statistical analyses 4.3.6
Fisher’s exact test for 2 x 2 contingency tables for comparing categorical data was 
carried out using GraphPad Instat 3 software (GraphPad Software). In all tests, P values 
(two-tailed) < 0.05 were regarded as significant. Antibody assay precision was 
evaluated by calculating the intra-assay coefficient of variation (expressed as a 
percentage) for a series of different serum samples that were measured in duplicate 
within the same assay run. Antibody assay reproducibility was evaluated by calculating 
the inter-assay coefficient of variation (expressed as a percentage) for a series of 
different serum samples that were measured in several consecutive assay runs. 
 DNA and protein sequences analyses 4.3.7
Analyses of DNA and protein sequences were carried out using Lasergene Core Suite 
sequence analysis software (DNASTAR, Inc., Madison, WI, USA), the network facilities 
of the European Bioinformatics Institute-European Molecular Biology Laboratory 
(www.ebi.ac.uk) (Cambridge, UK), and the ExPASy Bioformatics Resources Portal 
(web.expasy.org) (Swiss Institute of Bioinformatics, Switzerland). Protein and DNA 
homology searches against the GenBank database were performed using the BLAST 
service of the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov) 
(Bethesda, MD, USA). 
 Antigenicity predictions 4.3.8
Antigenicity predictions on the CaSR extracellular domain were made using the 
Immune Epitope Database and Analysis Resource (tools.immuneepitope.org) (National 
Institute of Allergy and Infectious Diseases, Bethesda, MD, USA) (Kolaskar and 
Tongaonkar, 1990). 
 In silico modelling of CaSR epitopes 4.3.9
Since the CaSR has not been crystallised, the 3D structure of the of the CaSR 
extracellular domain was solved at high resolution using the web-based Protein 
Homology/Analogy Recognition Engine (Phyre) service (www.sbg.bio.ic.ac.uk/phyre2) 
(Imperial College London, UK) (Kelley and Sternberg, 2009, Kelley et al., 2015) enabling 
a model to be made with a high degree of confidence (90% modelled at > 90% 
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confidence). The positions of the epitopes identified on the modelled CaSR were 
visualised using PyMOL molecular graphics system software (www.pymol.org) 
(Schrödinger, Cambridge, UK) (DeLano et al., 2000). 
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 Results 4.4
 Analysis of the unpanned CaSR peptide phage-display library 4.4.1
The titre of the phage-display library was determined as in Section 4.3.2, and was 
estimated at 9.3 x 1011 cfu/ml. The results of sequencing 20 randomly selected 
phagemid from the titration experiment indicated that the cloned CaSR cDNA 
fragments were varied with respect to their encoded amino acid sequence (Table 4.5) 
showing no bias in the reading frame or for any specific part of the CaSR. 
 Panning of the CaSR peptide phage-display library with APS1 patient and anti-4.4.2
CaSR antibody 
The CaSR peptide phage-display library was screened for immunoreactive CaSR 
peptides with sera from 16 CaSR antibody-positive APS1 patients and a CaSR antibody-
negative APS1 patient, and with anti-CaSR antibody ab79829 as a positive control. Five 
rounds of panning were carried out. In each round, the ratio of the number of phage 
eluted to the number of phage applied initially to the ELISA plate well was determined. 
Compared to the ratio found in the first round of panning, the fold increase in this ratio 
in each subsequent panning round was calculated. The results are given in Figure 4.5. 
In most cases, an increase in the ratio of phage eluted to phage applied was observed 
by the third round of panning, suggesting that enrichment of phage expressing IgG-
binding CaSR peptides had occurred during the successive rounds. In contrast, no 
increase was seen from panning of the library with the CaSR antibody-negative APS1 
patient serum (Figure 4.5). 
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Table ‎4.5: Amino acid sequences of translated CaSR cDNA fragments contained in the 
unpanned CaSR peptide phage-display library 
 
Clone 
number 
Amino acid sequence of CaSR peptide 
encoded by the cloned cDNA fragment 
Amino 
acid 
residues 
of the 
CaSR 
Reading 
frame in 
relation to 
the PelB 
leader 
sequence 
In-
frame 
with 
coat 
protein 
pIII 
1 HFGVAAKDQDLKSRPESVECIRYNFRGFRWLQA
MIFAIEEINSSPALLPNLTLGYRIF 
41-98 +1 Yes 
2 AKEFWEETFNCHLQEGAKGPLPVDTFLRGHEES
GDRFSNSSTAFRPLCTGDENISSVETPYIDY 
348-411 -1 No 
3 HNGFAKEFWEETFNCHLQEGAKGPLPVDTFLRG
HEESGDRFSNSSTAFRPLCTG 
344-397 -1 No 
4 KSFLRTIPNDEHQATAMADIIEYFRWNWVGTIA
ADDDYGRPGIEKFREEAEERDICIDFS 
180-240 -2 No 
5 AILAASFGLLACIFFNKIYIILFKPSRNTIEEV
RCSTAAHAFKVAARATL 
840-954 +2 No 
6 FRWLQAMIFAIEEINSSPALLPNLTLGYRIFDT
CNTVSKALEATLSFVAQNKIDSLNLDEFCNCSE
HIPSTIAVV 
68-142 -3 No 
7 PSTIAVVGATGSGVSTAVANLLGLFYIPQVSYA
SSSRLLSNKNQFKSF 
136-183 +1 Yes 
8 EDPFPQPERQKQQQPLALTQQEQQQQPLTLPQQ
QRSQQQPRCKQKVIFGSGTVTFSLSFD 
EPQKNA 
874-985 +2 No 
9 GFRWLQAMIFAIEEINSSPALLPNLTLGYRIFD
TCNTVSKALEAT 
67-111 +2 No 
10 HRNSTHQNSLEAQKSSDTLTRHQPLLPLQCGET
DLDLTVQE 
989-1028 +1 Yes 
11 ASACNKCPDDFWSNENHTSCIAKEIEFLSWTEP
FGIALTLFAVLGIFLTAFVLGVFIKFR 
578-638 -2 No 
12 IVVFSSGPDLEPLIKEIVRRNITGKIWLASEAW
ASSSLIAMPQYF 
267-311 +2 No 
13 CHEGSLMALGFLIGYTCLLAAICFFFAFKSRKL
PENFNEAKFITFSMLIFFIVWISFIPAYASTYG
KFVSAVEVI 
765-838 -3 No 
14 MAFYSCCWVLLALTWHTSAYGPDQRAQKKGDII
LGGLFPIHFGVAAKDQDLKSRPESVECIRYNFR
GFRWLQAMIFAIEEINSSPALLPNLTLGYRIFD
TCN 
1-102 -1 No 
15 PIVKATNRELSYLLLFSLLCCFSSSLFFIGEPQ
DWTCRLRQPAFGI 
639-686 +1 No 
16 TIEEVRCSTAAHAFKVAARATLRRSN 868-893 -2 No 
17 SNSSTAFRPLCTGDENISSVETPYIDYTHLRIS
YNVYLAVYSIAHALQD 
385-433 +3 No 
18 FTNNMGEQVTFDECGDLVGNYSIINWHLSPEDG
SIVFKEVGYYNVYA 
469-515 +2 No 
19 SPALVVSSSQSFVISGGGSTVTENVVNS 1068-1078 -2 No 
20 RVLLVFEAKIPTSFHRKWWGLNLQFLLVFLCTF
MQIVICVIWLYTAPPSSYRNQELEDEIIFITCH
EGSLMALGFLIGYTCLL 
701-782 +1 No 
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Figure ‎4.5: Panning experiments of the CaSR peptide phage-display library with APS1 
patient sera and anti-CaSR antibody ab79829. 
The results are shown as a fold increase in the ratio of phage eluted to phage applied with 
respect to the first round of panning. 
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 Identification of CaSR peptides enriched by panning  4.4.3
Phagemid DNA from 10-16 randomly selected bacterial clones isolated from the fifth 
round of panning with APS1 patient sera and anti-CaSR antibody ab79829 was 
subjected to DNA sequencing in order to identify if particular CaSR peptides had been 
selected during the panning process. Each cloned DNA fragment was translated and 
then analysed for matches to the CaSR amino acid sequence. The reading frame of 
each cloned fragment with respect to the PelB leader sequence and phage coat protein 
pIII was also determined. 
Table 4.6 summarises the CaSR peptide sequences encoded by 10 phagemid isolated 
from the fifth round of panning with anti-CaSR antibody ab79829. The results 
demonstrated that specific CaSR peptides were indeed enriched by panning of the 
phage display library with anti-CaSR antibody ab79829. Eight of the ten (80%) peptide 
sequences analysed included an identical CaSR peptide consensus sequence which 
encompassed the epitope (amino acid residues 47-69) of the anti-CaSR antibody 
ab79829. All eight peptide sequences were in-frame with the PelB leader sequence at 
the amino terminal and with the gIII-encoded coat protein pIII at the carboxy-terminal 
necessary for expression of the peptides on the surface of phage (Figure 4.2). The 
remaining two phagemid contained CaSR cDNA fragments that could not be expressed 
as fusion proteins as they were not in the correct reading frame with respect to the 
PelB leader sequence and phage coat protein pIII. 
Identical analysis was repeated for the panning experiments carried out with APS1 
patient sera. The CaSR peptide consensus sequences identified are given in Table 4.7. 
At least one CaSR peptide consensus sequence, assumed to represent a CaSR epitope, 
was identified for each CaSR antibody-positive APS1 patient. Two patients (APS1-2 and 
APS1-4) had each enriched one in-frame CaSR peptide (amino acids 850-909 and 260-
340, respectively) that was only represented once within the set of analysed 
sequences. However, these could still represent CaSR antibody binding sites, since they 
would have been expressed on the surface of the phage by virtue of their in-frame 
fusion with both the PelB leader sequence and phage coat protein pIII. The CaSR 
antibody-negative patient did not enrich any specific CaSR peptide sequences, and the 
phagemid analysed carried CaSR cDNA fragment inserts that would not be expressed 
as fusion proteins.  
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Table ‎4.6: CaSR peptide sequences displayed on the surface of phage enriched by 
panning of the CaSR peptide phage-display library with anti-CaSR antibody ab79829 
 
Sequence 
number 
Amino acid sequence of peptides recovered 
following five rounds of panning1 
 
Amino 
acid 
residues 
of the 
CaSR 
Reading 
frame 
in 
relation 
to the 
PelB 
leader 
sequence 
In-
frame 
with 
coat 
protein 
pIII 
1 
AYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKS
RPXSVECIRYNFRGFRWL 
19-71 +1 Yes 
2 
HTSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQD
LKSRPESVECIXYNFRGFRWLQAM 
16-74 +1 Yes 
3 
LTWHTSAYGPDQRAQKKGDIILGGLFPIHFGVAAK
DQDLKSRXXSVECIRYNFRGFRWL 
13-71 +1 Yes 
4 
LACIFFNKIYIILFKPSRNTIEEVRCSTAAHAFKV
AARATLRRSNVSR 
848-986 +3 No 
5 
SAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLK
SRPXSVECIXYNFRGFRWLQAM 
20-74 +1 Yes 
6 
TGKIWLASEAWASSSLIAMPQYFHVVGGTIGFALK
AGQIPGFREFLKKVHPRK 
289-341 +3 No 
7 
YGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSR
PXSVECIXYNFRGFRWLQAM 
20-74 +1 Yes 
8 
LTWHTSAYGPDQRAQKKGDIILGGLFPIHFGVAAK
DQDLKSRPESVECIRYNFRGFRWL 
13-71 +1 Yes 
9 
AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVEC
IRYNFRGFRWLQAMI 
26-75 +1 Yes 
10 
AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVEC
IRYNFRGFRWLQAM 
26-74 +1 Yes 
 
1
The consensus amino acid sequence (residues 26-70) is shown in red. The epitope of the anti-CaSR 
antibody ab79829 is between amino acid residues 41 and 69. 
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Table ‎4.7: CaSR peptide consensus sequences from panning experiments with APS1 
patient sera 
 
APS1 
patient 
CaSR peptide consensus sequence 
Amino 
acid 
residues 
of CaSR
1
 
Number of peptide 
sequences 
containing the in-
frame CaSR 
peptide consensus 
sequence (%)
2
 
APS1-1 
AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGF
RWL 
26-71 8/16 (50) 
APS1-2 
HFGVAAKDQDLKSRPESVECIRYNFRGFRWL 41-71 7/16 (44) 
ACIFFNKIYIILFKPSRNTIEEVRCSTAAHAFKVAARATLRRS
NVSRKRSSSLGGSTGST 
850-909
3
 1/16 (6) 
APS1-3 
AYGPDQRAQKKGDIILGGLFPIHFGV 19-44 5/16 (31) 
TIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQF
KSFLRTIPND 
138-190 2/16 (13) 
APS1-4 
DQRAQKKGDIILGGLFPIHFGVA 23-45 7/16 (44) 
QNKIDSLNLDEFCNCSEHIPSTIAVVGA 117-144 2/16 (13) 
QNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWASS
SLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPR 
260-340
3
 1/16 (6) 
APS1-5 
QKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFR
WL 
27-71 8/16 (50) 
KALAEATLSFVAQNKIDSLNLDEFCNC 106-131 3/16 (19) 
APS1-6 
HFGVAAKDQDLKSRPESVECIRYNFRGFRWL 41-71 8/16 (50) 
KALAEATLSFVAQNKIDSLNLDEFCN 106-130 2/16 (13) 
APS1-7 
HFGVAAKDQDLKSRPESVECIRYNFRGFRWL 41-71 3/16 (19) 
FVAQNKIDSLNLD 114-126 5/16 (31) 
APS1-8 
AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGF
RWL 
26-71 5/10 (50) 
APS1-9 
AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGF
R 
26-69 9/16 (56) 
SRLLSNKNQFKSFLRTIPNDEHQAT 171-195 2/16 (13) 
APS1-10 
GDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRW 30-70 7/16 (44) 
TVSKALAEATLSFVAQNKIDSLNLDEFCNCSE 103-133 2/16 (13) 
APS1-11 
AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGF
RWL 
26-71 3/30 (10) 
APS1-12 
AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGF
RWL 
26-71 10/16 (63) 
SRLLSNKNQFKSFLRTIPNDEHQAT 171-195 3/16 (19) 
APS1-13 
AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGF
RWL 
26-71 3/16 (19) 
APS1-14 
HFGVAAKDQDLKSRPESVECIRYNFRGFR 41-69 8/10 (80) 
SRLLSNKNQFKSFLRTIPNDEHQAT 171-195 2/10 (20) 
APS1-15 
HFGVAAKDQDLKSRPESVECIRYNFRGFR 41-69 8/16 (50) 
SRLLSNKNQFKSFLRTIPNDEHQAT 171-195 3/16 (19) 
APS1-16 
AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGF
RWL 
26-71 4/16 (25) 
TVSKALAEATLSFVAQNKIDSLNLDEFCNCSE 103-133 5/16 (31) 
  
1
Amino acid residues are numbered according to CaSR peptide sequence with the ATG initiation codon 
as residue number 1. 
2
CaSR peptide consensus sequences were in-frame with the PelB leader sequence and coat protein pIII 
which are encoded by the pComb3 vector (Figure 4.2) and are required for expression of peptides on 
the surface of phage. 
3
Unrepeated in-frame CaSR peptides such that a CaSR peptide consensus could not be identified by 
comparing sequences.  
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 CaSR peptide ELISAs with APS1 patient and control sera 4.4.4
To confirm the presence or not of antibodies against the potential epitope domains 
identified by phage display, serum samples from all 44 APS1 patients and 16 healthy 
controls were analysed in an ELISA format with specific CaSR peptides (Table 4.4), as 
detailed in Section 4.4.5. Positive control anti-CaSR antibodies ab79829 and ab19347 
were included in ELISAs when appropriate. The peptides chosen represented potential 
epitopes identified in the phage display experiments and those epitopes reported 
previously to be recognised by CaSR antibodies in patients with either APS1 (Kemp et 
al, 2010), autoimmune hypoparathyroidism (Kifor et al., 2004) or autoimmune 
hypocalciuric hypercalcaemia (Kifor et al., 2003, Pallais et al., 2004, Kemp et al., 2010) 
(Table 4.3). Immunoreactivity against the potential epitope represented by amino 
acids 850-890 was not investigated in peptide ELISA experiments. 
The antibody indices of the APS1 patient and control sera in the CaSR peptide ELISAs 
are shown in Figure 4.6. For each CaSR peptide ELISA, the mean antibody index of the 
APS1 patient and control groups, the antibody index range of the APS1 patient and 
control groups, the intra- and inter-assay coefficients of variation, and the upper limit 
of normal (mean antibody index + 3SD of 16 healthy individuals) are summarised in 
Table 4.8.  
All control sera were negative for antibodies against all the CaSR peptides tested, as 
their antibody indices (Table 4.8) were below the upper limits of normal in the ELISAs. 
In the APS1 patient group, some antibody indices were above the upper limit of 
normal (Table 4.9). The prevalence of antibody-positivity against each CaSR peptide is 
summarised in Table 4.8. Only in the case of the 41-69 CaSR peptide was antibody 
positivity significantly more prevalent in the APS1 patient group than in the healthy 
controls: P = 0.0032, Fisher’s exact test for 2 x 2 contingency tables. In contrast, the 
frequency of the antibody response against CaSR peptides 114-126, 171-195 and 260-
340 was not elevated to statistical significance when comparing the APS1 patient 
group with healthy controls: All P values were > 0.05 in Fisher’s exact test for 2 x 2 
contingency tables. 
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Figure ‎4.6: Antibody indices of APS1 patient and control sera in CaSR peptide ELISAs 
Sera from 44 APS1 patients and 16 healthy controls were evaluated for antibodies against 
CaSR peptides using ELISAs with (a) CaSR 41-69 peptide, (b) CaSR 75-115 peptide, (c) CaSR 114-
126 peptide, (d) CaSR 138-170 peptide, (e) CaSR 171-195 peptide, (f) CaSR 214-238 peptide, (g) 
CaSR 260-340 peptide, (h) CaSR 344-358 peptide, and (i) CaSR 374-391 peptide. The antibody 
index is shown for each APS1 patient and control serum and is the mean antibody index of at 
least two experiments.  
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Table ‎4.8: Summary of data from CaSR peptide ELISAs 
 
CaSR peptide 
ELISA 
Mean antibody index 
(± SD) of APS1 patient 
group (n = 44) 
Antibody 
index range 
of APS1 
patient group 
Mean antibody 
index (± SD) of 
control group 
(n = 16) 
Antibody 
index range 
of control 
group 
Upper limit 
of normal 
antibody 
index 
Intra-assay 
coefficient 
of variation 
Inter-assay 
coefficient 
of variation 
Antibody- 
positive APS1 
patients (%) 
Antibody- 
positive 
controls (%) 
41-69
1
 11.6 ± 21.2 0.11-83.8 1.01 ± 0.39 0.47-1.64 2.17 4.3% 8.7% 16/44 (36) 0/16 (0) 
75-115 0.79 ± 0.41 0.14-1.75 0.99 ± 0.44 0.25-2.00 2.32 3.1% 10.4% 0/44 (0) 0/16 (0) 
114-126 2.82 ± 6.14 0.31-24.5 0.99 ± 0.30 0.46-1.50 1.91 2.9% 7.2% 5/44 (11) 0/16 (0) 
138-170 0.82 ± 0.36 0.29-1.71 1.01 ± 0.39 0.36-1.86 2.18 3.6% 8.0% 0/44 (0) 0/16 (0) 
171-195 2.68 ± 4.71 0.27-17.3 1.00 ± 0.32 0.32-1.52 1.96 4.3% 6.9% 6/44 (14) 0/16 (0) 
214-238
2
 0.72 ± 0.27 0.31-1.19 0.98 ± 0.26 0.54-1.39 1.77 4.5% 7.6% 0/44 (0) 0/16 (0) 
260-340 4.41 ± 8.93 0.23-34.1 1.01 ± 0.29 0.53-1.41 1.87 5.1% 8.3% 7/44 (16) 0/16 (0) 
344-358 0.77 ± 0.24 0.30-1.20 1.00 ± 0.23 0.60-1.35 1.70 3.0% 11.2% 0/44 (0) 0/16 (0) 
374-391 0.79 ± 0.21 0.45-1.15 0.99 ± 0.22 0.58-1.33 1.66 3.3% 10.1% 0/44 (0) 0/16 (0) 
 
1
The CaSR antibody index of the anti-CaSR antibody ab79829 in the 41-69 CaSR peptide ELISA was 61.95. 
2
The CaSR antibody index of the anti-CaSR antibody ab19347 in the 214-238 CaSR peptide ELISA was 222.3. 
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Table ‎4.9: Antibody indices of APS1 patient sera in CaSR peptide ELISAs 
 
Patient 
number 
Antibody index in each CaSR peptide ELISA
1,2 
41-69 75-115 114-126 138-170 171-195 214-238 260-340 344-358 374-391 
APS1-1 82.11 1.17 0.81 1.14 0.80 0.83 0.83 0.88 0.83 
APS1-2 75.39 0.75 0.19 0.79 0.11 0.39 0.30 0.48 0.39 
APS1-3 11.39 0.67 0.61 0.57 14.23 0.69 23.58 0.70 0.72 
APS1-4 13.31 1.07 1.08 1.13 17.08 1.10 32.00 1.07 1.06 
APS1-5 19.97 1.04 14.31 1.05 1.78 0.88 0.93 0.93 0.95 
APS1-6 9.43 0.75 19.94 0.85 1.25 0.27 0.53 0.40 0.55 
APS1-7 7.16 0.14 13.03 0.43 0.56 0.42 0.63 0.53 0.65 
APS1-8 25.76 0.79 0.81 0.88 0.82 0.77 0.85 0.83 0.88 
APS1-9 21.59 0.36 0.44 0.58 11.79 0.31 21.05 0.43 0.58 
APS1-10 18.10 0.36 24.00 0.58 1.60 0.46 0.65 0.57 0.68 
APS1-11 16.22 0.50 0.56 0.68 0.67 0.46 0.65 0.57 0.68 
APS1-12 34.32 0.36 0.44 0.58 17.25 0.31 15.55 0.43 0.58 
APS1-13 10.27 1.11 1.09 1.10 1.06 1.12 1.08 1.13 1.10 
APS1-14 25.73 0.21 0.31 0.48 11.60 0.15 20.45 0.30 0.48 
APS1-15 36.20 0.54 0.59 0.70 12.95 0.50 20.48 0.60 0.70 
APS1-16 83.83 1.83 24.46 1.71 2.01 0.75 34.07 0.80 0.75 
APS1-17 0.57 0.68 0.72 0.80 0.83 0.65 0.78 0.73 0.80 
APS1-18 0.18 1.11 1.09 1.10 1.06 1.12 1.08 1.13 1.10 
APS1-19 0.22 1.18 1.16 1.15 1.14 1.19 1.13 1.20 1.15 
APS1-20 1.11 1.17 0.92 1.14 1.09 0.92 0.93 0.95 0.92 
APS1-21 0.11 0.17 0.31 0.29 0.27 0.47 0.40 0.55 0.47 
APS1-22 0.44 1.17 0.46 1.14 0.55 0.58 0.53 0.65 0.58 
APS1-23 0.36 0.33 0.35 0.43 0.48 0.50 0.43 0.58 0.50 
APS1-24 0.53 0.17 0.50 0.29 0.61 0.61 0.57 0.68 0.61 
APS1-25 1.33 1.75 1.15 1.64 1.27 1.08 1.13 1.10 1.08 
APS1-26 0.19 0.25 0.50 0.36 0.34 0.61 0.57 0.68 0.61 
APS1-27 0.19 0.25 0.35 0.36 0.34 0.50 0.43 0.58 0.50 
APS1-28 1.00 1.25 1.15 1.21 1.00 1.08 1.13 1.10 1.08 
APS1-29 1.39 1.58 1.23 1.50 1.32 1.14 1.20 1.15 1.14 
APS1-30 0.44 0.75 0.54 0.79 0.55 0.64 0.60 0.70 0.64 
APS1-31 0.96 0.79 0.75 0.73 0.76 0.81 0.69 0.80 0.82 
APS1-32 0.85 0.93 0.92 0.93 0.85 0.95 0.81 0.93 0.94 
APS1-33 0.96 0.55 0.47 0.40 0.53 0.57 0.31 0.59 0.62 
APS1-34 0.24 0.64 0.58 0.53 0.58 0.67 0.23 0.67 0.70 
APS1-35 0.11 0.86 0.83 0.83 0.86 0.88 0.73 0.87 0.88 
APS1-36 0.84 0.57 0.50 0.43 0.48 0.60 0.35 0.61 0.64 
APS1-37 1.24 1.07 1.08 1.13 1.03 1.10 1.00 1.07 1.06 
APS1-38 0.93 0.67 0.61 0.57 0.73 0.69 0.60 0.70 0.72 
APS1-39 0.79 0.57 0.50 0.43 0.55 0.60 0.33 0.61 0.64 
APS1-40 0.78 1.02 1.11 0.79 1.00 1.04 1.14 1.05 1.01 
APS1-41 1.06 0.93 0.94 1.15 1.12 1.12 0.92 0.96 0.84 
APS1-42 0.75 0.84 0.81 1.03 0.99 0.67 0.74 0.95 0.88 
APS1-43 1.02 0.92 0.67 1.02 1.04 0.81 0.78 0.64 1.05 
APS1-44 1.16 1.09 0.98 0.86 0.77 0.89 1.09 0.88 1.02 
 
1
Bold type-face indicates antibody-positive APS1 patient serum. 
2
The antibody index is the mean of two experiments. 
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 Summary of CaSR epitope identification 4.4.5
The identified CaSR epitope domains mapped by phage display and CaSR peptide ELISAs 
are given in Table 4.10. There was concordance between the majority of epitopes 
identified by phage display and those subsequently verified by CaSR peptide ELISAs. The 
exceptions were (a) antibody reactivity against CaSR peptide 260-340 in the ELISA, which 
was not identified as a target by phage display in patients APS1-3, APS1-9, APS1-12, APS1-
14, APS1-15, and APS1-16, (b) antibody reactivity against CaSR peptide 171-195 in the 
ELISA, which was not identified as a target by phage display in patient APS1-4, and (c) no 
reactivity against CaSR peptides 114-126 and 138-170 in the ELISAs, although the 
consensus peptide of CaSR residues 117-144 was identified as a target by phage display in 
patient APS1-4.  
All patients in the APS1 group had CaSR antibodies that recognised epitope/s within the 
domain 41-69 (Table 4.11). None of the patients had antibodies that bound to amino acid 
residues 75-115, 138-170, 214-238, 344-358 or 374-391 of the CaSR (Table 4.11). In 
addition, 31% (5/16), 38% (6/16) and 44% (7/16) of the APS1 patients showed 
immunoreactivity against CaSR peptides 114-126, 171-195 and 260-340, respectively 
(Table 4.11). Furthermore, the CaSR antibodies in 5/16 (31%), 4/16 (25%), and 7/16 (44%) 
of the APS1 patients recognised one, two and three different epitopes, respectively (Table 
4.12). Table 4.12 also gives the clinical details of the 16 CaSR antibody-positive patients 
and their respective CaSR epitope recognition patterns. 
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Table ‎4.10: CaSR epitope domains identified by phage display and/or CaSR peptide ELISA 
 
APS1 patient Epitope domain identified by phage- 
display 
Epitope domain identified or 
confirmed by CaSR peptide ELISAs 
APS1-1 26-71 41-69 
APS1-2 41-71 41-69 
APS1-3 19-44; 138-190 41-69; 171-195; 260-340 
APS1-4 23-45; 117-144; 260-340 41-69; 171-195; 260-340 
APS1-5 27-71; 106-131 41-69; 114-126 
APS1-6 41-71; 106-130 41-69; 114-126 
APS1-7 41-71; 114-126 41-69; 114-126 
APS1-8 41-71 41-69 
APS1-9 26-69; 171-195 41-69; 171-195; 260-340 
APS1-10 30-70; 103-133 41-69; 114-126 
APS1-11 26-71 41-69 
APS1-12 26-71; 171-195 41-69; 171-195; 260-340 
APS1-13 26-71 41-69 
APS1-14 41-69; 171-195 41-69; 171-195; 260-340 
APS1-15 41-69; 171-195 41-69; 171-195; 260-340 
APS1-16 26-71; 103-133 41-69; 114-126; 260-340 
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Table ‎4.11: Summary of epitopes recognised by CaSR antibodies in APS1 patients 
 
Epitope 
domain 
Number of CaSR antibody-positive 
APS1 patients (n = 16) with 
antibodies against epitope (%) 
APS1 patients with CaSR antibodies 
41-69 16 (100) 
APS1-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, -
11, -12, -13, -14, -15, -16 
75-115 0 (0) None detected 
114-126 5 (31) APS1-5, -6, -7, -10, -16 
138-170 0 (0) None detected 
171-195 6 (38) APS1-3, -4, -9, -12, -14, -15 
214-238 0 (0) None detected 
260-340 7 (44) APS1-3, -4, -9, -12, -14, -15, -16 
344-358 0 (0) None detected 
374-391 0 (0) None detected 
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Table ‎4.12: Summary of APS1 patient details and CaSR epitopes 
 
Patient Sex 
Age at 
sample 
(years) 
Age at 
onset 
(years) 
Disease 
duration 
(years) 
Clinical details
1 
Number 
of CaSR 
epitopes 
Epitopes 
APS1-1 F 46 2 44 
CMC; HP; AD; HT; POF; AA; AS; 
TIN 
1 41-69 
APS1-2 M 46 7 39 
CMC; HP; AD; HT; HG; AA; V; 
T1D; AS; K 
1 41-69 
APS1-3 F 51 3 48 CMC; HP; AD; POF; T1D; AS; OBS 3 
41-69; 
171-195; 
260-340 
APS1-4 M 37 2 35 CMC; HP; AD; T1D; 3 
41-69; 
171-195; 
260-340 
APS1-5 F 10 5 5 CMC; HP; AD 2 
41-69; 
114-126 
APS1-6 F 12 3 9 CMC; HP; AD; POF; GHD 2 
41-69; 
114-126 
APS1-7 M 9 4 5 CMC; HP; AD; K 2 
41-69; 
114-126 
APS1-8 M 13 5 8 CMC; HP; AD; K; V; CD; AS 1 41-69 
APS1-9 M 30 7 21 CMC; HP; AD; T1D 3 
41-69; 
171-195; 
260-340 
APS1-10 M 47 15 32 CMC; AD; PA; AA 2 
41-69; 
114-126 
APS1-11 F 16 4 12 CMC; HP; AD; H; POF; OBS 1 41-69 
APS1-12 F 27 2 25 CMC; HP; AD; K; AA; POF; OBS 3 
41-69; 
171-195; 
260-340 
APS1-13 M 25 4 21 
CMC; HP; AD; K; AA; V; OBS; AS; 
HG 
1 41-69 
APS1-14 F 43 5 38 CMC; HP; AD; POF; AA; V; CD 3 
41-69; 
171-195; 
260-340 
APS1-15 M 9 5 4 CMC; HP; AD 3 
41-69; 
171-195; 
260-340 
APS1-16 F 11 5 6 CMC; HP; AD 3 
41-69; 
114-126; 
260-340 
 
1
AA, alopecia areata; AD, Addison’s disease; AS, asplenia; CD, chronic diarrhoea; CMC, chronic 
mucocutaneous candidiasis; GHD, growth hormone deficiency; H, hepatitis; HG, hypogonadism (male); HP, 
hypoparathyroidism; HT, autoimmune hypothyroidism; K, keratoconjunctivitis; OBS, chronic obstipation; PA, 
pernicious anaemia; POF, premature ovarian failure; T1D, type 1 diabetes mellitus; TIN, tubulonephritis; V, 
vitiligo. 
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 Features of the identified CaSR epitopes  4.4.6
All the identified epitopes domains were in the extracellular domain of the CaSR (Figure 
4.7). The epitope at amino acids 41-69 overlaps the CaSR loop 1 domain (Hu and Spiegel, 
2007), and the epitope constituting amino acids 114-126 overlaps the CaSR loop 2 domain 
(Hu and Spiegel, 2007). The epitope encompassing amino acids 171-195 includes residues 
that have been predicted to participate in calcium binding (S147, S170, and D190) (Silve et 
al., 2005). The 260-340 epitope domain contains a critical amino acid residue E297 that 
forms part a Ca2+ binding pocket in the CaSR (Silve et al., 2005). 
The mapped epitopes were visualised on a 3D representation of the CaSR extracellular 
domain using PyMOL molecular graphics system software. The results indicated that in all 
four epitopes, there were several amino acid residues exposed on the surface of the 
receptor (Figure 4.8). This would indicate accessibility as antibody targets. 
Antigenicity predictions on the CaSR extracellular domain were made using the Immune 
Epitope Database and Analysis Resource. The analysis revealed several antigenic peptides 
within the CaSR extracellular domain (Figure 4.9 and Table 4.13). Comparison of the 
predicted CaSR antigenic peptides with the CaSR epitopes determined experimentally by 
phage-display and CaSR peptide ELISAs indicated there was overlap between them, 
particularly in the case of the antibody binding site identified between amino acid 
residues 260-340 (Table 4.13). 
In searches of relevant protein databases, amino acid homologies between the identified 
epitopes and either microbial or viral polypeptides were not demonstrated. 
  
 157 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎4.7: Position of identified epitopes on the linear sequence of the CaSR 
extracellular domain. 
The figure of the CaSR extracellular domain was created using the web-based service Protter 
(wlab.ethz.ch/protter) (Omasits et al., 2014). Amino acids forming the CaSR loop domains (Hu and 
Spiegel, 2007) are shown in squares. The epitope at amino acids 41-69 overlaps the CaSR loop 1 
domain (Hu and Spiegel, 2007), and the epitope constituting amino acids 114-126 overlaps the 
CaSR loop 2 domain (Hu and Spiegel, 2007). The epitope encompassing amino acids 171-195 
includes residues that have been predicted to participate in calcium binding (S147, S170, and 
D190) (Silve et al., 2005). The 260-340 epitope domain contains a critical amino acid residue E297 
that forms part a Ca2+ binding pocket in the CaSR (Silve et al., 2005).  
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Figure ‎4.8: 3D representation of the CaSR extracellular domain showing antibody 
binding sites. 
Identified CaSR epitopes were visualised on a 3D representation of the CaSR extracellular domain 
using PyMOL molecular graphics system software. The epitopes highlighted are at amino acids 41-
69 (red), 114-126 (yellow), 171-195 (pink), and 260-340 (blue). 
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Figure ‎4.9: Antigenicity predictions within the CaSR extracellular domain. 
Antigenicity predictions within the CaSR extracellular domain were carried out using the Immune 
Epitope Database and Analysis Resource. Local antigenicity values, calculated as previously 
detailed (Kolaskar and Tongaonkar, 1990), are plotted against the amino acid residues of the CaSR 
extracellular domain. The y-axis from 0-1.4 reflects increasing antigenicity. 
  
Amino acid residue 
Antigenicity 
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Table ‎4.13: Comparison of predicted antigenic peptides on the CaSR extracellular 
domain to the CaSR epitopes determined experimentally 
 
Predicted antigenic peptide1  Epitope domain2 
4-19 (YSCCWVLLALTWHTSA) - 
31-48 (DIILGGLFPIHFGVAAKD) 41-69 (HFGVAAKDQDLKSRPESVECIRYNFRGFR) 
55-63 (PESVECIRY) 41-69 (HFGVAAKDQDLKSRPESVECIRYNFRGFR) 
70-76 (WLQAMIF) - 
84-96 (SPALLPNLTLGYR)  
98-118 (FDTCNTVSKALEATLSFVAQN) 114-126 (FVAQNKIDSLNLD) 
125-144 (LDEFCNCSEHIPSTIAVVGA) 114-126 (FVAQNKIDSLNLD) 
149-174 (VSTAVANLLGLFYIPQVSYASSSRLL) 171-195 (SRLLSNKNQFKSFLRTIPNDEHQAT) 
181-186 (KSFLRT)  171-195 (SRLLSNKNQFKSFLRTIPNDEHQAT) 
233-246 (RDICIDFSELISQY)  
252-261 (IQHVVEVIQN)  
263-273 (TAKVIVVFSSG) 
260-340 
(QNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWAS
SSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPR) 
276-283 (LEPLIKEI) 
260-340 
(QNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWAS
SSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPR) 
291-297 (KIWLASE) 
260-340 
(QNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWAS
SSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPR) 
301-317 (SSSLIAMPQYFHVVGGT) 
260-340 
(QNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWAS
SSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPR) 
319-325 (GFALKAG) 
260-340 
(QNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWAS
SSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPR) 
333-342 (FLKKVHPRKS) 
260-340 
(QNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWAS
SSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPR) 
357-362 (NCHLQE) - 
366-373 (GPLPVDTF) - 
390-396 (AFRPLCT) - 
401-441 
(ISSVETPYIDYTHLRISYNVYLAVYSIAHALQDIYTCLP
GR) 
- 
449-467 (CADIKKVEAWQVLKHLRHL) - 
482-489 (CGDLVGNY) - 
501-516 (GSIVFKEVGYYNVYAK) - 
543-549 (SREVPFSNCSRDCLAG) - 
558-571 (EPTCCFECVECPDG) - 
579-588 (ASACNKCPDD) - 
 
1
Antigenic peptides predicted using the Immune Epitope Database and Analysis Resource. 
2
Epitopes on the CaSR identified by phage-display and CaSR peptide ELISAs. 
  
 161 
 Discussion 4.5
Identification of CaSR epitopes The aim of this part of the study was to use phage-display 
technology to identify the epitopes of APS1 patient CaSR antibodies. This method has 
been employed in identifying the binding sites of autoantibodies found in several 
autoimmune diseases (Myers et al., 2000, Dromey et al., 2004). Here, a phage-display 
library of CaSR peptides was used in panning experiments with anti-CaSR antibody 
ab79829, as a positive control, and with APS1 patient sera. Following five rounds of 
panning of the phage display library with anti-CaSR antibody ab79829, sequence analysis 
revealed that 80% of the phagemid contained an amino acid consensus sequence of 
residues 26-70, encompassing the target sequence (amino acids 41-69) of the antibody. 
This initial control experiment demonstrated that the phage display library could be 
screened successfully, at least with a specific antibody. 
Subsequent panning of the phage-display library with sera from CaSR antibody-positive 
APS1 patients resulted in the identification of at least one CaSR peptide consensus 
sequence, presumably representing a CaSR epitope, for each patient. In addition, two 
patients (APS1-2 and APS1-4) had each enriched one in-frame CaSR peptide (amino acids 
850-909 and 260-340, respectively) that was only represented once within the set of 
analysed sequences. Nevertheless, these sequences could represent CaSR epitopes as 
they would have been expressed on the phage surface and therefore accessible to 
antibody interaction during the panning process. The APS1 CaSR antibody-negative 
patient did not enrich any consensus peptide. 
To confirm the presence or not of antibodies against the potential epitope domains 
identified by phage display, serum samples from all 44 APS1 patients were analysed in an 
ELISA format with specific CaSR peptides. There was concordance between the majority of 
epitopes identified by phage display and those subsequently verified by CaSR peptide 
ELISAs. However, a lack of immunoreactivity against CaSR peptides 114-126 and 138-170 
in ELISAs in patient APS1-4, even though a consensus peptide of CaSR residues 117-144 
was identified as a target by phage-display, may indicate that the CaSR antibody binding 
site lies between amino acids 127 and 137, residues which were not present in the 
 162 
peptides tested in the ELISAs. In addition, there were two examples of epitopes (171-195 
and 260-340) that were not identified as antibody targets by phage display by certain 
APS1 patient sera (171-195 by APS1-4; and 260-340 by APS1-3, APS1-9, APS1-12, APS1-14, 
APS1-15, and APS1-16), but were subsequently characterised as binding sites in peptide 
ELISAs. Such discordance could be explained by a failure to screen sufficient numbers of 
clones in order to identify the particular peptide sequence following panning experiments. 
Indeed, the CaSR peptide 260-340 was only represented once amongst the set of clones 
isolated after panning of serum from patient APS1-4. 
Overall, CaSR antibody epitopes were identified between amino acid residues 41-69 (all 
patients), 114-126 (31% of patients), 171-195 (38% of patients) and 260-340 (44% of 
patients) at the N-terminal of the receptor’s extracellular domain. The first three epitope 
domains have been reported previously for CaSR antibodies in 12 APS1 patients (Kemp et 
al., 2010) and were found again here. Amino acid sequence 260-340 constituted a novel 
CaSR epitope. As before (Kemp et al., 2010), epitopes at amino acids 214-236, 374-391 
and 344-358 were not identified in this study, although all three binding sites have been 
reported as targets for CaSR autoantibodies in patients with hypocalciuric hypercalcaemia 
or autoimmune hypoparathyroidism (Kifor et al., 2003, Kifor et al., 2004, Pallais et al., 
2004). Furthermore, epitopes were not apparent in the CaSR extracellular domain 
between amino acids 75-115 and 138-170. 
Except for the potential epitope between amino acids 850-909, which was isolated in 
panning experiments with serum from patient APS1-2, but was not analysed in CaSR 
peptide ELISAs, antibody binding sites in either the membrane spanning region or the 
intracellular part of the CaSR were not characterised. As B cell epitopes are generally up to 
20 amino acids (von Mikecz et al., 1995), the larger two represented by amino acids 260-
340 (81 residues) and 41-69 (38 residues) require finer mapping experiments to determine 
the exact antibody binding sites. Of interest, is that since all patients reacted with amino 
acid residues 41-69, this might well be the (or part of the) immunodominant CaSR epitope 
and as such the peptide could form a simple assay if in future a larger panel of sera were 
to confirm the 100% reactivity. 
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Identified epitopes and CaSR function Notably, in all the identified epitopes there were 
several amino acid residues exposed on the surface of the CaSR such that they would be 
available for antibody binding. With regard to the possible effects that CaSR antibodies 
might have upon receptor function, the major epitope domain at amino acids 41-69 
overlaps with the loop 1 domain of the receptor which, if removed, reduces activation of 
the receptor (Reyes-Cruz et al., 2001, Hu and Spiegel, 2007). Binding of CaSR antibodies to 
this site might therefore modulate the receptor’s normal function. 
The epitope constituting amino acids 114-126 overlaps with the loop 2 domain of the 
CaSR (Hu and Spiegel, 2007). Point mutations in or deletions of this part of the receptor 
increase the sensitivity of the CaSR to Ca2+, and result in autosomal dominant 
hypoparathyroidism (Reyes-Cruz et al., 2001, Hu and Spiegel, 2007). From these 
observations, it has been suggested that loop 2 may have an important role in maintaining 
the inactive state of the CaSR involving disulphide links through cysteine residues C129 
and C131. Indeed, mutations involving either of these amino acid residues results in 
autosomal dominant hypoparathyroidism (www.casrdb.mcgill.ca). Antibody binding to 
epitopes that are found within loop 2 could either inhibit or activate the CaSR, depending 
on whether antibody binding favoured the active or inactive state of the receptor, 
respectively. 
Of particular interest is the antibody binding site at amino acids 171-195 since site-
directed mutagenesis and molecular models have indicated that some of these residues 
(S147, S170, and D190) form part of a binding site for Ca2+ that is found in the crevice 
between the two lobes of each receptor monomer (Hauache et al., 2000, Silve et al., 2005, 
Hu and Spiegel, 2007). Therefore, binding of an antibody to this area of the CaSR could 
disrupt the interaction of Ca2+ with this Ca2+-binding site. Furthermore, the 260-340 
epitope domain also contains a critical amino acid residue E297 that forms part a Ca2+ 
binding pocket (Silve et al., 2005). 
Further investigations are required to ascertain the possible functional effects of CaSR 
antibodies that recognise the different epitopes. Previously, antibodies that activate the 
receptor have been identified in two APS1 patients (Kemp et al., 2009). However, their 
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exact binding sites on the receptor remain to be determined. The epitopes characterised 
here are likely to be linear in nature as their recognition by patient CaSR antibodies was 
confirmed using synthetic peptide ELISAs. Nevertheless, it is possible that the identified 
linear binding sites contribute to discontinuous epitopes on the CaSR. It is generally 
assumed that autoantibodies affecting the function of a protein, and which lead to 
disease, bind to conformational epitopes. In Graves’ disease, for example, autoantibodies 
against the thyrotropin receptor, which are responsible for disease activity, recognise a 
number of different conformational epitopes (Morgenthaler et al., 1999). Identifying CaSR 
antibody binding sites that depend upon the native structure of the receptor is therefore 
an important future goal. 
Epitope spreading Immunoreactivity to more than one epitope was detected in many of 
the patients (11/16 = 69%), indicating a heterogeneous humoral immune response against 
the CaSR. Similarly, antibodies in autoimmune thyroiditis and type 1 diabetes mellitus 
have been reported to react against multiple epitopes on thyroid peroxidase and tyrosine 
phosphatase-like IA-2 autoantigens, respectively (Lampasona et al., 1996, Zanelli et al., 
1992). This has been explained by ‘intramolecular spreading’ of an autoimmune response 
from one or a small number of epitopes to multiple epitopes during disease progression. 
For example, in type 1 diabetes mellitus, a temporal spreading of the antibody responses 
has been described from immunodominant epitopes in an early pre-clinical phase to 
lesser immunogenic domains at the manifestation of disease (Naserke et al., 1998). 
Unfortunately, in the absence of longitudinal serum samples, no evidence of CaSR epitope 
spreading can be provided in the cases described in this study.  
Molecular mimicry Of note, homology between the identified epitopes and microbial 
proteins was not in evidence, suggesting that molecular mimicry (Wucherpfennig, 2001b) 
does not initiate the production of CaSR antibodies in APS1 patients. However, there may 
be as yet unidentified antibody binding sites on the receptor that do display cross-
reactivity with bacterial or viral antigens. 
Limitations of methodology A notable limitation of the study is in the use of human sera 
in the mapping of B cell epitopes which can be problematic because sera contain multiple 
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antibody species against a particular autoantigen and the immune response tends to 
diversify with duration. It is difficult therefore to examine the reactivity of a specific 
autoantibody in isolation. In order to characterise the array of autoantibodies present in a 
specifc serum and the epitope specificity of a particular autoantibody, the isolation of 
monoclonal antibodies from the patient would be needed. This has been done to identify 
an array of epitopes on glutamic acid decarboxylase in patients with type 1 diabetes 
mellitus (Syren et al., 1996). However, although the monoclonal antibody approach can 
allow the precise characterisation of epitopes recognised by a specific antibody, it is 
difficult to know the relative frequencies of the different monoclonal antibodies in the 
patient under investigation, and how typical these are for the general population. Despite 
this, the isolation of monoclonal CaSR antibodies from APS1 patients would allow a more 
detailed characterisation of the epitopes recognised by CaSR autoantibodies. 
Conclusions To conclude, several binding sites of CaSR autoantibodies have been 
identified. They confirm earlier reported epitopes, although a novel binding site (amino 
acids 260-340) was also discovered. It will be of interest to determine if any the antibodies 
recognising the specific epitopes are able to affect the function of the receptor. 
 
  
 
 
 
 
 
 
 
 
Chapter 5 
Characterisation of the properties of CaSR autoantibodies in APS1 patients 
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5 Characterisation of the properties of CaSR autoantibodies in APS1 
patients 
 Introduction 5.1
Immunoglobulin G (IgG) makes up in the region of 75% of the total immunoglobulins in 
the human circulation. It is a major effector of the antibody response. The remaining 25% 
of immunoglobulins comprises the four classes, IgM, IgA, IgD and IgE. Each class has its 
own distinctive functions and characteristics (Spiegelberg, 1974). Predominantly, the 
activity of IgG class antibodies is expressed during a secondary antibody response 
corresponding with repeated contact with an antigen. Antibodies of the IgG class persist in 
the blood for long periods, and have relatively high affinity compared with other 
immunoglobulin classes. The following sections will summarise some important properties 
of IgG antibodies that will be examined in the context of APS1 patient autoantibodies 
against the CaSR. 
 Antibody functional affinity (avidity) 5.1.1
Antibody affinity is a measure of the binding strength between one interacting antibody 
site and one antigenic determinant (Roitt and Delves, 1997). However, in practice, 
functional affinity (or avidity) is used to measure the overall strength of interaction 
between antibodies and multivalent antigens. Indeed, this is most applicable in describing 
the binding of a patient’s serum to its antigenic target (Roitt and Delves, 1997). It has been 
suggested that high functional affinity could be an important property of antibodies in 
autoimmune disease (Gharavi and Reiber, 1996). However, only in a few cases have 
antibodies with greater functional affinity been shown to have increased pathogenicity 
(Takeda et al., 2001, Cucnik et al., 2004, Cucnik et al., 2011). Examples include double-
stranded DNA and ribosomal P antibodies in systemic lupus erythematosus patients 
(Takeda et al., 2001), and antibodies against anti-β2-glycoprotein I in antiphospholipid 
syndrome patients (Cucnik et al., 2004, Cucnik et al., 2011). However, there are no reports 
on the functional affinity of CaSR autoantibodies. 
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 IgG subclasses 5.1.2
Four subgroups of IgG have been identified in humans and these are referred to as IgG1, 
IgG2, IgG3 and IgG4 (Gergely et al., 1967). There are differences in some of the biological 
properties of the different subclasses, and these are given in Table 5.1. Particularly, 
interactions with Fc receptors (FcγR), which are expressed primarily on immune effector 
cells, differ between the subclasses (Table 5.1). Consequently, IgG1, IgG2, IgG3 and IgG4 
can have different effects upon the induction of effector cell functions which may include 
phagocytosis, antibody-mediated cellular cytotoxicity, and antigen presentation (van de 
Winkel and Capel, 1993, van de Winkel and Capel, 1996). Furthermore, IgG4 cannot 
activate the complement system (Table 5.1) (Flanagan and Rabbitts, 1982, van Loghem, 
1986). 
In autoimmune diseases, subclass restriction of specific antibodies has been observed. For 
example, chiefly, autoantibodies against 21-hydroxylase, 17α-hydroxylase and side-chain 
cleavage enzyme, in patients with autoimmune Addison’s disease and autoimmune 
ovarian insufficiency, are of the IgG1 subclass (Boe et al., 2004, Brozzetti et al., 2010). 
Similarly, in patients with type 1 diabetes mellitus, IgG1 autoantibody responses 
predominate against protein tyrosine phosphatase IA-2 and glutamic acid decarboxylase 
65 (Bonifacio et al., 1999, Hawa et al., 2000). A predominance of IgG and IgG4 subclasses 
with respect to thyroid peroxidase autoantibodies has also been shown in patients with 
autoimmune hypothyroidism (Kohno et al., 1993, Silva et al., 2003, Xie et al., 2008). In 
patients with Graves’ hyperthyroidism or Hashimoto’s thyroiditis, IgG2 and IgG4 were the 
dominant subclasses, respectively, in relation to thyroglobulin autoantibodies (Caturegli et 
al., 1994). So far, the only report of IgG subclass in relation to CaSR autoantibodies has 
come from studying a patient with autoimmune hypocalciuric hypercalcemia; the anti-
CaSR autoantibodies were exclusively of the IgG4 subtype (Pallais et al., 2004). No studies 
have reported IgG subclasses for CaSR autoantibodies found in patients with 
hypoparathyroidism. 
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 Antibody functional effects 5.1.3
Several extracellular receptors are the targets of pathogenic autoantibodies in 
autoimmune disease. Examples are the thyroid-stimulating hormone receptor in Graves’ 
hyperthyroidism (Morgenthaler et al., 2007), and the acetylcholine receptor in myasthenia 
gravis (Jacob et al., 2012). To date, only a small number of patients with 
hypoparathyroidism have been identified with CaSR-activating autoantibodies that could 
theoretically diminish PTH-secretion: IgG from two patients with APS1 (both with 
hypoparathyroidism) activated the CaSR expressed in HEK293 cells (Kemp et al., 2009), 
and sera from two patients with idiopathic hypoparathyroidism inhibited PTH-release 
from human parathyroid cells (Kifor et al., 2004).  
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Table ‎5.1: Properties of IgG subclasses 
 
Property IgG1 IgG2 IgG3 IgG4 
Mean serum concentration in g/l 
(range)  
6.98 
(4.9-11.4)  
3.8 
(1.5-6.4) 
0.51 
(0.20-1.10) 
0.56  
(0.08-1.40) 
Percentage of total IgG  43-75  16-48  1.7-7.5  0.8-11.7  
Anti-protein activity1 ++  +/-  ++  +/-  
Anti-polysaccharide activity1 +  ++  - -  
Anti-allergen activity1 +  -  -  ++  
Complement C1q binding1  ++  +  +++  -  
Fc receptor for IgG binding 
FcγRI (CD64:monocytes, macrophages, 
neutrophils, dendritic cells)  
++  -  +++  +  
FcγRII (CD32):monocytes, macrophages, 
neutrophils, eosinophils, platelets, B 
cells, dendritic cells, endothelial cells)  
++  - +++  -  
FcγRIIa-H131  ++  +++  +++  -  
FcγRIIa-R131  ++  -  ++  -  
Fcγ RIII (CD16:neutrophils, eosinophils, 
macrophages, NK cells, subsets of T 
cells)  
++  -  ++  -  
FcγRIIIb-NA1  +++  -  +++  -  
FcγRIIIb-NA2  ++  -  ++  -  
 
 
1
+++, very strongly positive; ++, strongly positive; +, positive; -/+, weakly positive; -, negative. 
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 Aims 5.2
In light of the discussed properties of IgG molecules, the aims of this part of the study 
were to evaluate: 
 The titres of antibodies against the CaSR epitopes 41-69, 114-126, 171-195, and 
260-340. 
 The specificity of antibodies against the CaSR epitopes 41-69, 114-126, 171-195, 
and 260-340. 
 The functional affinity of antibodies against the CaSR epitopes 41-69, 114-126, 171-
195, and 260-340. 
 The IgG subclass of antibodies against the CaSR epitopes 41-69, 114-126, 171-195, 
and 260-340. 
 The functional effects of CaSR antibodies upon the CaSR. 
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 Materials and Methods 5.3
 Patient and control sera 5.3.1
The clinical and demographic details of the 16 CaSR antibody-positive APS1 patients used 
in this part of the study are given in Table 5.2.  
 Antibody titrations 5.3.2
To determine CaSR antibody titres, APS1 patient sera (n = up to 16, depending on the 
CaSR epitopes recognised by the patient’s antibodies) were analysed in CaSR peptide 
ELISAs at a range of dilutions from 1:100 to 1:5,000. Sera from healthy individuals (n = 10) 
were used in CaSR peptide ELISAs as controls at a 1:100 dilution. All CaSR peptides (Table 
5.3) were received dried and were solubilised and stored according to the manufacturer’s 
instructions (Cambridge Peptides Ltd., Birmingham, UK). For ELISAs, the required peptide 
was diluted in phosphate-buffered saline (pH 7.4) to 0.2 μg/ml and 100-μl samples used to 
coat the wells of a 96-well microtitre plate. An equivalent number of wells were coated 
with 100 μl of 0.1% (w/v) bovine serum albumin for the measurement of non-specific 
binding of the sera. The plates were then incubated overnight at 4°C.  
Excess peptide was removed by decanting and the wells were blocked with blocking buffer 
(phosphate-buffered saline, pH 7.4; 0.1% (w/v) Tween-20; 3% (w/v) bovine serum 
albumin) for 30 min at 37°C. Plates were washed four times with washing buffer 
(phosphate-buffered saline, pH 7.4; 0.1% (v/v) Tween-20). Duplicate 100-µl samples of 
sera at dilutions of 1:100, 1:200, 1:500, 1:1,000, 1:2,000, and 1:5,000 in blocking buffer 
were added to the wells. PBS was applied as a control to measure any non-specific binding 
of the secondary antibody. The plates were incubated at room temperature for 1 h and 
then washed four times with washing buffer. A 100-µl of goat anti-human IgG polyclonal 
antibody conjugated to alkaline phosphatase (Sigma-Aldrich, Poole, UK) diluted to 1:2000 
in blocking buffer was added to each well for 1 h at room temperature. After washing five 
times with washing buffer, 100 µl of alkaline phosphatase substrate Sigma Fast p-
nitrophenyl phosphate (Sigma-Aldrich) were applied to each well and plates incubated at 
room temperature to allow colour development. A LabSystems Integrated EIA 
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Management System spectrophotometer (Life Sciences International, Basingstoke, UK) 
was used to read absorption of the wells at 405 nm. All sera were tested in duplicate and 
the average OD405 value taken. Each mean OD405 value was corrected for background 
binding of the sera to the well without peptide. 
The CaSR peptide-binding reactivity of each APS1 patient serum at each dilution and of 
each control serum was expressed as an antibody index calculated as: mean OD405 of 
tested serum at specified dilution/mean OD405 of 10 healthy control sera. Each serum was 
tested in three experiments and the mean antibody index ± SD calculated. The upper limit 
of normal for each CaSR peptide ELISA was calculated using the mean antibody index + 
3SD of 10 healthy control sera. 
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Table ‎5.2: Summary of APS1 patients analysed 
 
Patient Sex 
Age at 
sample 
(years) 
Age at 
onset 
(years) 
Disease 
duration 
(years) 
Clinical details
1 
Number 
of CaSR 
epitopes 
Epitopes 
APS1-1 F 46 2 44 
CMC; HP; AD; HT; POF; AA; 
AS; TIN 
1 41-69 
APS1-2 M 46 7 39 
CMC; HP; AD; HT; HG; AA; 
V; T1D; AS; K 
1 41-69 
APS1-3 F 51 3 48 
CMC; HP; AD; POF; T1D; 
AS; OBS 
3 
41-69; 
171-195; 
260-340 
APS1-4 M 37 2 35 CMC; HP; AD; T1D; 3 
41-69; 
171-195; 
260-340 
APS1-5 F 10 5 5 CMC; HP; AD 2 
41-69; 
114-126 
APS1-6 F 12 3 9 CMC; HP; AD; POF; GHD 2 
41-69; 
114-126 
APS1-7 M 9 4 5 CMC; HP; AD; K 2 
41-69; 
114-126 
APS1-8 M 13 5 8 CMC; HP; AD; K; V; CD; AS 1 41-69 
APS1-9 M 30 7 21 CMC; HP; AD; T1D 3 
41-69; 
171-195; 
260-340 
APS1-10 M 47 15 32 CMC; AD; PA; AA 2 
41-69; 
114-126 
APS1-11 F 16 4 12 CMC; HP; AD; H; POF; OBS 1 41-69 
APS1-12 F 27 2 25 
CMC; HP; AD; K; AA; POF; 
OBS 
3 
41-69; 
171-195; 
260-340 
APS1-13 M 25 4 21 
CMC; HP; AD; K; AA; V; 
OBS; AS; HG 
1 41-69 
APS1-14 F 43 5 38 
CMC; HP; AD; POF; AA; V; 
CD 
3 
41-69; 
171-195; 
260-340 
APS1-15 M 9 5 4 CMC; HP; AD 3 
41-69; 
171-195; 
260-340 
APS1-16 F 11 5 6 CMC; HP; AD 3 
41-69; 
114-126; 
260-340 
 
1
AA, alopecia areata; AD, Addison’s disease; AS, asplenia; CD, chronic diarrhoea; CMC, chronic 
mucocutaneous candidiasis; GHD, growth hormone deficiency; H, hepatitis; HG, hypogonadism (male); HP, 
hypoparathyroidism; HT, autoimmune hypothyroidism; K, keratoconjunctivitis; OBS, chronic obstipation; PA, 
pernicious anaemia; POF, premature ovarian failure; T1D, type 1 diabetes mellitus; TIN, tubulonephritis; V, 
vitiligo. 
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Table ‎5.3: CaSR peptides used in ELISAs 
 
CaSR peptide1 
Number of amino 
acids 
Amino acid sequence of peptide 
41-69 38 HFGVAAKDQDLKSRPESVECIRYNFRGFR 
114-126 13 FVAQNKIDSLNLD 
171-195 25 SRLLSNKNQFKSFLRTIPNDEHQAT 
214-238 25 ADDDYGRPGIEKFREEAEERDICID 
260-340 81 
QNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWASSSLIA
MPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPR 
 
1
Amino acid residues are numbered according to CaSR peptide sequence with the ATG initiation codon as 
residue number 1. 
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 Absorption experiments  5.3.3
To determine CaSR antibody specificity, APS1 patient sera (n = up to 16, depending on the 
CaSR epitopes recognised by the patient’s antibodies) were pre-absorbed at non-
saturating dilutions (Table 5.4), which were pre-determined by antibody titration, with a 
200X molar excess of the required synthetic CaSR peptide (Table 5.5) in 1 ml of PBS, and 
then analysed in CaSR peptide ELISAs. A CaSR-unrelated peptide against the melanin-
concentrating receptor 1 (Alpha Diagnostic International Inc., San Antonio, Texas, USA) 
was also included as a control peptide. APS1 patient sera at non-saturating dilutions and 
healthy control sera (n = 6) at 1:100 dilutions were also incubated without any peptide. 
To estimate how much peptide to use in each absorption experiment, the following serves 
as an example. It was assumed that IgG concentration in serum was 10 mg/ml (or 0.01 
g/ml). Using the molecular weight for IgG of 150,000 Da (or 150,000 g/mol), this 
calculated as 6.67 x 10-8 mol/ml in undiluted serum, where mol/ml = (g/ml)/(g/mol). If a 
750X dilution of serum was required in the absorption experiment (Table 5.4), then the 
concentration of IgG was estimated at 8.89 x 10-11 mol/ml. The antibody concentration 
was then multiplied by 200 to arrive at the peptide concentration that would give a 200X 
molar excess of peptide in the absorption experiment. In the given example, the required 
concentration of peptide was therefore 1.78 x 10-8 mol/ml. If using the 41-69 CaSR 
peptide with a stock concentration of 1 mg/ml (or 0.001 g/ml) and a molecular weight of 
3427 Da (or 3427 g/mol) (Table 5.5), and therefore at 2.92 x 10-7 mol/ml, where mol/ml = 
(g/ml)/(g/mol), the required dilution of the stock peptide in the absorption experiment 
was 16.4X.  
After incubation at 4°C for 2 h, the pre-absorbed and unabsorbed serum samples were 
centrifuged in a MiniSpin microcentrifuge (Eppendorf UK Ltd., Stevenage, UK) at 13,000 
rpm for 15 min and the supernatant collected. Duplicate 100-µl samples of the pre-
absorbed APS1 patient sera and unabsorbed APS1 patient and unabsorbed healthy control 
sera were then analysed in CaSR peptide ELISAs, as detailed in Section 5.3.2. The CaSR 
peptide-binding reactivity of each serum was expressed as an antibody index calculated 
as: mean OD405 of tested serum/mean OD405 of six healthy unabsorbed control sera. Each 
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serum was tested in three experiments and the mean antibody index ± SD calculated. 
Antibody indices of unabsorbed and pre-absorbed APS1 patient sera were compared in 
Student’s paired t tests. P values (two-tailed) < 0.05 were considered significant. 
 Functional affinity experiments  5.3.4
To analyse CaSR antibody functional affinity, APS1 patient sera (n = up to 16, depending 
on the CaSR epitopes recognised by the patient’s antibodies) at non-saturating dilutions 
(Table 5.4) were pre-incubated with 0-1000 nM of the required CaSR peptide (Table 5.5) 
in 0.5 ml of PBS for 30 min. Healthy control sera (n = 6) at 1:100 dilutions were also pre-
incubated without any peptide. Duplicate 100-µl samples of sera were then analysed in 
the appropriate CaSR peptide ELISA, as detailed in Section 5.3.2. The CaSR peptide-binding 
reactivity of each APS1 patient and each control serum was expressed as an antibody 
index calculated as: mean OD405 of tested serum/mean OD405 of six healthy control sera. 
Each serum was tested in three experiments and the mean antibody index ± SD calculated. 
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Table ‎5.4: Non-saturating dilutions of APS1 patient sera used in absorption and 
functional affinity experiments 
 
APS1 
patient 
Non-saturating serum 
dilution used in 41-69 
CaSR peptide 
absorption and 
functional affinity 
experiments 
Non-saturating serum 
dilution used in 114-
126 CaSR peptide 
absorption and 
functional affinity 
experiments 
Non-saturating serum 
dilution used in 171-
195 CaSR peptide 
absorption and 
functional affinity 
experiments 
Non-saturating serum 
dilution used in 260-
340 CaSR peptide 
absorption and 
functioanl affinity 
experiments 
APS1-1 300 - - - 
APS1-2 300 - - - 
APS1-3 300 - 750 500 
APS1-4 300 - 300 500 
APS1-5 750 300 - - 
APS1-6 150 750 - - 
APS1-7 150 300 - - 
APS1-8 500 - - - 
APS1-9 150 - 300 300 
APS1-10 500 500 - - 
APS1-11 150 - - - 
APS1-12 200 - 300 300 
APS1-13 150 - - - 
APS1-14 200 - 500 300 
APS1-15 200 - 500 750 
APS1-16 200 500 - 750 
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Table ‎5.5: Details of peptides used in absorption and functional affinity experiments 
 
Peptide 
Molecular weight 
(Da = g/mol) 
Stock concentration 
(g/ml) 
Stock concentration 
(mol/ml) 
CaSR 41-69 3427 0.001 2.92 x 10-7 
CaSR 114-126 1468 0.001 6.81 x 10-7 
CaSR 171-195 2945 0.001 3.40 x 10-7 
CaSR 260-340 8906 0.001 1.12 x 10-7 
MCHR1 1636 0.001 6.11 x 10-7 
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 IgG subclass ELISAs 5.3.5
To determine CaSR antibody IgG subclass, duplicate 100-µl samples of APS1 patient (n = 
16) and control (n = 10) sera were analysed in CaSR peptide ELISAs at a 1:100 dilution, as 
detailed in Section 5.3.2, with the exception that anti-human IgG1, IgG2, IgG3 and IgG4 
alkaline phosphate-conjugates (SouthernBiotech, Birmingham, AL, USA) were applied as 
the secondary antibody at 1:2000 dilutions. The CaSR peptide-binding reactivity of each 
APS1 patient and control serum was expressed as an antibody index calculated as: mean 
OD405 of tested serum/mean OD405 of 10 healthy control sera. Each serum was tested in 
three experiments and the mean antibody index ± SD calculated. 
The upper limit of normal for each CaSR peptide ELISA using different secondary 
antibodies was calculated using the mean antibody index + 3SD of 10 healthy control sera. 
Patient sera with an antibody index greater than the upper limit of normal were regarded 
as positive for binding to the CaSR peptide used in the ELISA. ELISA precision was 
evaluated by calculating the intra-assay coefficient of variation (expressed as a 
percentage) for a series of different serum samples that were measured in duplicate 
within the same assay run. ELISA reproducibility was evaluated by calculating the inter-
assay coefficient of variation (expressed as a percentage) for a series of different serum 
samples that were measured in several consecutive assay runs. 
 IgG preparation 5.3.6
IgG was isolated from sera by affinity column chromatography using protein G-Sepharose 4 
Fast Flow (Amersham Biosciences AB, Uppsala, Sweden) according to the manufacturer’s 
instructions. Eluted IgG fractions were extensively dialysed against PBS (pH 7.4; Sigma, 
Poole, UK), and concentrated using an Amicon Concentrator (Amicon Inc., Beverly, MA, 
USA). IgG samples were sterilised with a Millex Filter Unit (Millipore Corp., Bedford, MA, 
USA), and the final concentrations were measured by photometry at 280 nm. All IgG 
samples were stored at 10 mg/ml at -20oC. 
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 Ca2+-stimulation of the CaSR expressed in human embryonic kidney cells 5.3.7
The response to Ca2+ of the CaSR expressed in human embryonic kidney cells (HEK293-
CaSR) was assessed by measuring intracellular inositol-1-phosphate (IP1) accumulation, as 
previously detailed (Kemp et al., 2009). The assay involves stimulating the CaSR expressed 
in HEK293 cells with Ca2+ in order to activate phospholipase C (Figure 5.1). The activation 
triggers the intracellular formation of inositol 1,4,5-triphosphate (IP3). This metabolite is 
transformed extremely rapidly into IP1, which in turn degrades to myo-inositol (Figure 
5.1). The degradation of IP1 can be inhibited by the addition of lithium chloride to the 
culture medium (Figure 5.1). The intracellular accumulation of IP1, which reflects CaSR 
activation, can then be analysed by ELISA (Section 5.3.8). 
For the assay, HEK293-CaSR cells, which were a gift from Dr Edward Brown (Division of 
Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and 
Women’s Hospital, and Harvard Medical School, Boston, MA, USA), were cultured in T75 
tissue culture flasks (Nalge Nunc International, Rochester, NY, USA) in Dulbecco’s DMEM 
medium (Invitrogen, Paisley, UK) containing 4.5 g/l glucose, 110 mg/ml sodium pyruvate, 
10% (v/v) fetal calf serum, 100 units/ml penicillin G, 100 g/ml streptomycin sulphate, 2 
mM L-glutamine (all from Invitrogen) at 37°C in a 95% humidified atmosphere of 5% CO2. 
To act as a control in Ca2+-stimulation experiments, HEK293 cells (European Collection of 
Animal Cell Cultures, Salisbury, UK) were cultured in the same manner. 
After reaching 80-100% confluence, the culture medium was removed from the cells 
which were then washed twice with PBS followed by incubation in Gibco® Cell Dissociation 
Buffer (Thermo Fisher Scientific, Waltham, MA, USA) at room temperature for 1 to 2 min. 
After discarding the buffer, cells were resuspended in culture medium and then counted 
in a haemocytometer.  
Cells were plated in 24-well plates (Nalge Nunc International) at 4 x 105 cells per well in 
500 μl of culture medium and incubated overnight at 37°C. Cell monolayers were washed 
first with serum-free medium and then with stimulation buffer containing 146 mM sodium 
chloride, 2.5 mM potassium chloride, 50 mM lithium chloride, 0.2 mM magnesium 
chloride, 2.8 mM glucose and 10 mM HEPES buffer (pH 7.4). Cells were subsequently 
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incubated for 1 h at 37°C in 200 μl of stimulation buffer or 200 μl of stimulation buffer 
containing 0.5, 1.0, 1.5, 2.0, 3.0, 5.0 or 10.0 mM calcium chloride. Following treatment, 
cells were lysed for 30 min at 37°C with 50 μl of 2.5% IP-One ELISA Kit Lysis Reagent (CIS 
Bio International, Gif-sur-Yvette, France). To assess IP1 accumulation, each cell 
supernatant was then analysed in an IP-One ELISA (CIS Bio International) (Section 5.3.8).  
 Inositol-1-phosphate ELISAs 5.3.8
The IP-One ELISA is based on competition between free IP1 and IP1 conjugated to horse-
radish peroxidase (HRP) for binding to an anti-IP1 monoclonal antibody, as shown in 
Figure 5.2. Three 50-µl samples of each cell supernatant were tested in an IP-One ELISA. 
Each sample was applied to a separate well of the goat anti-mouse IgG-pre-coated ELISA 
plate (CIS Bio International) along with 25 µl of anti-IP1 monoclonal antibody (CIS Bio 
International) and 25 µl IP1-HRP conjugate (CIS Bio International). Duplicate 25 µl samples 
of IP1-HRP conjugate without anti-IP1 monoclonal antibody were included in each ELISA 
to measure any non-specific binding to the pre-coated ELISA plate. The plate was then 
incubated for 3 h with shaking at room temperature. The wells were washed six times 
with 250 µl of 0.05% (v/v) Tween 20, before the addition of 100 µl of 3,3′,5,5′-
tetramethylbenzidine (TMB) liquid substrate (CIS Bio International) for HRP. The plate was 
incubated in the dark for 30 min at room temperature, 100 µl of stop solution (CIS Bio 
International) added to each well, and then OD readings taken at 450 and 620 nm using a 
LabSystems Integrated EIA Management System spectrophotometer. 
For each well, the OD at 620 nm was subtracted from OD at 450 nm, and the average of 
the corrected OD450 readings calculated for replicates. The OD450 readings were then 
corrected by subtracting the OD450 obtained for non-specific binding of IP1-HRP conjugate. 
The results for IP1 accumulation were expressed as: percentage inhibition of IP1-HRP 
conjugate binding = [1 – corrected OD450 for Ca
2+-stimulated cells/corrected OD450 in non-
stimulated cells] x 100. Increasing percentage inhibition of the binding of the IP1-HRP 
conjugate reflects increasing amounts of IP1 in the HEK293-CaSR cell supernatants, due to 
CaSR activation. 
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 Effect of IgG on Ca2+-stimulation of the CaSR 5.3.9
For measuring the effects of 16 APS1 patient and 10 control IgG (Section 5.3.6) on Ca2+-
stimulation of the CaSR, HEK293-CaSR cell monolayers were washed first with serum-free 
medium and then with stimulation buffer. Subsequently, cells were pre-incubated either 
with IgG at a 1:100 dilution in 100 μl of stimulation buffer or with 100 μl of stimulation 
buffer without any IgG. After 10 min at 37°C, a further 100 μl of stimulation buffer or 100 
μl of stimulation buffer containing 1.0, 3.0, 6.0, 12.0 or 18.0 mM calcium chloride was 
applied to the cells and incubation continued for 1 h at 37°C. Cells were lysed for 30 min at 
37°C with 50 μl of 2.5% IP-One ELISA Kit Lysis Reagent, and IP1 accumulation analysed in 
an IP-One ELISA (Section 5.3.8). The percentage inhibition of the binding of the IP1-HRP 
conjugate, which reflects increasing amounts of IP1 in the HEK293-CaSR cell supernatants, 
were compared between Ca2+-stimulated and unstimulated cells using Student’s paired t 
tests. P values (two-tailed) < 0.05 were considered significant. 
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Figure ‎5.1: Schematic representation of the activation of the CaSR and accumulation of 
inositol-1-phosphate. 
In HEK293-CaSR cells via the CaSR, high Ca2+ concentrations stimulate Gαq protein-mediated 
activation of phospholipase C (PLC). Phospholipase C cleaves phospholipid phosphatidylinositol 
4,5-bisphosphate (PIP2) into diacyl glycerol and inositol 1,4,5-trisphosphate (IP3). IP3 is released 
into the cytosol and evokes the release of Ca2+ from the endoplasmic reticulum (ER) by binding to 
IP3 receptors. IP3 is transformed extremely rapidly into inositol-1-phosphate (IP1), which in turn 
degrades to myo-inositol. The degradation of IP1 can be inhibited by the addition of lithium 
chloride to the culture medium. The intracellular accumulation of IP1, which indicates CaSR 
activation, can then be quantified by ELISA.  
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Figure ‎5.2: Schematic representation of the IP-One ELISA. 
The IP-One ELISA is a competitive ELISA for the quantitative determination of inositol-1-phosphate 
(IP1) based on the competition between free IP1 and IP1 conjugated to horse-radish peroxidase 
(HRP) for binding to an anti-IP1 monoclonal antibody. After washing to remove unbound IP1 and 
IP1-HRP, HRP substrate TMB is added, followed by stop solution and the OD of the wells read at 
450 nm and 620 nm. As the concentration of IP1 in the cell supernatant increases, then the OD450, 
which reflects the amount of IP1-HRP conjugate bound, decreases. 
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 Results 5.4
 Determination of APS1 patient CaSR antibody titres  5.4.1
APS1 patient antibody titres against identified CaSR epitopes (Table 5.2) were determined 
by testing a series of dilutions from 1:100 to 1:5,000 of patient sera in CaSR peptide 
ELISAs, as detailed in Section 5.3.2. Serum samples from 16, five, six, and seven APS1 
patients were analysed in CaSR peptide 41-69, 114-126, 171-195, and 260-340 ELISAs, 
respectively, this being dependent on the CaSR epitopes recognised by the patient’ serum. 
Sera from 10 healthy individuals were used as controls in each ELISA. 
The results of the antibody titration experiments are shown in Figures 5.3, 5.4, 5.5 and 
5.6, where the antibody index of each APS1 patient serum at each dilution is plotted 
against the serum dilution. In Table 5.6, the titration results are summarised, and show 
the serum dilution at which antibody reactivity could still be detected at levels above the 
upper limit of normal in each CaSR peptide ELISA.  
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Figure ‎5.3: Titration of APS1 patient CaSR antibodies against CaSR 41-69 peptide. 
Sixteen CaSR antibody-positive APS1 patient sera were analysed at dilutions of 1:100, 1:200, 1:500, 
1:1,000, 1:2,000, and 1:5,000 in CaSR peptide 41-69 ELISAs. The antibody index (± SD) of each 
APS1 patient serum at each dilution is shown and is the mean of three experiments. The upper 
limit of normal for the CaSR peptide 41-69 ELISA was an antibody index of 2.17. 
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Figure ‎5.4: Titration of APS1 patient CaSR antibodies against the CaSR 114-126 peptide. 
Five CaSR antibody-positive APS1 patient sera were analysed at dilutions of 1:100, 1:200, 1:500, 
1:1,000, 1:2,000, and 1:5,000 in CaSR peptide 114-126 ELISAs. The antibody index (± SD) of each 
APS1 patient serum at each dilution is shown and is the mean of three experiments. The upper 
limit of normal for the CaSR peptide 114-126 ELISA was an antibody index of 1.91. 
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Figure ‎5.5: Titration of APS1 patient CaSR antibodies against the CaSR 171-195 peptide. 
Six CaSR antibody-positive APS1 patient sera were analysed at dilutions of 1:100, 1:200, 1:500, 
1:1,000, 1:2,000, and 1:5,000 in CaSR peptide 171-195 ELISAs. The antibody index (± SD) of each 
APS1 patient serum at each dilution is shown and is the mean of three experiments. The upper 
limit of normal for the CaSR peptide 171-195 ELISA was an antibody index of 1.96. 
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Figure ‎5.6: Titration of APS1 patient CaSR antibodies against the CaSR 260-340 peptide. 
Seven CaSR antibody-positive APS1 patient sera were analysed at dilutions of 1:100, 1:200, 1:500, 
1:1,000, 1:2,000, and 1:5,000 in CaSR peptide 260-340 ELISAs. The antibody index (± SD) of each 
APS1 patient serum at each dilution is shown and is the mean of three experiments. The upper 
limit of normal for the CaSR peptide 260-340 ELISA was an antibody index of 1.87. 
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Table ‎5.6: Summary of titration of APS1 patient autoantibodies against CaSR epitopes 
 
APS1 
patient 
CaSR 
41-69 antibody titre
1
 
CaSR 114-126 
antibody titre
1
 
CaSR 171-195 
antibody titre
1
 
CaSR 260-340 
antibody titre
1
 
APS1-1 1:1000 - - - 
APS1-2 1:500 - - - 
APS1-3 1:500 - 1:1000 1:500 
APS1-4 1:500 - 1:500 1:500 
APS1-5 1:1000 1:500 - - 
APS1-6 1:200 1:500 - - 
APS1-7 1:200 1:500 - - 
APS1-8 1:1000 - - - 
APS1-9 1:100 - 1:200 1:500 
APS1-10 1:500 1:500 - - 
APS1-11 1:100 - - - 
APS1-12 1:500 - 1:500 1:500 
APS1-13 1:200 - - - 
APS1-14 1:1000 - 1:500 1:500 
APS1-15 1:1000 - 1:500 1:500 
APS1-16 1:1000 1:1000 - 1:2000 
 
1Each antibody titre is given as the dilution at which immunoreactivity in the serum sample could 
still be detected at levels above the upper limit of normal in the CaSR peptide ELISA. The upper 
limits of normal were CaSR autoantibody indices of 2.17, 1.91, 1.96, and 1.87 for CaSR peptides 
41-69, 114-126, 171-195, and 260-340, respectively. 
2-, denotes negative for CaSR autoantibodies. 
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 Determination of APS1 patient CaSR antibody specificity 5.4.2
The specificity of APS1 patient CaSR antibodies was evaluated using absorption 
experiments, as detailed in Section 5.3.3. Sera from 16, five, six, and seven APS1 patients 
were pre-absorbed with CaSR peptides 41-69, 114-126, 171-195, and 260-340, 
respectively, this being dependent on the CaSR epitopes recognised by the patient’ serum. 
As a control, a melanin-concentrating hormone receptor 1 (MCHR1) peptide was also used 
to pre-absorbed sera. Following pre-absorption, the CaSR antibody-binding of each of the 
sera was assessed in the relevant CaSR peptide ELISA, along with unabsorbed APS1 patient 
sera and unabsorbed sera from six healthy controls. 
The results of the absorption experiments are given in Figures 5.7, 5.8, 5.9 and 5.10, 
where the antibody index of each patient serum is shown in relation to the peptide used 
in pre-absorption. When comparing the antibody index of unabsorbed versus pre-
absorbed patient sera in CaSR peptide ELISAs, CaSR antibody-binding was significantly 
reduced by pre-absorption of APS1 patient sera with the corresponding CaSR peptide: all P 
values (two-tailed) were < 0.05 (Student’s paired t test). In contrast, there was no 
significant decrease in CaSR antibody-binding following pre-absorption with either non-
corresponding CaSR peptides or the MCHR1 peptide: all P values (two tailed) were > 0.05 
(Student’s paired t test) when comparing the antibody index of unabsorbed versus pre-
absorbed APS1 patient sera. Overall, the results indicated that patient CaSR antibodies 
recognised specific CaSR epitopes and were not cross-reactive with other antibody binding 
sites on the receptor. 
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Figure ‎5.7: Absorption of APS1 patient CaSR antibodies with CaSR peptides prior to 
analysis in CaSR peptide 41-69 ELISA. 
Sixteen CaSR antibody-positive APS1 patient sera were pre-absorbed with an excess of CaSR 
peptide before analysis in the CaSR peptide 41-69 ELISA. A melanin-concentrating hormone 
receptor 1 (MCHR1) peptide was used as a pre-absorption control peptide. The antibody index (± 
SD) of each APS1 patient serum is shown, and is the mean of three experiments. The antibody 
index of each patient sera pre-absorbed with CaSR peptide 41-69 was significantly reduced 
compared with unabsorbed sera. All P values (two-tailed) were < 0.05 (Student’s paired t test): 
APS1-1, APS1,-2, APS1-3, < 0.0001; APS1-4, 0.0050; APS1-5, 0.0002; APS1-6, 0.0038; APS1-7, 
0.0016; APS1-8, 0.0004; APS1-9, 0.0085; APS1-10, 0.0007; APS1-11, 0.0036; APS1-12, 0.0005; 
APS1-13, 0.0025; APS1-14, 0.0010; APS1-15, 0.0006; and APS1-16, 0.0003.There was no significant 
decrease in CaSR antibody-binding following pre-absorption with either non-corresponding CaSR 
peptides or the MCHR1 peptide: all P values (two tailed) were > 0.05 (Student’s paired t test) when 
comparing the antibody index of unabsorbed versus pre-absorbed APS1 patient sera. 
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Figure ‎5.8: Absorption of APS1 patient CaSR antibodies with CaSR peptides prior to 
analysis in CaSR peptide 114-126 ELISA. 
Five CaSR antibody-positive APS1 patient sera were pre-absorbed with an excess of CaSR peptide 
before analysis in the CaSR peptide 114-126 ELISA. A melanin-concentrating hormone receptor 1 
(MCHR1) peptide was used as a pre-absorption control peptide. The antibody index (± SD) of each 
APS1 patient serum is shown, and is the mean of three experiments. The antibody index of each 
patient sera pre-absorbed with CaSR peptide 114-126 was significantly reduced compared with 
unabsorbed sera. All P values (two-tailed) were < 0.05 (Student’s paired t test): APS1-5, 0.0028; 
APS1-6, 0.0040; APS1-7, 0.0036; APS1-10, 0.0011; and APS1-16, 0.0023. There was no significant 
decrease in CaSR antibody-binding following pre-absorption with either non-corresponding CaSR 
peptides or the MCHR1 peptide: all P values (two tailed) were > 0.05 (Student’s paired t test) when 
comparing the antibody index of unabsorbed versus pre-absorbed APS1 patient sera. 
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Figure ‎5.9: Absorption of APS1 patient CaSR antibodies with CaSR peptides prior to 
analysis in CaSR peptide 171-195 ELISA. 
Six CaSR antibody-positive APS1 patient sera were pre-absorbed with an excess of CaSR peptide 
before analysis in the CaSR peptide 171-195 ELISA. A melanin-concentrating hormone receptor 1 
(MCHR1) peptide was used as a pre-absorption control peptide. The antibody index (± SD) of each 
APS1 patient serum is shown, and is the mean of three experiments. The antibody index of each 
patient sera pre-absorbed with CaSR peptide 171-195 was significantly reduced compared with 
unabsorbed sera. All P values (two-tailed) were < 0.05 (Student’s paired t test): APS1-3, 0.0004; 
APS1-4, 0.0017; APS1-9, 0.0007; APS1-10, 0.0010; APS1-14, 0.0019; and APS1-15, 0.0008. There 
was no significant decrease in CaSR antibody-binding following pre-absorption with either non-
corresponding CaSR peptides or the MCHR1 peptide: all P values (two tailed) were > 0.05 
(Student’s paired t test) when comparing the antibody index of unabsorbed versus pre-absorbed 
APS1 patient sera. 
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Figure ‎5.10: Absorption of APS1 patient CaSR antibodies with CaSR peptides prior to 
analysis in CaSR peptide 260-340 ELISA. 
Seven CaSR antibody-positive APS1 patient sera were pre-absorbed with an excess of CaSR peptide 
before analysis in the CaSR peptide 260-340 ELISA. A melanin-concentrating hormone receptor 1 
(MCHR1 peptide) was used as a pre-absorption control peptide. The antibody index (± SD) of each 
APS1 patient serum is shown, and is the mean of three experiments. The antibody index of each 
patient sera pre-absorbed with CaSR peptide 171-195 was significantly reduced compared with 
unabsorbed sera. All P values (two-tailed) were < 0.05 (Student’s paired t test): APS1-3, 0.0001; 
APS1-4, < 0.0001; APS1-9, 0.0008; APS1-12, 0.0005; APS1-14, 0.0003; APS1-15, 0.0010; and APS1-
16, 0.0002. There was no significant decrease in CaSR antibody-binding following pre-absorption 
with either non-corresponding CaSR peptides or the MCHR1 peptide: all P values (two tailed) were 
> 0.05 (Student’s paired t test) when comparing the antibody index of unabsorbed versus pre-
absorbed APS1 patient sera. 
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 Determination of APS1 patient CaSR antibody functional affinity 5.4.3
APS1 patient CaSR antibody functional affinity was evaluated as detailed in Section 5.3.4. 
Sera from 16, five, six, and seven APS1 patients were pre-incubated with a range of 
concentrations (0-1000 nM) of CaSR peptides 41-69, 114-126, 171-195, and 260-340, 
respectively, this being dependent on the CaSR epitopes recognised by the patient’ serum. 
Following pre-incubation, the CaSR antibody-binding of each of the APS1 patient sera was 
assessed in the relevant CaSR peptide ELISA, along with sera from six healthy controls 
which had not been pre-incubated with any peptide.  
The results of the functional affinity experiments are shown in Figures 5.11, 5.12, 5.13 and 
5.14, where the antibody index of each patient serum in the CaSR peptide ELISAs is 
plotted against the CaSR peptide concentration used in the pre-incubation step. From the 
graphs, the antibody index representing a 50% decrease in binding of sera in the CaSR 
peptide ELISAs was used to estimate the molar concentration of peptide that resulted in 
this 50% reduction. In Table 5.7, the functional affinity for each APS1 patient sera with 
each relevant CaSR peptide are summarised. 
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Figure ‎5.11: Functional affinity of APS1 patient CaSR antibodies against CaSR peptide 41-
69. 
Sixteen CaSR antibody-positive APS1 patient sera were pre-incubated with 0-1000 nM of CaSR 
peptide 41-69 before analysis in CaSR peptide 41-69 ELISAs. The antibody index (± SD) of each 
APS1 patient serum is shown, and is the mean of three experiments.  
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Figure ‎5.12: Functional affinity of APS1 patient CaSR antibodies against CaSR 
peptide114-126. 
Five CaSR antibody-positive APS1 patient sera were pre-incubated with 0-1000 nM of CaSR 
peptide 114-126 before analysis in CaSR peptide 114-126 ELISAs. The antibody index (± SD) of each 
APS1 patient serum is shown, and is the mean of three experiments.  
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Figure ‎5.13: Functional affinity of APS1 patient CaSR antibodies against CaSR peptide 
171-195. 
Six CaSR antibody-positive APS1 patient sera were pre-incubated with 0-1000 nM of CaSR peptide 
171-195 before analysis in CaSR peptide 171-195 ELISAs. The antibody index (± SD) of each APS1 
patient serum is shown, and is the mean of three experiments.  
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Figure ‎5.14: Functional affinity of APS1 patient CaSR antibodies against CaSR peptide 
260-340. 
Seven CaSR antibody-positive APS1 patient sera were pre-incubated with 0-1000 nM of CaSR 
peptide 260-340 before analysis in CaSR peptide 260-340 ELISAs. The antibody index (± SD) of each 
APS1 patient serum is shown, and is the mean of three experiments.  
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Table ‎5.7: Functional affinity of APS1 patient CaSR antibodies 
 
APS1 
patient 
Functional affinity (M)1 
CaSR 41-69 
antibody 
CaSR 114-126 
antibody 
CaSR 171-195 
antibody 
CaSR 260-340 
antibody 
APS1-1 7.50 x 10-08 - - - 
APS1-2 1.00 x 10-07 - - - 
APS1-3 1.00 x 10-07 - 2.50 x 10-07 1.50 x 10-07 
APS1-4 1.00 x 10-07 - 2.50 x 10-07 1.50 x 10-07 
APS1-5 2.50 x 10-07 2.00 x 10-07 - - 
APS1-6 9.00x 10-08 2.00 x 10-07 - - 
APS1-7 1.50 x 10-07 5.00 x 10-08 - - 
APS1-8 3.00 x 10-07 - - - 
APS1-9 2.00 x 10-07 - 8.00 x 10-08 7.50 x 10-08 
APS1-10 2.50 x 10-07 4.00 x 10-08 - - 
APS1-11 4.00 x 10-08 - - - 
APS1-12 1.50 x 10-07 - 7.50 x 10-08 7.20 x 10-08 
APS1-13 1.50 x 10-07 - - - 
APS1-14 2.00 x 10-07 - 3.50 x 10-07 7.50 x 10-08 
APS1-15 2.00 x 10-07 - 3.50 x 10-07 5.00 x 10-08 
APS1-16 2.00 x 10-07 4.00 x 10-08 - 1.50 x 10-07 
 
1
Antibody functional affinity is given as the molar concentration of peptide that resulted in a 50% reduction 
of antibody binding as represented by the antibody index of the sera. 
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 Determination of APS1 patient CaSR antibody IgG subclass  5.4.4
APS1 patient CaSR antibody subclass was evaluated as detailed in Section 5.3.5. Sera from 
16 APS1 patients and from 10 healthy controls were analysed in CaSR peptide ELISAs with 
IgG subclass-specific secondary antibodies being used to detect the binding of patient 
CaSR antibodies. The results of the CaSR peptide ELISAs are given in Figure 5.15, where 
the antibody index of each patient and control serum is shown. For each ELISA, the mean 
antibody index of the APS1 patient and control groups, the antibody index range of the 
APS1 patient and control groups, the intra- and inter-assay coefficients of variation, and 
the upper limit of normal are summarised in Table 5.8.  
All control sera were negative for antibody binding, as their antibody indices were below 
the upper limits of normal for each ELISA (Table 5.8). In the APS1 patient group, some sera 
had an antibody index above the upper limit of normal in certain IgG subclass ELISAs and 
so were considered positive for antibody binding (Table 5.8). From the results of the IgG 
subclass ELISAs, the IgG subclasses of APS1 patient CaSR antibodies were determined and 
these are summarised in Table 5.9. In all APS1 patients, antibodies against the CaSR 
epitopes 41-69, 171-195, and 260-340 were of the IgG1 subclass. Antibody responses 
against CaSR epitope 114-126 were of the IgG1 and IgG3 subclasses.  
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Figure ‎5.15: IgG subclass of APS1 patient CaSR antibodies against CaSR peptides 
Sixteen CaSR antibody-positive APS1 patient sera and 10 healthy control (C) sera at a dilution of 
1:100 were analysed in CaSR peptide ELISAs and IgG subclass-specific secondary antibodies. The 
antibody index is shown for each serum, and is the mean of three experiments. The results are 
shown for (a) CaSR peptide ELISAs with peptide 41-69; (b) CaSR peptide ELISAs with peptide114-
126; (c) CaSR peptide ELISAs with peptide 171-195; and (d) CaSR peptide ELISAs with peptide 260-
340. 
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Table ‎5.8: Summary of data from CaSR peptide IgG subclass ELISAs 
 
CaSR 
peptide 
IgG 
subclass 
ELISA 
Mean 
antibody 
index (± 
SD) of 
APS1 
patient 
group (n 
= 16) 
Antibody 
index 
range of 
APS1 
patient 
group 
Mean 
antibody 
index (± 
SD) of 
control 
group 
(n = 10) 
Antibody 
index 
range of 
healthy 
control 
group 
Upper 
limit of 
normal 
antibody 
index 
Intra-
assay 
coefficient 
of 
variation 
Inter-
assay 
coefficient 
of 
variation 
Antibody 
positive 
APS1 
patients 
(%) 
Antibody 
positive 
controls 
(%) 
41-69 
IgG1 
25.4 ± 
21.1 
4.81-
69.4 
1.08 ± 
0.26 
0.60-
1.47 
1.86 
5.1% 9.3% 
16/16 
(100) 
0/10 (0) 
41-69 
IgG2 
0.74 ± 
0.28 
0.29-
1.10 
1.12 ± 
0.22  
0.74-
1.42 
1.78 
3.8% 8.4% 
0/16 (0) 0/10 (0) 
41-69 
IgG3 
1.02 ± 
0.29 
0.41-
1.56 
1.03 ± 
0.27 
0.46-
1.35 
1.84 
5.5% 7.3% 
0/16 (0) 0/10 (0) 
41-69 
IgG4 
0.87 ± 
0.32 
0.50-
1.52 
1.11 ± 
0.25 
0.67-
1.46 
1.85 
3.2% 8.9% 
0/16 (0) 0/10 (0) 
114-126 
IgG1 
2.45 ± 
4.74 
0.32-
17.1 
1.00 ± 
0.27 
0.74-
1.32 
1.81 
4.7% 10.1% 
2/16 
(12.5) 
0/10 (0) 
114-126 
IgG2 
1.04 ± 
0.29 
0.43-
1.58 
1.08 ± 
0.25 
0.76-
1.43 
1.82 
5.3% 9.4% 
0/16 (0) 0/10 (0) 
114-126 
IgG3 
2.20 ± 
2.97 
0.51-
10.1 
1.05 ± 
0.26 
0.57-
1.44 
1.83 
3.6% 8.2% 
3/16 
(18.8) 
0/10 (0) 
114-126 
IgG4 
0.76 ± 
0.28 
0.31-
1.11 
1.09 ± 
0.22 
0.71-
1.39 
1.75 
4.7% 6.7% 
0/16 (0) 0/10 (0) 
171-195 
IgG1 
4.99 ± 
5.78 
0.43-
14.9 
1.10 ± 
0.25 
0.67-
1.46 
1.85 
4.2% 9.3% 
6/16 (38) 0/10 (0) 
171-195 
IgG2 
0.97 ± 
0.17 
0.62-
1.16 
1.11 ± 
0.22 
0.73-
1.41 
1.78 
4.8% 10.4% 
0/16 (0) 0/10 (0) 
171-195 
IgG3 
0.88 ± 
0.23 
0.54-
1.31 
1.09 ± 
0.27 
0.62-
1.49 
1.89 
5.3% 9.2% 
0/16 (0) 0/10 (0) 
171-195 
IgG4 
0.85 ± 
0.19 
0.42-
1.23 
1.01 ± 
0.27 
0.44-
1.33 
1.82 
5.7% 9.9% 
0/16 (0) 0/10 (0) 
260-340 
IgG1 
9.19 ± 
9.92 
0.41-
25.0 
1.02 ± 
0.22 
0.64-
1.32 
1.69 
2.6% 6.4% 
7/16 (44) 0/10 (0) 
260-340 
IgG2 
0.92 ± 
0.19 
0.60-
1.28 
1.00 ± 
0.27 
0.53-
1.40 
1.80 
3.4% 6.5% 
0/16 (0) 0/10 (0) 
260-340 
IgG3 
0.83 ± 
0.14 
0.63-
1.14 
0.92 ± 
0.27 
0.35-
1.24 
1.73 
4.1% 5.1% 
0/16 (0) 0/10 (0) 
260-340 
IgG4 
0.86 ± 
0.15 
0.51-
1.03 
1.01 ± 
0.25 
0.58-
1.37 
1.76 
3.3% 7.7% 
0/16 (0) 0/10 (0) 
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Table ‎5.9: IgG subclasses of APS1 patient CaSR antibodies 
 
APS1 
patient 
Antibody 
reactivity 
in CaSR 
peptide 
41-69 
ELISA
1
 
IgG 
subclass 
Antibody 
reactivity 
in CaSR 
peptide 
114-126 
ELISA
1
 
IgG 
subclass 
Antibody 
reactivity 
in CaSR 
peptide 
171-195 
ELISA
1
 
IgG 
subclass 
Antibody 
reactivity 
in CaSR 
peptide 
260-340 
ELISA
1
 
IgG 
Subclass 
APS1-1 + IgG1 - - - - - - 
APS1-2 + IgG1 - - - - - - 
APS1-3 + IgG1 - - + IgG1 + IgG1 
APS1-4 + IgG1 - - + IgG1 + IgG1 
APS1-5 + IgG1 + IgG1 - - - - 
APS1-6 + IgG1 + IgG1 - - - - 
APS1-7 + IgG1 + IgG3 - - - - 
APS1-8 + IgG1 - - - - - - 
APS1-9 + IgG1 - - + IgG1 + IgG1 
APS1-10 + IgG1 +  IgG3 - - - - 
APS1-11 + IgG1 - - - - - - 
APS1-12 + IgG1 - - + IgG1 + IgG1 
APS1-13 + IgG1 - - - - - - 
APS1-14 + IgG1 - - + IgG1 + IgG1 
APS1-15 + IgG1 - - + IgG1 + IgG1 
APS1-16 + IgG1 + IgG3 - - + IgG1 
 
1
+, denotes positive for CaSR antibody reactivity; -, denotes negative for CaSR antibody reactivity. 
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 Effect of APS1 patient IgG on the response of the CaSR to Ca2+-stimulation 5.4.5
The results of Ca2+-stimulation on HEK293-CaSR and HEK293 cells are shown in Figure 
5.16. A response to Ca2+-stimulation was only detected in HEK293-CaSR cells where IP1 
accumulated with increasing Ca2+ concentrations up to an estimated concentration of 5.0 
mM. 
To determine the effects of IgG from APS1 patients (n = 16) and healthy controls (n = 10) 
on CaSR function, HEK293-CaSR cells were pre-incubated with IgG at a 1:100 dilution prior 
to stimulation with Ca2+ concentrations of 0.0, 0.5, 1.5, 3.0, 6.0 and 9.0 mM. Each 
experiment also included HEK293-CaSR cells without pre-incubation with IgG. 
Subsequently, IP1 accumulation was measured using an IP-One ELISA Kit and the 
percentage inhibition of IP1-HRP conjugate binding calculated, as detailed in Section 
5.3.8. The results of pre-incubation of HEK293-CaSR cells with APS1 patient and control 
IgG samples are shown in Figures 5.17, 5.18, 5.19 and 5.20, where IP1 accumulation is 
plotted against Ca2+ concentration. 
The percentage inhibition of the binding of the IP1-HRP conjugate, which reflects 
increasing amounts of IP1 in the HEK293-CaSR cell supernatants, were compared between 
Ca2+-stimulated and unstimulated cells using Student’s paired t tests. P values < 0.05 were 
considered significant. Of the 10 control IgG samples analysed, none had any statistically 
significant effect upon IP1 accumulation in HEK293-CaSR cells when compared with 
stimulation by Ca2+ alone: P values (two-tailed) were > 0.05. The same results were 
obtained for the effects of 12/16 of the APS1 patient IgG samples tested: there was no 
statistically significant increase in IP1 accumulation with all P values (two-tailed) were > 
0.05. In contrast, IgG samples from four APS1 patients (APS1-5, APS1-9, APS1-11, and 
APS1-16) statistically significantly increased IP1 accumulation at Ca2+ concentrations of 
0.5, 1.5 and 3.0 mM when compared with Ca2+-stimulation alone: P values (two-tailed) 
were < 0.0001. The results indicated the presence of CaSR-stimulating activity in these 
four APS1 patient IgG samples. However, when Ca2+ was not present, the IgG samples 
from these four patients had no effect upon IP1 accumulation, indicating that some 
degree of receptor activation was needed to see the functional effect of the antibodies.  
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Figure ‎5.16: Measuring the effect of Ca2+-stimulation on the CaSR. 
HEK293-CaSR and HEK293 cells were treated with Ca2+ at 0.0, 0.5, 1.0, 1.5, 2.0, 3.0, 5.0 and 10.0 
mM. Intracellular IP1 accumulation was then measured in an IP-One ELISA. The results show the 
mean percentage (±SD) inhibition of IP1-HRP conjugate binding from three experiments. 
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Figure ‎5.17: Effect of APS1 patient and control IgG on the response of the CaSR to Ca2+-
stimulation-1. 
HEK293-CaSR cells were pre-incubated with IgG samples at a 1:100 dilution from APS1 patient (n = 
16) and healthy controls (n = 10) prior to treatment with Ca2+ at 0.0, 0.5, 1.5, 3.0, 6.0 and 9.0 mM. 
Intracellular IP1 accumulation was then measured in an IP-One ELISA. The results show the mean 
percentage (±SD) inhibition of IP1-HRP conjugate binding from three experiments for two control 
and four APS1 patient IgG samples. Both controls and three of the APS1 patient IgG samples had 
no statistically significant effect upon IP1 accumulation in HEK293-CaSR cells when compared with 
cells stimulated by Ca2+ alone: all P values were > 0.05 (Student’s paired t test). IgG samples from 
one APS1 patients (APS1-5) statistically significantly increased IP1 accumulation at Ca2+ 
concentrations of 0.5 mM (P = 0.0034), 1.5 mM (P = 0.0092) and 3.0 mM (P = 0.0021) when 
compared with Ca2+-stimulation alone. 
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Figure ‎5.18: Effect of APS1 patient and control IgG on the response of the CaSR to Ca2+-
stimulation-2. 
HEK293-CaSR cells were pre-incubated with IgG samples at a 1:100 dilution from APS1 patient (n = 
16) and healthy controls (n = 10) prior to treatment with Ca2+ at 0.0, 0.5, 1.5, 3.0, 6.0 and 9.0 mM. 
Intracellular IP1 accumulation was then measured in an IP-One ELISA. The results show the mean 
percentage (±SD) inhibition of IP1-HRP conjugate binding from three experiments for two control 
and four APS1 patient IgG samples. Both controls and two of the APS1 patient IgG samples had no 
statistically significant effect upon IP1 accumulation in HEK293-CaSR cells when compared with 
cells stimulated by Ca2+ alone: all P values were > 0.05 (Student’s paired t test). IgG samples from 
two APS1 patients (APS1-11 and APS1-9) statistically significantly increased IP1 accumulation at 
Ca2+ concentrations of 0.5 mM (P = 0.0015 and 0.0059, respectively), 1.5 mM (P = 0.0061 and 
0.015, respectively) and 3.0 mM (P = 0.0067 and 0.0057, respectively) when compared with Ca2+-
stimulation alone. 
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Figure ‎5.19: Effect of APS1 patient and control IgG on the response of the CaSR to Ca2+-
stimulation-3. 
HEK293-CaSR cells were pre-incubated with IgG samples at a 1:100 dilution from APS1 patient (n = 
16) and healthy controls (n = 10) prior to treatment with Ca2+ at 0.0, 0.5, 1.5, 3.0, 6.0 and 9.0 mM. 
Intracellular IP1 accumulation was then measured in an IP-One ELISA. The results show the mean 
percentage (±SD) inhibition of IP1-HRP conjugate binding from three experiments for two control 
and four APS1 patient IgG samples. Both controls and two of the APS1 patient IgG samples had no 
statistically significant effect upon IP1 accumulation in HEK293-CaSR cells when compared with 
cells stimulated by Ca2+ alone: all P values were > 0.05 (Student’s paired t test). IgG samples from 
one APS1 patients (APS1-16) statistically significantly increased IP1 accumulation at Ca2+ 
concentrations of 0.5 mM (P = 0.015), 1.5 mM (P = 0.026) and 3.0 mM (P = 0.0006) when 
compared with Ca2+-stimulation alone. 
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Figure ‎5.20: Effect of APS1 patient and control IgG on the response of the CaSR to Ca2+-
stimulation-4. 
HEK293-CaSR cells were pre-incubated with IgG samples at a 1:100 dilution from APS1 patient (n = 
16) and healthy controls (n = 10) prior to treatment with Ca2+ at 0.0, 0.5, 1.5, 3.0, 6.0 and 9.0 mM. 
Intracellular IP1 accumulation was then measured in an IP-One ELISA. The results show the mean 
percentage (±SD) inhibition of IP1-HRP conjugate binding from three experiments for three control 
and four APS1 patient IgG samples. All controls and APS1 patient IgG samples had no statistically 
significant effect upon IP1 accumulation in HEK293-CaSR cells when compared with cells 
stimulated by Ca2+ alone: all P values were > 0.05 (Student’s paired t test).  
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 Results Summary  5.5
The results from this chapter are summarised in Tables 5.10, 5.11, and indicated that: 
CaSR autoantibody titres ranged from 1:200 to 1:2000. 
 CaSR autoantibodies were specific for recognition of their CaSR binding site. 
 CaSR autoantibody functional affinity ranged from 1.00 x 10-07 M to 9.00 x 10-08 M. 
 Autoantibodies against the different CaSR epitopes were predominantly of the 
IgG1 subclass. 
 Only a minority (4/16 = 25%) of APS1 patients had autoantibodies that activated 
the CaSR. 
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Table ‎5.10: Summary of APS1 patient CaSR antibody titres, specificity, functional affinity, and IgG subclass-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
+, denotes positive for CaSR antibody reactivity; -, denotes negative for CaSR antibody reactivity. 
2
The CaSR antibody titre is given as the dilution at which immunoreactivity of the serum sample could still be detected at levels above the upper limit of 
normal in the specific CaSR peptide ELISA. 
3
Antibody functional affinity is given as the molar concentration of peptide that resulted in a 50% reduction of antibody binding as represented by the 
antibody index of the sera. 
  
APS1 
patient 
CaSR epitope 41-69 antibodies 
 
CaSR epitope 114-126 antibodies 
Antibody 
reactivity1 
Antibody 
titre2 
Functional 
affinity (M)3 
 
IgG 
subclass 
Antibody 
reactivity1 
Antibody 
titre2 
Functional 
affinity (M)3 
 
IgG 
subclass 
APS1-1 + 1:1000 7.50 x 10
-08
 IgG1 - - - - 
APS1-2 + 1:500 1.00 x 10
-07
 IgG1 - - - - 
APS1-3 + 1:500 1.00 x 10
-07
 IgG1 - - - - 
APS1-4 + 1:500 1.00 x 10
-07
 IgG1 - - - - 
APS1-5 + 1:1000 2.50 x 10
-07
 IgG1 + 1:500 2.00 x 10-07 IgG1 
APS1-6 + 1:200 9.00 x 10
-08
 IgG1 + 1:500 2.00 x 10-07 IgG1 
APS1-7 + 1:200 1.50 x 10
-07
 IgG1 + 1:500 5.00 x 10-08 IgG3 
APS1-8 + 1:1000 3.00 x 10
-07
 IgG1 - - - - 
APS1-9 + 1:100 2.00 x 10
-07
 IgG1 - - - - 
APS1-10 + 1:500 2.50 x 10
-07
 IgG1 + 1:500 4.00 x 10-08 IgG3 
APS1-11 + 1:100 4.00 x 10
-08
 IgG1 - - - - 
APS1-12 + 1:500 1.50 x 10
-07
 IgG1 - - - - 
APS1-13 + 1:200 1.50 x 10
-07
 IgG1 - - - - 
APS1-14 + 1:1000 2.00 x 10
-07
 IgG1 - - - - 
APS1-15 + 1:1000 2.00 x 10
-07
 IgG1 - - - - 
APS1-16 + 1:1000 2.00 x 10
-07
 IgG1 + 1:1000 4.00 x 10-08 IgG3 
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Table ‎5.11: Summary of APS1 patient CaSR antibody titres, specificity, functional affinity, and IgG subclass-2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
+, denotes positive for CaSR antibody reactivity; -, denotes negative for CaSR antibody reactivity. 
2
The CaSR antibody titre is given as the dilution at which immunoreactivity of the serum sample could still be detected at levels above the upper limit of 
normal in the specific CaSR peptide ELISA. 
3
Antibody functional affinity is given as the molar concentration of peptide that resulted in a 50% reduction of antibody binding as represented by the 
antibody index of the sera. 
 
APS1 
patient 
CaSR epitope 171-195 antibodies 
 
CaSR epitope 260-340 antibodies 
Antibody 
reactivity1 
Antibody 
titre2 
Functional 
affinity (M)3 
 
IgG 
subclass 
Antibody 
reactivity1 
Antibody 
titre2 
Functional 
affinity (M)3 
 
IgG 
subclass 
APS1-1 - - - - - - - - 
APS1-2 - - - - - - - - 
APS1-3 + 1:1000 2.50 x 10-07 IgG1 + 1:500 1.50 x 10-07 IgG1 
APS1-4 + 1:500 2.50 x 10-07 IgG1 + 1:500 1.50 x 10-07 IgG1 
APS1-5 - - - - - - - - 
APS1-6 - - - - - - - - 
APS1-7 - - - - - - - - 
APS1-8 - - - - - - - - 
APS1-9 + 1:200 8.00 x 10-08 IgG1 + 1:500 7.50 x 10-08 IgG1 
APS1-10 - - - - - - - - 
APS1-11 - - - - - - - - 
APS1-12 + 1:500 7.50 x 10-08 IgG1 + 1:500 7.20 x 10-08 IgG1 
APS1-13 - - - - - - - - 
APS1-14 + 1:500 3.50 x 10-07 IgG1 + 1:500 7.50 x 10-08 IgG1 
APS1-15 + 1:500 3.50 x 10-07 IgG1 + 1:500 5.00 x 10-08 IgG1 
APS1-16 - - - - + 1:2000 1.50 x 10-07 IgG1 
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 Discussion 5.6
Titre and specificity Antibody titres can present a simple and effective method for 
determining the progression of an autoimmune disorder. Such examples include anti-
alpha-galactosyl autoantibody levels in Graves’ disease (Etienne-Decerf et al., 1987). In the 
case of autoantibodies against the CaSR, assessment of one patient with autoimmune 
hypocalciuric hypercalcemia showed that their CaSR autoantibody titres were strongly 
correlated with high serum calcium and elevated PTH levels (Pallais et al., 2004). 
Furthermore, there was a dramatic decrease in CaSR autoantibody levels in response to 
steroid therapy (Pallais et al., 2004). However, in the case of CaSR autoantibody titres in 
the APS1 patients included in this study, longitudinal serum samples were not analysed in 
relation to disease progression so conclusions are unable to be drawn at this stage. 
Interestingly, the CaSR autoantibodies showed specificity for their particular epitope on 
the receptor and did not appear to be cross-reactive, suggesting that patients may have 
an array of different CaSR autoantibodies in their sera. Indeed, patients with type 1 
diabetes mellitus have an array of autoantibodies against glutamic acid decarboxylase 65 
that recognise specific antibody-binding sites (Syren et al., 1996). 
Functional affinity The functional affinity of the CaSR autoantibodies varied between the 
individual APS1 patients. Previously, it has been suggested that the avidity of 
autoantibodies could be an important feature in autoimmune disease (Gharavi and 
Reiber, 1996). For example, in the case of β2-glycoprotein I autoantibodies in patients 
with antiphospholipid syndrome, autoantibodies with high avidity have been shown to be 
associated with increased pathogenicity (Cucnik et al., 2004, Cucnik et al., 2011). However, 
further studies will be needed, with respect to CaSR autoantibodies in APS1, to investigate 
potential pathogenic properties such as complement-fixation, antibody-dependent 
cellular cytotoxicity, and CaSR-activation before these can be related or not to antibody 
avidity.  
IgG subclasses Similar to previous studies on IgG subclass determination in autoimmune 
disease (Boe et al., 2004, Brozzetti et al., 2010), CaSR autoantibodies against all identified 
epitopes were mainly of the IgG1 subclass. In a minority of APS1 patients, antibodies 
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against epitope 114-126 were of the IgG3 subclass. CaSR antibodies of the IgG2 and IgG4 
subclasses were not identified. This is the first report regarding IgG subclass for antibodies 
against the CaSR in patients with hypoparathyroidism in the context of APS1, although 
CaSR autoantibodies exclusively of the IgG4 subtype have been found in a patient with 
autoimmune hypocalciuric hypercalcemia (Pallais et al, 2004). Interestingly, both IgG1 and 
IgG3 subclass antibodies can induce cell-mediated effector mechanisms as well as having 
the capacity to activate complement (Flanagan and Rabbitts, 1982, van Loghem, 1986). 
However, these pathomechanisms require investigation in relation to autoantibodies 
against the CaSR. It is possible that affinity purification of IgG subclasses might show less 
restriction than was found here in relation to CaSR autoantibodies. Indeed, fractionation 
into IgG subclasses has revealed the presence of all IgG subclass antibodies, including 
IgG4, with respect to thyroglobulin and thyroid peroxidase autoantibodies in Hashimoto’s 
thyroiditis (Weetman et al., 1989). 
The T helper cell Th1/Th2 balance of the immune response influences the profile of IgG 
subtypes (Finkelman et al., 1990, Snapper and Paul, 1987). The Th1 cell subset induces the 
activation of macrophage and cytotoxic T lymphocytes as well as immunoglobulin IgG 
subclass switching in favour of complement-fixation and opsonisation (Romagnani, 1995, 
Mosmann and Sad, 1996). Indeed, the levels of IgG1 and IgG3 have been related to a Th1 
immune response (Finkelman et al., 1990, Snapper and Paul, 1987), which is characterised 
also by the production of IFN-γ, IL-2, and TNF-β. In contrast, a predominant Th2 cell 
immune response, defined by the secretion of IL-4, IL-5, and IL-10, induces the selection of 
IgG4 subclass antibodies (Finkelman et al., 1990, Snapper and Paul, 1987). However, in 
APS1, there are no available studies on the potential immunopolarisation to a Th1-type 
immune profile which could be related to the finding that CaSR autoantibodies are mainly 
of the IgG1 subclass. 
Effects of CaSR autoantibodies on CaSR function Only a minority of patients (4/16 = 25%) 
had CaSR autoantibodies that stimulated the receptor. Indeed, to date, only a small 
number of patients with hypoparathyroidism have been identified with CaSR-activating 
antibodies that could potentially reduce PTH-secretion. Firstly, sera from two patients 
with idiopathic hypoparathyroidism inhibited PTH-release from human parathyroid cells 
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(Kifor et al., 2004). Secondly, IgG from two patients with APS1 both of whom had 
hypoparathyroidism, activated the CaSR expressed in HEK293 cells (Kemp et al., 2009). 
However, it was not determined if these IgG samples would consequently affect PTH 
secretion from parathyroid chief cells. In patients with CaSR-stimulating autoantibodies, it 
could be that their hypoparathyroidism is caused by autoantibody activity against the 
CaSR instead of parathyroid gland destruction. This would be analogous to the action of 
pathogenic autoantibodies against the thyroid-stimulating hormone receptor in Graves’ 
disease (Morgenthaler et al., 2007). However, there were no data on whether or not the 
parathyroid of the APS1 patients with CaSR autoantibodies did or did not have lymphocyte 
infiltration. 
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Chapter 6 
Development of an ELISA for the Detection of CaSR Autoantibodies 
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6 Development of an ELISA for the Detection of CaSR Autoantibodies  
 Introduction 6.1
One of the main aims of this project was investigate the prevalence of CaSR 
autoantibodies in APS1 patients. However, there is no gold standard method to detect 
CaSR autoantibodies. The few methods established already are either labour-intensive, 
time-consuming or are not quantitative. The detection methods used have included 
radioligand binding assays (RLBAs), immunoprecipitation, immunoblotting, and ELISA 
(Table 6.1). 
Radioligand binding assays using in vitro translated CaSR were initially used to detect CaSR 
autoantibodies (Li et al., 1996, Gylling et al., 2003). Such assays are often the gold 
standard for measuring autoantibodies in patients with APS1 (Soderbergh et al., 2004). 
One of the advantages of this methodology is that there is less background compared to 
the assays that use autoantigens expressed in a cell system which may therefore be 
contaminated with other proteins. Although Tomar and colleagues (Tomar et al., 2013) 
showed that this assay was very specific in recognising CaSR autoantibodies, earlier work 
by our group did not manage to detect the reactivity of such receptor autoantibodies 
using this assay (Gavalas et al., 2007). Similar results were reported also by Soderbergh 
and co-workers (Soderbergh et al., 2004). 
Immunoblotting of the CaSR expressed in HEK293 cells (Li et al., 1996, Kifor et al., 2003, 
Tomar et al., 2013) or recombinant CaSR extracellular domain expressed in E. coli (Mayer 
et al., 2004) are other strategies which have been used to detect autoantibodies against 
the receptor. However, it is more difficult to use immunoblotting as an accurate 
quantitative measurement of autoantibodies present in patient serum samples. 
Immunoprecipitation using extracts of HEK293 cells expressing the receptor has also been 
employed to detect immunoreactivity against the CaSR (Gavalas et al., 2007). This assay 
method probably allows the detection of autoantibodies that recognise the native 
receptor as the antibody-antigen binding is done in solution under non-denaturing 
conditions. However, the technique is labour-intensive, involving several stages, so it is 
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difficult to test many samples at one time. Flow cytometry has also been successfully used 
in the detection of autoantibodies against the CaSR expressed in HEK293 cells (Gavalas et 
al., 2007). However, the technique appeared less sensitive than immunoprecipitation, 
detecting CaSR autoantibodies at a lesser frequency. The method is also less amenable to 
automation than an ELISA, for example. 
Compared to other immunoassay methods, there are many advantages of ELISAs. They 
are considered highly sensitive, specific, possess the added advantage of not needing 
radioisotopes and large numbers of samples can be analysed at one time. This method 
was, therefore, chosen as the basis for an assay for CaSR autoantibodies. Previously, 
synthetic peptides which correspond to specific parts of the CaSR have been used was 
used as targets to detect autoantibodies against the receptor in an ELISA format (Kifor et 
al., 2003, Kemp et al., 2010, Tomar et al., 2013). Although specific peptides have shown a 
high specificity in the detection of CaSR autoantibodies, this approach is less useful as it 
cannot detect all at once the array of autoantibodies against the receptor that might be 
present in a patient (Kemp et al., 2010). It was necessary, therefore, to consider using at 
least the extracellular domain of the CaSR as the antigen in an ELISA. 
Since glycosylation of the CaSR is not seemingly required for antigen-antibody interaction 
(Li et al., 1996), and several non-conformational CaSR epitopes in the extracellular domain 
are recognised by APS1 patient autoantibodies (Mayer et al., 2004, Kemp et al., 2010), it 
was decided to express the extracellular domain of the receptor in E. coli. This would 
provide a large quantity of the antigen when compared to expression in mammalian cells. 
Indeed, one commercially available kit (Alpco Immunoassays, Salem, NH, USA), which has 
been made available during the course of this study, uses the CaSR extracellular domain as 
the antigen in an ELISA system.  
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Table ‎6.1: Summary of CaSR antibody detection methods 
 
Source of antigen Method of antibody 
detection 
Reference 
In vitro translation of the CaSR   Radioligand binding 
assay 
(Li et al., 1996, Gylling et al., 
2003) 
Full-length CaSR expressed in 
HEK293 cells 
Immunoblotting (Tomar et al., 2013) 
Extracellular domain of the 
CaSR expressed in E. coli 
Immunoblotting (Mayer et al., 2004, Tomar et 
al., 2013) 
Full-length CaSR expressed in 
HEK293 cells  
Immunoprecipitation (Kifor et al., 2003, Gavalas et 
al., 2007) 
Full-length CaSR expressed in 
HEK293 cells 
Flow cytometry (Gavalas et al., 2007) 
Synthetic peptides representing 
parts of the CaSR extracellular 
domain 
ELISA (Kifor et al., 2003, Tomar et 
al., 2013) 
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 Aims  6.2
The broad aims of this part of the study were: 
 To express His-tagged CaSR-ECD in bacterial cells and purify the fusion protein 
using nickel-chelation chromatography.  
 To investigate the usefulness of the purified CaSR-ECD for detecting CaSR 
antibodies in an ELISA format. 
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 Strategy for expressing the CaSR extracellular domain 6.3
As explained in the previous section, E. coli was chosen to express the extracellular 
domain of the CaSR. Plasmid pET14b vector (Figure 6.1) was chosen for this purpose. In 
this vector, the DNA of interest is cloned such that a 6XHis-tag is located at the N-terminal 
of the expressed fusion protein. The His-tag can subsequently be used to purify the 
expressed protein using metal affinity chromatography. The His-tag was chosen because it 
is small in size and has been shown to result in high yields of protein without affecting the 
structure and function of the protein (Bornhorst and Falke, 2000). Although the elution 
buffers used in the purification of His-tag proteins are mild, the His-tag can be used under 
conditions where there is detergent or a strong ionic environment (Bornhorst and Falke, 
2000). 
In the pET14b vector, expression of the cloned DNA is under the control of the T7 
promotor and T7 RNA polymerase (Figure 6.2). So that expression of the required protein 
can take place, E. coli strains are used in which the T7 RNA polymerase gene is integrated 
into the bacterial genome under the control of the lac operon promoter (Figure 6.2) 
(Rosano and Ceccarelli, 2014). Expression of T7 RNA polymerase is therefore inducible by 
isopropyl β-D-1-thiogalactopyranoside (IPTG) (Figure 6.2) (Bell and Lewis, 2000, Daber et 
al., 2007). Several strains are available for using with the pET14b expression system. Strain 
E. coli BL21 (DE3) expresses high levels of protein, but can show protein expression before 
IPTG-induction (Rosano and Ceccarelli, 2014). This can be overcome in E. coli BL21 
(DE3)pLysS which is better in terms of controlling leaky expression (Rosano and Ceccarelli, 
2014). The strain encodes T7 lysozyme which degrades any T7 RNA polymerase produced 
due to leaky expression. The E. coli BL21 GOLD (DE3) and BL21 GOLD (DE3)pLysS strains 
are engineered to be deficient for proteases such that expressed proteins are not 
degraded (Greener et al., 1997). Finally, the E. coli BL21 CODONPLUS (DE3)-RIPL strain is 
engineered to contain extra copies of genes that encode the tRNAs that most frequently 
limit the translation of proteins in E. coli (Carstens et al., 2002). The availability of such 
tRNAs allows high-level expression of recombinant genes in this strain.  
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The signal peptide of the CaSR is highly hydrophobic (Hu and Spiegel, 2007), and removing 
this part of the protein has been shown to increase the solubility of the extracellular 
domain of the CaSR when expressed in bacterial cells (Tomar et al., 2013). Plasmid 
pPROEX-HTb-CaSREx containing the CaSR extracellular domain cDNA but without a signal 
peptide (Figure 6.3) (Tomar et al., 2013) was therefore used as a second option to express 
the extracellular domain of the receptor. In this plasmid, the CaSR extracellular domain is 
also linked to a His-tag at the N-terminal. Protein expression is driven from the synthetic 
IPTG-inducible trc promoter (Brosius et al., 1985), derived from the E. coli trp and lacUV5 
promoters. 
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Figure ‎6.1: Plasmid vector pET14b. 
The cloning sites and sequencing primer binding sites are illustrated. 
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Figure ‎6.2: Expression of target genes in the pET14b expression system. 
In the pET14b vector, expression of the cloned DNA is under the control of the T7 promotor and T7 
RNA polymerase. So that expression of the required protein can take place, E. coli strains are used 
in which the T7 RNA polymerase gene is integrated into the bacterial genome under the control of 
the lac operon promoter. Expression of T7 RNA polymerase is therefore inducible by isopropyl β-
D-1-thiogalactopyranoside (IPTG). As a result, T7 RNA polymerase is produced, which then 
promotes the transcription of the cloned DNA of interest. © EMD Millipore Corporation. All rights 
reserved. Reproduced with permission. 
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Nucleotide sequence from the start of the 6XHis-CaSR-ECD fusion protein: 
 
ATGTCGTACTACCATCACCATCACCATCACGATTACGATATCCCAAGGACCGAAAACCTGTATTTTGAGGGCG
CCATGGGATTCTAC 
 
Amino acid sequence from the start of the 6XHis-CaSR-ECD fusion protein: 
MSYYHHHHHHDYDIPTTENLYFQGAMGSYGPD 
 
 
Figure ‎6.3: Details of plasmid pPROEX-HTb-CaSREx. 
Plasmid pPROEX-HTb-CaSREx is vector pPROEX-HTb containing the cDNA of the extracellular 
domain (ECD) of the CaSR (1743 base pairs) without the receptor signal sequence. The CaSR 
extracellular domain cDNA was cloned between the BamHI and HindIII restriction sites and was in 
the correct orientation for expression in E. coli from the trc promoter present in pPROEX-HTb. The 
selectable marker for propagation in bacteria was ampicillin resistance. In the nucleotide 
sequence, the 6XHis codons are underlined and the ATG start codon is given in bold type. The 5’ 
BamHI restriction site is in italics. In the amino acid sequence, the 6XHis-tag is underlined and the 
start methionine residue is given in bold. 
 
Amino acid sequence of cDNA-encoded CaSR-ECD  
YGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPE
SVECIRYNFRGFRWLQAMIFAIEEINSSPALLPNLTL
GYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCN
CSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSY
ASSSRLLSNKNQFKSFLRTIPNDEHQATAMADIIEYF
RWNWVGTIAADDDYGRPGIEKFREEAEERDICIDFSE
LISQYSDEEEIQHVVEVIQNSTAKVIVVFSSGPDLEP
LIKEIVRRNITGKIWLASEAWASSSLIAMPQYFHVVG
GTIGFALKAGQIPGFREFLKKVHPRKSVHNGFAKEFW
EETFNCHLQEGAKGPLPVDTFLRGHEESGDRFSNSST
AFRPLCTGDENISSVETPYIDYTHLRISYNVYLAVYS
IAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKH
LRHLNFTNNMGEQVTFDECGDLVGNYSIINWHLSPED
GSIVFKEVGYYNVYAKKGERLFINEEKILWSGFSREV
PFSNCSRDCLAGTRKGIIEGEPTCCFECVECPDGEYS
DETDASACNKCPDDFWSNENHTSCIA 
Nucleotide sequence of CaSR-ECD cDNA in plasmid pPROEX-HTb-CaSREx 
TACGGCCCCGACCAGAGGGCCCAGAAGAAGGGCGACATCATCCTGGGCGGCCTGTTCCCCATCCACTTCGGCGTGGCCGCCAAGGACCAGGA
CCTGAAGAGCAGGCCCGAGAGCGTGGAGTGCATCAGGTACAACTTCAGGGGCTTCAGGTGGCTGCAGGCCATGATCTTCGCCATCGAGGAGA
TCAACAGCAGCCCCGCCCTGCTGCCCAACCTGACCCTGGGCTACAGGATCTTCGACACCTGCAACACCGTGAGCAAGGCCCTGGAGGCCACC
CTGAGCTTCGTGGCCCAGAACAAGATCGACAGCCTGAACCTGGACGAGTTCTGCAACTGCAGCGAGCACATCCCCAGCACCATCGCCGTGGT
GGGCGCCACCGGCAGCGGCGTGAGCACCGCCGTGGCCAACCTGCTGGGCCTGTTCTACATCCCCCAGGTGAGCTACGCCAGCAGCAGCAGGC
TGCTGAGCAACAAGAACCAGTTCAAGAGCTTCCTGAGGACCATCCCCAACGACGAGCACCAGGCCACCGCCATGGCCGACATCATCGAGTAC
TTCAGGTGGAACTGGGTGGGCACCATCGCCGCCGACGACGACTACGGCAGGCCCGGCATCGAGAAGTTCAGGGAGGAGGCCGAGGAGAGGGA
CATCTGCATCGACTTCAGCGAGCTGATCAGCCAGTACAGCGACGAGGAGGAGATCCAGCACGTGGTGGAGGTGATCCAGAACAGCACCGCCA
AGGTGATCGTGGTGTTCAGCAGCGGCCCCGACCTGGAGCCCCTGATCAAGGAGATCGTGAGGAGGAACATCACCGGCAAGATCTGGCTGGCC
AGCGAGGCCTGGGCCAGCAGCAGCCTGATCGCCATGCCCCAGTACTTCCACGTGGTGGGCGGCACCATCGGCTTCGCCCTGAAGGCCGGCCA
GATCCCCGGCTTCAGGGAGTTCCTGAAGAAGGTGCACCCCAGGAAGAGCGTGCACAACGGCTTCGCCAAGGAGTTCTGGGAGGAGACCTTCA
ACTGCCACCTGCAGGAGGGCGCCAAGGGCCCCCTGCCCGTGGACACCTTCCTGAGGGGCCACGAGGAGAGCGGCGACAGGTTCAGCAACAGC
AGCACCGCCTTCAGGCCCCTGTGCACCGGCGACGAGAACATCAGCAGCGTGGAGACCCCCTACATCGACTACACCCACCTGAGGATCAGCTA
CAACGTGTACCTGGCCGTGTACAGCATCGCCCACGCCCTGCAGGACATCTACACCTGCCTGCCCGGCAGGGGCCTGTTCACCAACGGCAGCT
GCGCCGACATCAAGAAGGTGGAGGCCTGGCAGGTGCTGAAGCACCTGAGGCACCTGAACTTCACCAACAACATGGGCGAGCAGGTGACCTTC
GACGAGTGCGGCGACCTGGTGGGCAACTACAGCATCATCAACTGGCACCTGAGCCCCGAGGACGGCAGCATCGTGTTCAAGGAGGTGGGCTA
CTACAACGTGTACGCCAAGAAGGGCGAGAGGCTGTTCATCAACGAGGAGAAGATCCTGTGGAGCGGCTTCAGCAGGGAGGTGCCCTTCAGCA
ACTGCAGCAGGGACTGCCTGGCCGGCACCAGGAAGGGCATCATCGAGGGCGAGCCCACCTGCTGCTTCGAGTGCGTGGAGTGCCCCGACGGC
GAGTACAGCGACGAGACCGACGCCAGCGCCTGCAACAAGTGCCCCGACGACTTCTGGAGCAACGAGAACCACACCAGCTGCATCGCC 
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 Experiments and Results 6.4
 Preparation of pPROEX-HTb-CaSREx 6.4.1
Plasmid pPROEX-HTb-CaSREx (Figure 6.3) containing the CaSR extracellular domain (CaSR-
ECD) cDNA, but without the CaSR signal sequence was a kind gift from Professor Ravinder 
Goswami (Department of Endocrinology and Metabolism, All India Institute of Medical 
Sciences, New Delhi, India). Initially, the plasmid was used to transform E. coli JM109, as 
detailed earlier (Section 2.13). One transformant was purified by streaking onto a fresh LB 
agar plate (Section 2.3) containing ampicillin at 100 μg/ml (Section 2.3) followed by 
incubation overnight at 37°C. The purified bacterial clone was then inoculated into 10 ml 
of LB medium (Section 2.3) containing ampicillin at 100 μg/ml and incubated at 37°C 
overnight. Subsequently, plasmid DNA was purified from the bacterial culture using a 
Wizard Miniprep DNA Purification System (Section 2.6). Successful preparation of the 
plasmid was confirmed by electrophoresis in a 1% (w/v) agarose gel (Section 2.8). A large-
scale plasmid preparation of pPROEX-HTb-CaSREx was carried out, as detailed in Section 
2.7. Finally, the CaSR-ECD cDNA sequence in the plasmid was verified using primers M13 
forward, M13 Reverse, CaSR-451, CaSR-951, and CaSR-1151 (Section 2.15; Table 2.5). 
 Cloning of the CaSR extracellular domain for expression in E. coli  6.4.2
The experiment to clone the CaSR-ECD cDNA into pET14b (Figure 6.1), for ultimate use in 
the expression of a 6XHis-CaSR-ECD fusion protein, is detailed in the following sections. 
 PCR amplification of the CaSR extracellular domain  6.4.2.1
A cDNA fragment of the CaSR-ECD, encompassing base pairs 1-1800 of the CaSR cDNA 
sequence (Figure 3.2), was generated from the full-length CaSR cDNA present in pDEST14-
CaSR (Figure 6.4) by PCR amplification (Section 2.10). The oligonucleotide primers CaSR-
ECD-F and CaSR-ECD-R, which were used to generate the CaSR-ECD cDNA, are listed in 
Table 2.4. A restriction site for XhoI was incorporated into each of the primers in order to 
allow eventual cloning of the PCR amplification product into the XhoI restriction site of the 
expression vector pET14b. The composition of the PCR amplification reaction and the PCR 
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amplification conditions used with the template pDEST14-CaSR DNA were as previously 
described (Section 2.10). To check the PCR amplification product, a 5-μl aliquot of the PCR 
amplification reaction was electrophoresed in a 1% (w/v) agarose gel (Section 2.8). The 
result is shown in Figure 6.5, and this indicated a PCR amplification product with an 
estimated size of 1.8 kb. 
 TOPO® cloning of the CaSR-ECD cDNA PCR product 6.4.2.2
According to a TOPO® TA Cloning Kit (Section 2.14), a TOPO® cloning reaction was used to 
clone the CaSR-ECD cDNA PCR amplification product directly into plasmid vector pCR®2.1-
TOPO® (Figure 6.6). Following transformation of E. coli TOP10F’ cells the TOPO® cloning 
reaction, individual colonies were purified by streaking onto fresh LB agar plates (Section 
2.3) with kanamycin at 50 μg/ml (Section 2.3) and growing them overnight at 37°C. 
For screening of E. coli TOP10F’ transformants for recombinant plasmids that contained 
the correct CaSR cDNA fragment, 10 individual bacterial clones were inoculated separately 
into 10 ml of LB medium (Section 2.3) containing kanamycin at 50 μg/ml (Section 2.3), and 
then incubated at 37°C overnight. Subsequently, plasmid DNA was purified from individual 
transformants using a Wizard Miniprep DNA Purification System (Section 2.6). Plasmids 
were then checked for the presence of a DNA insert of the correct size by restriction 
enzyme digestion of a 0.5-µg sample with XhoI in a 25-µl reaction (Section 2.9), followed 
by analysis by electrophoresis in a 1% (w/v) agarose gel (Section 2.8). 
The results indicated that the frequency of recombinant plasmids was 90%, with 9/10 
plasmids having a DNA insert of the expected size at 1.8 kb (Figure 6.7). One recombinant 
plasmid was designated as pCR®2.1-TOPO®-CaSR-ECD (Figure 6.8), and this was further 
analysed. 
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Figure ‎6.4: A map of the pDEST14-CaSR plasmid. 
Restriction enzyme sites and sequencing primer binding sites (T7 promoter and T7 terminator) are 
shown. The CaSR cDNA is cloned as a 3234-base pair fragment into the 6.4-kilobase pDEST14 
vector. 
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Figure ‎6.5: Agarose gel of PCR amplification product amplified from pDEST14-CaSR. 
Plasmid pDEST-CaSR was subjected to PCR amplification using primers CASR-ECD-F and CASR-ECD-
R. The PCR amplification products were analysed by electrophoresis in a 1% (w/v) agarose gel. The 
gel shows: 1-kb DNA Ladder with DNA fragments from 500 to 10,000 bp (lane 1); no DNA control 
with primers CASR-ECD-F and CASR-ECD-R (lane 2); plasmid pDEST-CaSR amplified with primers 
CASR-ECD-F and CASR-ECD-R (lane 3). 
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Figure ‎6.6: Plasmid vector pCR®2.1-TOPO®. 
The PCR product insertion site and sequencing primer binding sites are illustrated. 
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Figure ‎6.7: Agarose gel of plasmids prepared from E. coli TOP10F’ clones. 
The plasmids prepared from ten E. coli TOP10F’ clones were restricted with XhoI to determine the 
presence of a CaSR-ECD cDNA insert. (a) The 1% (w/v) agarose gel shows: 1-kb DNA Markers with 
DNA fragments from 500-10,000 bp (lane 1); unrestricted plasmids (lanes 2-11). (b) The gel 1% 
(w/v) agarose shows: 1-kb DNA Markers with DNA fragments from 500-10,000 bp (lane 1); XhoI-
restricted plasmids (lanes 2-11). 
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Figure ‎6.8: Schematic diagram of plasmid pCR®2.1-TOPO®-CaSR-ECD. 
The CaSR-ECD cDNA is cloned into the PCR cloning site of pCR2.1-TOPO as a fragment with Xhol 
restriction sites incorporated at the 5’ and 3’ ends. The positions of the T7 promoter, M13 reverse 
and M13 forward primers are indicated. 
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 Sequencing of cloned CaSR-ECD cDNA fragment 6.4.2.3
To verify that no sequence errors had been introduced into the CaSR-ECD cDNA fragment 
during PCR amplification, plasmid pCR®2.1-TOPO®-CaSR-ECD was subjected to DNA 
sequencing (Section 2.15) using primers T7 Promoter, M13 Reverse and CASR646-F (Table 
2.5). The results verified that the recombinant plasmid contained the correct CaSR-ECD 
cDNA fragment when compared with the sequence of the CaSR cDNA template (Figure 
3.2) using the Pairwise Alignment tool at the network facilities of the EBI-EMBL (Section 
2.16). This plasmid was used in subsequent cloning experiments as the source of the 
cloned CaSR-ECD. 
 Preparation of the CaSR-ECD cDNA fragment for cloning into pET14b 6.4.2.4
To prepare the CaSR-ECD cDNA fragment, 1 μg of pCR®2.1-TOPO®-CaSR-ECD was digested 
with XhoI in a 25-μl reaction and then electrophoresed in a 1% (w/v) agarose gel. 
Subsequently, the 1.8-kb DNA fragment was purified from the gel using a Wizard PCR 
Preps DNA Purification System (Section 2.11). Finally, a 3-μl aliquot of the restricted and 
purified product was analysed by agarose gel electrophoresis in a 1% (w/v) gel, and the 
concentration determined by spectrophotometry (Section 2.6). 
 Preparation of vector pET14b 6.4.2.5
Plasmid vector pET14 (Novagen/Merck KgaA, Darmstadt, Germany) was already available 
in the laboratory (Dr Helen Kemp, University of Sheffield). For cloning of the CaSR-ECD 
fragment into pET14b, 1 μg of the plasmid vector was digested with XhoI in a 25-μl 
reaction. The linearised vector was purified from a 1% (w/v) agarose gel using a Wizard 
PCR Preps DNA Purification System. A 3-μl aliquot of the restricted and purified vector 
was checked on a 1% (w/v) agarose gel, and the concentration determined by 
spectrophotometry. 
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 Cloning of CaSR-ECD cDNA fragment into pET14b 6.4.2.6
The XhoI-restricted CaSR-ECD cDNA fragment was cloned into XhoI-digested pET14b by 
setting up 20-µl ligation reaction (Section 2.12). A 5-µl aliquot of the ligation reaction was 
then used to transform 100 µl of chemically competent E. coli JM109 cells (Section 2.13) 
with transformants being selected on LB agar containing ampicillin at 100 µg/ml. 
Following overnight incubation at 37°C, 60 individual bacterial colonies from the 
transformation were purified by streaking on to fresh LB agar containing ampicillin at 100 
µg/ml and subsequently incubating at 37°C overnight. 
For screening of E. coli JM109 transformants for recombinant plasmid that contained the 
CaSR-ECD cDNA fragment, 60 individual bacterial clones were subjected to PCR 
amplification. For this, a small amount of each bacterial clone was taken from the 
selective LB agar plate and suspended in 100 µl of nuclease-free water in a 0.5-ml tube. 
After heating at 95°C for 5 min, the lysed cells were centrifuged for 5 min at 12,000 g to 
remove cellular debris. The supernatant containing DNA was removed to a clean 0.5-ml 
tube. Using primers CaSR-ECD-F and CaSR-ECD-R, a 2-µl aliquot of each DNA sample was 
subjected to PCR amplification. To check the PCR amplification products, a 5-μl aliquot of 
each of the PCR amplification reactions was electrophoresed in a 1% (w/v) agarose gel. 
The results are illustrated in Figure 6.9, and these indicated that a product with an 
estimated size of 1.8 kb was produced in 2/60 (3%) clones.  
The two bacterial clones carrying recombinant plasmids were inoculated separately into 
10 ml of LB medium with ampicillin at 100 µg/ml, and then incubated at 37°C overnight. 
Plasmid DNA was purified from the bacterial cultures using a Wizard Miniprep DNA 
Purification System. Plasmids were then checked for the presence of the correctly sized 
DNA insert by restriction enzyme digestion of a 0.5-µg sample with XhoI in a 25-µl 
reaction, followed by analysis by electrophoresis in 1% (w/v) agarose gels. The results are 
given in Figure 6.10, and these indicated that both recombinant plasmids contained a DNA 
insert of the expected size at 1.8 kb.  
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Figure ‎6.9: Agarose gel of PCR amplification products arising from the screening of E. coli 
JM109 clones isolated from the pET14b/CaSR-ECD cDNA cloning experiment. 
DNA prepared from E. coli JM109 clones (n = 60) was subjected to PCR amplification using primers 
CASR-ECD-F and CASR-ECD-R. The PCR amplification products were analysed by electrophoresis in 
1% (w/v) agarose gels. The gel shows: 1-kb DNA Ladder with DNA fragments from 500 to 10,000 
bp (lane 1); clone 1 DNA amplified with primers CASR-ECD-F and CASR-ECD-R (lane 2); clone 2 DNA 
amplified with primers CASR-ECD-F and CASR-ECD-R (lane 3); clone 3 DNA amplified with primers 
CASR-ECD-F and CASR-ECD-R (lane 4); clone 4 DNA amplified with primers CASR-ECD-F and CASR-
ECD-R (lane 5); clone 5 DNA amplified with primers CASR-ECD-F and CASR-ECD-R (lane 6); and no 
DNA control with primers CASR-ECD-F and CASR-ECD-R (lane 7). 
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Figure ‎6.10: Agarose gel of recombinant plasmids from the pET14b/CaSR-ECD cDNA 
cloning experiment. 
The recombinant plasmids prepared from two E. coli JM109 clones were restricted with XhoI to 
determine the presence of a CaSR-ECD cDNA insert. The 1% (w/v) agarose gel shows: 1-kb DNA 
Markers with DNA fragments from 500-10,000 base pairs (lane 1); unrestricted pET14b (lane 2); 
XhoI-restricted pET14b (lane 3); unrestricted recombinant plasmid 1 (lane 4); XhoI-restricted 
recombinant plasmid 1 (lane 5); unrestricted recombinant plasmid 2 (lane 6); XhoI-restricted 
recombinant plasmid 2 (lane 7). 
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 Sequencing of the CaSR-ECD cDNA fragment cloned in pET14b 6.4.2.7
To determine the orientation of the DNA insert and to verify that the CaSR-ECD cDNA was 
in-frame with the 6XHis-tag in pET14b, both recombinant plasmids were subjected to DNA 
sequencing using the T7 Promoter primer. The results verified that the recombinant 
plasmids contained the CaSR-ECD cDNA fragment in the correct reading frame for 
expression as a 6XHis-CaSR-ECD fusion protein (Figure 6.11). One recombinant plasmid 
was designated as pET14b-CaSR-ECD (Figure 6.11), and this was used in further 
experiments. A large-scale plasmid preparation of pET14b-CaSR-ECD was carried out as 
detailed in Section 2.7.  
 Expression of the CaSR-ECD in E. coli BL21 strains 6.4.3
 Transformation of E. coli BL21 strains with pET14b-CaSR-ECD, pET14b, and 6.4.3.1
pPROEX-HTb-CaSREX 
Initially, E. coli strains BL21 (DE3), BL21 (DE3)pLysS, BL21 GOLD (DE3)pLysS, BL21 GOLD 
(DE3), and BL21 CODONPLUS (DE3)-RIPL (Agilent Technologies Inc., Santa Clara, CA, USA) 
were transformed with plasmids pET14b-CaSR-ECD, pET14b, and pPROEX-HTb-CaSREx, as 
detailed earlier (Section 2.13). Transformants were selected on LB agar containing 
ampicillin at 100 µg/ml. Following overnight incubation at 37°C, 10 individual bacterial 
colonies from the transformation were purified by streaking on to fresh LB agar containing 
ampicillin at 100 µg/ml and subsequently incubating at 37°C overnight. 
For screening of E. coli BL21 transformants for recombinant plasmids, 10 individual 
bacterial clones were inoculated separately into 10 ml of LB medium with ampicillin at 100 
µg/ml, and then incubated at 37°C overnight. Subsequently, plasmid DNA was purified 
from individual transformants using a Wizard Miniprep DNA Purification System, and 
plasmids analysed by electrophoresis in a 1% (w/v) agarose gel. One transformant of each 
E. coli BL21 strain containing pET14b-CaSR-ECD, pET14b or pPROEX-HTb-CaSREx was kept 
as a frozen stock at -80°C, as detailed in Section 2.4. 
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Figure ‎6.11: Schematic diagram of plasmid pET14b-CaSR-ECD. 
The nucleotide and amino acid sequences of the N-terminal of the 6XHis-CaSR-ECD fusion protein 
are shown. In the nucleotide sequence, the 6XHis codons are underlined and the ATG codon is 
given in bold. The 5’ XhoI restriction site is in italics and underlined. In the amino acid sequence, 
the 6XHis-tag is underlined and the methionine start is given in bold. The positions of the T7 
promoter and T7 terminator primers are indicated. 
  
Nucleotide sequence from the start of the 6XHis-CaSR-ECD fusion protein: 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGCTCGAGATG 
 
Amino acid sequence from the start of the 6XHis-CaSR-ECD fusion protein: 
MGSSHHHHHHSSGLVPRGSHMLEMAFYSCCWVLLALTWHTSAYGPDQRAQKKGDIILGGLFPIHFGVAA
KDQDLKSRPESVECIRYNFRGFRWLQAMIFAIEEINSSPALLPNLTLGYRIFDTCNTVSKALEATLSFV
AQNKIDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQFKSFL
RTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDFSELISQYSDEEEIQ
HVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWASSSLIAMPQYFHVVGGTIGFAL
KAGQIPGFREFLKKVHPRKSVHNGFAKEFWEETFNCHLQEGAKGPLPVDTFLRGHEESGDRFSNSSTAF
RPLCTGDENISSVETPYIDYTHLRISYNVYLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQV
LKHLRHLNFTNNMGEQVTFDECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEEKIL
WSGFSREVPFSNCSRDCLAGTRKGIIEGEPTCCFECVECPDGEYSDETDASACNKCPDDFWSNENHTSC
IA 
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 Small-scale expression of the CaSR-ECD in E. coli BL21 strains 6.4.3.2
For small-scale expression of the CaSR-ECD, a fresh overnight colony of the required E. coli 
BL21 strain was inoculated into 10 ml of LB medium containing ampicillin at 100 µg/ml. 
The culture was incubated with shaking at 37°C until an OD600 of 0.5 was reached after 
approximately 2-3 h. Subsequently, 3 ml of the culture was transferred to 50 ml of LB 
without antibiotics and incubated with shaking at 37°C until an OD600 of 0.5 was reached. 
At this point, a 1-ml aliquot of the culture was removed into a 1.5-ml microfuge tube on 
ice and designated as the uninduced sample (T=0). To the remaining culture, isopropyl β-
D-1-thiogalactopyranoside (IPTG) (Sigma-Aldrich) was added to a final concentration of 1 
mM and incubation of the culture continued in order to induce the expression of the 
CaSR-ECD. At time points of 1 h (T=1), 2 h (T=2), 3 h (T=3) and 4 h (T=4), the OD600 of the 
culture was taken, and a 1-ml sample was removed to a 1.5-ml microfuge tube on ice. The 
collected samples were centrifuged at 13,000 g and the cell pellet stored at -80°C. 
Identical experiments were undertaken with E. coli BL21 strains containing pET14b. 
Before analysis by SDS-PAGE, the resuspended cell pellets were diluted with PBS to 
equivalent OD600 values so that the same amount of cell extract was loaded on to SDS-
polyacrylamide gels. Samples of cell extract (10 µl) from uninduced and IPTG-induced 
BL21/pET14b-CaSR-ECD, BL21/pET14b and BL21/pPROEX-HTb-CaSREx strains were mixed 
with 10 µl of SDS-sample buffer (Section 2.17), heated at 95°C, and applied to 10% (w/v) 
SDS-polyacrylamide gels. Following SDS-PAGE (Section 2.17), gels were stained with 
Coomassie® Blue stain and then destained to reveal the separated proteins (Section 2.17). 
For the BL21/pET14b strains, no difference was evident between the proteins in the cell 
extracts made from uninduced and IPTG-induced cultures. This is illustrated as a hourly 
time-course for BL21 (DE3)/pET14b in Figure 6.12a. For the BL21/pET14b-CaSR-ECD 
strains, a band of increased intensity at 70 kDa was clearly visible in cell extracts that were 
made from cultures 1 h after IPTG had been added. This is illustrated as a hourly time-
course for strain BL21 (DE3)/pET14b-CaSR-ECD in Figure 6.12b. The expected size of the 
CaSR-ECD protein was 66 kDa. Figures 6.13a and b show expression of the CaSR-ECD in all 
of the BL21/pET14b-CaSR-ECD strains analysed at times T=0 and T=4. Figure 6.13c shows 
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the expression of the CaSR-ECD in strain BL21 CODONPLUS (DE3)-RIPL/pPROEX-HTb-
CaSREx at T=0 and T=4. 
 Western blotting of uninduced and induced E. coli BL21/pET14b-CaSR-ECD cell 6.4.3.3
extracts 
Before analysis by western blotting, samples of cell extract (10 µl) from uninduced and 
IPTG-induced BL21/pET14b-CaSR-ECD strains were mixed with 10 µl of SDS-sample buffer 
(Section 2.17), heated at 95°C, and applied to 10% (w/v) SDS-polyacrylamide gels. 
Following SDS-PAGE (Section 2.17), gels were subjected to western blotting as detailed in 
Section 2.19. After the transfer of proteins to PVDF membrane, the blots were probed 
with either primary anti-His-tag antibody (Table 2.6) (Life Technologies Ltd., Paisley, UK) 
or anti-CaSR antibody ab79829 against the CaSR (Table 2.6) (Abcam, Inc., Cambridge, MA, 
USA). Both were used at a 1:500 dilution. Appropriate secondary antibodies were anti-
mouse IgG-HRP (Table 2.6) and anti-rabbit IgG-HRP (Table 2.6), respectively, and these 
were used at a 1:2000 dilution.  
The results indicated that following IPTG-induction, a protein band of approximately 70 
kDa, which reacted with both primary anti-His-tag and anti-CaSR antibodies, was present 
in cell extracts made from all the different BL21/pET14b-CaSR-ECD strains used for 
expression. However, the protein band was not seen in cell extracts prepared from 
uninduced cultures. This is illustrated in Figures 6.14a and b for strain BL21 CODONPLUS 
(DE3)-RIPL/pET14b-CaSR-ECD.  
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Figure ‎6.12: SDS-PAGE and Coomassie blue staining of gels containing cell extracts of E. 
coli BL21 (DE3)/pET14b-CaSR-ECD and E. coli BL21 (DE3)/pET14b strains 
Cell extracts were prepared from E. coli BL21 (DE3)/pET14b-CaSR-ECD and BL21 (DE3)/pET14b 
strains prior to and following the addition of IPTG. The 10% (w/v) SDS-polyacrylamide gels show: 
(a) Prestained SDS-PAGE Standards, Low Range (20-104 kDa) (lane 1); uninduced (T=0) BL21 
(DE3)/pET14b (lane 2); post induction (T=1) BL21 (DE3)/pET14b (lane 3); post induction (T=2) BL21 
(DE3)/pET14b (lane 4); post induction (T=3) BL21 (DE3)/pET14b (lane 5); and post induction (T=4) 
BL21 (DE3)/pET14b (lane 6). (b) Prestained SDS-PAGE Standards, Low Range (lane 1); uninduced 
(T=0) BL21 (DE3)/pET14b-CaSR-ECD (lane 2); post induction (T=1) BL21 (DE3)/pET14b-CaSR-ECD 
(lane 3); post induction (T=2) BL21 (DE3)/pET14b-CaSR-ECD (lane 4); post induction (T=3) BL21 
(DE3)/pET14b-CaSR-ECD (lane 5); and post induction (T=4) BL21 (DE3)/pET14b-CaSR-ECD (lane 6).  
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Figure ‎6.13: SDS-PAGE and Coomassie blue staining of gels containing cell extracts of E. 
coli BL21/pET14b-CaSR-ECD strains. 
Cell extracts were prepared from E. coli BL21/pET14b-CaSR-ECD strains prior to and following the 
addition of IPTG to induce the expression of CaSR-ECD. The 10% (w/v) SDS-polyacrylamide gels 
show: (a) Prestained SDS-PAGE Standards, Low Range (20-104 kDa) (lane 1); uninduced (T=0) BL21 
(DE3)pLysS/pET14b-CaSR-ECD (lane 2); post induction (T=4) BL21 (DE3)pLysS/pET14b-CaSR-ECD 
(lane 3); uninduced (T=0) BL21 GOLD (DE3)pLysS/pET14b-CaSR-ECD (lane 4); and post induction 
(T=4) BL21 GOLD (DE3)pLysS/pET14b-CaSR-ECD (lane 5). (b) Prestained SDS-PAGE Standards, Low 
Range (lane 1); uninduced (T=0) BL21 (DE3)/pET14b-CaSR-ECD (lane 2); post induction (T=4) BL21 
(DE3)/pET14b-CaSR-ECD (lane 3); uninduced (T=0) BL21 GOLD (DE3)/pET14b-CaSR-ECD (lane 4); 
post induction (T=4) BL21 GOLD (DE3)/pET14b-CaSR-ECD (lane 5); uninduced (T=0) BL21 
CODONPLUS (DE3)-RIPL/pET14b-CaSR-ECD (lane 6); and post induction (T=4) BL21 CODONPLUS 
(DE3)-RIPL/pET14b-CaSR-ECD (lane 7). (c) Prestained SDS-PAGE Precision Plus Protein™ Standards 
(20-250 kDa) (lane 1); uninduced (T=0) BL21 CODONPLUS (DE3)-RIPL/pPROEX-HTb-CaSREx (lane 2); 
and post induction (T=4) BL21 CODONPLUS (DE3)-RIPL/pPROEX-HTb-CaSR-Ex (lane 3). 
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Figure 6.13: SDS-PAGE and Coomassie blue staining of gels containing cell extracts of E. 
coli BL21/pET14b-CaSR-ECD strains.  
Cell extracts were prepared from E. coli BL21/pET14b-CaSR-ECD strains prior to and following the 
addition of IPTG to induce the expression of CaSR-ECD. The 10% (w/v) SDS-polyacrylamide gels 
show: (a) Prestained SDS-PAGE Standards, Low Range (20-104 kDa) (lane 1); uninduced (T=0) BL21 
(DE3)pLysS/pET14b-CaSR-ECD (lane 2); post induction (T=4) BL21 (DE3)pLysS/pET14b-CaSR-ECD 
(lane 3); uninduced (T=0) BL21 GOLD (DE3)pLysS/pET14b-CaSR-ECD (lane 4); and post induction 
(T=4) BL21 GOLD (DE3)pLysS/pET14b-CaSR-ECD (lane 5). (b) Prestained SDS-PAGE Standards, Low 
Range (lane 1); uninduced (T=0) BL21 (DE3)/pET14b-CaSR-ECD (lane 2); post induction (T=4) BL21 
(DE3)/pET14b-CaSR-ECD (lane 3); uninduced (T=0) BL21 GOLD (DE3)/pET14b-CaSR-ECD (lane 4); 
post induction (T=4) BL21 GOLD (DE3)/pET14b-CaSR-ECD (lane 5); uninduced (T=0) BL21 
CODONPLUS (DE3)-RIPL/pET14b-CaSR-ECD (lane 6); and post induction (T=4) BL21 CODONPLUS 
(DE3)-RIPL/pET14b-CaSR-ECD (lane 7). (c) Prestained SDS-PAGE Precision Plus Protein™ Standards 
(20-250 kDa) (lane 1); uninduced (T=0) BL21 CODONPLUS (DE3)-RIPL/pPROEX-HTb-CaSREx (lane 2); 
and post induction (T=4) BL21 CODONPLUS (DE3)-RIPL/pPROEX-HTb-CaSR-Ex (lane 3). 
 
 
  
CaSR-ECD 
1 2 3 
250 kDa 
150 kDa 
100 kDa 
75 kDa 
50 kDa 
37 kDa 
25 kDa 
20 kDa 
 247 
 (a) 
 
 
 
 
 
(b) 
 
 
 
 
 
 
Figure ‎6.14: Western blotting of cell extracts of E. coli BL21 CODONPLUS (DE3)-
RIPL/pET14b-CaSR-ECD. 
Cell extracts were prepared from E. coli BL21 CODONPLUS (DE3)-RIPL/pET14b-CaSR-ECD prior to 
and following the addition of IPTG to induce the expression of CaSR-ECD. The extracts were 
applied to 10% (w/v) SDS-polyacrylamide gels, and then the separated proteins subjected to 
western blotting with primary anti-His-tag and anti-CaSR antibodies. (a) Western blot of cell 
extracts probed with anti-CaSR antibody. Uninduced (T=0) BL21 CODONPLUS (DE3)-RIPL/pET14b-
CaSR-ECD (lane 1); post induction (T=2) BL21 CODONPLUS (DE3)-RIPL/pET14b-CaSR-ECD (lane 2); 
and post induction (T=4) BL21 CODONPLUS (DE3)-RIPL/pET14b-CaSR-ECD (lane 3). (b) Western 
blot of cell extracts probed with anti-His-tag antibody. Uninduced (T=0) BL21 CODONPLUS (DE3)-
RIPL/pET14b-CaSR-ECD (lane 1); post induction (T=1) BL21 CODONPLUS (DE3)-RIPL/pET14b-CaSR-
ECD (lane 2); post induction (T=2) BL21 CODONPLUS (DE3)-RIPL/pET14b-CaSR-ECD (lane 3); post 
induction (T=3) BL21 CODONPLUS (DE3)-RIPL/pET14b-CaSR-ECD (lane 2); and post induction (T=4) 
BL21 CODONPLUS (DE3)-RIPL/pET14b-CaSR-ECD (lane 3). Prestained SDS-PAGE Standards, Low 
Range (20-104 kDa) were included in the gels.  
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 Purification of the His-tagged CaSR-ECD 6.4.4
 Large-scale expression of the His-tagged CaSR-ECD  6.4.4.1
E. coli BL21 CODONPLUS (DE3)-RIPL/pET14b-CaSR-ECD and BL21 CODONPLUS (DE3)-
RIPL/pPROEX-HTb-CaSREx were chosen for large-scale expression of His-tagged CaSR-ECD, 
as they showed the best results for the expression of the His-tagged CaSR-ECD, based on 
the results of the Coomassie blue staining of gels and western blotting. A small-scale 
culture was prepared by inoculating a single colony of the bacterial strain into 10 ml of LB 
medium with ampicillin at 100 µg/ml. This was grown with shaking at 37°C until an OD600 
of 0.5 was reached after approximately 2-3 h. Subsequently, 5 ml of the culture was 
transferred to 100 ml of LB medium with ampicillin at 100 µg/ml and incubated with 
shaking at 37°C until an OD600 of 0.5 was reached. Then, 50 ml of the culture were 
transferred to 500 ml of LB medium and the culture incubated with shaking at 37°C until 
an OD600 of 1.0 was reached. Samples (1-ml) of the culture were collected and labelled as 
uninduced (T=0). Following this, IPTG was added to a final concentration of 1 mM and 
incubation of the culture continued for 3 h to induce the expression of the His-tagged 
CaSR-ECD. After measuring the OD600, samples of 1 ml were collected and labelled as 
induced (T=3). All culture samples were spun at 13,000 g and the pellets kept for analysis 
at -80°C. The remainder of the culture was harvested at 6,000 g for 15 min at 4°C. The cell 
pellet was weighed and then stored at -80°C until analysis. The 1-ml culture samples were 
used to confirm His-tagged CaSR-ECD expression using SDS-PAGE, as described in Section 
6.4.3.2, before proceeding with purification of the His-tagged CaSR-ECD from the cell 
pellet of the large-scale culture.  
 Solubility of the His-tagged CaSR-ECD  6.4.4.2
Solubility analysis was undertaken to determine whether the His-tagged CaSR-ECD was in 
soluble form or was present as an insoluble form as inclusion bodies. The cell pellet from 
the 500-ml culture containing expressed His-tagged CaSR-ECD was resuspended in 10 ml 
of phosphate-buffered saline containing Protease Inhibitor Cocktail (Roche, Mannheim, 
Germany). To lyse the cells, lysozyme (Sigma-Aldrich) was added to concentration of 200 
 249 
µg/ml followed by incubation on ice for 20 min. Subsequently, sodium deoxycholate 
(Sigma-Aldrich) was added to a final concentration of 200 µg/ml, and the lysed cells left 
for 20 min on ice with gentle mixing. The lysed cells were sonicated for four times for 10 
sec and then centrifuged at 20,000 g for 20 min at 4°C. The supernatant was removed and 
the pellet of inclusion bodies was resuspended in 20 ml of inclusion body wash buffer (30 
mM Tris-hydrochloride, pH 8.0; 5 mM dithiothreitol; 2 M urea; 2% (v/v) Triton X-100) 
using a SHM1 handheld homogeniser (Bibby Scientific Limited, Stone, UK) for three 20-sec 
bursts at 10,000 rpm at 4°C with a 20-sec break between bursts. 
Samples of 10 µl of the supernatant and the resuspended inclusion bodies were added to 
10 µl of SDS-sample buffer (Section 2.17), heated at 95°C, and analysed by SDS-PAGE 
(Section 2.17). The results of Coomassie blue staining of the gel are illustrated in Figure 
6.15, with the His-tagged CaSR-ECD clearly present in the insoluble inclusion body 
fraction.  
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Figure ‎6.15: Solubility of the His-tagged CaSR-ECD. 
Samples (10 µl) of the soluble and insoluble fractions from the large-scale cell extracts were 
applied to a 10% (w/v) SDS-polyacrylamide gel. The results show: (a) Prestained SDS-PAGE 
Standards, Low Range (20-104 kDa) (lane 1); soluble fraction of extract of BL21 CODONPLUS (DE3)-
RIPL/pET14b-CaSR-ECD (lane 2); and insoluble fraction (inclusion bodies) of extract of BL21 
CODONPLUS (DE3)-RIPL/pET14b-CaSR-ECD (lane 3). (b) Prestained SDS-PAGE Precision Plus 
Protein™ Standards (20-250 kDa) (lane 1); soluble fraction of extract of BL21 CODONPLUS (DE3)-
RIPL/pPROEX-HTb-CaSREx (lane 2); and insoluble fraction (inclusion bodies) of extract of BL21 
CODONPLUS (DE3)-RIPL/pPROEX-HTb-CaSREx (lane 3). 
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 Purification and solubilisation of inclusion bodies containing the His-tagged 6.4.4.3
CaSR-ECD 
Resuspended inclusion bodies (Section 6.4.4.2) were collected by centrifugation at 30,000 
g for 30 min at 4°C. A 20-µl sample of the supernatant was saved and remainder was 
discarded. The pelleted inclusion bodies were washed three times (washes 1-3) using 
inclusion body wash buffer (Section 6.4.4.2). Samples (20-µl) of the supernatant were 
retained after each wash. The final wash (wash 4) was done with inclusion body wash 
buffer without Triton X-100, and with centrifugation at 40,000 g for 40 min at 4°C. Again, a 
20-µl sample of the supernatant was saved. 
The pellet of inclusion bodies was resuspended in buffer (20 mM Tris-hydrochloride, pH 
8.0; 1 M sodium chloride), and centrifuged at 40,000 g for 20 min at 4°C. A 20-µl sample of 
supernatant was retained (wash 5). Next, the inclusion body pellet was resuspended in 20 
mM Tris-hydrochloride (pH 8.0) and centrifuged as before (wash 6), and a 20-µl sample of 
the supernatant was saved. The inclusion body pellet was solubilised in buffer containing 
30 mM Tris-hydrochloride (pH 8.0), 6 M guanidine hydrochloride and 100 mM sodium 
chloride, overnight at 4°C. The solubilised inclusion bodies were then centrifuged at 
40,000 g for 45 min at 4°C, and the supernatant containing the solubilised His-tagged 
CaSR-ECD protein was collected and stored at 4°C.  
The supernatants from the washing procedures and the final solubilised protein were 
analysed by SDS-PAGE. Samples of 10 µl were added to 10 µl of SDS-sample buffer 
(Section 2.17), heated at 95°C, and analysed by SDS-PAGE (Section 2.17). The results of 
Coomassie blue staining of the gel are illustrated in Figure 6.16, and show the His-tagged 
CaSR-ECD protein remaining in the pellet at each stage of washing. 
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Figure ‎6.16: SDS-PAGE analysis of the preparation of inclusion bodies of the His-tagged 
CaSR-ECD. 
Samples (10 µl) of the soluble and insoluble fractions and washes from the inclusion body 
preparation were analysed by SDS-PAGE in a 10% (w/v) SDS-polyacrylamide gel. The result shows: 
Prestained SDS-PAGE Standards Precision Plus Protein™ (range 20-250 kDa) (lane 1); soluble 
fraction of extract of BL21 CODONPLUS (DE3)-RIPL/pPROEX-HTb-CaSREx cells (lane 2); supernatant 
from wash 1 of inclusion bodies (lane 3); supernatant from wash 2 of inclusion bodies (lane 4); 
supernatant from wash 3 of inclusion bodies (lane 5); supernatant from wash 4 of inclusion bodies 
(lane 6); supernatant from wash 5 of inclusion bodies (lane 7); supernatant from wash 6 of 
inclusion bodies (lane 8); and solubilised inclusion bodies of the His-tagged CaSR-ECD (lane 9). 
  
CaSR-ECD 
 253 
 Purification of His-tagged CaSR-ECD by Ni2+-chelation chromatography 6.4.4.4
6.4.4.4.1 Use of HisTrap FF Crude columns 
Initial attempts to purify the solubilised His-tagged CaSR-ECD (obtained from both E. coli 
BL21 CODONPLUS (DE3)-RIPL/pET14b-CaSR-ECD and BL21 CODONPLUS (DE3)-
RIPL/pPROEX-HTb-CaSREx) (Section 6.4.4.2) used HisTrap FF Crude 1-ml columns (GE 
Healthcare, Little Chalfont, UK). The columns were prepacked with pre-charged Ni 
Sepharose 6 Fast Flow. The column was rinsed with 10 column volumes of filtered water 
at 2 ml per min and then equilibrated with 10 column volumes of equilibration buffer (30 
mM Tris-hydrochloride, pH 8.0; 6 M guanidine hydrochloride; 100 mM sodium chloride; 
20 mM imidazole) at 2 ml per min. Before the solubilised his-tagged CaSR-ECD protein was 
loaded onto the column, 20 mM imidazole was to the protein added to reduce the chance 
of non-specific binding of the protein to the column. His-tagged CaSR-ECD protein was 
loaded on to the column at 2 ml per min and the flow-through collected. Attempts were 
then made to wash the with 10 column volumes of wash buffer (30 mM Tris-
hydrochloride, pH 8.0; 100 mM sodium chloride; 50 mM imidazole) at 2 ml per min. 
However, there was no flow through the column at this point. In order to alleviate the 
problem with flow through the column, 6 M guanidine hydrochloride was included in the 
wash buffer, in order to keep the His-tagged CaSR-ECD protein solubilised. However, there 
was no improvement in flow through the column when washing buffer was applied. 
6.4.4.4.2 Use of cOmplete™ His-Tag purification resin 
A second protocol for purifying the His-tagged CaSR-ECD protein used cOmplete™ His-Tag 
purification resin (Roche Mannheim, Germany). The resin was used to pack a disposable 5-
ml Polypropylene Column (Qiagen, Manchester, UK). The column was rinsed with 10 
column volumes of filtered water at 2 ml per min and then equilibrated with 10 column 
volumes of equilibration buffer (30 mM Tris-hydrochloride, pH 8.0; 6 M guanidine 
hydrochloride; 100 mM sodium chloride; 20 mM imidazole) at 2 ml per min. Before the 
solubilised his-tagged CaSR-ECD protein was loaded onto the column, 20 mM imidazole 
was to the protein added to reduce the chance of non-specific binding of the protein to 
the column. His-tagged CaSR-ECD protein was loaded on to the column at 2 ml per min 
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and the flow-through collected. The column was washed with 10 column volumes of wash 
buffer (30 mM Tris-hydrochloride, pH 8.0; 6 M guanidine hydrochloride; 100 mM sodium 
chloride; 50 mM imidazole) at 2 ml per min. The elution of the protein was performed in 
two stages. Firstly, elution buffer 1 (30 mM Tris-hydrochloride, pH 8.0; 6 M guanidine 
hydrochloride; 100 mM sodium chloride; 150 mM imidazole) was applied to the column 
followed by elution buffer 2 (30 mM Tris-hydrochloride, pH 8.0; 6 M guanidine 
hydrochloride; 100 mM sodium chloride; 500 mM imidazole). Seven 1-ml fractions were 
collected during each of the two elution steps. A sample of each fraction was analysed 
qualitatively in a Bradford protein assay according to the manufacturer’s protocol (Bio-Rad 
Laboratories Ltd. Hemel Hempstead, UK), in order to determine which fractions contained 
protein. 
Of the 14 fractions analysed, fractions 8-11 obtained after elution with buffer containing 
500 mM imidazole were the ones that contained the protein. The four fractions containing 
the protein were pooled. Then, to remove guanidine hydrochloride and imidazole, the 
pooled protein fractions were dialysed in SnakeSkin™ Dialysis Tubing, 10K MWCO (Life 
Technologies Ltd., Paisley, UK) against dialysis buffer containing 30 mM Tris-hydrochloride 
(pH 8.0) and 100 mM sodium chloride. This was carried out at 4°C overnight. However, 
during dialysis, the His-tagged CaSR-ECD precipitated from solution.   
 Purification of His-tagged CaSR-ECD using gel-filtration chromatography 6.4.4.5
6.4.4.5.1 Gel-filtration 
As there was no success with using Ni2+-chelation chromatography, gel-filtration 
chromatography was used as an alternative method to purify the His-tagged CaSR-ECD. 
This method separates molecules according to their size as they pass through a matrix 
filled column.  
For gel-filtration chromatography, a XK 16/100 column (GE Healthcare) was packed with 
150 ml of Superdex™ 200 beads (GE Healthcare) to a height of 70 cm. The column was 
washed with 200 ml of filtered water to remove the preservation buffer containing 20% 
(v/v) ethanol. The column was then by equilibrated with equilibration buffer (30 mM Tris-
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hydrochloride, pH 8.0; 4 M guanidine hydrochloride; 100 mM sodium chloride) at 1 ml per 
min. Solubilised inclusion bodies (obtained from E. coli BL21 CODONPLUS (DE3)-
RIPL/pPROEX-HTb-CaSREx) (Section 6.4.4.3) in buffer containing 30 mM Tris-hydrochloride 
(pH 8.0), 4 M guanidine hydrochloride, and 100 mM sodium chloride were then loaded on 
to the column. Elution buffer (30 mM Tris-hydrochloride, pH 8.0; 4 M guanidine 
hydrochloride; 100 mM sodium chloride) was applied to the column at 1 ml per min. The 
elution of the protein was monitored against time by a BioLogic LP UV detector (Bio-Rad 
Laboratories Ltd. Hemel Hempstead, UK) at an absorbance of 280 nm. During the elution, 
approximately 40 fractions of 1.5 ml were collected and these were stored at 4°C. The 
results of the elution process are given in Figure 6.17 and show that the protein was 
eluted between fractions 38 and 42 min from the start of the elution process. From the 
absorbance, the protein was indicated to be in three fractions (25, 26 and 27) of the 
eluate.  
6.4.4.5.2 Western blot of eluted protein samples 
For western blotting analysis of the eluted proteins, samples (10 µl) from the eluted 
fractions containing the His-tagged CaSR-ECD were mixed with 10 µl of SDS-sample buffer 
(Section 2.17), heated at 95°C, and separated on 10% (w/v) SDS-polyacrylamide gels. 
Following SDS-PAGE (Section 2.17), gels were subjected to western blotting as detailed 
above in Section 6.4.3.3. After the transfer of proteins to PVDF membrane, the blots were 
probed with anti-CaSR antibody ab79829 (Table 2.6) as the primary antibody which was 
used at a 1:500 dilution. The secondary antibody anti-rabbit IgG-HRP (Table 2.6) was used 
at a 1:2000 dilution. 
The results indicated the presence of the His-tagged CaSR-ECD protein in the eluted 
fractions as a band running at the predicted molecular weight of 70 kDa was detected by 
the anti-CaSR antibody ab79829 (Figure 6.18). A smaller molecular weight band was seen 
at 50 kDa. This was assumed to be a degradation product of the His-tagged CaSR-ECD 
protein since it was detected by the anti-CaSR antibody (Figure 6.18). No other proteins 
were visible in the His-tagged CaSR-ECD protein samples when analysed by Coomassie 
blue staining following SDS-PAGE.  
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6.4.4.5.3 Concentration of the eluted protein 
Fractions containing the His-tagged CaSR-ECD protein were pooled. The concentration of 
the eluted protein was measured using a Bradford assay according to the manufacturer’s 
protocol (Bio-Rad Laboratories Ltd.). The concentration of the protein was 200 µg/ml. The 
protein was stored in 20% (v/v) glycerol at -20°C. 
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Figure ‎6.17: The elution of protein by gel-filtration chromatography. 
Solubilised inclusion bodies in buffer containing 30 mM Tris-hydrochloride (pH8.0), 4 M guanidine 
hydrochloride, and 100 mM sodium chloride were loaded on to the gel-filtration column. Elution 
buffer (30 mM Tris-hydrochloride, pH 8.0; 4 M guanidine hydrochloride; 100 mM sodium chloride) 
was then applied to the column at 1 ml per min. The elution of the protein was monitored against 
time at an absorbance of 280 nm, which is shown by the blue line. During elution, fractions of 1.5 
ml were collected. The peak shows the time at which the protein was eluted from the column. 
  
Absorbance at 
280 nm 
Time (min)  
 258 
 
 
 
 
 
 
 
 
 
Figure ‎6.18: Western blotting of fractions eluted from the gel-filtration column during 
the purification of His-tagged CaSR-ECD expressed in E. coli BL21 CODONPLUS (DE3)-
RIPL/pPROEX-HTb-CaSREx. 
Samples of 10 µl of the fractions from the gel-filtration column, which were presumed to contain 
the His-tagged CaSR-ECD protein, were applied to a 10% (w/v) SDS-polyacrylamide gel. The 
separated samples were transferred to PVDF membrane and the blot probed with anti-CaSR 
antibody ab79829 and secondary antibody anti-rabbit IgG-HRP. The blot shows: Elution fraction 23 
(lane 1); elution fraction 24 (lane 2); elution fraction 25 (lane 3); elution fraction 26 (lane 4); 
elution fraction 27 (lane 5); and elution fraction 28 (lane 6). Prestained SDS-PAGE Standards 
Precision Plus Protein™ (range 20-250 kDa) were included in the gel. 
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 Use of the purified CaSR-ECD in an ELISA format 6.4.5
 Assay procedure 6.4.5.1
For ELISAs, the purified CaSR-ECD was diluted in coating buffer (1.5 mM sodium 
carbonate; 3.5 mM sodium hydrogen carbonate; pH 9.2) to 200 ng/ml. Samples of 100 µl 
were used to coat the wells of a 96-well microtitre plate. Plates were then incubated 
overnight at 4°C. The coating buffer was removed by decanting and the wells were 
blocked with blocking buffer (PBS; 0.1% (w/v) Tween-20; 3% (w/v) bovine serum albumin) 
for 30 min at 37°C. 
Plates were washed four times with washing buffer (PBS/0.1% (v/v) Tween-20). To avoid 
possible cross-reactivity with any remaining E. coli proteins, all serum samples and 
antibodies were pre-incubated with E. coli BL21 cell lysate (a gift from Dr Helen Kemp, 
Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK) at 100 μg 
per 50 μl of diluted serum sample for 30 min. Aliquots of 100 µl of serum at a 1:100 
dilution in blocking buffer were added to the wells. Phosphate-buffered saline (pH 7.4) 
was applied as a control to measure any non-specific binding of the secondary antibody. 
Anti-CaSR antibodies ab79829 (Table 2.6) and CaSR11-S (Table 2.6) were used as positive 
controls at a 1:100 dilution. The plates were incubated at room temperature for 1 h and 
then washed four times with washing buffer. To detect primary antibody binding, a 100-µl 
sample of horse-radish peroxidase conjugated to either goat anti-human IgG or goat anti-
rabbit IgG (Sigma-Aldrich) diluted to 1:2000 in blocking buffer was added to each well for 
1 h at room temperature. After washing five times with washing buffer, 100 µl of 3,3',5,5'-
tetramethylbenzidine (TMB) (Sigma-Aldrich) were applied to each well and plates 
incubated at room temperature away from light for 30-45 min to allow colour 
development. Stop the colour-forming reaction by the addition of 100 µl of 0.5 M 
hydrochloric acid. A LabSystems Integrated EIA Management System spectrophotometer 
was used to read absorption of the wells at 450 nm. All sera were tested in duplicate and 
the average OD450 value taken. Each mean OD450 value was corrected for background 
binding of the sera to the well without antigen. 
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In each ELISA, the binding reactivity of each patient and control sera to the peptide was 
expressed as an antibody index calculated as: mean OD450 of tested serum/mean OD450 of 
a population of healthy control sera. The antibody index was the mean of three 
experiments. The upper limit of normal for the ELISA was calculated using the mean 
antibody index + 3SD of a population of healthy control sera. Sera with an antibody index 
greater than the upper limit of normal were regarded as antibody-positive. 
 Assay of APS1 patient sera in the CaSR-ECD ELISA 6.4.5.2
To confirm the presence or not of antibodies against the CaSR-ECD, serum samples from 
44 APS1 patients and 10 healthy controls were analysed in an ELISA format, as detailed in 
Section 6.4.5.1. Positive control anti-CaSR antibodies ab79829 and CASR11-S were 
included in the ELISA.  
The results of three experiments testing the 44 APS1 patient and 10 control sera in the 
CaSR-ECD ELISA are shown in Figure 6.19. All control sera were negative for antibodies 
against the CaSR-ECD, as their antibody indices were below the upper limit of normal 
(mean antibody index + 3SD of 10 healthy individuals) in the ELISA (Figure 6.19). This was 
calculated as an antibody index of 1.23. In the APS1 patient group, the antibody indices of 
15 (34%) patients were above this upper limit of normal (Figure 6.19). The mean CaSR 
antibody index ± SD for the APS1 patient group and for the control group was, 
respectively, 6.28 ± 9.29 (range: 0.58-28.3) and 1.00 ± 0.08 (range: 0.88-1.10). Anti-CaSR 
antibodies ab79829 and CASR11-S had an antibody index of 20.1 and 1.04, respectively. 
The negativity of binding of the CASR11-S to the CaSR-ECD was expected in that the 
antibody recognises a C-terminal peptide in the full-length receptor which is not present 
in the purified CaSR-ECD. 
 Analysis of the results of the CaSR-ECD ELISA 6.4.5.3
Antibody assay precision was evaluated by calculating the intra-assay coefficient of 
variation (expressed as a percentage) for a series of ten serum samples that were 
measured in duplicate within the same assay run. The intra-assay coefficient of variation 
for the CaSR-ECD ELISA was in the range of 7.2-8.4%. Antibody assay reproducibility was 
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evaluated by calculating the inter-assay coefficient of variation (expressed as a 
percentage) for a series of six serum samples that were measured in three consecutive 
assay runs. The inter-assay coefficient of variation for the CaSR-ECD ELISA was 12.2%. 
Cohen's kappa was used to measure the agreement between the CaSR 
immunoprecipitation assay (Chapter 3) and the CaSR-ECD ELISA for detecting CaSR 
autoantibodies (www.statstodo.com/CohenKappa_Pgm.php). Conventionally, a Cohen’s 
kappa is considered of poor agreement at a value of < 0.2, fair at 0.21-0.4, moderate at 
0.41-0.6, strong at 0.61-0.8, and near complete agreement at > 0.8. Of the 16 CaSR 
autoantibody-positive APS1 patient sera, as measured in the CaSR immunoprecipitation 
assay (Chapter 3), 15 were also sero-positive in the CaSR-ECD ELISA. The remaining 29 
APS1 patient sera were CaSR autoantibody-negative in the ELISA. The two methods of 
measuring CaSR autoantibodies concurred in 98% of APS1 cases with near complete 
agreement between the two assays (Cohen’s kappa = 0.95; standard error = 0.05; 95% 
confidence interval = 0.85-1.05). 
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Figure ‎6.19: CaSR antibody indices of APS1 patient and control sera. 
Sera from 44 APS1 patients and 10 healthy controls were evaluated for CaSR antibodies using the 
CaSR-ECD ELISA. The CaSR antibody index (mean of three experiments) is shown for each APS1 
patient and control serum. The mean CaSR antibody index ± SD for the APS1 patient group and for 
the control group was, respectively, 6.28 ± 9.29 (range: 0.58-28.3) and 1.00 ± 0.08 (range: 0.88-
1.10).  
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 Discussion 6.5
All the current assays for CaSR autoantibodies are either labour-intensive, time-consuming 
or are not quantitative. The aim of this part of the project was to develop an ELISA 
method that would allow the measurement of CaSR autoantibodies in patient serum 
samples. This would be based on the CaSR-ECD as antigen for ELISA plate coating. Initially, 
the CaSR-ECD was expressed in E. coli using the pET system. Although this was successful, 
difficulties were accounted with protein purification using nickel-chelation 
chromatography to bind the His-tagged CaSR-ECD. Eventually, the CaSR-ECD was purified 
using gel-filtration chromatography. Future experiments will use a specific antibody 
column to prepare the CaSR-ECD. A polyclonal or monoclonal antibody will be bound to an 
activated solid support matrix using a mild and irreversible coupling method that will 
retain biological activity of the antibody. In the case of the antibodies against the CaSR, 
several polyclonal and monoclonal antibodies are available which recognise different 
epitopes on the receptor. As antigen-binding affinity varies between different antibodies, 
binding and elution conditions will need to be optimised. 
The purified CaSR-ECD was then used in an ELISA format to detect autoantibodies against 
the receptor’s ECD in APS1 patient sera. All of the 15 APS1 patient sera that were 
considered positive for autoantibodies against the CaSR-ECD had previously been classed 
as antibody-positive by the CaSR immunoprecipitation assay (Chapter 3). Indeed, the two 
methods of measuring CaSR autoantibodies concurred in 98% of APS1 cases with near 
complete agreement between the two assays (Cohen’s kappa = 0.95). The serum sample 
from one APS1 patient (APS1-1), which had previously tested positive for CaSR 
autoantibodies in the CaSR immunoprecipitation assay, was negative for immunoreactivity 
against the CaSR-ECD. This anomaly requires further investigation. For intra- and inter-
assay precision, the CaSR-ECD ELISA had coefficients of variation of 7.2-8.4% and 12.2%, 
respectively. This is line generally with the values reported for measuring autoantibodies 
in patients with autoimmune disease (Van Campenhout et al., 2007).  
In these preliminary ELISAs, antibody binding was expressed as an antibody index and the 
cut-off point for antibody positivity set as the mean + 3SD of a population of controls. To 
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improve the ELISA, a better calibration system needs to be devised where a standard 
curve is generated by plotting the absorbance values against the respective antibody 
concentration in each of a set of CaSR antibody primary reference standards (Wright et al., 
1993). The concentration of human anti-CaSR autoantibody in test samples could then be 
determined directly from this standard curve. In addition, a set of internal quality control 
CaSR antibody samples will need to be defined which will represent defined binding 
reactivities within the ELISA (Wright et al., 1993). These will need to be included in every 
assay run, and will be used to verify or not that the ELISA is operating within acceptable 
limits, and to monitor variability within and between ELISAs. The ELISA needs to be further 
developed to establish antigen reproducibility between batches as this is a critical reagent 
in the ELISA. This would be addressed by preparing at least four different batches of the 
CaSR-ECD and testing each batch in the ELISA protocol. 
Overall, the preliminary results for the CaSR antibody ELISA are encouraging, but the assay 
requires further refinement and validation for use in testing patient sera.  
 
 
  
 
 
 
 
 
 
 
 
Chapter 7 
General Discussion 
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7 General Discussion 
The CaSR is involved the control of serum calcium levels via its effects upon the secretion 
of PTH (Brown et al., 1993). Previously, the receptor was identified as autoantigen in APS1 
in a small cohort of patients (Gavalas et al., 2007). In some patients, CaSR autoantibodies 
increased the activity of the receptor in response to Ca2+-stimulation (Kemp et al., 2009). 
The binding sites (epitopes) of CaSR autoantibodies were determined for, and appeared to 
be restricted to, the extracellular domain of the receptor (Kemp et al., 2010). Following on 
from these initial studies, the aims of my study were (i) to investigate the prevalence of 
CaSR autoantibodies in a larger group of 44 APS1 patients, (ii) to determine if there were 
any associations between the presence of CaSR autoantibodies and hypoparathyroidism in 
APS1 patients, (iii) to determine the CaSR autoantibody binding sites (epitopes) on the 
receptor, (iv) to investigate the characteristics of CaSR autoantibodies in terms of their 
subclasses, functional affinities and affects upon the function of the CaSR, and (v) to 
design an ELISA for CaSR measurement in APS1 patient sera. 
Initially, the prevalence of immunoreactivity against the CaSR in APS1 patients was 
investigated (Kemp et al., 2014). Autoantibodies against the receptor were detected in 
36% of patients. This prevalence was lower than that found in a previous study carried out 
in our laboratory (Gavalas et al., 2007). Most likely, this is due to the difference in cohort 
size (44 APS1 patients versus 14 APS1 patients), as the same CaSR immunoprecipitation 
assay was used with APS1 patients of the same ethnic origin. Although CaSR 
autoantibodies were detected at an increased of patients with hypoparathyroidism 
compared to those without (39% versus 17%, respectively), the difference in their 
frequency did not reach statistical significance (P = 0.392), suggesting that autoantibodies 
against the receptor were not clinically useful markers for parathyroid dysfunction. In this 
way, they may resemble thyroid autoantibodies which are found in patients with overt 
thyroid diseases and in those who are at risk of developing it. However, it must be 
stressed that only six patients without hypoparathyroidism were available for study, and 
that there may have been CaSR autoantibodies in some patients that might not have been 
detected by the assay methods used. 
 267 
As part of characterising CaSR autoantibodies, phage-display technology was applied to 
identify the targets of autoantibodies against the receptor, which were confirmed 
subsequently using ELISAs with the relevant CaSR peptide (Kemp et al., 2010). 
Autoantibody targets resided in the extracellular domain of the receptor confirming 
previous results (Kemp et al., 2010). As before (Kemp et al., 2010), a major epitope was 
identified between amino acid residues 41 and 69, with minor epitopes at residues 114-
126, and 171-195. A novel epitope was found in the current study, different from those 
reported before (Kemp et al., 2010). The binding site was between residues 260 and 340. 
Immunoreactivity against more than one CaSR epitope was found in nine out of 16 (56%) 
APS1 patients, indicating there was a heterogeneous antibody response against the 
receptor. Similarly, in autoimmune thyroid disease and in type 1 diabetes mellitus, 
multiple epitopes have been detected on thyroid peroxidase and tyrosine phosphatase-
like IA-2 autoantigen, respectively (Lampasona et al., 1996). In the case of in type 1 
diabetes mellitus this has been explained by the ‘spreading’ of autoimmune responses 
against a single or a few epitopes from early childhood to multiple and different epitopes 
with the advancing years (Naserke et al., 1998). However, in the context of this study, 
serum samples taken at different disease durations from the same individual APS1 patient 
were not analysed, so the possibility of epitope spreading was not evaluated.  
All the epitopes identified overlapped with domains on the CaSR that are thought to be 
involved in receptor function (Hauache et al., 2000, Silve et al., 2005, Hu and Spiegel, 
2007). However, how exactly the CaSR autoantibodies with different epitope specificities 
might affect CaSR function needs more investigation. Further studies are also required to 
determine the exact epitope/s recognised by the CaSR-stimulating autoantibodies which 
were detected in four of the APS1 patients. The characterised CaSR epitopes were linear 
by nature, so further studies need to be undertaken to identify autoantibodies that may 
recognise conformational epitopes which would depend on the native structure of the 
receptor. Such antibodies are usually important in disease (Pettersson, 1992, 
Morgenthaler et al., 1999). For example, in Graves’ disease, pathogenic autoantibodies 
against the thyrotropin receptor target several different conformational epitopes 
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(Morgenthaler et al., 1999). This is also the case for pathogenic autoantibodies against 
thyroid peroxidase in autoimmune hypothyroidism (Gora et al., 2004). 
The IgG isotypes of APS1 patient CaSR autoantibodies were determined also in this study. 
Autoantibodies against the receptor were mainly of the IgG1 subclass. In a minority of 
APS1 patients, antibodies against epitope 114-126 were of the IgG3 subclass. CaSR 
antibodies of the IgG2 and IgG4 subclasses were not identified. This is the first report 
regarding IgG subclass for antibodies against the CaSR in patients with 
hypoparathyroidism in the context of APS1, although CaSR autoantibodies exclusively of 
the IgG4 subtype were found in one patient with autoimmune hypocalciuric 
hypercalcemia (Pallais et al., 2004). Interestingly, both IgG1 and IgG3 subclass antibodies 
can induce antibody-dependent cellular cytotoxicity, as well as having the capacity to 
activate complement (Flanagan and Rabbitts, 1982, van Loghem, 1986). However, these 
pathogenic mechanisms require investigation in relation to autoantibodies against the 
CaSR. It is possible that affinity purification of IgG subclasses might show less restriction 
than was found here in relation to CaSR autoantibodies: fractionation into IgG subclasses 
has revealed the presence of all IgG subclass antibodies, including IgG4, with respect to 
thyroglobulin and thyroid peroxidase autoantibodies in Hashimoto’s thyroiditis (Weetman 
et al., 1989). 
Autoantibodies that affect CaSR function are more likely to have a role in disease 
pathogenesis than autoantibodies that simply bind to the receptor. For example, thyroid-
stimulating autoantibodies activate the thyrotropin receptor leading to hyperthyroidism in 
Graves’ disease by mimicking the binding of thyroid-stimulating hormone (Weetman and 
McGregor, 1994). Autoantibodies against the acetylcholine receptor block the 
acetylcholine-binding site and provoke accelerated receptor degradation causing 
myasthenia gravis (Hoedemaekers et al., 1997). Indeed, a small number of patients with 
either APS1 or isolated autoimmune hypoparathyroidism have been identified with CaSR-
stimulating autoantibodies that could potentially reduce PTH secretion (Posillico et al., 
1986, Kifor et al., 2004, Kemp et al., 2009). In this study, four patients with APS1 had CaSR 
autoantibodies that activated the receptor in the presence of calcium. However, further 
studies are needed to investigate if these autoantibodies also consequently inhibit the 
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release of PTH from the parathyroid glands. This could be done in vitro initially using a 
parathyroid cell line (Fabbri et al., 2014). It could be that in the aforementioned cases of 
hypoparathyroidism, the CaSR autoantibodies cause dysfunction of the parathyroid 
without causing irreversible damage to the glands (Kifor et al., 2004). This would need to 
be clarified in the APS1 patients used in this study. 
Further to affecting the function of the CaSR, autoantibodies against the receptor could 
also destroy parathyroid cells through complement-fixation or antibody-dependent 
cellular cytotoxicity. Such activities of anti-parathyroid autoantibodies from patients with 
autoimmune hypoparathyroidism have been reported previously, although their 
molecular target was not defined (Brandi et al., 1986). This potential activity needs further 
analysis in relation to CaSR autoantibodies. Of course, it is also possible that CaSR 
autoantibodies are an epiphenomenon and play no part in APS1 pathogenesis, but rather 
they indicate the presence of autoreactive anti-CaSR T lymphocytes. 
The targets of autoreactive T cells have been little studied in APS1 compared with that of 
the humoral immune response, although the autoimmune diseases found in the syndrome 
are thought to result from T cell-mediated damage of the specific organs. This has been 
supported by the examination of available tissue samples from various endocrine glands 
which show lymphocytic infiltration (Betterle and Zanchetta, 2003). In a study of an ASP1 
patient with alopecia, in addition to other diseases, a biopsy of the affected scalp showed 
a significant infiltration of T cells in the hair follicles (Faiyaz-Ul-Haque et al., 2009). To date, 
however, the targets of T cells in APS1 patients have not been studied extensively, but 
there are some examples such as aromatic L-amino acid decarboxylase (Kluger et al., 
2015). This autoantigen was recognised by cytotoxic T cells in 43% of APS1 patients with 
gastrointestinal dysfunction (Kluger et al., 2015). However, autoreactive T cells against the 
CaSR in patients with APS1 have not been investigated so far. 
There are many questions to be answered regarding the development of self-tolerance 
towards the CaSR. Many well-known targets of immune responses in autoimmune 
endocrine disease are controlled by AIRE. For example, the thyrotropin receptor, 
thyroglobulin, thyroid peroxidase and the sodium-iodide symporter, which are 
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autoantigens in autoimmune thyroid disease, are reliant upon AIRE for their expression 
and the consequent induction of tolerance to them (Misharin et al., 2009); so too are the 
pemphigus vulgaris-related autoantigen desmoglein 3 (Wada et al., 2011), and the vitiligo-
associated autoantigen gp100 (Trager et al., 2012, van den Boorn et al., 2009). However, 
certain vitiligo-associated autoantigens such as tyrosinase-related protein-2 are not under 
AIRE control (Trager et al., 2012). Future questions include: Is the CaSR under AIRE 
control? Is this centrally or peripherally controlled? Are Tregs responsible for tolerance to 
the CaSR? Understanding the CaSR tolerance mechanism may improve our understanding 
of the presence of immune responses against the receptor in APS1. 
This study aimed to develop a fast and quantitative ELISA for detecting CaSR 
autoantibodies in APS1 patient sera using the CaSR extracellular domain expressed in E. 
coli as the antibody-capture antigen. Although the ELISA developed was able to detect the 
presence of CaSR autoantibodies in APS1 patient sera, further work is required to optimise 
and validate the method.         
This thesis has concentrated on characterising autoantibodies against the CaSR in APS1 
patients. However, their relevance to the pathogenesis of hypoparathyroidism in APS1 has 
yet to be fully established. The possibility that CaSR autoantibodies play no part in APS1 
pathogenesis, but rather indicate the presence of autoreactive anti-CaSR T lymphocytes, 
needs to be investigated. Future investigations should aim also to identify whether any 
other novel parathyroid antigens exist besides CaSR and NALP5. By analogy with other 
autoimmune endocrinopathies, T cells are likely to play the major role in parathyroid 
destruction in hypoparathyroidism in APS1, and so it will also be essential to characterise 
any parathyroid autoantigens and the epitopes that are targeted by T cells. 
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